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Abstract 
There is a need for sensitive measures of disease progression in multiple sclerosis (MS) to 
monitor  treatment  effects  and  understand  disease  evolution.  MRI  measures  of  brain 
atrophy  have  been  proposed  for  this  purpose.  This  thesis  investigates  a  number  of 
measurement techniques to assess their relative ability to monitor disease progression in 
clinically isolated syndromes (CIS) and early relapsing remitting MS (RRMS). 
 
Presented, is work demonstrating that measurement techniques and MR acquisitions can 
be optimised to give small but significant improvements in measurement sensitivity and 
precision,  which  provided  greater  statistical  power.  Direct  comparison  of  numerous 
techniques demonstrated significant differences  between them. Atrophy  measurements 
from  SIENA  and  the  BBSI  (registration-based  techniques)  were  significantly  more 
precise than segmentation and subtraction of brain volumes, although larger percentage 
losses were observed in grey matter fraction. Ventricular enlargement (VE) gave similar 
statistical power and these techniques were robust and reliable; scan-rescan measurement 
error was <0.01% of brain volume for BBSI and SIENA and <0.04ml for VE. 
 
Annual atrophy rates (using SIENA) were -0.78% in RRMS and -0.52% in CIS patients 
who progressed to MS, which were significantly greater than the rate observed in controls 
(-0.07%). Sample size calculations for future trials of disease-modifying treatments in 
RRMS, using brain atrophy as an outcome measure, are described. For SIENA, the BBSI 
and  VE  respectively,  an  estimated  123,  157  and  140  patients  per  treatment  arm 
respectively would be required to show a 30% slowing of atrophy rate over two years. In 
CIS subjects brain atrophy rate was a significant prognostic factor, independent of T2 
MRI lesions at baseline, for development of MS by five year follow-up. It was also the 
most significant MR predictor of disability in RRMS subjects. Cognitive assessment of 
RRMS  patients  at  five  year  follow-up  is  described,  and  brain  atrophy  rate  was  a 
significant  predictor  of  overall  cognitive  performance,  and  more  specifically,  of 
performance in tests of memory. 
 
The work in this thesis has identified methods for sensitively measuring progressive brain 
atrophy in MS. It has shown that brain atrophy changes in early MS are related to early 
clinical evolution, providing complementary information to clinical assessment that could 
be utilised to monitor disease progression. 4 
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Problem and aims 
The identification and provision of effective new disease-modifying therapies for people 
with multiple sclerosis (MS) are key research and public health aims. These aims have in 
turn  increased  the  need  to  improve  the  assessment  of  disease  progression  and  the 
measurement  of  therapeutic  effects.  Clinically-stable  individuals  with  MS  often  have 
underlying disease activity, including progressive loss of myelin and nerve fibres in the 
central nervous system, which means that clinical measures are an insensitive way of 
monitoring  disease  activity  and  detecting  disease-slowing  effects  of  treatments.  With 
magnetic resonance imaging (MRI) now assisting diagnosis and early detection of MS, 
there is an even greater need for sensitive measures of disease progression to monitor 
treatment effects at all stages and understand disease evolution.  
 
There is increasing evidence that damage to myelin, axons and neurons result in brain 
atrophy. Although brain atrophy provides a measure of one aspect of disease progression 
in MS, highly sensitive, reproducible, robust and precise techniques are required in order 
to detect subtle treatment effects. A number of manual, semi-automated and automated 
techniques have been developed to measure rates of brain atrophy from serially acquired 
MRI scans. It is unclear however which of these different methodologies provides the 
most effective measure of atrophy rate in MS, and therefore which could be utilised most 
efficiently as a marker to monitor the disease process.  
 
Sample sizes needed to power therapeutic trials are driven by the variance in outcome 
measure. Even a small reduction in the variance of atrophy rates could have a major 
impact  on  the  power  of  studies  in  MS,  potentially  allowing  smaller  and  more  cost 
effective trials to be conducted. It would in turn allow effective treatments to be provided 
more  rapidly to people  with MS in  addition to  reducing the number of  trial subjects 
exposed to ineffective treatments, or treatments with significant side effects. This thesis 
aims to optimise, assess and compare different brain atrophy measurement techniques in 
terms of their ability to quantify rates of cerebral atrophy for use as a marker of disease 
progression in MS. 
 
The project will assess the association of brain atrophy rate with clinical measures, with a 
view  to  aid  in  our  understanding  of  the  disease  process.  Clinical  correlation  is  also 
essential to establish the meaningfulness and relevance of an MRI measure of disease 16 
progression. Development of new and existing research tools used in the analysis of MRI 
may  help  us  to  determine  the  distribution  and  rate  of  disease  activity.  A  greater 
understanding of the early phase of MS may also aid in the development of new disease-
modifying drugs. 
 
Aims 
To  investigate  a  wide  range  of  image  analysis  techniques  of  potential  value  in  the 
measurement of disease progression and assessment of therapeutic efficacy in MS by: 
1.  comparing  and  cross-validating  different  MRI  methodologies  for  longitudinal 
analysis of brain atrophy, including current methods used in MS research, together 
with novel techniques; 
2.  estimating the number of subjects necessary to detect a disease-modifying effect 
in  a  trial  of  a  putative  disease-modifying  drug,  using  brain  atrophy  rate  as  a 
marker of disease progression; 
3.  using MRI techniques to understand the longitudinal pattern of brain atrophy in 
relapsing remitting MS and its relationship to clinical disease progression. 17 
1  Neuroimaging in multiple sclerosis  
 
1.1  Introduction 
Multiple sclerosis (MS)  is a chronic inflammatory  autoimmune disease of the central 
nervous  system  (CNS)  and  the  most  common  neurological  condition  affecting  young 
adults, with approximately 100-200 cases per 100,000 persons in the United Kingdom 
(Forbes & Swingler, 1999). Females are more often affected than males by a ratio of 2:1 
(Mumford et al., 1992), and age at clinical onset is typically between 20 and 40 years of 
age (Williams & McKeran, 1986). In about 85% of cases, the early course is with relapses 
and  remissions  (relapsing  remitting  MS  (RRMS)),  while  in  15%  there  is  steadily 
progressive disability from onset (primary progressive MS (PPMS)). After a period that is 
usually several years, or sometimes decades, progressive disability ensues in about two 
thirds  of  those  with  a  relapsing-remitting  onset  (secondary  progressive  MS  (SPMS)). 
Symptoms vary between patients but include muscle weakness, problems with balance, 
loss of coordination and mobility, visual and sensory problems, difficulties with speech, 
bowel, bladder and sexual dysfunction and mild impairments in cognition. The disease 
therefore often causes a significant personal, social and economic impact for patients and 
healthcare services. 
 
Magnetic resonance imaging (MRI) exploits the properties of hydrogen molecules within 
different tissues and fluid, allowing pathological changes within the brain and spinal cord 
to be monitored in vivo. It is now established as a key investigation in the diagnosis of MS 
and is increasingly used in studies seeking to monitor disease progression. It may also 
help us understand the underlying mechanisms and course of MS. MRI can easily be 
applied at the earliest stages of disease, when samples for histopathological study are 
unlikely to be available, allowing indirect assessment of pathology. It is a non-invasive 
technique and unlike computerised tomography does not utilise ionising radiation, making 
it  more  practical  for  repeated  examination  of  people  with  a  condition  that  may  last 
decades. 
 
Quantitative  MRI  has  confirmed  -  and  to  an  extent  preceded  -  post-mortem  studies 
showing  widespread  abnormalities  in  the  brain  well  beyond  obvious  “lesions”. 
Furthermore these studies provide evidence for the important roles of axonal damage and 18 
neurodegeneration in the pathogenesis of MS. Conventional MRI (e.g. T2-weighted) has 
allowed focal demyelinating lesions within the white matter (WM) and more rarely grey 
matter (GM) to be visualised and quantified in both post-mortem tissue and in vivo (Bø et 
al., 2007; Calabrese et al., 2007b; Geurts et al., 2005; Molyneux et al., 1998c). Whilst 
these  areas  of  focal  WM  damage  have  been  studied  extensively,  the  knowledge  that 
pathological changes are occurring in normal appearing tissue has increased support for 
the measurement of tissue loss (atrophy) from MRI as a marker of overall tissue damage 
and neuroaxonal loss. A number of MRI-based techniques measuring CNS atrophy in 
vivo have shown progressive brain atrophy, at a rate greater than that seen in normal 
aging, in subjects with MS (Chard et al., 2004; Rovaris et al., 2005a); this has been 
associated with disability progression over long-term studies (Fisher et al., 2000). 
 
This  chapter  will  begin  by  considering  the  disease  of  MS  before  focussing  on  MRI 
measures of brain atrophy in MS. However for inclusiveness and to allow comparison 
with  brain  atrophy  measures,  it  will  firstly  address  conventional  MRI  of  lesions  and 
quantitative MRI techniques that have been used increasingly in the last 10  years. A 
discussion of some of the practical issues involved, methods developed for measuring 
atrophy,  and  the  application  of  atrophy  measurements  in  clinical  and  research 
environments will be presented. Whilst important studies have documented MRI changes 
in the spinal cord and optic nerves in patients with MS, this thesis will focus only on brain 
MRI. 
 
1.2  Multiple sclerosis 
1.2.1  Pathogenesis of multiple sclerosis 
Whilst  the  exact  causes  of  MS  are  unknown,  several  genetic  and  environmental  risk 
factors have been suggested, and MS is likely to occur as a complex combination of these, 
and as yet unidentified, influences. Postulated risk factors include the alleles associated 
with major histocompatibility complex molecules, infectious agents such as the Epstein-
Barr virus and Chlamydia pneumoniae, lack of exposure to sunlight and vitamin D, and 
smoking (Levin et al., 2005; Lincoln et al., 2005; Pekmezovic et al., 2006; van der Mei et 
al., 2003; Yao et al., 2001).  
 
Although  inflammatory  WM  lesions  in  the  CNS  are  the  hallmark  of  the  disease,  the 
pathology is now understood to be more extensive, with areas of focal demyelination 19 
occurring in the GM (Bø et al., 2003b; Geurts et al., 2005; Kidd et al., 1999; Peterson et 
al.,  2001),  gliosis  within  lesions  (van  Walderveen  et  al.,  1998),  diffuse  inflammation 
(Kutzelnigg et al., 2005) and progressive neuroaxonal loss in normal appearing tissue 
(Bjartmar et al., 2001; Evangelou et al., 2000a). Microscopic examination of MS post-
mortem brain tissue has provided direct evidence of neuroaxonal damage including a 
decrease in neuronal size, disturbance of the neuronal cell cycle, neuronal death, axonal 
transection, neuronal loss, and dendritic and synaptic loss (Bitsch et al., 2000; Lu et al., 
2000; Peterson et al., 2001; Trapp et al., 1998; van Waesberghe et al., 1999). Decreases 
in axonal number and density have been shown within chronic and acute WM lesions 
(van Waesberghe et al., 1999; van Walderveen et al., 1998) and normal appearing WM 
(NAWM)  (Evangelou  et  al.,  2000b),  and  axonal  transection  and  loss  underlies  GM 
lesions found at post-mortem (Peterson et al., 2001). Axonal spheroids, transections and 
abnormal constrictions and dilatations have all been shown both within lesions and their 
surrounding tissue using immunostaining (Kuhlmann et al., 2002; Trapp et al., 1998). 
Whilst inflammation and demyelination are reversible to an extent, neuroaxonal damage 
is permanent and is likely to be a relevant mechanism of permanent disability. 
 
The mechanisms by which MS pathology occurs are clearly complex and not entirely 
understood at present. It is likely that different mechanisms operate in different patients 
and that a number of processes overlap, for example demyelination and remyelination. 
However evidence suggests that initially, inflammatory cells cross into the CNS through 
the blood brain barrier, the integrity of which is altered in patients with MS particularly 
during the acute stages of the disease (Leech et al., 2007; Soon et al., 2007). The immune 
response  involving  T-lymphocytes,  macrophages  and  microglia  is  propagated  by  the 
expression  of  major  histocompatibility  complex  molecules  and  release  of  cytokines. 
Ultimately there is destruction of oligodendrocytes and myelin (Barnett & Prineas, 2004; 
Bitsch et al., 2000) most likely involving cytokines, glutamate, macrophages, reactive 
oxygen  species  and  proteolytic  enzymes.  Demyelination  of  the  GM  appears  to  occur 
independently of WM change (Bø et al., 2007) and involves less inflammation (Bø et al., 
2003a), but the exact mechanisms are unclear.  
 
Evidence of neuroaxonal degeneration within lesions, particularly active lesions, supports 
the idea that this pathology may be a consequence of acute focal inflammation (Peterson 
et al., 2001; Trapp et  al., 1998). Numbers of CD8
+ T-cells increase in  inflammatory 20 
lesions (Babbe et al., 2000) and myelin breakdown leaves  axons vulnerable to direct 
attack from inflammatory and other biological mediators such as proteolytic enzymes, 
soluble antibodies, cytokines, glutamate, oxidative products and free radicals. A positive 
correlation of CD8
+ T-cells, macrophages and microglia with the extent of axonal damage 
has been shown (Bitsch et al., 2000; Kuhlmann et al., 2002). In particular, nitric oxide has 
been  identified  as  contributing  to  neuroaxonal  degeneration  within  lesions  through 
changes  which  include  altering  mitochondrial  DNA  and  energy  metabolism;  this 
mechanism may be more prominent during high axonal firing, when energy demands are 
greater, and leads to calcium-mediated cell death (Dutta et al., 2006; Lu et al., 2000; 
Smith  et  al.,  2001a).  It  has  also  been  suggested  that  defects  in  astrocyte  beta-
adrenoceptors cause a decrease in the energy supply to axons (De Keyser et al., 2004), 
and that voltage-gated calcium channels are redistributed following initial axonal injury 
(Kornek et al., 2001), both of which may also lead to calcium-mediated cell death. In 
addition to exposing axons to direct attack, secondary effects may result from myelin loss. 
Myelin breakdown products may contribute to the disease process by activating microglia 
which  mediate  neuronal  damage  (Diestel  et  al.,  2003).  There  is  also  evidence  that 
oligodendrocytes provide trophic support to axons, the loss of which leads to degeneration 
(Lappe-Siefke et al., 2003; Sanchez et al., 1996; Wilkins et al., 2003). These factors 
appear to be more important than myelin itself, as degeneration has been shown to occur 
despite  intact  surrounding  myelin  and  a  lack  of  inflammation  (Bjartmar  et  al.,  2001; 
Lappe-Siefke  et  al.,  2003).  Lastly,  correlations  observed  between  focal  lesions  and 
NAWM changes are consistent with Wallerian degeneration whereby axonal transection 
within lesions causes distant neuroaxonal damage, possibly due to the loss of pre- and 
post-synaptic signals (Bjartmar et al., 2001; Evangelou et al., 2000b). Axonal loss within 
NAWM  has  been  found  to  correlate  with  the  regional  lesion  load  (Evangelou  et  al., 
2000b). There may also be other less well understood but quantitatively important causes 
of axonal loss.  
 
1.2.2  Clinical onset and diagnosis 
Clinical onset of MS is varied, but involves focal or multi-focal neurological symptoms 
resulting  from  inflammatory  lesions,  demyelination  and  progressive  neuroaxonal  loss 
causing disruption in nerve signalling pathways. The heterogeneous location of pathology 
leads to the diverse symptoms observed but the most common first symptoms reported 
include changes in sensation in the arms, legs or face, optic neuritis, weakness, double 21 
vision and balance problems. Approximately 15% of patients present with multi-focal 
symptoms  whilst  others  may  have  more  unusual  presentations  such  as  aphasia  or 
psychosis. Whilst in the majority of patients these symptoms will abate over the course of 
a few weeks, in some patients there is insidious progression of neurological symptoms 
from onset.  
 
A clinical diagnosis cannot be made by a single test and at initial clinical presentation of 
symptoms, as evidence of dissemination in time and space of lesions is required. A further 
clinical attack implicating a different lesion site will allow diagnosis based on objective 
clinical evidence of two or more lesions. The most recent criteria for the diagnosis of MS, 
the McDonald criteria (McDonald et al., 2001) which were revised in 2005 (Polman et 
al.,  2005),  incorporate  MRI  and  laboratory  tests  into  the  diagnostic  scheme.  These 
investigations  can  provide  evidence  of  dissemination  of  lesions  in  time  and  space, 
allowing a diagnosis of MS to be given in patients who have experienced only a single 
clinical  monosymptomatic  event  (so  called  clinically  isolated  syndrome  (CIS)). 
Approximately 70% of people who present with a CIS will be subsequently diagnosed 
with MS (Brex et al., 2002) and it has been shown that the McDonald criteria predict a 
clinically definite MS diagnosis (i.e. a second clinical relapse) in those people presenting 
with a CIS (Dalton et al., 2002b). In patients with an insidious progression from onset, at 
least one year of disease progression and additional evidence from MRI, cerebrospinal 
fluid (CSF) and/or visual evoked potentials is required for diagnosis. 
 
1.2.3  Disease course and clinical subtypes 
The  complex  pathogenesis  and  pathology  of  MS  (both  destructive  and  restorative), 
pathology occurring in clinically silent locations and cortical plasticity combine to make 
the clinical disease course of MS extremely unpredictable. Whilst some people will have 
a relatively benign course of disease others are more likely to develop disability (Sayao et 
al., 2007). In spite of this, several clinical patterns have been characterised in MS (Lublin 
& Reingold, 1996).  Around 85% of patients initially have a relapsing remitting disease 
type. RRMS consists of clearly defined disease relapses (attacks of acute neurological 
symptoms) with full or partial recovery and no further progression of disease between 
relapses. Inflammation and lesion formation are likely to be the precursor to relapses. Of 
those patients with RRMS most will go on to develop a progressive form of the disease 
within an average of 20 years (Vukusic & Confavreux, 2003). This is called SPMS and 22 
these patients may have occasional superimposed relapses, minor remissions and plateaus 
during the progressive phase. PPMS describes the 15% of people who have a progressive 
form of the disease from onset with gradual but almost continuous worsening of disability 
and  only  occasional  plateaus  and  temporary  minor  improvements  in  function.  New 
inflammatory lesions are seen less in the progressive stages of the disease. A progressive-
relapsing disease course has also been described and is seen in a minority of patients. It is 
characterised  by  progressive  disease  from  onset,  but  with  clear  acute  relapses  and 
continued progression between relapses.  
 
Prognosis  for  an  individual  with  MS  appears  to  depend  to  some  extent  on  the  early 
clinical course, gender, age at onset and initial symptoms (Langer-Gould et al., 2006). 
However, around 15-25% of people diagnosed with MS appear not to progress, even after 
periods of 15 years or more, and are classed as having benign MS (Pittock et al., 2004). 
 
Whilst  there  is  no  cure  for  MS  several  immunomodulatory  treatments  have  been 
developed and licensed for use in RRMS; these have been shown to reduce the relapse 
rate and reduce the accumulation of disability (Jacobs et al., 1996; Johnson et al., 1998; 
Polman et al., 2006; The IFNB Multiple Sclerosis Study Group, 1995). Additionally, one 
of these treatments, interferon beta-1b, has also been shown to delay the conversion to 
clinically definite MS and the development of disability in patients presenting with a CIS 
(Kappos et al., 2007). Steroid treatment can be given in the event of a relapse to reduce 
inflammatory events and expedite recovery from a relapse, but this does not appear to 
alter long-term prognosis. Symptomatic treatments are available for a number of disease 
manifestations  including  tremor,  spasticity  and  incontinence.  There  is  no  effective 
disease-modifying  treatment  for  progressive  forms  of  MS,  and  current  research  is 
focussed on developing neuroprotective therapies to prevent the ongoing neuroaxonal loss 
thought to underlie progressive disability. 
 
Disease progression is traditionally assessed by neurological examination and disability 
rating scales. The scale most commonly used is the Expanded Disability Status Scale 
(EDSS)  (Kurtzke,  1983)  (Appendix  1),  which  consists  of  scoring  eight  different 
functional systems. However the EDSS is weighted towards  assessment  of the motor 
symptoms  of  MS  and  does  not  consider  symptoms  such  as  pain,  or  the  cognitive 
dysfunction which has been estimated to occur in 30-70% of cases (Amato et al., 2001; 23 
Lazeron et al., 2005; Möller et al., 1994; Portaccio et al., 2006; Rovaris et al., 1998). 
Moreover, at least a one-point sustained change on the EDSS is needed to be confident of 
progression in the degree of disability, due to the difficulty in precisely defining the level 
of  impairment  in  some  functional  categories  and  inter-rater  variability  (Noseworthy, 
1994). MRI has therefore gained importance in the last 15 years, not only for its role in 
diagnosing MS, but as a tool for monitoring disease progression in a more objective and 
potentially more sensitive manner. 
 
1.3  Conventional MRI of focal lesions 
Conventional  MRI  allows  visualisation  of  the  structure  of  the  brain.  Areas  of  focal 
damage within the WM and GM can be visualised in vivo due to the increased water 
content of lesions relative to the surrounding tissues. Conventional spin echo (CSE) and 
fast spin echo (FSE) sequences, which result in a proton density-weighted image (PD-
weighted) and a T2-weighted image, have commonly been used in MS for diagnostic 
purposes.  New  and  enlarging  lesions  appear  hyperintense  on  PD-  and  T2-weighted 
imaging  (Figure  1-1a  and  Figure  1-1b),  although  it  can  be  difficult  to  detect  lesions 
situated near the periventricular border on T2-weighted images, due to the similar contrast 
of CSF. Fluid attenuated inversion recovery (FLAIR) sequences have partly overcome 
this problem by suppressing the signal from CSF. Many lesions seen on T2-weighted 
imaging can also be visualised on T1-weighted images where they appear hypointense 
(Figure 1-1c) and tend to correspond to areas where there is severe tissue disruption (van 
Walderveen et al., 1998). During the active stage of MS there is increased permeability of 
the blood brain barrier and the contrast agent gadolinium (Gd) has been used with T1-
weighted  imaging  to  identify  areas  of  acute  inflammation  and  distinguish  active  and 
inactive lesions (Figure 1-1d).  
 
Whilst visual examination of these images can be performed to aid diagnosis, quantitative 
methods have been developed to assess the extent of lesion burden as a guide to disease 
severity and progression. At the simplest level assessment of the number of lesions can be 
performed and scoring systems based on the number and size of lesions have been applied 
(Thompson et al., 1991). However the intra- and inter-observer reliability is low, even 
when  incorporating  consensus  criteria  and  training  observers  (Filippi  et  al.,  1995; 
Molyneux et al., 1999).  24 
Figure 1-1 White matter lesions visualised on MRI. a) PD-weighted, b) T2-weighted, c) 
T1-weighted,  d)  T1-weighted  with  gadolinium  enhancement  (indicating  active 
inflammatory lesions). PD- and T2-weighted imaging is from a different subject to T1-
weighted imaging. 
 
 
An  alternative  approach  is  to  outline  lesions  on  MRI  and  quantify  the  volume,  and 
numerous methods have been developed for this. Whilst manual outlining of lesions may 
be  more  accurate  it  is  labour-intensive  and  subject  to  intra-  and  inter-observer 25 
reproducibility  problems  (Filippi  et  al.,  1995;  Mitchell  et  al.,  1996).  Semi-automated 
methods for delineating lesions have been shown to be equivalent to manual outlining 
with regard to accuracy but with improved reproducibility (Filippi et al., 1995; Grimaud 
et  al.,  1996;  Molyneux  et  al.,  1998a).  These  include  global  and  local  thresholding 
(Grimaud et al., 1996; Molyneux et al., 1998c; Wicks et al., 1992), and cluster-based 
identification and delineation of lesions based on fuzzy-connectedness principles (Udupa 
et al., 1997). Unfortunately semi-automated methods may require almost the same level 
of operator input as manual delineation (Grimaud et al., 1996). Manual identification of 
lesions  prior  to  contouring  may  be  needed,  or  errors  in  lesion  identification  (false 
negatives or false positives) and incorrect contouring using a global threshold may need 
correcting. Even when voxel intensities are standardised across an image, sensitivity may 
still be poor (Molyneux et al., 1998c).  
 
Developments in the area of fully automated lesion identification and delineation have 
mainly involved the use of multispectral image data and studies of these algorithms have 
shown that the accuracy, specificity and reproducibility of lesion volumes are comparable 
to manual or local threshold methods (Achiron et al., 2002; Datta et al., 2006; Wu et al., 
2006). Automated techniques have also been useful in the longitudinal assessment of 
lesion load. New, enlarging and shrinking lesions can be more easily detected following 
rigid or non-rigid registration of images and can be used to distinguish between gain and 
loss in lesion volume rather than net change only (Rey et al., 2002; Tan et al., 2002a). 
Registration overcomes problems associated with repositioning errors that may lead to 
bias when only small changes in lesion volume have occurred (Gawne-Cain et al., 1996) 
and automated analysis has been shown to identify a greater number of evolving lesions 
than manual detection (Bosc et al., 2003). 
 
Despite  lesions  being  an  obvious  pathological  feature  of  MS,  their  correlation  with 
disability and disease progression has been mixed (Dastidar et al., 1999; Held et al., 2005; 
Kappos et al., 1999; Sailer et al., 2001; Stevenson et al., 2004). In one study, correlation 
between the change in lesion volume over 0-5, 5-10 and 10-14 years, and EDSS score at 
year 14 ranged between 0.29 and 0.61 (Brex et al., 2002). This is particularly true in 
patients with PPMS in whom a smaller MRI lesion load and less lesion activity is seen 
than in patients with RRMS and SPMS, but disability progresses nonetheless (Revesz et 
al., 1994; Thompson et al., 1991). Several reasons may lie behind this paradox. Firstly, 26 
lesions may be heterogeneous, both in the extent of demyelination, remyelination and 
permanent  tissue  disruption  that  has  occurred  (Lucchinetti  et  al.,  2000),  and  in  the 
location they develop. Both these factors are likely to influence the effects that lesions 
have on the extent of permanent disability (Charil et al., 2003). Secondly, monitoring 
lesions does not encompass the global changes that are now known to occur in normal 
appearing tissue. Thirdly, the MRI acquisition will affect both detection of lesions and 
lesion measurements. Typically, lesion measurements are performed on MRI with slices 
that are a minimum of 3mm thick, and this may cause small lesions to go undetected 
because they are smaller than the resolution of the scan. In addition measurements from 
these acquisitions will be more prone to repositioning errors over serial studies and the 
effects from partial volume voxels at lesion edges will be greater. Although volumetric 
FSE and FLAIR acquisitions exist (with slice thicknesses as little as 1mm), and have been 
shown  to  increase  the  number  of  detectable  lesions  compared  with  conventional 
acquisitions (Ciccarelli et al., 2002; Molyneux et al., 1998b; Tan et al., 2002b), the time 
required  for  analysis  using  manual  or  semi-automated  techniques  will  be  greater  and 
correlations with disability may not improve (Ciccarelli et al., 2002). It has also been 
shown that lesions occur within the GM and at the GM/WM boundary, but often go 
undetected on MRI using conventional sequences at the field strengths currently used at 
the majority of centres (1.5 Tesla (T) and 3T) (Geurts et al., 2005; Kangarlu et al., 2007). 
 
1.4  Non-conventional MRI to assess global effects in multiple sclerosis 
Non-conventional quantitative MRI techniques have been developed which have provided 
indirect evidence of the global pathology occurring in MS and aided in our understanding 
of the disease. More sophisticated methods are required for image acquisition and image 
post-processing than conventional MRI and these techniques are therefore mainly limited 
to research settings.  
 
1.4.1  Diffusion imaging 
Diffusion of  water molecules inside biological tissues can be measured in vivo using 
diffusion  weighted  MRI  (DW-MRI).  The  motion  of  water  molecules  is  hindered  by 
microstructural barriers including cell membranes and organelles, meaning that diffusion 
is lower in brain tissue than in free water. Pathological processes in MS may change the 
structural barriers within the brain, increasing permeability and diffusivity and providing 
information  regarding  tissue  integrity.  An  extension  to  DW-MRI  is  diffusion  tensor 27 
imaging  (DTI)  which  allows  the  motion  of  water  molecules  in  all  directions  to  be 
characterised. WM has an organised structure of aligned axons and diffusion is greater 
along the axis of axonal fibres compared with across the fibres; this feature of diffusion 
(the  property  of  anisotropy)  can  provide  additional  information  regarding  changes  in 
tissue structure. In addition, DTI has been used to perform tractography and determine 
WM connectivity (Pagani et al., 2005a). Whilst early DW-MRI studies were limited to 
region  of  interest  (ROI)  analysis,  which  is  subject  to  selection  bias,  reproducibility 
problems and insensitivity to overall disease effect, methodology has been developed that 
has allowed analysis of global changes (Cercignani et al., 2001b). However the origin of 
any  changes  cannot  be  determined  and  partial  volume  effects  need  correcting  for, 
particularly when atrophy is occurring (diffusion will be greater in partial CSF voxels 
than pure GM or WM voxels) (Rashid et al., 2004). 
 
Despite these limitations, DW-MRI studies have shown that diffusion in both MRI-visible 
lesions and NAWM of MS patients is significantly greater than in controls, suggesting an 
increase in permeability due to myelin damage and axonal loss (Coombs et al., 2004; 
Droogan et al., 1999; Oh et al., 2004a; Vrenken et al., 2006b). In addition, anisotropy 
within  lesions  and  NAWM  is  decreased  in  patients  with  MS,  suggesting  there  is 
disruption to the structural organisation of tissue (Droogan et al., 1999; Oh et al., 2004a; 
Vrenken  et  al.,  2006b).  Increased  diffusivity  has  also  been  shown  within  the  normal 
appearing  GM  (NAGM)  and  basal  ganglia  of  patients  with  MS,  providing  further 
evidence that MS pathology is not merely restricted to the WM (Bozzali et al., 2002; 
Cercignani  et  al.,  2001a).  Moreover,  increased  diffusivity  has  been  demonstrated  in 
people presenting with a CIS, suggesting that these changes are present from the earliest 
stages of disease (Gallo et al., 2005; Ranjeva et al., 2003). However, these measurements 
are altered by temporary damage to tissues, such as demyelination, and it is difficult to 
determine whether changes in diffusion and anisotropy are reversible or permanent from 
cross-sectional  studies.  Longitudinal  studies  however  have  demonstrated  progressive 
changes  in  diffusivity  in  NAWM  and  NAGM  in  patients  with  CIS,  RRMS  and 
progressive MS (Caramia et al., 2002; Cassol et al., 2004; Garaci et al., 2007; Oreja-
Guevara et al., 2005; Rovaris et al., 2005a). 
 
One of the current limitations of DW-MRI is the trade-off between long acquisition times 
and spatial resolution.  Low spatial resolution can lead to reproducibility problems for 28 
ROI analysis and increase partial volume effects in global analyses. However, techniques 
are  being  developed  that  could  provide  high-resolution  3D  acquisitions  with  minimal 
increases  in  acquisition  time  (Cercignani  et  al.,  2005).  DW-MRI  also  requires 
standardisation  of  hardware  and  acquisition  protocols  in  order  for  findings  to  be 
comparable across patients. 
 
1.4.2  Magnetisation transfer imaging 
Magnetisation transfer MRI (MT-MRI) quantifies the ratio between the concentration of 
protons in the brain that are free, for example as tissue water, to those that are bound up as 
macromolecules in myelin and other cell membranes and therefore restricted in motion. 
The MT ratio (MTR) between free and restricted protons can be measured. A change in 
the organisation of brain tissue as a result of demyelination and neuroaxonal damage 
reduces the number of protons bound up as macromolecules and MTR decreases as a 
result. In post-mortem tissue MTR has been correlated with axonal density and myelin 
content (Schmierer et al., 2004; van Waesberghe et al., 1999). As with DW-MRI, MT-
MRI can be conducted on an ROI or on a global level through histogram analysis of MTR 
values over the whole brain, NAWM or NAGM. 
 
In vivo MT-MRI has shown a decrease in MTR values in lesions and in normal appearing 
brain tissue compared with controls in patients presenting with a CIS (Audoin et al., 
2004;  Fernando  et  al.,  2005;  Rovaris  et  al.,  2003)  and  MS  (Davies  et  al.,  2004; 
Traboulsee et al., 2003; Vrenken et al., 2006a). Although MT-MRI may be a good way to 
help  elucidate  pathological  mechanisms,  it  is  not  a  completely  specific  marker  of 
demyelination and neuroaxonal damage. Inflammation alone could cause MT values to 
fall, as the density of macromolecules is diluted by oedema. There may be partial or 
complete  recovery  of  MTR  over  a  period  of  months  as  inflammation  subsides  and 
remyelination occurs. However longitudinal studies have shown that there is a progressive 
decrease in MTR values over one year in patients with a CIS and MS (Rovaris et al., 
2003) and these have been shown to correlate with worsening of disability over an eight 
year period (Agosta et al., 2006). Voxel-wise statistical analyses of global MTR values 
have  been  performed  in  CIS  and  RRMS  cohorts,  which  have  allowed  localisation  of 
changes relative to controls without the a priori assumptions involved with ROI analysis 
(Audoin et al., 2004; Audoin et al., 2007a).  
 29 
As  with  DW-MRI,  partial  volume  effects  will  alter  MTR  values,  particularly  over 
longitudinal studies when atrophy is occurring, although normalising MTR values for 
brain volume and applying a strict threshold for voxel inclusion should minimise these 
effects. Again, standardisation of scanners, acquisition parameters and protocols would 
need to be performed if MT-MRI were to be used in a wider clinical or research setting. 
 
1.4.3  Proton magnetic resonance spectroscopy 
Proton  magnetic  resonance  spectroscopy  (
1H-MRS)  allows  a  number  of  metabolites 
common in the brain to be measured. Changes in these metabolites can be used to infer 
inflammation, demyelination and neuronal damage. The major resonances are i) choline 
(contained in phospholipids), ii) creatine and phosphocreatine (Cr), iii) N-acetyl groups 
(mainly N-acetylaspartate (NAA)), iv) lactate. Choline, lactate and Cr are thought to be 
markers  of  acute inflammation or demyelination. Membrane lipids  containing choline 
increase  during  active  myelin  breakdown  and  lactate  may  increase  as  a  result  of  the 
increase in metabolism by inflammatory cells. Likewise, decreased levels of NAA, an 
amino acid found within mature neurons, are thought to provide indirect assessment of 
neuronal integrity.  
 
Decreased NAA has been observed within normal appearing brain tissue (both WM and 
GM) in MS subjects compared with controls (Chard et al., 2002a; De Stefano et al., 2001; 
Oh et al., 2004b; Sastre-Garriga et al., 2005b), providing evidence from yet another MR 
modality that neuroaxonal damage is a consistent feature of MS. Whilst these findings 
have  also  been  found  in  studies  of  CIS  (Filippi  et  al.,  2003;  Rovaris  et  al.,  2005b), 
supporting the hypothesis that neuroaxonal damage occurs from the earliest stages of MS, 
normal NAA in NAWM has also been noted in these subjects (Fernando et al., 2004; 
Ranjeva  et  al.,  2003)  and  MS  patients  (Vrenken  et  al.,  2005).  Normal  metabolite 
concentrations  have  also  been  found  within  the  cortex  of  MS  patients  (Geurts  et  al., 
2006). The application of methods to obtain absolute NAA concentrations, rather than 
relative to other metabolites, has decreased the possibility of false effects and error in data 
interpretation. However 
1H-MRS may still be limited in detecting the low signal-to-noise 
ratio metabolite signals when voxel of interest methods are applied, which may lead to a 
lack of sensitivity to global changes, reproducibility problems and selection bias. Methods 
for whole brain quantification of NAA have been developed but these do not allow the 
localisation of changes (Adalsteinsson et al., 2003; Gonen et al., 2000). 30 
Changes in NAA may not represent neuroaxonal loss, but rather be affected by axonal 
metabolic  function  independent  of  structural  integrity  (Cader  et  al.,  2007).  Indeed 
longitudinal studies have shown recovery or increases in NAA over time (Audoin et al., 
2007c; Tiberio et al., 2006). Single-voxel spectroscopy may be sensitive to changes in 
hardware and acquisition, which makes implementation on a multicentre scale difficult. 
 
1.5  Brain atrophy as a marker of neuroaxonal damage in multiple sclerosis 
Unlike inflammation and demyelination, neuroaxonal degeneration is irreversible, and is 
likely  to  result  in  brain  atrophy  through  the  loss  of  tissue.  Its  measurement  would 
therefore provide a marker of MS pathology particularly relevant to clinical disability. 
Furthermore, diffuse neuroaxonal losses across the whole brain can feasibly be tracked. 
Despite the potential value of brain atrophy as a marker of neuroaxonal loss however, it 
should be pointed out that a) cerebral volume is composed of many different cell types 
and may therefore be altered by many changes other than neuronal or axonal loss, and b) 
other pathological and physiological factors may alter brain volume and should be taken 
into account when interpreting results (Table 1-1).  
 
1.5.1  Definition of qualities of a good brain atrophy measure 
Rating scales for the visual assessment of atrophy have been used in MS, but can be 
difficult  to  apply  and  interpret  (Benedict  et  al.,  2002;  Rao  et  al.,  1985).  A  good 
quantitative  brain  atrophy  measurement  technique  would  demonstrate  many  of  the 
features listed in Table 1-2.  
 
Measurement accuracy and precision are desirable, however they are less important in 
practical  terms  than  sensitivity  to  disease-related  change  and  measurement 
reproducibility.  Techniques  that  can  be  automated  and  are  robust  to  differences  in 
acquisition are particularly relevant qualities for large longitudinal multicentre studies. In 
addition, methods that work on volumes (three dimensions) as opposed to on a slice-by-
slice basis may be advantageous, as they should be more accurate due to higher spatial 
resolution.31 
Table  1-1  Pathological  and  physiological  variables  that  may  affect  brain  volume 
measurements in MS. 
Factors causing brain volume increases  Factors causing brain volume decreases 
Oedema  Axonal loss 
Inflammation  
Gliosis (tissue bulk) 
Neuronal damage with neurone loss (e.g. 
dentritic pruning) 
Remyelination  Resolution of inflammation and oedema 
  Gliosis (retraction scarring) 
  Demyelination 
  Dehydration 
  Anti-inflammatory agents 
  Normal aging 
 
 
 
Table 1-2 Desirable qualities of a brain atrophy measure. 
Quality  Comment 
Sensitive to brain atrophy  Allows subtle pathological changes to be detected. 
Techniques that can measure differences at a subvoxel 
level may be advantageous. 
Reproducible  Avoids measurement errors that may lead to erroneous 
results. 
Accurate  Detects actual tissue loss. Accuracy is difficult to verify 
however, and small errors are insignificant if consistent 
between subjects and over time. 
Precise  Repeated measurements of the same volume will be of the 
same value to within a small percentage of the volume. 
Automated  Fast to implement, thereby reducing operator time and 
costs. Operator-dependent errors are minimised. 
Robust to image quality  Results are more reliable and comparable between subjects 
and imaging sites where acquisitions may vary slightly, 
and minimally affected by image artefacts. 
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The reproducibility and precision of atrophy measurement techniques depend to some 
extent on variations in the scanner and imaging parameters (i.e. echo time, repetition time, 
flip angle, slice thickness etc); greater precision in brain parenchymal fraction (BPF) has 
been obtained on dual-echo T2-weighted and FLAIR images compared with T1-weighted 
volumetric images from the same subjects (Horsfield et al., 2003). In addition fluctuations 
in the performance of scanner gradients can lead to drift in voxel sizes (Freeborough et 
al., 1996). Although this variation may at least partly be corrected for by normalisation to 
a  constant  such  as  skull,  brain  atrophy  measures  that  are  less  affected  by  gradient 
strengths are preferable. Reproducibility and precision may also be affected by the quality 
of images and presence of artefacts.  
 
1.5.2  MR acquisition for brain atrophy measurement 
The optimum MRI acquisition for atrophy quantification may to some extent depend on 
the measurement technique and the subjects to be studied. However it would be expected 
that the optimal acquisition would be one with a high signal-to-noise ratio (SNR), high 
contrast-to-noise ratio (CNR), high spatial resolution and short acquisition time. 
 
Signal-to-noise ratio 
SNR can be defined as the ratio of the mean voxel signal (from a homogenous region with 
high signal intensity within the object of interest) divided by the standard deviation of the 
background signal (measured from several regions outside the object). Alternatively a 
difference image can be generated from two consecutively acquired images, and the mean 
voxel signal within this image divided by the standard deviation of voxels in this same 
region. Increasing MR scanner field strength will amplify the signal intensity from the 
object and consequently SNR (Figure 1-2). Most MR scanners currently in use operate at 
1.5T or 3T, although in research settings higher magnetic fields are sometimes used. SNR 
can also be improved by imaging larger voxels which can be achieved by increasing the 
field of view (FOV) whilst maintaining the matrix size, and changing the radio frequency 
receiver coil to a phased array (multi-channel) coil. Atrophy measures will benefit from 
increased SNR which “sharpens” the edges of tissue boundaries. 33 
Figure 1-2 T1-weighted images showing different signal-to-noise ratios due to scanner 
field  strength.  Images  are  from  a  single  subject  and  corrected  for  intensity 
inhomogeneity. Signal-to-noise ratio is lower when acquired on (a) a 1.5 Tesla scanner 
(9:36 minute acquisition time) than on (b) a 3 Tesla scanner (9:14 minute acquisition 
time).  Images  are  from  the  Alzheimer’s  Disease  Neuroimaging  Initiative 
(http://www.loni.ucla.edu/ADNI). 
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Contrast-to-noise ratio 
The CNR can be defined as the ratio of the difference in signal intensity between regions 
with different cellular constituents, and the background signal. The contrast of images 
must be good to obtain robust brain atrophy measurements as many techniques rely on 
high contrast boundaries between brain and CSF (Figure 1-3). Regional atrophy measures 
are also likely to benefit from a high contrast between GM and WM. Good tissue contrast 
requires  selection  of  an  appropriate pulse sequence  (T1-weighted  sequences  are often 
used), and increasing field strength will also increase CNR. 
 
Spatial resolution 
Spatial resolution is the distance between adjacent voxels in the image and therefore to 
achieve  higher  resolution  and  visualisation  of  more  detail,  image  voxel  size  must  be 
reduced (Figure 1-4). Although atrophy measurement techniques have been successfully 
applied to “2D” acquisitions with slice thicknesses of 3mm or greater (Collins et al., 
2001; Losseff et al., 1996; Rudick et al., 1999), higher resolution imaging should improve 
atrophy measures. Partial volume effects result when multiple tissue types contribute to a 
voxel and there is blurring of intensity across boundaries. It is common to acquire 3D 
volumetric acquisitions with isotropic voxels of around 1mm which reduce partial volume 
effects on some measurements, provide good brain/CSF and GM/WM contrast, and allow 
visualisation and measurement of small regional structures. Atrophy measures applied to 
3D acquisitions are less dependent on slice positioning and slice selection, and may give 
more accurate results from automated techniques (Sharma et al., 2004). In addition 3D 
acquisitions  allow  reformatting  and  accurate  re-slicing  of  data  for  registration-based 
techniques, and provide good boundary definition in all views which is important for 
atrophy measurement. The disadvantage of increasing resolution through smaller voxels 
is  that  SNR  is  decreased  and  acquisition  time  is  increased.  However  standard  high-
resolution 3D acquisitions (e.g. 1 x 1 x 1.2mm
3 voxels) can be acquired in less than 10 
minutes. 35 
Figure 1-3 T1-weighted images showing differences in contrast-to-noise ratio due to changes in scanner hardware (a has higher CNR than b). 
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Figure 1-4 T1-weighted images showing differences in spatial resolution. a)-c) show an 
image acquired with 3mm thick axial slices (1x1mm in-plane resolution), giving limited 
resolution in the coronal and sagittal planes (non-isotropic voxels), d)-f) show an image 
acquired with 1.5mm thick coronal slices (1x1mm in-plane resolution), giving similar 
resolution in the axial and sagittal planes (near isotropic voxels). 
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1.5.3  MRI artefacts 
When imaging the brain, MRI artefacts can result from different sources including the 
scanner, the patient and the MR acquisition. These may only affect a few voxels or they 
may be on a larger scale affecting visualisation and processing of the image. Some of the 
more common artefacts that arise and that may affect brain atrophy measures will be 
addressed in the following section. It should be pointed out that for acquisition-related 
and patient-related artefacts, the degree of artefact will often be worse the higher the field 
strength of the scanner. Although the artefact may be present at lower field strengths, the 
increase in SNR and CNR makes them more conspicuous. 
 
Inhomogeneity 
A common artefact seen on MR images of the brain is intensity inhomogeneity (bias), 
where the signal intensity from supposedly homogeneous tissue (i.e. GM, WM, CSF, 
skull etc) is non-uniform. These bias fields usually vary smoothly across an image (Figure 
1-5a) and may be due to poor radio frequency coil uniformity leading to a non-uniform 
B1 field (the strength of the radio frequency pulse varies at different positions within the 
coil), non-uniform sensitivity of the receiver coil and eddy currents caused by magnetic 
field gradients. Anatomical variability, regional differences in the magnetic properties of 
the tissues being imaged, position of the head within the MRI scanner and electrodynamic 
interactions with the object being imaged may also result in variations in the image signal, 
particularly at higher field strengths.  
 
This  inhomogeneity  across  an  image  can  cause  inaccuracies  in  atrophy  measurement 
techniques that rely on homogeneity of intensity within a tissue class. Techniques that 
depend  on  operators  recognising  tissue  boundaries  may  also  be  influenced,  therefore 
correcting  this  intensity  inhomogeneity  within  an  image  may  improve  atrophy 
measurements.  Inter-slice  variations  observed  in  2D  sequences  can  be  dealt  with  by 
methods that normalise the intensities between individual slices. However the smooth 
intensity variations present in most acquisitions are approached differently. Several post-
processing  techniques  have  been  developed  to  retrospectively  correct  for  these 
inhomogeneities, using a number of different approaches (Ahmed et al., 2002; Chen & 
Reutens, 2005; Cheng & Huang, 2006; Cohen et al., 2000; Gispert et al., 2004; Luo et al., 
2005; Van Leemput et al., 1999; Vokurka et al., 1999; Vovk et al., 2004). In addition 
some segmentation algorithms simultaneously delineate brain regions and estimate and 38 
correct for the inhomogeneity. This procedure offers the advantage that information from 
the segmentation can be used to aid inhomogeneity correction. 
 
A study published in 2001 directly compared six commonly used algorithms for intensity 
inhomogeneity correction and found that two methods which evaluate spatial variation in 
tissue  intensity  parameters  generally  performed  better  with  regard  to  the  accuracy, 
precision and stability of the non-uniformity correction (Arnold et al., 2001). These were 
the bias field corrector (Shattuck et al., 2001) and nonparametric nonuniform intensity 
normalisation  (N3)  (Sled  et  al.,  1998).  Indeed,  N3  has  been  shown  to  increase  the 
reproducibility  of  brain  segmentation  in  a  study  of  10  control  subjects  (Chard  et  al., 
2002c).  
 
Motion 
Motion of the head during scanning can lead to artefacts (Figure 1-5b). Many patients are 
unable to cooperate in keeping still during scanning and it can be beneficial to avoid long 
sessions in the scanner when patients may become uncomfortable. Motion effects are also 
minimised to some extent by the use of head restraints. Motion artefacts may also present 
as a result of pulsatile blood flow or breathing. These effects can be averaged out of the 
image  or  reduced  by  synchronising  the  imaging  sequence  with  the  cardiac  cycle  or 
suppressing  the  signal  from  blood.  PROPELLER  (Periodically  Rotated  Overlapping 
ParallEL Lines with Enhanced Reconstruction) MRI has been described as a means by 
which to quantify and correct for motion artefact prior to image reconstruction (Forbes et 
al., 2001; Pipe, 1999). Movements of the eye and swallowing may also cause motion 
artefacts and are difficult to correct for.  
 
Chemical shift  
Chemical  shift  describes  the  artefact  that  occurs  due  to  differences  in  the  resonance 
frequencies of fat and water, which cause displacement in the signal from fat relative to 
water.  This  displacement  can  make  it  difficult  to  determine  brain  boundaries  (Figure 
1-5c). Fat suppression techniques and changes to the imaging sequence can help reduce 
chemical shift artefacts. 39 
Figure 1-5 Examples of MR image artefacts. a) intensity inhomogeneity, b) motion, c) 
chemical  shift  d)  susceptibility  and  pulsation  artefact,  e)  and  f)  infolding  and 
inadequate field of view. 
 
 
Susceptibility artefacts 
This class of problems refers to a number of artefacts caused by the different magnetic 
susceptibilities of tissues and materials leading to local non-uniformity of the magnetic 40 
field. This can result in signal dropout, bright spots and spatial distortion in images. Metal 
implants may also cause these artefacts, e.g. dental plates (Figure 1-5d). These artefacts 
can be reduced using SE or FSE sequences compared with gradient echo sequences and a 
high bandwidth and short echo time may also help. 
 
Inadequate field-of-view or number of image slices 
If the FOV is too small or the number of slices not adequate to include the whole head, 
this can lead to wrap-around (aliasing) where one side of the image folds into the opposite 
side of the image (Figure 1-5e). It is caused by a corruption in the spatial encoding of 
objects outside the FOV which cannot be distinguished from objects inside the FOV. This 
is because areas outside the FOV still give a signal because the RF pulse(s) (and phase-
encoding gradient) are applied to the whole head. However the value of the phase shift 
caused by the phase encode gradient will be outside the range of values assigned to cover 
the FOV, with the value assigned to a point just outside the FOV at one side of the image 
being identical to that assigned to a point just within the FOV at the other side. These 
points are therefore indistinguishable, and signal from objects at these points will overlap 
in the reconstructed image. This will cause a problem for analysis of atrophy if the wrap-
around is large enough to overlay the brain (Figure 1-5f). In addition to wrap-around, if 
the FOV is very tight around the object being scanned then this can cause signal drop-out 
towards the edges of the image which may cause problems for segmentation of the brain 
or atrophy measurement techniques that rely on a constant intensity throughout the image. 
Both of these problems can be remedied by using a larger FOV. 
 
Gradient non-linearity 
Linear variation in the gradient field is required for accurate spatial encoding. However, 
gradient non-linearity may occur towards the edge of the imaging volume. This non-
linearity can lead to distortions in the signal and geometry of images, which may affect 
the  shape  and  boundaries  of  the  brain,  and  as  such  influence  the  accuracy  of  cross-
sectional volumes and longitudinal atrophy measures.  This can be particularly apparent 
when the same subject is positioned differently between time-points, as the distortion is 
position dependent. As such, the distortion may be different between scans which can 
lead  to  error  in  measurements.  Whilst  scanner  manufacturers  supply  software  for  the 
correction of linear variation, there is a discrepancy between the actual magnetic field and 
the gradient corrected for by the scanner software when non-linear variation is present. In 41 
addition, most software works only in two dimensions which is not a complete solution. 
Recently  three-dimensional  algorithms  have  been  applied  to  brain  MRI  and  shown  a 
significant improvement in distortion correction over two-dimensional methods (Jovicich 
et al., 2006).  
 
1.6  Brain atrophy measurement methods 
Although  visual  assessment  of  brain  atrophy  does  not  require  specialist  hardware  or 
software, it is subject to reproducibility problems and is unlikely to be sensitive to small 
amounts of change. Quantitative approaches include manual methods that may be used 
for  simple  linear  and  area  measurements,  and  automated  or  semi-automated  software 
which is generally used for volume measurements to minimise operator-input time and 
increase reproducibility. This section provides an overview of methods that have been 
applied to MS subjects.  
 
1.6.1  Cross-sectional or longitudinal? 
Single time-point measurements of the length or width, area, and volume of whole brain 
and  sub-regions  have  been  utilised  in  studies  of  MS  patients.  Comparison  with 
measurements from control subjects may indicate atrophy in these patients.  However 
measurements based on a single scan can be difficult to interpret because of wide normal 
variability; normalisation to intracranial volume should be performed as small volume 
changes tend to be masked by the biological inter-individual variability in absolute brain 
size and volume. In addition, the progression and rate of atrophy can be assessed only 
indirectly  from  cross-sectional  measurements,  and  one  must  assume  that  atrophy 
progresses linearly and at a similar rate between individuals. Gender and age, amongst 
other factors, have been shown to influence brain volumes and must be taken into account 
in  analyses  of  cross-sectional  data  (Chard  et  al.,  2002c).  Longitudinal  measurements 
allow disease progression to be monitored more precisely and the extent of true inter-
individual  differences  identified.  These  may  be  obtained  following  the  subtraction  of 
serial cross-sectional measures (Equation 1.1), or by methods which directly measure the 
difference between ROIs following registration of images (Chapter 1.6.4).  
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1.6.2  Two-dimensional brain measurements  
Linear measures are the simplest atrophy measurements as they are quick to perform and 
can be applied to most structural MR acquisitions. Measurement of brain width on axially 
formatted MRI, has demonstrated atrophy rates of -0.64% year
-1 in RRMS subjects  with 
an  intra-rater  measurement  coefficient  of  variation  (CV,  the  standard  deviation  of 
measurements  divided  by  the  mean  (σ/µ))  of  1%  (Simon  et  al.,  1999).  Linear 
measurements of ventricular spaces, including the fourth, third and lateral ventricles, have 
been applied more widely and provide indirect assessment of brain atrophy (Simon et al., 
1999; Turner et al., 2001) (Figure 1-6). Ventricular enlargement occurs as a result of 
tissue loss, and small losses can result in relatively large increases in CSF compartments. 
In cross-sectional studies, these measures may be normalised to brain size, by determining 
the brain width at the same level as ventricular width (Caon et al., 2003). One study 
measuring third and lateral ventricle width on axial MRI demonstrated annual increases of 
4.5% and 5.5% respectively in MS subjects (Simon et al., 1999), and third ventricle width 
has been shown to correlate with third ventricle volume (Turner et al., 2001). Intra-rater 
CVs of 7% and 4% for third and lateral ventricle width measurements respectively have 
been shown (Simon et al., 1999). 
 
Mid-sagittal measurements of corpus callosum (CC) area have also been performed in a 
number of MS studies. The CC is comprised of axonal tracts connecting the left and right 
brain hemispheres and has long been recognised as being particularly affected in MS. 
Cross-sectional  analysis  has  shown  significantly  smaller  average  CC  areas,  by 
approximately 20%, in MS subjects relative to controls (Barkhof et al., 1998; Liu et al., 
1999; Paolillo et al., 2000). Rate of atrophy in one of these studies was estimated to be  
-5.3% year
-1 in patients with RRMS (Liu et al., 1999). Significant decreases in CC area 
have also been observed longitudinally (Martola et al., 2007; Pelletier et al., 2001; Simon 
et al., 1999), -4.9% year
-1 in one study (Simon et al., 1999) and -1.8% year
-1 in another 
(Martola  et  al.,  2007).  Methodological  variability  between  studies  in  terms  of 
measurement position, and the dependence of these two-dimensional measures on slice 
positioning and selection which are often based on subjective criteria (Benedict et al., 
2004; Bermel et al., 2002; Sharma et al., 2004) limits these techniques however, and an 
intra-rater CV of 3% has been shown. Furthermore, slice selection may be harder when 
the head position and orientation within the MR scanner varies between patients and over 
time. 43 
Figure 1-6 Linear measures of a) the fourth ventricle, b) the third ventricle and c) the lateral ventricles. 
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1.6.3  Cross-sectional methods 
Delineation  (segmentation)  or  classification  of  brain  and  CSF  voxels  on  MRI  allows 
global, regional or GM/WM volume quantification. Manual outlining of the brain is time-
consuming, subjective and less reproducible than algorithms performing semi- or fully-
automated segmentation. Numerous algorithms have been developed and may be based 
on  thresholding  (driven  by  the  difference  in  brain/CSF  or  GM/WM  signal  intensity), 
region growing, clustering, deformable models or combinations of these. Some of the 
more commonly used methods and specific software packages that have been used in MS 
studies are discussed in this section. 
 
Anatomatic 
This  semi-automated  segmentation  software  uses  a  number  of  processes  to  obtain  a 
volumetric  estimate  of  the  brain  and  GM/WM  (Heinonen  et  al.,  1997).  Thresholds 
obtained from histogram analysis or defined manually are applied to images in order to 
classify skull, GM and WM. Region growing is then applied to the images to fill the 
segmentations and determine accurate intersections between the scalp, skull and CSF. The 
filled GM and WM images are subsequently combined with the skull image on a pixel-
by-pixel basis with the aid of decision trees, which specify the voxels that should be 
retained from each image according to a set of rules (Heinonen et al., 1998). In this way 
classification of different tissue types within the image is achieved, including GM and 
WM,  allowing  investigation  into  the  specific  contributions  of  their  pathology  in  MS. 
Misclassified brain lesions can also be identified on GM images prior to region filling and 
integrated into the final image according to rules designed for this purpose (Heinonen et 
al., 1998). This method has been successfully applied to T1 and T2/PD-weighted images 
(Ukkonen  et  al.,  2003;  Wu  et  al.,  2007b),  and  based  on  known  volume  phantoms 
accuracy tests showed the error to be 1.5% of the total true volume (Heinonen et al., 
1997). Although this method is semi-automated, manual implementation of thresholds 
and region growing applied on a slice by slice basis is recommended in some regions that 
are more difficult to segment. This method may therefore require considerable user input. 
Volumes must also be normalised to head size for cross-sectional analyses, but this is 
straightforward given that CSF is classified with the technique. 
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Brain parenchymal fraction 
BPF is the ratio of brain parenchymal tissue volume to the total volume within the surface 
contour of the whole brain (Equation 1.2).  
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Whilst this term can be used to describe any technique that normalises brain volume 
measures in this way, a method designed to automatically determine brain and intracranial 
cavity volume was described by the Cleveland group and has been applied in numerous 
studies (Autoseg MS, Cleveland Clinic Foundation, Cleveland, OH) (Fisher et al., 1997; 
Rudick et al., 1999). This method includes CSF within the sulci but unlike many other 
methods, not that external to the outer brain surface (Figure 1-7). The method firstly 
applies  an  algorithm  to  a  dual  echo  subtraction  image  to  provide  an  initial  brain 
segmentation based on optimal thresholding and connected components analysis. A 3D 
radial search operation is performed to detect the outer brain surface, non-brain structures 
are removed, and a smoothly contoured surface surrounding brain and CSF is produced. 
Within this surface contour, brain parenchymal tissue is separated from CSF by applying 
an optimal threshold. BPF is calculated using Equation 1.2. 
 
Figure  1-7  Segmentation  for  the  brain  parenchymal  fraction  and  the  brain  to 
intracranial capacity ratio. a) original MRI, b) segmentation for calculation of brain 
parenchymal fraction, c) segmentation for calculation of brain to intracranial capacity 
ratio.  
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Using the BPF, changes in voxel size, scanner gradient strengths or positioning within the 
scanner  are  minimised,  as  one  segmentation  is  performed  to  obtain  both  brain  tissue 
volume  and  normalising  volume.  This  cancels  out  differences  and  improves 
reproducibility. Partial volume effects and intensity inhomogeneity are also accounted for 
during volume calculation, increasing accuracy. Scan-rescan reproducibility is the most 
stringent test of techniques. This fully automated method has a mean scan-rescan CV of 
0.19%  (Rudick  et  al.,  1999)  whilst  mean  absolute  error  of  volume  measurements 
performed  on  phantom  images  was  less  than  1.1%  (Rudick  et  al.,  1999).  A  semi-
automated  technique  based  on  this  original  method  has  been  applied  to  T1-weighted 
images (Bermel et al., 2003b; Sharma et al., 2004). The need for operator input to the 
algorithms and manual correction of the region makes these methods potentially more 
accurate but also more labour intensive and introduces greater variability. Relative to a 
phantom, accuracy has been estimated at 99.08%, but mean scan-rescan CV was higher 
than that of the original Cleveland method, ranging from 0.35% to 1.1% depending on 
image slice thickness (Bermel et al., 2003b; Sharma et al., 2004; Zivadinov et al., 2003; 
Zivadinov et al., 2004a). In addition mean intra- and inter-rater CV have been shown to 
vary between 0.03-0.37% and 0.31-1.00% respectively (Sharma et al., 2004; Zivadinov et 
al.,  2003;  Zivadinov  et  al.,  2004a).  One  study  directly  comparing  a  fully-  and  semi-
automated BPF method on different acquisitions found that the fully-automated technique 
did not provide satisfactory brain segmentation  on the subtracted  dual  echo image in 
severely atrophied subjects, and that scan-rescan CV was greater on acquisitions with 
thicker slices (Horsfield et al., 2003). However the automated method used in this study 
was not the Cleveland algorithm. 
 
Potential drawbacks of the BPF include possible insensitivity to increases in CSF spaces 
occurring  with  greater  atrophy,  peripheral  atrophy  being  missed,  and  brain  surface 
contour volumes changing over time thereby altering normalisation. 
 
Brain to intracranial capacity ratio 
Brain to intracranial capacity ratio (BICCR) is a measure similar to BPF, but includes 
extra  cerebral  CSF  (between  outer  brain  surface  and  dura)  in  addition  to  sulcal  CSF 
(Figure 1-7). It has been used to detect atrophy from dual-echo T2/PD-weighted images 
(Brass et al., 2004; Collins et al., 2001). Each image is first registered into standard space 
(Talairach),  to  normalise  for  individual  head  size  variations,  before  intensity 47 
normalisation. A filter is applied to reduce noise within the image and improve voxel 
classification by a Bayesian classifier identifying GM, WM, CSF, lesion and background 
voxels. Mathematical morphology and masking is used to remove extracranial tissues and 
the total volume of voxels in each class is calculated and entered into Equation 1.3. 
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Mean scan-rescan CV is 0.21% (Collins et al., 2001). WMF and GM fraction (GMF) may 
also be calculated. Like BPF, some scanner-related longitudinal variations, e.g. scanner 
gradient strength, are cancelled out. However the BICCR may be susceptible to partial 
volume effects, which could cause underestimation of CSF volume. This method also 
requires “training data” for the Bayesian classification of voxels which includes manual 
selection of approximately 50 voxels belonging to each tissue class in 20 subjects (Collins 
et al., 2001). Using the same training set for large numbers of scans may lead to biased 
results that do not take into account anatomical and physiological variability between 
subjects. 
 
K-means clustering algorithm 
Segmentation algorithms based on clustering utilise the data available in an image to 
iteratively  characterise  tissue  properties  and  segment  the  image.  One  such  automated 
method,  based  on  the  k-means  algorithm  (Goldszal  et  al.,  1998),  performs  an  initial 
segmentation of a skull-stripped image into voxel groups by minimising total intercluster 
variance with maximum likelihood estimation. Based on the mean intensity values of the 
tissue clusters an adaptive and iterative algorithm subsequently models and smoothes the 
estimated regions to obtain accurate segmentations of GM, WM and CSF by classifying 
each pixel into the class with the closest mean. In tests of accuracy on a phantom the 
method yielded errors (as a percentage of the total volume) of 0.43% for brain volume, 
1.96%  for  GM  volume  and  2.71%  for  WM  volumes.  Mean  scan-rescan  absolute 
difference based on three subjects was 0.31% for brain volume, 0.71% for GM volume 
and 0.75% for WM volume (Goldszal et al., 1998). In addition to providing estimates of 
tissue classes, another advantage of this approach is that image inhomogeneity can be 
simultaneously corrected for. Whilst this technique is able to quantify separate GMF and 
WMF, additional processing must be performed in order to correct these volumes for 48 
lesion misclassification. This method has successfully been applied to T1 and dual echo 
subtraction images, however results from FLAIR images were unsatisfactory (Leigh et 
al., 2002). Disadvantages of this technique include the need for a separate skull stripping 
procedure, which in the original method (Goldszal et al., 1998) removed an undetermined 
amount  of  sulcal  CSF,  making  it  difficult  to  accurately  normalise  brain  volumes.  In 
addition it is thought that the segmentation algorithm may not perform adequately on the 
cerebellum (Goldszal et al., 1998). 
 
Fuzzy connected principles (FCP) 
Another algorithm based on clustering and using the theory of “fuzzy connectedness” 
(Pham & Prince, 1999; Udupa & Samarasekera, 1996) has been applied to segment brains 
on different acquisitions and quantify  atrophy in MS (Ge  et al., 2000b;  Leigh  et al., 
2002). As with the k-means algorithm initialisation is required, which in this case is an 
operator identifying points of GM, WM and CSF within dual echo images, each of which 
is then automatically detected as a 3D fuzzy-connected object. Subtraction of the dual 
echo images is effective in obtaining a CSF-only image. Voxels can belong to multiple 
classes with varying degrees of membership, allowing greater information to be retained 
from the original image, and dealing with partial volume effects. Again, developments to 
the algorithm have allowed intensity inhomogeneity to be corrected for simultaneously, 
albeit at the cost of greater computational time (Pham & Prince, 1999) and lesions can 
also be identified semi-automatically during the procedure. Scan-rescan CV for whole 
brain measured on dual-echo images was 0.23% (Ge et al., 2000b), whilst intra-rater and 
inter-rater reproducibilities of 0.38% and 0.68% respectively have been shown (Leigh et 
al., 2002). Scan-rescan CV for GMF and WMF respectively are 2.1% and 1.9% (Ge et 
al., 2001). Although this method has been applied to T1-weighted images with similar 
results, application to FLAIR images resulted in greater inter-rater reproducibility (Leigh 
et  al.,  2002).  The  simultaneous  generation  of  CSF  volumes  allows  for  calculation  of 
normalised volumes.  
 
Histogram segmentation 
Histogram  segmentation  algorithms  are  based  on  the  intensity  distribution  of  voxels 
within an image (Figure 1-8). One scheme, optimised for T1-weighted images (Kovacevic 
et  al.,  2002;  Leigh  et  al.,  2002),  initially  requires  a  dual  echo  image  histogram  to 
determine  the  optimal  thresholds  for  separation  of  brain  from  non-brain  voxels.  An 49 
automated spatial connectivity algorithm is applied to refine the classification and manual 
editing can be performed where necessary. The extracted brain region is used to mask the 
corresponding  T1-weighted  image  following  registration,  and  classify  brain  voxels  as 
GM, WM and CSF, based on the Gaussian distribution of voxel intensities. Partial volume 
voxels are  assigned  according to a weighting  factor. Separate  skull-stripping must be 
performed  prior to image  analysis.  A scan-rescan error of  0.13% of total intracranial 
capacity has been reported whilst mean absolute scan-rescan differences in proportional 
tissue volume were 0.8% and 1.3% for GM and WM respectively  (Kovacevic et al., 
2002). One of the disadvantages of this particular method is the requirement of both T1-
weighted and dual echo images. 
 
Figure 1-8 Example of an intensity histogram. 
                
 
Similarly  MeVisLab  Brain  Volumetry  software  uses  automated  regional  histogram 
analysis  to  derive  whole  brain,  WM,  GM  and  intracranial  volume  from  3D  images 
following skull stripping (Lukas et al., 2004). Image noise and partial volume effects are 
taken  into  account  which  will  increase  the  accuracy  of  this  technique.  Based  on  six 
subjects scan-rescan CV was 0.3% for whole brain volume (WBV), 1.1% for GM and 
1.7%  for  WM.  However  suboptimal  repositioning  of  subjects  resulted  in  image 
inhomogeneity  and  considerable  increases  in  CV  for  GM  and  WM  (2.1%  and  3.4% 
respectively), demonstrating the reliance of this method on consistent placement of the 
patient in the scanner or pre-processing methods to remove intensity inhomogeneities. 50 
Based on phantoms, absolute error for whole brain, GM or WM was shown to be less 
than 5ml for each volume. 
 
MIDAS 
This interactive software (Medical Image Display and Analysis System ) enables semi-
automated  3D  analysis  of  T1-weighted  MR  images  based  on  intensity  thresholding, 
region growing and morphological operators (Figure 1-9) (Freeborough et al., 1997). To 
obtain an initial approximation of the brain an operator must select two thresholds that 
represent the range of brain voxel signal intensities, in addition to the most inferior point 
in the brain. Conditional erosion(s) and dilation(s) of the resulting region are performed, 
with thresholds defined  to prevent erosion of WM or dilation into points outside the 
intensity of brain tissue. Rethresholding is subsequently performed in order to reclassify 
brain voxels that have been removed by the previous steps, for example thin structures 
like the fornix. Mean absolute error as a proportion of brain volume was estimated to be 
0.34% (Freeborough et al., 1997). A CV of 0.46% for intra-rater and 0.54% for inter-rater 
reproducibility have been shown (Fox et al., 2000b). This technique simultaneously skull-
strips the image and performs brain segmentation, however partial volume effects are not 
taken  into  consideration  with  this  technique  and  normalisation  for  head  size  must  be 
performed  separately  through  estimation  of  total  intracranial  volume  (Figure  1-9) 
(Whitwell et al., 2001). 
 
Figure 1-9 MIDAS segmentation of a) brain, b) total intracranial volume, based on 
intensity thresholding. 
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Region growing 
Semi-automated  segmentation  algorithms  based  on  region  growing  require  manual 
positioning of a seed in any part of the brain parenchyma, and an ROI is grown from this 
containing all connected pixels until an edge in the image is met (Gasperini et al., 2001; 
Kalkers  et  al.,  2002;  Rovaris  et  al.,  2000).  This  condition  is  usually  based  on  local 
thresholds and the lower threshold can be automatically determined by an edge detection 
filter, designed to perceive strong intensity  gradients. However both upper  and lower 
thresholds  can  be  changed  manually  on  a  slice-by-slice  basis  and  boundaries  can  be 
drawn to limit the ROI. A mean intra-observer CV of 1.9% was demonstrated on T1-
weighted images (Rovaris et al., 2000). This technique may be subject to reproducibility 
problems with manual implementation of thresholds, requires separate normalisation for 
head-size in cross-sectional studies, and may take considerable time for 3D volumetric 
acquisitions if segmentation is performed on a slice-by-slice basis. Due to the complex 
structure of the brain and partial volume effects, this method can lead to distinct regions 
becoming connected, or extracted regions containing holes or becoming disconnected.  
 
SIENAX 
SIENAX  (Structural  Image  Evaluation,  using  Normalisation,  of  Atrophy  –  Cross-
sectional)  (Smith  et  al.,  2002)  uses  a  fully  automated  algorithm,  based  on  a  Markov 
Random Field model, to estimate volume measurements of whole brain, GM and WM 
(Figure 1-10). An automated algorithm, the Brain Extraction Tool (BET) (Smith, 2002), is 
used to extract brain from non-brain and estimate the outer skull surface. This is based on 
histogram  analysis  to  find  an  approximate  brain/non-brain  threshold  followed  by  a 
deformable model-based technique using triangular tessellation of the surface of a sphere. 
The brain image is registered to standard space (based on the Montreal Neurological 
Institute  (MNI)  standard  template,  MNI-152)  using  the  estimated  skull  surface  to 
constrain  scaling,  thereby  normalising  for  head  size,  and  a  brain  mask  is  applied  to 
exclude extracerebral tissue. SIENAX can segment the extracted brain into GM, WM and 
CSF  and  includes  partial  volume  modelling  and  intensity  inhomogeneity  correction 
thereby  increasing  measurement  accuracy  (Zhang  et  al.,  2001a).  However  for  MS 
subjects, separate lesion classification must be performed and included as a mask in the 
process. Mean scan-rescan whole brain volume error is 1%, which has been shown to be 
independent of slice thickness (Smith et al., 2002). However a study found this method to 
be less accurate than semi-automated methods of brain extraction (Hahn et al., 2004) and 52 
adjustment  of  parameters  may  be  required,  particularly  placement  of  the  initial 
deformable model. The procedure can be applied to T1- or T2-weighted images. 
 
Figure  1-10  SIENAX  segmentation.  a)  BET  extracted  brain,  b)  BET  extracted 
estimation  of  skull,  c)  estimation  of  brain  volume,  d)  estimation  of  CSF  volume,  e) 
estimation of grey matter volume, f) estimation of white matter volume. 
 
 
SPM brain parenchymal fraction 
SPM  software  (Statistical  Parametric  Mapping;  Wellcome  Department  of  Cognitive 
Neurology, Queen Square, London) (Ashburner & Friston, 1997; Ashburner & Friston, 
2000) is a widely used package originally applied to functional imaging studies. Within 
SPM,  methods  exist  to  classify  MR  image  voxels  into  GM,  WM  and  CSF.  Before 
segmentation  all  images  are  placed  into  stereotactic  space  (based  on  the  MNI-152 
standard  template),  corrected  for  intensity  inhomogeneity  and  masked  to  remove 
extracranial tissue. Segmentation is based on a stereotactically normalised a priori atlas 
(from a database of normal brain images) and image intensity thresholds, and mutually 
exclusive masks are generated for each tissue class (Figure 1-11). Misclassification of 53 
WM lesions as GM or CSF, may introduce error to quantification, and the problem has 
been approached in two different ways. One approach is to delineate lesions manually and 
apply this information to override all SPM tissue classifications. A BPF-like measure is 
calculated from the sum of GM, WM and lesion volumes divided by the sum of GM, 
WM,  lesion  and  CSF  volumes  (Chard  et  al.,  2002b).  Alternatively,  each  mutually 
exclusive mask is subjected to a morphological erosion followed by a conditional dilation 
where only voxels previously classified as GM or WM are dilated. Resulting GMFs and 
WMFs are regarded as corrected for lesions, and BPF is calculated from the sum of GM 
and WM volumes divided by the sum of GM, WM and CSF volumes (Kassubek et al., 
2003). However it is unclear how accurate this approach may be. 
 
Figure 1-11 SPM segmentation. 
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Although SPM has been applied to acquisitions with different slice thicknesses, it has 
been  suggested  that  acquisitions  with  thick  slices  (5mm)  may  result  in  poorer 
segmentations (Sharma et al., 2004). Scan-rescan CVs of 0.5% for BPF, 0.7% for GMF 
and 1.1% for WMF have been shown on 3D T1-weighted control images (Chard et al., 
2002c) whilst mean intra- and inter-rater CVs of 0.09% and 0.19% respectively have been 
reported (Zivadinov et al., 2004a). 
 
Central cerebral volume (CCV) 
This  method  attempts  to  quantify  brain  atrophy  on  acquisitions  with  thick  slices,  by 
measuring the volume of four to seven (dependent on image slice thickness) contiguous 
axial slices from the central portion of the brain (Figure 1-12). The most caudal slice is 
chosen at the level of the velum interpositum cerebri, which is thought to be a stable 
landmark in the presence of atrophy, thus reducing measurement error that could present 
over longitudinal analyses (Gasperini et al., 2002; Ingle et al., 2002; Losseff et al., 1996).  
 
Figure 1-12 Central cerebral volume measured over four axial slices (5mm thick). 
 
 
The original automated method was applied to selected slices in order to extract the brain 
from skull and CSF but other algorithms could be used to determine this measure. The 55 
algorithm involves discriminant analysis of the intensity histogram to identify the optimal 
threshold separating brain from non-brain, creating a binary image of background/brain. 
Erosion of the binary image, followed by dilation separates brain from other extracerebral 
tissue. The binary image is used to mask the original image, producing the segmented 
brain, which can be manually edited if required. A four-slice (5mm) measure scan-rescan 
CV was 0.56% (Losseff et al., 1996). Although only a limited number of slices are used 
to estimate cerebral atrophy, MS lesions are often located in the selected region which 
also includes a large proportion of the lateral ventricles and cortical sulci where atrophy is 
often qualitatively prominent. In addition segmentation may be less time consuming than 
other  semi-automated  methods  segmenting  the  whole  brain.  However,  although  this 
technique may show larger percentage losses of tissue than whole brain measures it may 
be  less  reproducible  due  to  differences  in  acquisition  (slice  thickness),  and  subject 
repositioning and orientation.  
 
CSF measures 
The  high  contrast  boundary  between  CSF  and  brain  tissue  on  some  MR  acquisitions 
allows  highly  accurate  identification  of  ventricular  borders  using  intensity-based 
techniques. Semi-automated thresholding and region growing techniques, such as MIDAS 
and Anatomatic, have been used to outline the lateral ventricles and temporal horn regions 
(Dalton et al., 2002a; Dastidar et al., 1999; Fox et al., 2000b; Kalkers et al., 2002) (Figure 
1-13).  
 
Figure 1-13 MIDAS segmentation of the lateral ventricles. 
 
 
Reported intra-rater CV for the MIDAS technique ranges from 0.02% to 0.89% (Brex et 
al., 2000; Dalton et al., 2002a; Fox et al., 2000b), whilst an inter-rater CV of 0.32% has 56 
been  reported  (Fox  et  al.,  2000b).  SIENAX  is  also  able  to  automatically  obtain  an 
estimate of ventricular CSF volume. Whilst SIENAX is fully automated, semi-automated 
thresholding  techniques  are  quick  and  easy  to  perform  given  the  clear  high-contrast 
boundary between brain and CSF. 
 
Cortical grey matter 
Recently, automated methods for measuring cortical thickness of the entire brain and 
estimating  cortical  GM  atrophy  have  been  developed.  Knowledge  of  the  regional 
distribution  and  evolution  of  GM  atrophy  may  provide  useful  information  on  the 
pathogenesis of MS. Two methods that have been applied in MS, Freesurfer and CLASP 
(Constrained Laplacian Anatomic Segmentation using Proximity), reconstruct the cortical 
surface from volumetric MRI (Dale et al., 1999; Kim et al., 2005). Deformable surface 
algorithms are used to obtain estimates of the GM/WM and GM/CSF interfaces which are 
accurate at the subvoxel level (Figure 1-14a). The thickness of the cortex is computed at 
each  point  within  the  surface,  and  global  and  regional  mean  thicknesses  can  be 
determined with a high level of sensitivity and accuracy. Based on scan-rescan data from 
one control subject, points on the cortical surface were matched and the mean standard 
deviation of the measures from each of these points was 0.25mm in one method (Fischl & 
Dale, 2000). In addition, this study found that over 99% of measures across the cortical 
surface were within the known bounds of 1-4.5mm. Individual mean cortical thickness 
can be computed, in addition to statistical analyses of group differences (Sailer et al., 
2003), which may aid identification of regional cortical atrophy. Disadvantages of this 
technique include the fact that good GM/WM contrast is necessary for these analyses and 
that  the  GM/WM  surface  is  deformed  to  create  the  GM/CSF  surface,  therefore  WM 
segmentation  errors  may  be  propagated.  Although  errors  can  be  corrected  manually, 
including lesions that have been identified as cortex, this may be time-consuming and will 
decrease the reproducibility of the technique.  
 
Based on the GM segmentation obtained, SIENAX will also quantify cortical GM volume 
and  has  the  advantage  that  it  is  fully  automated  (Figure  1-14b)  (Smith  et  al.,  2002). 
Measures will be subject to the same advantages and disadvantages as other measures 
obtained using this software.  
 57 
Figure 1-14 Freesurfer and SIENAX cortical segmentations. a) Freesurfer estimates the 
grey matter/white matter surface (yellow line) and the grey matter/CSF surface (red 
line) to determine cortical thickness, b) SIENAX estimates cortical grey matter volume 
(yellow region). 
 
 
Regional analysis 
From visual inspection of MR images, atrophy appears to be a global phenomenon in MS. 
However regional analysis of the caudate, cerebellum, cerebral hemispheres, frontal and 
temporal lobes, and thalamus have been investigated (Benedict et al., 2005; Bermel et al., 
2003a; Cifelli et al., 2002; Filippi et al., 1998; Liu et al., 1999; Zivadinov et al., 2003). 
Segmentation of these regions has usually involved manual outlining or volume estimates 
using point counting based on the Cavalieri method (Liu et al., 1999). A semi-automated 
parcellation  method  was  reported  in  2004  (SABRE  –  Semi-Automatic  Brain  Region 
Extraction)  which  divides  each  brain  hemisphere  into  13  regions  taking  into  account 
anatomical  divisions  (separation  of  cortical  lobes),  identified  areas  of  interest,  and 
optimisation  of  reliability  and  efficiency  (Dade  et  al.,  2004).  Images  must  be  pre-
processed  to  remove  extracerebral  tissue  and  align  scans  before  15  landmarks  are 
manually identified. These provide co-ordinates for an individual Talairach atlas grid to 
be transformed to an image, from which the algorithm automatically delineates the 26 
brain  regions.  This  method  has  been  used  in  conjunction  with  tissue  compartment 
segmentation software (Kovacevic et al., 2002) to provide regional volumes of GM and 
WM. Whilst intra-rater correlation coefficients ranged between 0.95 and 0.99 depending 
on the region, it is unclear how accurate this method is. However a validation study did 58 
demonstrate significant overall loss in regional GM and WM volumes in old compared 
with young normal control subjects (Dade et al., 2004).  
 
SPM software has been utilised to perform voxel based morphometry (VBM), a fully 
automated whole-brain technique, allowing unbiased analysis of regional differences in 
tissue  density  between  subject  groups  from  structural  imaging  (Ashburner  &  Friston, 
2000). Images are registered to a template and robust statistical techniques are used to 
make voxel-wise group comparisons over the whole brain without the need for regional 
segmentations relying on a priori assumptions. It can provide insights into characteristic 
patterns of atrophy and anatomical differences between subject groups. However VBM 
may be less sensitive to changes between groups in areas with high natural variance. 
 
1.6.4  Longitudinal registration-based methods 
Detection  of  small  diffuse  brain  volume  changes  from  serial  MRI  is  difficult  using 
methods that rely on outlining of the brain, because the results are critically dependent on 
the  reproducibility  of  segmentation.    Image  subtraction  is  an  alternative  method  of 
assessing diffuse atrophy from serial scans. Direct quantification of volume change is 
subject to less error than quantifying and subtracting brain volumes at different time-
points  where  errors  may  occur  in  measurements  at  both  time-points.  For  image 
subtraction to produce meaningful results however, serial images must be positionally 
registered (spatially matched) (Figure 1-15).  
 
Brain boundary shift integral 
The brain boundary shift integral (BBSI) (Fox & Freeborough, 1997) has been used on 
serial 3D T1-weighted images to calculate atrophy from difference images (Fox et al., 
2000b). Semi-automated segmentation of baseline and repeat brain regions allows brain 
registration  and  provides  an  estimate  of  the  brain  boundary  region.  An  automated 
registration algorithm determines the rotations, translations, scalings and shear that are 
required to obtain a subvoxel match over the whole brain, and a linear scaling is used to 
account for variations in voxel size due to scanner drift. Atrophy quantification is based 
on integrating the sampled difference in brain voxel intensities between the baseline and 
registered  repeat  image  and  represents  the  total  volume  traversed  by  the  brain/CSF 
boundaries in going from baseline to registered repeat scan (Figure 1-16). 59 
Figure 1-15 Registration of serial brain MRI for atrophy quantification. a) Registration of serial images allows volume change to be quantified 
directly by looking at the difference image, b) A difference image (coronal plane) of an MS patient following registration of serial brain MRI 
(one year interval), showing change particularly around the ventricles (arrow). 
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Figure 1-16 Calculation of the brain boundary shift integral. The figure shows a one-
dimensional representation of the intensity profile through a brain boundary on serial 
imaging. The boundary shift ( x) is approximated as the area A divided by (I1 – I2). 
 
 
Slight segmentation errors, small positional shifts, or shape changes should not affect the 
BBSI. Mean absolute error on scan-rescan testing was estimated to be approximately 
0.13% of mean brain volume and comparison of the BBSI with simulated volume loss 
yielded correlation coefficients of 1.000 (Fox & Freeborough, 1997). The BSI has also 
been applied to quantify ventricular enlargement directly (Freeborough & Fox, 1997). As 
the BSI relies on an intensity transition between different tissues, the contrast of images 
must be consistent across serial imaging. Changes in voxel intensity between a baseline 
and repeat image could be incorrectly interpreted as atrophy or “growth” of the brain. 
Differential bias correction (DBC), has been described for the correction of differences in 
the  bias  field  between  two  images  to  improve  the  precision  of  atrophy  measurement 
(Lewis & Fox, 2004). 
 
SIENA 
Another automated registration-based atrophy measurement method SIENA (Structural 
Image  Evaluation,  using  Normalisation,  of  Atrophy)  (Smith  et  al.,  2002),  is  the 
longitudinal version of SIENAX. Similarly, it achieves segmentation of the brain using a 
deformable tessellated mesh to model the brain surface. Estimation of the outer skull 
surface, in the case of SIENA, is used to constrain the registration of serial images whilst 
normalising for imaging geometry changes. The brain surface is detected using a robust 61 
method  that  generates  a  full  tissue-type  segmentation,  and  percentage  brain  volume 
change (PBVC) is based on the movement of this edge between images, with sub-voxel 
accuracy. Edge finding is relatively insensitive to changes of intensity in tissues through 
serial images, and this technique can be applied to both T1- and T2-weighted acquisitions, 
and images with different slice thicknesses (Smith et al., 2002). Median absolute scan-
rescan error for brain volume change was reported to be 0.15% (Smith et al., 2002). 
Developments  to  this  software  have  made  it  possible  to  perform  voxelwise  group 
statistical analysis, potentially enabling identification of areas that preferentially atrophy 
in MS. However this has not been employed in studies to date, possibly because changes 
at the edges of the brain may not be specific to atrophy in that region. 
 
Non-linear registration methods  
Affine rigid-body registration of serial images followed by a non-linear registration can 
also be used to assess atrophy directly, but studies using these methods in MS are lacking 
to  date.  The  non-linear  registration  transforms  the  rigidly-registered  repeat  image  to 
match the baseline and at each voxel a Jacobian matrix can be obtained that describes the 
deformation  (Freeborough  &  Fox,  1998;  Rueckert  et  al.,  1999;  Shen  &  Davatzikos, 
2003). Each voxel is considered as expanded or contracted and the Jacobians can be 
summed over a previously derived region (e.g. brain) in order to obtain an estimate of 
atrophy. 
 
A method that utilises non-linear registration in order to propagate segmentations from 
the baseline image to repeat images was developed by Calmon et al. (Calmon & Roberts, 
2000).  This  technique  firstly  registers  serial  images  using  an  automated  rigid-body 
registration  algorithm  that  detects  crest-lines  in  the  images  and  matches  points 
corresponding to a maximum curvature in the principle directions. Intensity scaling is 
performed so that serial images are the same average intensity and an automated non-
linear  registration  is  used  (“demons”  method)  to  calculate  the  residual  deformations 
between  serial  images  that  are  not  accounted  for  by  rigid-body  registration.  The 
deformation  field  is  applied  to  a  segmentation  of  the  baseline  image  which  is 
automatically deformed and propagated through any number of serial images to provide 
an estimate of volume change. Reported scan-rescan CV was 0.5% for this technique, 
which  has  also  been  successfully  applied  to  the  lateral  ventricles  with  a  CV  of  1% 
(Calmon & Roberts, 2000).  62 
Regional group-based analysis 
SPM  and  VBM  can  be  utilised  with  other  longitudinal  image  analysis  techniques  to 
investigate regional differences in atrophy rates (Ashburner & Friston, 2000). Non-linear 
registration can be used to localise changes within individuals and VBM can be used to 
determine consistent changes within groups, although this method has not been applied in 
longitudinal studies of brain atrophy in MS to date (Ashburner & Friston, 2000; Scahill et 
al., 2002). Images must be spatially normalised and smoothed prior to analysis. As with 
cross-sectional  VBM,  it  may  provide  insights  into  characteristic  patterns  of  atrophy 
between subject groups, without a priori assumptions, whilst in addition it is likely to be 
less influenced by the natural morphologic variability between subjects.  
 
SPM statistics have also been utilised with SIENA in one study of MS (Pagani et al., 
2005b). For each subject, scalar values from each boundary point calculated by SIENA 
were  saved  as  displacement  maps.  Following  spatial  normalisation  and  smoothing  of 
these maps group analysis was performed using SPM. 
 
Cortical thickness 
Another method of computing cortical thickness is based on analysis of the derivative of 
image intensity profiles which allows determination of GM/WM and GM/CSF interfaces 
at the subvoxel level (Chen et al., 2004) and is an extension of the SIENA technique.  The 
derivative of the intensity profile is affected only by the rate of change of the intensity and 
cortical thickness is estimated as the difference in the maxima of this profile (Figure 
1-17). This technique is not reliant on high-resolution MRI (images with 3mm thick slices 
have been successfully analysed) and does not require segmentation of images, thereby 
reducing the errors associated with this process. It also provides a measure of the integrity 
of the GM/WM interface. Although this method can be performed for the cross-sectional 
analysis  of  images,  several  features  of  the  sampling  method  used  to  create  intensity 
profiles make it more robust for longitudinal analysis. Firstly, sampling is performed at 
the crowns of the gyri as opposed to in the sulci. As gyri generally have thicker cortex this 
may mean there is bias towards greater measurements; indeed the study by Chen et al. 
showed a trend for greater thickness measures in patients with MS compared with post-
mortem  studies.  Secondly,  sampling  is  performed  on  a  point-by-point  basis  over  the 
exposed cortical surface and this will vary from subject to subject. Investigating change 
within a subject from registered imaging overcomes these potential problems.  63 
Figure 1-17 Calculation of cortical thickness from the derivative of the intensity profile 
perpendicular to the brain boundary. Cortical thickness is the distance between the two 
maxima on this profile. (Reproduced from Chen et al., 2004). 
 
 
Longitudinal methods within Freesurfer exist and are based on using processed results 
from cross-sectional data to analyse later time-points. This mainly involves initialisation 
of the processing of longitudinal data sets using the processed results from another time-
point, following registration of images. 
 
1.6.5  Effect of lesions on brain atrophy measures  
It is possible that lesions may affect segmentation- and registration-based brain atrophy 
measurements, for example T1-hypointense lesions could be misclassified as CSF, or GM 
lesions might cause subtle signal intensity changes that affect segmentation. However 
analysis of ten MS patients with high T1 lesion loads found that lesion misclassification 
had a negligible effect on BPF measurements from SPM (Sharma et al., 2004).  Likewise, 
another study showed no significant differences in tissue volumes calculated from SPM, 
between  images  with  simulated  WM  lesions  and  those  without,  although  GMF  was 
slightly higher and WMF slightly lower when lesions were present (Chard et al., 2002c; 
Dalton  et  al.,  2004).  It  may  be  concluded  that  brain  volumes  derived  using  SPM 
segmentations  are  relatively  insensitive  to  WM  lesions,  but  it  is  unclear  how  other 64 
measurement techniques may be affected. Measurement of GM atrophy may provide a 
more direct assessment of neurodegeneration in MS, unhindered by fluctuations in tissue 
volume associated with inflammation. 65 
2  Brain atrophy in multiple sclerosis 
 
2.1  Clinically isolated syndromes 
Sixty  to  eighty  percent  of  patients  presenting  with  CIS  suggestive  of  MS  (e.g.  optic 
neuritis) develop clinically definite MS, and the proportion is greater in those who have 
MRI-visible brain lesions (Brex et al., 2002).  
 
Studies have demonstrated significantly greater ventricular enlargement within one year 
in people who develop MS compared with those who remain stable (+0.3 to 0.8cm
3 year
-1 
compared with -0.1 to +0.06cm
3 year
-1) (Brex et al., 2000; Dalton et al., 2002a; Dalton et 
al.,  2006).  A  three  year  follow-up  of  58  CIS  subjects  also  found  that  in  31  subjects 
developing MS, ventricular volume increased by a mean of 38.9%, whilst in 27 subjects 
remaining stable only a 5.4% increase was observed (Dalton et al., 2004). 
 
Brain atrophy has been measured in CIS using SIENA. A study of 31 subjects in which 
the follow-up period was only four to six months found a -0.27% (standard error 0.16%) 
loss  of  brain  volume  (Filippi  et  al.,  2003).  Assuming  a  linear  atrophy  rate  this  was 
equated to a -0.69% year
-1 brain volume loss, however because of the short interval there 
is a wide 95% confidence interval (CI) on the annualised rate of loss. Median estimated 
atrophy rate was only -0.3% year
-1 (SD 0.6) in another study of 20 CIS subjects studied 
over one year (Rovaris et al., 2003), and SPM measures of BPF, GMF and WMF showed 
a small non-significant decrease over this period (Agosta et al., 2006). Another study, 
from the same author, of 35 CIS subjects, which may have included some of the same 
patients, found an annual brain atrophy rate of -0.41% year
-1 (SD 0.58) (Rovaris et al., 
2005b).  None  of  these  studies  grouped  patients  according  to  clinical  follow-up  or 
inflammatory  activity  however,  which  may  have  increased  variability  in  the 
quantifications.  
 
Analysis  of  38  CIS  subjects  who  remained  relapse  free  after  an  18  month  follow-up 
period, showed a median -1.1% (interquartile range (IQR) -1.91 to -0.67) loss of brain 
volume over this period (Paolillo et al., 2004). However when subdivided into patients 
with (n=25) and without (n=13) at least one new active lesion during the first six months 
of study, a significant difference was found between atrophy rates: -1.71% in active and  66 
-0.48% in inactive patients over 18 months. Likewise in the placebo arm of a trial of 
interferon  beta-1a  in  CIS,  which  included  over  100  subjects,  brain  volume  loss  was  
-0.83% year
-1 (SD 1.09) (Filippi et al., 2004). Importantly, atrophy rates were greater in 
subjects who developed clinically definite MS compared with those who did not. A cross-
sectional  study  grouping  CIS  patients  according  to  whether  there  was  evidence  of 
dissemination in space of lesions at presentation (10 patients without (CIS) and 32 with 
(“probable” MS), both groups with a mean disease duration 0.7 years), found that BPF, 
GMF and WMF were all reduced in the “probable” MS group compared with controls 
and CIS subjects (Calabrese et al., 2007a). Measures of cortical thickness were also lower 
in the “probable” MS group compared with the CIS group, 2.22mm (SD 0.09) versus 
2.51mm (SD 0.11). Similarly a longitudinal analysis using SPM to analyse BPF, WMF 
and GMF grouped subjects presenting with a CIS into those who met the McDonald 
criteria at three year follow-up and those that did not (Dalton et al., 2004). Significant 
decreases in both MS (31 subjects) and CIS (27 subjects) groups were observed at three 
years: respectively -1.4% and -0.6% in BPF and -3.3% and -1.1% in GMF. The decreases 
were significantly greater in the MS group, which also showed a weak but significant 
1.3% increase in WMF that was suggested possibly to have been due to inflammation.  
 
2.2  Relapsing remitting multiple sclerosis 
Many cross-sectional studies have shown that brain volume is reduced in RRMS subjects 
compared  with  age-matched  controls  (Bermel  et  al.,  2003b;  Collins  et  al.,  2001;  De 
Stefano  et  al.,  2003;  Kalkers  et  al.,  2001a;  Lin  et  al.,  2003;  Paolillo  et  al.,  2000; 
Traboulsee et al., 2003). The majority of longitudinal studies estimate atrophy rates of 
around -0.7 to -1.5% year
-1; these rates of loss are seen even in those subjects at the 
earliest stages of disease prior to significant disability (Chard et al., 2004; Rovaris et al., 
2000) (Table 2-1). Mean atrophy rate in 34 subjects, estimated using SIENA, found a  
-0.7% year
-1 (SD 0.9) loss in brain volume over an interval of one year (Rovaris et al., 
2003). In concordance, another study using SIENA on RRMS subjects with a similar 
mean  disease  duration  found  a  volume  change  of  -0.91%  over  an  18  month  interval 
(Oreja-Guevara et al., 2005). Other measurement methods show similar findings; BPF 
volume loss was -0.7% year
-1 (IQR -1.3 to -0.01) in 42 subjects with RRMS (Kalkers et 
al., 2002) and analysis of 3D fast spoiled gradient recall (FSPGR) images found that over 
two years BPF volume loss was -1.5% in 21 RRMS subjects compared with -0.6% in 
controls (Tiberio et al., 2005). In addition, application of the BBSI to 3D FSPGR images 67 
showed a median atrophy rate of -0.8% year
-1 (IQR -0.9 to 0.2) in RRMS subjects which 
was greater than the control rate (-0.3%year
-1 (IQR -0.6 to 0.1) (Fox et al., 2000b). Other 
studies  have  shown  greater  atrophy  rates,  possibly  due  to  differences  in  cohorts  or 
measurement method (Table 2-1). Indeed mean change in brain fractional volume over 
one year in 10 RRMS patients ranged from -1.6% to +2.1% depending on the acquisition 
and segmentation technique used (Leigh et al., 2002). In addition, with disease-modifying 
treatments now licensed for RRMS, it can be difficult to study the natural history of the 
disease in treatment-naïve subjects. To the best of my knowledge, the studies discussed in 
this section included subjects who were not on treatment at the time of study entry, and 
MRI acquisition was delayed for several days following the administration of steroids to 
treat relapses, due to the known effects that they have on brain volume (Hoogervorst et 
al.,  2002;  Rao  et  al.,  2002).  Additional  examples  of  brain  atrophy  rates  observed  in 
RRMS  patients  can  be  seen  in  the  retrospective  analyses  of  placebo  MRI  data  from 
treatment trials; atrophy rates in a range similar to those already detailed have been shown 
(Table 2-5). Lateral ventricular enlargement measures performed in RRMS patients are 
presented in Table 2-2.  
 
Tissue  specific  atrophy  has  also  been  investigated  in  RRMS.  Reductions  in  both  the 
thickness and volume of the cortex have been shown in MS subjects relative to controls, 
with thinning observed in precentral, frontal, temporal and occipital regions early in the 
disease (Amato et al., 2004; Calabrese et al., 2007a; Sailer et al., 2003). Progressive 
cortical atrophy has also been observed in these areas (Chen et al., 2004). Ideally for any 
method  of  analysis,  cross-sectional  and  longitudinal  measures  would  be  consistent, 
however SPM has shown no difference in GMF between 13 early RRMS subjects and 
controls at study entry but found a significantly greater change in GMF in patients over 18 
months (Chard et al., 2004). The converse was found with WMF, which was significantly 
reduced in patients compared with controls at baseline, but there was no evidence that 
WMF changed at a different rate in the two groups. A recent extension of this study, 
including 21 subjects, supported the initial results except that baseline GMF was found to 
be significantly smaller in patients than controls (Tiberio et al., 2005). Similarly in a large 
study of 117 placebo subjects, mean estimated change in GM volume was -0.30% per 
month, whilst WM volume did not change significantly over the study period (Valsasina 
et al., 2005). Uncertainty over the precision and reliability of all these methods means that 
some of these results need to be interpreted cautiously. 68 
Table 2-1 Longitudinal studies of brain atrophy in relapsing remitting MS. 
Study  MRI  Method  N  Age
a  
(years) 
Disease duration
a 
(years) 
EDSS 
(median (range) 
unless otherwise 
stated) 
Estimated volume change 
per year
a 
Estimated volume change 
per year as a % of baseline 
brain volume
a  
(Fox et al., 
2000b) 
Coronal T1-weighted, 
1.5mm slices 
Brain  
(BBSI) 
6  36.7 (9.5)  5.6 (2.6)  3.25 (1.5-6.5)  -  median -0.8%  
(IQR -0.9 to 0.2) 
(Ge et al., 2000b)  Axial dual echo, 3mm 
slices 
Brain   
(FCP) 
27  35.0 (5.2)  4.1 (2.3)  2.5 (SD 1.0)  median -17.3ml  -1.5% 
(Kalkers et al., 
2002) 
Axial T1-weighted, 5mm 
slices (0.5mm interslice 
gap) 
BPF  
(region growing) 
42
b  35.0 (8.6)  4.2 (4.5)  1.5 (IQR 1.0-2.0)  -  median -0.7%  
(IQR -1.3 to -0.01) 
(Oreja-Guevara 
et al., 2005) 
Axial T1-weighted 5mm 
slices, post-Gd-DTPA 
Brain  
(SIENA) 
26  36.0  
(range 25-50) 
10.0  
(range 1-15) 
1.5 (0-4.0)  -  -0.61% (SE 0.18%) 
(Rovaris et al., 
2000) 
Axial T1-weighted, 3mm 
slices 
Brain  
(region growing) 
50  31.4 (7.3)  median 3  
(range 1-13) 
1.5 (0-4.0)  -14.9ml  
(range -65.1 to 38.7) 
-1.3%  
(range -6.3 to 3.2) 
(Rovaris et al., 
2000) 
Axial T1-weighted, 3mm 
slices 
CCV  
(7 slices) 
50  31.4 (7.3)  median 3  
(range 1-13) 
1.5 (0-4.0)  -5.3ml  
(range -22.3 to 5.7) 
-1.7%  
(range -7.9 to 2.0) 
(Rovaris et al., 
2003) 
Axial T1-weighted, 5mm 
slices 
Brain 
(SIENA) 
34  32.7 (8.4)  median 7  
(range 2-25) 
2.5 (1.0-5.5)  -  -0.7% (0.9) 
(Sailer et al., 
2001) 
Axial T1-weighted, 5mm 
slices, post Gd-DTPA 
CCV  
(4 slices) 
13  38.2 (6.6)
c  8.8 (6.3)
c  6.0 (2-7)
c  median -1.5cm
3 
(range -20.7 to 2.1) 
-0.51%
d 
(Saindane et al., 
2000) 
Axial dual echo, 3mm 
slices 
Brain  
(FCP) 
24  37.0 (7.5)  4.7 (3.3)  2.5 (SD 1.1)    -0.92% (1.20) 69 
Continued from page 68 
Study  MRI  Method  N  Age
a  
(years) 
Disease duration
a 
(years) 
EDSS 
(median (range) 
unless otherwise 
stated) 
Estimated volume change 
per year
a 
Estimated volume change 
per year as a % of baseline 
brain volume
a  
(Tiberio et al., 
2005) 
Axial T1-weighted, 
1.5mm slices 
BPF  
(SPM) 
21  37.5 
(range 26.9-
56.1) 
2.1  
(range 1.2-3.7) 
1.0 (0-3.0)  -0.0058  
(CI -0.0146 to -0.0055) 
-0.75% 
(Zivadinov et al., 
2001b) 
Axial T1-weighted, 
5mm slices 
Brain 
(Semi-auto 
Trieste method) 
53  30.2 (9.4)  3.8 (1.3)  1.0 (0-5.0)  -16.2ml  -1.33% 
amean (SD) unless otherwise stated, 
b16 patients receiving interferon beta-1a at the time of follow-up examination, 
cincludes data from 16 secondary progressive multiple sclerosis subjects also, 
destimation based on a median baseline volume of 299.0cm
3, BBSI, brain boundary shift integral; BPF, brain parenchymal fraction; CCV, central cerebral volume; CI, 95% confidence interval; 
FCP, fuzzy connected principles; IQR, interquartile range; SE, standard error; SPM, statistical parametric mapping. 70 
Table 2-2 Longitudinal studies of lateral ventricular enlargement in relapsing remitting MS. 
Study  MRI  N  Age
a 
(years) 
Disease duration
a 
(years) 
EDSS 
(median (range) 
unless otherwise 
stated) 
Enlargement?  Estimated volume change 
per year 
Estimated volume change 
per year as a percentage 
(Dalton et al., 
2006) 
Axial T1-weighted, 
3mm slices 
41  median 40 
(range 22-62) 
median 5  
(range 1-25) 
3.5 (2.0-7.0)  yes  median 0.5ml  
(range -1.7 to 4.2) 
- 
(Fox et al., 
2000b) 
Coronal T1-weighted, 
1.5mm slices 
6  36.7 (9.5)  5.6 (2.6)  3.25 (1.5-6.5)  yes  median 2.1ml  
(IQR 0.7 to 3.7) 
- 
 
(Kalkers et al., 
2002) 
Axial T1-weighted, 
5mm slices (0.5mm 
interslice gap) 
42
b  35.0 (8.6)  4.2 (4.5)  1.5 (1.0-2.0)  yes  -  median 3.9%
c 
(IQR 0.8 to 8.5) 
(Luks et al., 
2000) 
Axial T1-weighted, 
3mm slices 
15  36  
(range 18-56) 
0.5  
(range 2-18 months) 
1.0 (0-4.0)  yes  mean 2.78cm
3  mean 20.2%
d 
(range -5.5 to 91.1) 
(Redmond et al., 
2000) 
Axial T1-weighted, 
4mm slices, post Gd-
DTPA 
7  33 (7)  3.8 (1.7)
e  mean 3.4 (range 
1.5-6.0) 
yes  median 4.6ml  
(IQR -1.88 to 5.02)  
mean 29.8%
d 
(Turner et al., 
2003) 
Axial T1-weighted, 
1mm slices, post Gd-
DTPA 
7  median 32 
(range 21-47)
f 
median 4   
(range 1-17)
f 
2.0 (0-4.0)
f  yes  -  median 2.69%
d 
(range 0.45-10.11) 
amean (SD) unless otherwise stated, 
b16 patients receiving interferon beta-1a at the time of follow-up examination, 
cas a percentage of baseline ventricular fraction (ventricular volume/intracranial 
volume), 
das a percentage of baseline ventricular volume,
 econverted from months, 
 fincludes data from 13 patients receiving interferon beta-1a during the study.  
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2.3  Secondary progressive multiple sclerosis 
Although  smaller  brain  volumes  have  been  shown  in  SPMS  subjects  compared  with 
controls (Benedict et al., 2006; Bermel et al., 2003b; Lin et al., 2003; Turner et al., 2001), 
estimates of rates of tissue loss have varied considerably (Table 2-3 and Table 2-5). This 
may be due to the disease duration in these cohorts often being relatively heterogeneous. 
A mean -1.40% (SD 1.69) change in CCV was found in 38 SPMS placebo patients over 
the  initial  year  of  a  36  month  study  (Molyneux  et  al.,  2000a).  As  discussed  earlier 
(Chapter 1.6.3) this method is heavily weighted to ventricular enlargement and therefore 
may show higher rates of change than a whole brain measure. However whole brain 
techniques have shown similar annual rates of -1.4% (SD 2.0) (Rovaris et al., 2003) and  
-1.18% (SD 0.19) (Rovaris et al., 2005a). Whilst a decrease in brain volume of -2.0% 
year
-1 was observed in another analysis (Ge et al., 2000b), estimation may be less reliable 
due to the inclusion of only nine patients and varying follow-up periods (one to seven 
years). Atrophy measured on 3D volumetric images has been estimated at only -0.6% 
year
-1 (IQR -1.3 to 0.3) and -0.41% over 18 months (range -0.58 to -0.01) in two separate 
studies however (Fox et al., 2000b; Turner et al., 2003), although both estimations were 
based on only six subjects. Intermediate to these studies, a median -0.8% year
-1 (IQR -1.1 
to -0.3) loss of brain tissue was observed in 21 patients (Kalkers et al., 2002). Estimates of 
lateral ventricular enlargement have varied and it is difficult to compare findings between 
studies.  Over six months no  enlargement  was observed in one study; median change  
-0.07ml (IQR -0.82 to 0.66) (Redmond et al., 2000). However over 12 months in another 
study, median enlargement was 1.0ml (IQR 0.02 to 2.6) (Fox et al., 2000b). A change of 
2.94% of baseline ventricular volume (range 0.56 to 19.73) was observed over 18 months 
in a further study (Turner et al., 2003). These rates were each estimated on only six or 
seven subjects however and disease duration ranged considerably between studies, so 
findings  should  be  regarded  with  caution.  A  larger  study  of  23  subjects  observed  a 
statistically significant median increase of 1.1ml (range -1.1 to 6.9) (Dalton et al., 2006) 
which is the same as that observed in the study by Fox et al. (Fox et al., 2000b). 
 
Although measures of global and cortical GM are observed to be lower in SPMS subjects 
than in controls (Benedict et al., 2006; Calabrese et al., 2007a; Carone et al., 2006), few 
studies have investigated longitudinal changes in this subgroup of patients so it is unclear 
whether significant progressive GM atrophy is occurring (Agosta et al., 2006; Chen et al., 
2004). 72 
Table 2-3 Longitudinal studies of brain atrophy in secondary progressive MS. 
Study  MRI  Method  N  Age
a  
(years) 
Disease duration
a 
(years) 
EDSS 
(median (range) 
unless otherwise 
stated) 
Estimated volume change 
per year
a 
Estimated volume change 
per year as a % of 
baseline brain volume
a 
(Fox et al., 
2000b) 
Coronal T1-weighted, 
1.5mm slices 
Brain  
(BBSI) 
6  43.7 (6.3)  19.3 (2.9)  7.25 (6.0-8.0)  -  median -0.6%  
(IQR -1.3 to 0.3) 
(Ge et al., 2000b)  Axial dual echo, 3mm 
slices 
Brain   
(FCP) 
9  46.3 (4.5)  5.4 (3.6)  mean 4.3 (SD 3.0)  median -23.6ml  -2.0% 
(Kalkers et al., 
2002) 
Axial T1-weighted, 
5mm slices (0.5mm 
interslice gap) 
BPF  
(region growing) 
21
b  41.9 (8.8)  5.2 (7.2)  4.0 (2.5-5.5)  -  median -0.8%  
(IQR -1.1 to -0.3) 
(Rovaris et al., 
2003) 
Axial T1-weighted, 
5mm slices 
Brain 
(SIENA) 
19  40.5 (10.6)  median 8  
(range 3-23) 
5.5 (3.5-6.5)  -  -1.4% (2.0) 
(Rovaris et al., 
2005a) 
Axial T1-weighted, 
5mm slices 
Brain 
(SIENA) 
22
c   48.3 
(range 34-60) 
median 17.9 
(range 6-29) 
6.0 (4.0-7.0)  -  -0.94% (0.15) 
(Sailer et al., 
2001) 
Axial T1-weighted, 
5mm slices, post Gd-
DTPA 
CCV  
(4 slices) 
16  38.2 (6.6)
 d  8.8 (6.3)
d  6.0 (2-7)
d  median -3.0cm
3 
(range -8.3 to 2.1) 
-1.01%
e 
amean (SD) unless otherwise stated, 
bsix patients receiving interferon beta-1a at the time of follow-up examination, 
c15 patients treated with disease-modifying treatments during follow-up, 
dincludes 
data from 13 relapsing remitting multiple sclerosis subjects, 
eestimation based on a median baseline volume of 299.0cm
3, BPF, brain parenchymal fraction; CCV, central cerebral volume; FCP, 
fuzzy connected principles; IQR, interquartile range. 73 
2.4  Primary progressive multiple sclerosis 
Like  SPMS  fewer  longitudinal  studies  investigating  atrophy  in  PPMS  have  been 
performed, although cross-sectional analysis has shown reduced brain volumes in PPMS 
compared with controls (De Stefano et al., 2003; Sastre-Garriga et al., 2004). One large 
longitudinal analysis of 137 PPMS patients estimated a change in CCV of -1.3% year
-1 
(Stevenson et al., 2000) (Table 2-4). A subset of these patients (n=100) were followed up 
for a second year and by the end of this period a -2.7% change relative to baseline was 
observed (Ingle et al., 2002). Using the same method in another 39 subjects followed for 
18-28  months  the  mean  change  was  -2.31%  (SD  2.69)  (Stevenson  et  al.,  2002). 
Interestingly atrophy was quantified using SIENA in these same 39 subjects and was 
estimated to be only -0.56% (SD 0.57). This disparity may be because the two techniques 
measure different volumes, and volume loss is greater around the ventricles; the CCV 
change may be driven strongly by the ventricular expansion, thereby giving higher rates 
of change but, equally, higher variances. Brain atrophy rates in three other studies using 
SIENA ranged from -0.64 to -1.24% over approximately 12 months, which did not appear 
to be related to disease duration (Jasperse et al., 2007a; Rovaris et al., 2005a; Sastre-
Garriga et al., 2005a). Estimated brain atrophy rate on 3D FSPGR images was -0.9% 
year
-1 (IQR -1.4 to -0.3) using the BBSI (Fox et al., 2000b) and -1.03% year
-1 (SD 1.30) 
using BPF (SPM method) (Sastre-Garriga et al., 2005a). Progressive brain atrophy and 
ventricular enlargement has been observed over periods up to five years (Ingle et al., 
2003). Lateral ventricular enlargement of 1.68ml year
-1 (SD 11.3) and 2.9ml year
-1 (IQR 
0.6 to 4.5) has been observed (Fox et al., 2000b; Stevenson et al., 2004), but over a 
shorter period of six months no significant atrophy appeared to occur (mean -0.24ml (IQR 
-1.84 to 0.71) (Redmond et al., 2000); however only five patients were included in this 
analysis and the study lacked power.  
 
As in RRMS and SPMS cohorts, GM atrophy appears to progress at a relatively greater 
rate than WM atrophy: -1.50% (SD 1.6%) compared with -0.07% in one investigation 
(Sastre-Garriga et al., 2005a). 74 
Table 2-4 Longitudinal studies of brain atrophy in primary progressive MS. 
Study  MRI  Method  N  Age
a  
(years) 
Disease duration
a 
(years) 
EDSS 
(median (range) 
unless otherwise 
stated) 
Estimated volume change 
per year
a 
Estimated volume change 
per year as a % of baseline 
brain volume
a 
(Fox et al., 
2000b) 
Coronal T1-weighted, 
1.5mm slices 
Brain  
(BBSI) 
9  49.3 (8.7)  11.3 (5.8)  6.0 (3.5-8.5)  -  median -0.9%  
(IQR -1.4 to -0.3) 
(Jasperse et al., 
2007a) 
Axial T1-weighted, 
5mm slices 
Brain  
(SIENA) 
15  43.6 (8.9)  median 1.5 (IQR 
0.9-3) 
3.0 (2.5-4.0)  - 
 
-0.9% (0.6) 
(Kalkers et al., 
2002) 
Axial T1-weighted, 
5mm slices (0.5mm gap) 
BPF  
(region growing) 
20  47.9 (10.3)  7.1 (8.1)  4.0 (2.5-6.0)  -  median -0.5%  
(IQR -0.9 to -0.2) 
(Rovaris et al., 
2005a) 
Axial T1-weighted, 
5mm slices 
Brain 
(SIENA) 
54  51.3 
(range 25-68) 
median 10 
(range 2-26) 
5.5 (2.5-7.5)  -  -0.99% (0.13) 
(Sastre-Garriga 
et al., 2005a) 
Axial T1-weighted, 
1.5mm slices 
Brain  
(SIENA) 
31  median 46 
(range 26-62) 
median 3.0  
(range 2-5) 
4.5 (3.5-7.0)  -  -0.63% (1.05) 
(Sastre-Garriga 
et al., 2005a) 
Axial T1-weighted, 
1.5mm slices 
BPF  
(SPM) 
31  median 46 
(range 26-62) 
median 3.0  
(range 2-5) 
4.5 (3.5-7.0)  -  -1.03% (1.30) 
(Stevenson et al., 
2000) 
Axial T1-weighted, 
3mm slices 
CCV  137
b  not given  not given  6.0 (2.0-8.5)  -3.44ml (6.85)  -1.30% 
(Stevenson et al., 
2002) 
Axial T1-weighted, 
3mm slices 
CCV  39  51  
(range 29-74) 
10.7 
(range 1-26) 
6.0 (2.0-8.5)  - 
 
-1.22% (1.42) 
(Stevenson et al., 
2002) 
Axial T1-weighted, 
3mm slices 
Brain 
(SIENA) 
39  51  
(range 29-74) 
10.7 
(range 1-26) 
6.0 (2.0-8.5)  -  -0.29% (0.30) 
amean (SD) unless otherwise stated, 
b16 patients receiving disease-modifying treatment, BBSI, brain boundary shift integral; BPF, brain parenchymal fraction; CCV, central cerebral volume; FCP, 
fuzzy connected principles; IQR, interquartile range. 75 
2.5  Regional atrophy 
Volumetric measurements of regional structures thought to be differentially affected in 
MS may prove more sensitive markers of pathology than whole brain atrophy. Group 
analysis of parenchymal volume in 13 different hemispheric regions in RRMS and SPMS 
subjects found that the largest reductions in brain volume relative to controls were in the 
GM areas of the posterior basal ganglia/thalamus, superior frontal and superior parietal 
regions (Carone et al., 2006). Mean percentage volume differences relative to control 
subjects  were  -19.3%,  -15.7%  and  -14.3%  respectively  in  these  regions.  Similarly  in 
RRMS a VBM study  found GM was significantly  reduced in the left  frontotemporal 
cortex, anterior  cingulate gyrus and bilateral caudate nuclei  (Prinster  et al., 2006).  In 
concordance with these findings bicaudate ratio (BCR), a linear atrophy measure, has 
been shown to be greater in MS patients than controls (Bermel et al., 2002). Although this 
measure could represent whole brain atrophy and subsequent ventricular enlargement, 
caudate volumes when measured directly have been reduced, by 19% in RRMS subjects 
compared with controls in one study (Bermel et al., 2003a). 
 
The thalamus may be a good structure through which to investigate atrophy, specifically 
GM atrophy. It has well defined boundaries, thereby minimising partial volume effects, 
and has extensive reciprocal cortical and subcortical connections and may therefore be 
sensitive to effects of pathology in widespread areas. VBM analysis has also identified 
progressive thalamic atrophy in RRMS and PPMS subjects when compared with controls 
(Audoin et al., 2006; Sepulcre et al., 2006). A post-mortem study of 10 subjects (one 
RRMS, six SPMS and three PPMS) found a 22% decrease in whole thalamic volume 
compared with controls, and decreased neuronal density (Cifelli et al., 2002). The same 
study obtained normalised thalamic volumes after manual outlining on 3D FSPGR images 
in a further 14 SPMS subjects, and a 17% decrease was observed relative to controls. 
Likewise, in 14 RRMS subjects, normalised thalamic volume was 25% less than controls, 
and volume was correlated with disease duration (Wylezinska et al., 2003). However a 
longitudinal study of eight RRMS and three SPMS patients found mixed results (Taylor et 
al.,  2004).  Average  (of  three  measurements  by  the  same  operator)  left  and  right 
percentage thalamic volume  change varied between -8.5%  and +14.2%, whilst  whole 
brain atrophy was detected in all but one of the subjects. The range was partly due to 
differing  study  periods  (ranging  from  12  to  41  months)  but  the  increased  thalamic 
volumes in six of the subjects may be due to the difficulty of reliably outlining thalamic 76 
regions  on  T2-weighted  images  compared  with  3D  volumetric  T1-weighted  coronal 
images. 
 
2.6  Clinical and research applications of brain atrophy measures 
2.6.1  Brain atrophy as a marker of disability 
The key factors when assessing atrophy measurements are a) how well they relate to 
progression of disability, and b) whether they explain disability better than established 
measures of focal inflammation. Although redistribution of Na
+ channels on axons and 
cortical reorganisation have been observed in MS and may result in a return of function 
(Craner  et  al.,  2004;  Rocca  et  al.,  2003),  these  processes  are  likely  to  become  less 
effective over time as a threshold of damage is reached, beyond which it is impossible to 
compensate for the changes occurring. Evidence of significantly greater brain atrophy 
rates in CIS subjects who develop MS compared with those who remain clinically stable 
has been presented (Brex et al., 2000; Dalton et al., 2002a; Dalton et al., 2004; Filippi et 
al., 2004). However in a group of CIS subjects, no significant correlation between annual 
ventricular enlargement and baseline EDSS, one year EDSS or the change in EDSS was 
shown (Dalton et al., 2002a). It may be that atrophy in the early stages of MS does not 
result immediately in clinical disability (possibly due to cortical reorganisation), and that 
there is a threshold of axonal loss, which may vary between individuals, beyond which 
progressive  disability  is  apparent.  Equally,  measurement  of  volume  loss  may  be 
confounded by active inflammation resulting in some areas of tissue swelling. In MS 
subjects showing sustained progression in disability on the EDSS, significantly greater 
atrophy  rates  have  been  observed  compared  with  subjects  showing  no  progression  in 
disability (Coles et al., 1999; Ingle et al., 2002; Jasperse et al., 2007a; Losseff et al., 
1996; Molyneux et al., 2000a; Rudick et al., 2000; Zivadinov et al., 2001b). Equally, 
subjects who have shown a significant amount of brain atrophy over periods of up to four 
years are more likely to show an increase in EDSS score than subjects without significant 
atrophy (Gasperini et al., 2002; Losseff et al., 1996; Turner et al., 2003). GM atrophy 
may be particularly relevant; progressive thalamic atrophy has been shown to be related to 
EDSS  change  over  two  years  (Audoin  et  al.,  2006)  and  significantly  greater  cortical 
thinning has been observed in patients with progressive disability compared with those 
that  are  stable  (Chen  et  al.,  2004).  Although  some  investigations  have  shown  no 
relationship of atrophy with disability (Fox et al., 2000b; Kalkers et al., 2002; Rovaris et 
al., 2001; Stevenson et al., 2004), this may be due to the insensitivity of clinical disability 77 
scales or that atrophy may not cause immediate effects. Significant correlations between 
change  on  clinical  disability  scales  and  brain  atrophy  have  also  been  observed  over 
periods of two to six years (Fisher et al., 2000; Rudick et al., 2001; Zivadinov et al., 
2001b). Importantly, an eight year follow-up of 138 RRMS subjects who had taken part in 
a trial of interferon beta-1a, showed that atrophy rate during the two year trial was the 
only  significant  MRI  predictor  of  disability  status  at  year  eight  (Fisher  et  al.,  2002). 
Similarly brain atrophy over two years was significantly correlated with EDSS at five 
year follow-up in another study (Rovaris et al., 2007). It appears that atrophy is a relevant 
marker of disease progression and may precede the development of measurable disability, 
but the mechanisms of this interaction need to be investigated further. It is likely that there 
is heterogeneity between subjects, which is evidenced by the fact that similar atrophy 
rates have been observed in RRMS and PPMS, but that disability progresses differently. 
 
2.6.2  Brain atrophy as a marker of cognitive impairment 
Cognitive impairment is seen in around 50% of MS patients even early in the disease and 
appears to progress over time (Achiron & Barak, 2003; Amato et al., 2001; Lazeron et al., 
2005; Zivadinov et al., 2001b). Typically deficits in processing speed and attention are 
observed, although a range of subcortical and cortical deficits may be seen, such as short- 
and long-term verbal and visuospatial memory, which may affect daily living for people 
with MS (Amato et al., 2001; Lazeron et al., 2006; Sanfilipo et al., 2006). Brain atrophy 
may be useful as a marker or predictor of cognitive changes and it has been shown to be 
associated  with  neuropsychological  impairment  where  correlations  with  MRI  lesion 
measures  have  been  weak  or  absent  (Lazeron  et  al.,  2006;  Sanfilipo  et  al.,  2006; 
Zivadinov et al., 2001b). Significantly smaller normalised brain volumes (NBV) have 
been observed in RRMS subjects considered to be impaired on neuropsychological tests 
of verbal memory, verbal fluency and attention/concentration compared with unimpaired 
patients (Amato et al., 2004; Zivadinov et al., 2001a). In SPMS and PPMS also, subjects 
have been shown to perform poorly in tests of verbal memory, verbal fluency, attention 
and spatial reasoning, and composite cognitive impairment scores have been shown to 
correlate significantly with cerebral volume (Camp et al., 1999; Molyneux et al., 2000a). 
Correlations between longitudinal measures of brain atrophy rate and cognition have also 
been  observed;  in  both  early  RRMS  and  SPMS,  subjects  who  worsened  on 
neuropsychological tests had greater brain atrophy rates than the subjects whose cognition 
was stable or improved (Molyneux et al., 2000a; Zivadinov et al., 2001b). 78 
Whilst  regional  atrophy  measurements  may  not  be  an  accurate  indicator  of  global 
cognitive changes, the size of the CC in MS has been found to correlate with measures of 
mental processing speed and rapid problem solving (Pelletier et al., 2001). However one 
must  be  careful  in  ascribing  a  direct  structure-function  association  in  these  types  of 
studies, where only one region is measured. In addition, superior frontal cortex atrophy 
has been correlated with tests of new learning, divided attention and conceptual reasoning 
(Benedict et al., 2002). Cortical volume has also been found to be reduced in mildly 
cognitively impaired RRMS subjects compared with cognitively normal RRMS subjects 
(Amato et al., 2004; Benedict et al., 2006; Portaccio et al., 2006). A VBM study found 
that a test of processing speed/working memory was correlated not only with global GM 
volume, but with GM volume in regions associated with working memory and executive 
function including the bilateral prefrontal cortex (Morgen et al., 2006). In concordance, 
measures of regional GM have been associated with neuropsychological impairment; left 
frontal atrophy was associated with auditory and verbal memory tests whilst right frontal 
atrophy was associated with visual episodic and working memory (Tekok-Kilic et al., 
2007). Regional atrophy measures of  GM and  WM may  aid in  our understanding  of 
specific cognitive changes occurring throughout the disease. More longitudinal studies 
need to be performed, but may be difficult due to the relative changes in cognition being 
small,  changes  to  imaging  and  scanners  over  these  periods  and  practice  effects  on 
neuropsychological tests. 
 
2.6.3  Prognosis  for  patients  with  clinically  isolated  syndromes  and  early  multiple 
sclerosis 
Brain atrophy rate could prove to be a useful marker for future prognosis in CIS or early 
MS patients in terms of MS diagnosis, disability and speed of progression, and cognitive 
decline. Studies described in Chapter 2.1 show that CIS subjects who go on to develop 
MS have significantly greater atrophy rates at the earliest stages of disease. In addition, 
early brain  atrophy  rate  may be  related to cognitive changes that can influence  daily 
living.  Longer  follow-up  studies  of  brain  atrophy  and  clinical  characteristics  in  these 
patient cohorts are required. 
 
2.6.4  Understanding the causes of multiple sclerosis  
Apolipoprotein E  (ApoE) expressed in the brain plays  an important role in lipid  and 
cholesterol transport and is involved in growth and regeneration of neurons. Experimental 79 
and clinical evidence exists for a pathogenic role of ApoE in Alzheimer’s disease (AD), 
the  prototypic  neurodegenerative  disease,  but  its  role  has  also  been  investigated  with 
respect to MS. Of 76 RRMS subjects in one study, 18 had the ApoE e4 allele and had 
significantly smaller NBV compared with controls and non-carriers, who were matched in 
age and disease duration (De Stefano et al., 2004). The same result was found when only 
subjects with short disease duration (less than three years) and low disability (EDSS < 2) 
were studied, suggesting that the e4 allele may either affect brain development or brain 
integrity very early in the disease. In contrast, a study that determined ApoE genotype in 
117 MS patients and 100 controls, found that it was not related to the degree of brain 
atrophy  (Zakrzewska-Pniewska  et  al.,  2004),  although  atrophy  was  assessed  using  a 
subjective visual rating scale, which may have led to inaccuracy. 
 
Longitudinal  studies  have  also  produced  contrasting  results.  In  RRMS  patients  who 
underwent ApoE genotyping, significant differences were found in brain atrophy rates 
between six different genotype groups, mainly due to patients possessing the e4 allele 
(Enzinger et al., 2004). Brain volume loss was -0.66% year
-1 (SD 0.62) in 22 subjects 
with one or two e4 alleles but only -0.13% year
-1 (SD 0.36) in 76 subjects without an e4 
allele, despite longer disease duration. A separate study of 174 MS patients found no 
major association of ApoE genotype and brain atrophy rate however (Zwemmer et al., 
2004). 
 
2.6.5  Understanding disease mechanisms 
Relationship to lesions 
There is evidence that focal inflammation may lead to brain atrophy, but correlations of 
brain atrophy with lesion measures have been mixed. Whilst some studies of CIS and MS 
have shown an association between brain volumes and T1-hypointense lesions (Chard et 
al., 2002b; Dalton et al., 2004; Sailer et al., 2003), T2-hyperintense lesions (Chard et al., 
2002b; Dalton et al., 2004; De Stefano et al., 2003; Lin et al., 2003; Sailer et al., 2003; 
Sastre-Garriga et al., 2004) and Gd-enhancing lesions (Lin & Blumhardt, 2001; Luks et 
al., 2000), others have not (Chard et al., 2002b; De Stefano et al., 2003; Ge et al., 2000b). 
However cross-sectional studies present only an isolated view of ongoing disease activity 
and comprehensive evaluation of the relationship requires assessment of serial data. 
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Significantly greater ventricular enlargement has been observed over one  year in CIS 
subjects with T1, T2 or Gd-enhancing lesions at baseline, compared with subjects who 
had no lesions on baseline imaging (Dalton et al., 2002a). Moreover, this study suggested 
that atrophy was to a greater extent due to the presence of T1 lesions than T2 lesions. 
Likewise studies in MS have found the number and volume of lesions at baseline or over 
the initial study phase are significantly correlated with brain atrophy over periods of 18 
months to three years (Gasperini et al., 2002; Jasperse et al., 2007a; Luks et al., 2000; 
Molyneux et al., 2000a; Paolillo et al., 2004). Several studies have shown a relationship 
between brain atrophy and change over the same period in lesion volumes (Horakova et 
al., 2007; Ingle et al., 2002; Richert et al., 2006; Rudick et al., 1999; Rudick et al., 2000), 
however an absence of any correlation has also been observed (Gasperini et al., 2002; 
Losseff  et  al.,  1996;  Rashid  et  al.,  2007;  Rovaris  et  al.,  2001;  Rudick  et  al.,  1999; 
Stevenson  et  al.,  2002).  It  may  be  that  focal  inflammation  has  a  delayed  effect  on 
neuroaxonal  degeneration  and  subsequent  atrophy.  Several  studies  including  longer 
patient follow-up support this argument. One study following 28 RRMS subjects for 14 
years after first symptoms found that the change in lesion load in the first five years after 
onset was more closely correlated to brain atrophy at 14 years than later changes in lesion 
load (Chard et al., 2003). Similarly a 13 year follow-up of RRMS patients found that the 
change in T2 lesion volume during the first two years correlated significantly with BPF at 
year 13 (Rudick et al., 2006). In two-year trials of interferon beta-1a greater brain atrophy 
at  six  and  eight  year  follow-up  respectively  was  significantly  associated  with  Gd-
enhancing, T1 and T2 lesion loads during the pre-trial and trial periods (Fisher et al., 
2002; Paolillo et al., 2002).  
 
The absence of a correlation between lesions and atrophy seen in some studies and the 
only moderate correlations seen in others could be due to factors such as small lesion 
loads,  lesion  activity  resulting  in  different  degrees  of  axonal  damage,  inflammation 
causing  oedema  which  masks  atrophy,  or  GM  lesions  (not  commonly  seen  on  MRI) 
having  a  greater  effect  on  subsequent  atrophy  than  WM  lesions.  Little  research  has 
investigated the association of tissue fractions or regional atrophy with global or regional 
lesion  measures  due  to  technical  difficulties.  However  there  is  evidence  that  factors 
unrelated to lesion formation may play a role in atrophy progression. PPMS have fewer 
lesions than patients experiencing relapses, but progressive atrophy occurs (Ingle et al., 
2003; Sastre-Garriga et al., 2004). In addition absence of a correlation between lesion 81 
measures and WMF has been observed in at least two studies (Chard et al., 2002b; Dalton 
et al., 2004) whilst a study showed that administration of autologous haematopoietic stem 
cells had a dramatic and sustained effect on Gd-enhancement and T2 lesion formation but 
did not inhibit atrophy (-1.9% year
-1) (Inglese et al., 2004). A similar effect has been 
observed  with  Campath-1H,  a  powerful  lymphocyte  depleting  monoclonal  antibody 
(Coles et al., 1999). It appears that whilst possibly conditioned by inflammatory lesion 
load, atrophy may proceed even in the absence of evidence of inflammation, and other 
mechanisms  underlying  neuroaxonal  degeneration  must  be  explored.  Once  again, 
different time courses for these processes may confound studies of short duration: for 
instance if there is a long delay between the effects of lesions (or treatment) and the 
progression of atrophy. 
 
Progression of atrophy 
Atrophy  appears  to  occur  from  the  earliest  stages  of  MS  and  continues  into  the 
progressive stages of disease, but it is unclear whether differences in the development of 
atrophy exist between progressive and relapsing forms of MS, or if atrophy rate changes 
during  the  course  of  disease.  Investigation  is  difficult  also  because  of  treatment 
intervention in some patients and groups of patients. One study has suggested that atrophy 
is  confined  to  the  cerebral  hemispheres  during  the  RR  stage,  but  extends  to  the 
cerebellum, brainstem and spinal cord during the SP phase (Lin et al., 2003). A trend for 
global cortical thickness to be lower in subjects with SPMS relative to  subjects with 
RRMS has been observed (Calabrese et al., 2007a). Recently, SPM analysis of brain 
atrophy measured by SIENA was used to investigate the evolution of brain atrophy in MS 
patients  according  to  phenotype  (RRMS,  SPMS  and  PPMS)  (Pagani  et  al.,  2005b). 
Results suggested that ventricular enlargement was predominant in RRMS, whilst cortical 
atrophy was more important in progressive MS.  
 
Cross-sectional  associations  between  normalised  brain  volume  and  disease  duration 
(Bermel et al., 2003b; Ge et al., 2000b; Kalkers et al., 2001a; Paolillo et al., 2000; Rudick 
et al., 2000) suggest brain atrophy is progressive, and a longitudinal analysis of 27 RRMS 
and nine SPMS patients, found that brain atrophy rate was greater in patients with SPMS, 
who had a longer disease duration, than in patients with RRMS (Ge et al., 2000b). In 
addition no significant differences in NBV or annual atrophy rate have been observed in 
two studies of patients with RRMS and PPMS where the subjects had a similar disease 82 
duration (De Stefano et al., 2003; Jasperse et al., 2007a). However, a trend for greater 
annual atrophy rates in RRMS and SPMS compared with PPMS has also been observed 
(Kalkers et al., 2002), despite PPMS subjects having longer disease duration. Whether 
atrophy rates decelerate or accelerate during the course of progressive disease is unclear. 
Analysis of 100 subjects with PPMS found that the degree of atrophy over the first year 
did not correlate with that over the second year (Ingle et al., 2002). However a subsequent 
five year follow-up report, found a relatively consistent atrophy rate within individuals 
(Ingle et al., 2003). In addition, no obvious change in the atrophy rate over 36 months was 
observed in 44 placebo subjects with SPMS taking part in a trial of interferon beta-1a who 
were observed at six-monthly intervals (Molyneux et al., 2000a), or in a five year study of 
36 patients on combination therapy analysed annually (Horakova et al., 2007). Studies of 
patients  over  longer  periods  need  to  be  performed  in  order  to  clarify  the  temporal 
dynamics of atrophy in MS. However this may be difficult due to patient drop-out from 
studies and changes in MR imaging and scanner upgrades. 
 
2.6.6  Clinical trials and sample size calculations  
Although there is no cure for MS, several disease-modifying treatments have been tested 
in patients, some of which are now licensed for administration in RRMS and SPMS 
following demonstration of their capacity to reduce relapse rates and slow the progression 
of mild clinical disability (Jacobs et al., 1996; Johnson et al., 1998; The IFNB Multiple 
Sclerosis  Study  Group,  1995).  Brain  atrophy  measurements  have  been  applied 
retrospectively  to  data  from  some  of  these  clinical  trials,  to  assess  their  effect  on 
neurodegeneration,  and  more  recently  it  has  been  included  as  a  secondary  (and 
retrospective) outcome measure in treatment trials (Miller et al., 2007; Rovaris et al., 
2001;  Rudick  et  al.,  1999)  (Table  2-5).  Brain  atrophy  appears  to  continue  despite 
treatment with these putative disease-modifying drugs, although longer follow-up periods 
in three studies suggest that either therapeutic action is delayed, or that a beneficial effect 
from  baseline  becomes  apparent  only  in  later  atrophy  measures  (Frank  et  al.,  2004; 
Paolillo et al., 2002; Turner et al., 2003). 
 
As  chronic  disease  and  disability  progression  is  the  principle  clinical  challenge,  and 
development  of  neuroprotective  agents  is  a  key  objective,  brain  atrophy  rate  as  an 
outcome  measure  is  becoming  increasingly  important.  It  is  vital  that  clinical  trials 
attempting to measure cerebral atrophy as a marker of progression are of sufficient power 83 
to detect a treatment effect. Determining natural brain atrophy rates in MS allows some 
estimation of the patient numbers that are required if clinical trials are to show a treatment 
effect. Large variability in atrophy rates in patient and control groups, whether due to 
measurement error or biological inter-subject differences, will increase the sample sizes 
required  in  parallel  group  design  trials  however.  Calculation  of  sample  sizes  from 
different brain atrophy measurement techniques will help to identify the best method to 
implement  into  future  trials  of  disease-modifying  drugs.  Evidence  that  different 
acquisitions  and  measurement  techniques  affect  observed  atrophy  rates  advocates 
standardisation of acquisition and methods to increase the reproducibility and robustness 
of results, especially in the context of multicentre longitudinal clinical trials (Leigh et al., 
2002). 
 
If brain atrophy is to be used as a marker of neuronal or axonal degeneration in clinical 
trials, reliable detection of atrophy over short intervals would potentially improve trial 
efficiency and reduce costs. However the effect of measurement errors on brain atrophy 
quantification  is  increased  over  short  intervals,  and  consequently  results  in  greater 
variance  of  atrophy  rate measures. Sufficient power to detect  significant decreases in 
brain  volume  over  short  intervals  is  therefore  likely  to  require  much  larger  subject 
numbers than would be expected in a longer interval study. Over short intervals, results of 
atrophy  studies  have  been  mixed.  In  two  studies  of  30  and  28  patients  with  RRMS 
respectively, it was not possible to show significant brain atrophy over three months using 
three different BPF calculation methods or SIENA (Fritz et al., 2006; Zivadinov et al., 
2004a). Nonetheless, a significant mean change in BPF of -0.23% was observed over 
approximately 2.5 months in 128 patients in one study, and estimated annual atrophy rate 
was -1.06% (95% CI -1.50% to -0.62%), a figure comparable to studies following patients 
over one year or more (Hardmeier et al., 2003). One must be careful extrapolating results 
obtained over such short intervals however due to the fact that measured atrophy rates are 
unlikely to be linear. 84 
Table 2-5 Brain atrophy in MS cohorts taking part in therapeutic trials. 
Study  Treatment  Method  Group  N 
(placebo/treated) 
MRI 
assessments 
(months) 
Estimated atrophy in 
placebo over interval
a 
(shown in months) 
Estimated atrophy in 
treated over interval
a 
(shown in months) 
Significant difference 
in atrophy rate, 
placebo vs treatment? 
Significant 
decrease in 
atrophy rate 
in treated? 
(Filippi et al., 
2004) 
IFN β-1a 
(ETOMS study) 
Brain  
(SIENA) 
CIS  98/111  12/24  0-12=-0.83% (1.09) 
12-24=-0.67% (1.10) 
0-12=-0.62% (1.40) 
12-24=-0.61% (0.99) 
0-24 placebo>treated  - 
(Frank et al., 
2004) 
IFN β-1b  Brain  RRMS  0/30  12/24/36  -  0-12=-1.35% (0.79) 
0-24=-1.48% (0.77) 
0-36=-1.68% (0.73) 
-  yes 
(Gasperini et 
al., 2002) 
IFN β-1a  CCV  RRMS  0/52  monthly -6-9/ 
12/24 
-6-0=0.02% 
 
6-30=-2.2%  -  no 
(Ge et al., 
2000a) 
Glatiramer acetate 
(US study)  
Brain  
(FCP) 
RRMS  13/14  24   0-24=-1.8% year
-1 
(1.8) 
0-24=-0.6% year
-1 
(0.9) 
0-24 placebo>treated  - 
(Hardmeier et 
al., 2005) 
IFN β-1a  
(European study) 
BPF 
(Cleveland) 
RRMS  0/386  12/24/36  -  0-12=-0.69% (0.79) 
12-24=-0.38% (0.77) 
24-36=-0.38% (0.73) 
-  yes 
(Miller et al., 
2007) 
Natalizumab 
(AFFIRM study) 
BPF 
(Cleveland) 
RRMS  315/627  12/24  0-12=-0.40% 
12-24=-0.43% 
0-12=-0.56% 
12-24=-0.24% 
0-12 treated>placebo 
12-24 placebo>treated 
- 
(Molyneux et 
al., 2000a) 
IFN β-1b  
(European study) 
CCV  SPMS  46/49  6/12/18/24/30/
36 
0-6=-0.89% (1.35) 
0-12=-1.40% (1.69) 
0-18=-2.02% (2.83) 
0-24=-2.76% (3.30) 
0-30=-2.74% (3.38) 
0-36=-3.86% (3.53) 
0-6=-1.39% (1.47) 
0-12=-1.60% (2.50) 
0-18=-1.65% (2.34) 
0-24=-2.17% (2.90) 
0-30=-2.84% (3.12) 
0-36=-2.91% (3.11) 
no  no 
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(Rovaris et al., 
2001) 
Glatiramer acetate 
(Euro/Canadian 
study) 
CCV  RRMS  114/113 
(9-18 months 
open-label) 
9/18   0-9=-0.7% (2.2) 
9-18=-0.6% (2.0) 
0-9=-0.8% (1.9) 
9-18=-0.4% (1.7) 
no 
 
no 
(Rovaris et al., 
2007) 
Glatiramer acetate 
(Euro/Canadian 
study) – long-term 
follow-up 
Brain  
(SIENA) 
RRMS  69/73  60  18-60=-3.46% (2.47)  18-60=-3.32% (2.40)  no  - 
(Rudick et al., 
1999) 
IFN β-1a  BPF 
(Cleveland) 
RRMS  72/68  12/24  0-12=-0.70% (0.92) 
12-24=-0.52% (0.80) 
0-12=-0.76% (1.11) 
12-24=-0.23% (0.74) 
12-24 placebo>treated  - 
(Sormani et al., 
2004) 
Glatiramer acetate 
(Euro/Canadian 
study) 
Brain  
(SIENA) 
RRMS  105/102 
(9-18 months 
open-label) 
9/18   0-9=-0.9% (1.2) 
9-18=-1.0% (1.1) 
0-9=-0.8% (1.0) 
9-18=-0.6% (1.2) 
9-18 placebo>treated  - 
(Turner et al., 
2003) 
IFN β-1a  
(PRISMS study) 
Brain  
(Seg prop) 
RRMS  7/13  18/48  0-18=-1.11%  
(range -2.25 to 1.10) 
0-48=0.83%  
(range -3.47 to 1.24) 
0-18=-0.69%  
(range -2.65 to 0.08) 
0-48=-1.02%  
(range -7.52 to 0.64) 
0-18 placebo>treated  no 
(Turner et al., 
2003) 
IFN β-1a 
(SPECTRIMS 
study) 
Brain  
(Seg prop) 
SPMS  6/12  18/48  0-18=-0.41%  
(range -0.58 to -0.01) 
0-48=-0.26%  
(range -1.16 to 1.34) 
0-18=-0.51%  
(range -3.03 to 1.67) 
0-48=-0.32%  
(range -2.90 to 1.05) 
no 
 
yes 
(Zivadinov et 
al., 2007) 
IFN β-1a  BPF  
(SPM) 
RRMS  28/26  36  BPF =-2.5% 
GMF=-1.4% 
BPF=-1.3% 
GMF= 0.2% 
yes  - 
amean (SD) unless otherwise stated, BPF, brain parechymal fraction; CCV, central cerebral volume; FCP, fuzzy connected principles; IFN, interferon; Seg prop, segmentation propagation. 86 
2.7  Chapter conclusions 
In  conclusion,  MRI  measures  of  brain  atrophy  provide  a  feasible  in  vivo  measure  of 
neuroaxonal  degeneration  in  MS.  A  wide  range  of  methods  have  been  developed  to 
measure global atrophy that have been shown to be sensitive to changes from early in the 
course of disease to later progressive stages. Brain atrophy rate appears to provide a better 
marker for clinical disability than conventional lesion measures and may provide clues for 
patient prognosis and understanding disease mechanisms. As the clinical applications of 
brain atrophy are moving forward and the likelihood that it will be applied as an outcome 
measure in clinical trials increase, more work validating different brain atrophy measures 
in MS and determining the best measure is required. In addition to improving the stability 
of MR acquisitions, easily applicable methods for quantifying brain atrophy and improved 
measurement precision, will be particularly important factors with the future emergence 
of putative neuroprotective agents. 
 
However there are important discrepancies between brain atrophy and clinical measures. 
It is still unclear when and at what rate atrophy develops, how it relates to pathology, and 
whether a threshold of atrophy exists beyond which progressive disability is inevitable. 
The  location  of  atrophy,  and  by  implication  axonal  loss,  will  also  be  relevant. 
Longitudinal MRI and clinical studies of subjects from first symptoms to post-mortem are 
required to give insight into the underlying disease mechanisms and verify MRI findings.  
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3  Methods overview 
 
3.1  Subjects 
Patients and control subjects used in the studies described in this thesis were taking part in 
two longitudinal clinical and MRI research studies being undertaken at the Institute of 
Neurology, University College London, Queen Square, London, United Kingdom. The 
aim of these studies was to investigate early MR markers of prognosis and pathogenic 
mechanisms in MS and details of the cohorts are described below. The studies in this 
thesis were a retrospective analysis of the MR and clinical data obtained. Ethical approval 
for the studies was obtained from the Joint Medical Ethics Committee of the Institute of 
Neurology and National Hospital for Neurology and Neurosurgery, University College 
London, Queen Square, London, United Kingdom. In addition, written informed consent 
was obtained from all study participants. All patients underwent appropriate clinical and 
laboratory investigations to exclude alternative diagnoses. 
 
3.1.1  Clinically isolated syndrome study 
Approximately 90% of patients were recruited to this study from Moorfields Eye Hospital 
where they had presented with optic neuritis. Other patients were recruited from general 
neurology  and  out-patient  clinics  at  the  National  Hospital  for  Neurology  and 
Neurosurgery where they had presented with a CIS suggestive of MS including brainstem 
and spinal cord syndromes. A baseline assessment for the study was performed within 12 
weeks of presentation with a CIS.  Further clinical and MRI assessments were performed 
at three months, one year, three years and five years. A subsequent diagnosis of MS in 
CIS patients was made according to the McDonald criteria (McDonald et al., 2001). 
 
3.1.2  Relapsing remitting multiple sclerosis study 
Patients were recruited from general neurology and out-patient clinics at the National 
Hospital  for  Neurology  and  Neurosurgery.  All  patients  had  clinically  definite  MS 
according to the Poser criteria (Poser et al., 1983) and fulfilled established criteria for 
RRMS (Lublin & Reingold, 1996). A total of 41 patients were recruited within four years 
of  symptom  onset  and  none  had  previously  received  disease-modifying  treatment. 
Patients on disease-modifying treatment or with longer disease duration were excluded 
from  the  study.  None  of  the  patients  had  experienced  a  clinical  relapse  or  received  
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corticosteroids within the month before assessments. Patients were assessed at baseline 
and then at six-monthly intervals for up to three years. An additional assessment was 
performed at five years, which included cognitive assessment. 
 
3.1.3  Control subjects 
Control subjects were all healthy volunteers with no previous history of neurological or 
major medical disease, and three control cohorts were utilised in this study. All subjects 
gave written informed consent for involvement in imaging studies. Twenty-six subjects 
were recruited as controls in the longitudinal study of RRMS. Assessment was at baseline 
with follow-up at six-monthly intervals for up to three years. These subjects were staff, or 
relatives  and  friends  of  staff,  from  within  the  National  Hospital  for  Neurology  and 
Neurosurgery  and  Institute  of  Child  Health,  or  were  relatives  and  friends  of  patients 
taking part in the longitudinal study of RRMS. 
 
In  addition,  five  control  subjects,  who  were  staff  at  the  Institute  of  Neurology,  were 
recruited  to  be  scanned  over  a  planned  MRI  scanner  upgrade.  These  subjects  were 
scanned  approximately  10  times  over  a  24  week  period  prior  to  the  upgrade  and 
approximately 10 times over a 33 week period following the upgrade.  
 
A further 22 control subjects who had two MR scans acquired on the same day were also 
used in this thesis. These subjects were taking part in a project aimed at determining the 
shortest interval required to detect volumetric change based on MRI, to distinguish AD 
subjects  from  normal  controls  (The  Minimum  Interval  Resonance  Imaging  in  AD 
(MIRIAD) project). In addition to two MR scans being acquired at baseline, MRI was 
acquired at two, six, 14, 26, 38 and 52 weeks. 
 
3.2  Clinical assessment of patients 
At baseline assessment a comprehensive patient history and neurological examination was 
performed.  At  subsequent  assessments  a  history  since  the  last  assessment  was  taken, 
including  any  relapses  (number,  time  and  length  of  relapse,  symptoms),  a  review  of 
current  medication  (if  any)  or  changes  in  medication,  and  any  other  pathology. 
Neurological  examination  included  assessment  and  scoring  of  Kurtzke’s  Functional 
Systems and EDSS (Kurtzke, 1983) through a combination of questions and physical 
assessments by the examiner (Appendix 1). The Multiple Sclerosis Functional Composite  
89 
(MSFC) (Appendix 2) (Cutter et al., 1999; Fischer et al., 1999), a composite measure of 
clinical  impairment,  was  assessed  in  patients  with  RRMS  at  all  time-points.  This 
encompassed a test of cognition (the paced auditory serial addition test (PASAT)), a test 
of upper limb function (the nine-hole peg test (9HPT)) and a test of lower limb function 
(the 25-foot timed walk (TW)). 
 
3.3  Magnetic resonance imaging 
All  brain  MRI  was  acquired  on  a  1.5  Tesla  GE  Signa  Horizon  Echospeed  scanner 
(General Electric Medical Systems, Milwaukee, WI, USA) on the same day as clinical 
assessment.  The  details  of  the  acquisitions  are  described  below.  Image  analysis  was 
performed on digitised images. 
 
3.3.1  Clinically isolated syndrome subjects 
A coronal three-dimensional inversion recovery prepared FSPGR sequence was acquired 
with  acquisition  parameters  TR=10.9ms,  TE=4.2ms,  TI=450ms,  matrix  256x192,  flip 
angle 20˚, FOV 240x180mm, resulting in 124 contiguous 1.5mm thick slices. Axial dual 
echo PD and T2-weighted images of the brain were acquired using a FSE sequence with 
acquisition parameters TR=3200ms, TE=19/95ms, matrix 256x256, flip angle 90˚, FOV 
240x180mm,  resulting  in  46  contiguous  3mm  thick  slices.  Gd-DTPA  (Magnevist 
(Schering  AG,  Berlin,  Germany))  (0.1mmol/kg)  was  injected,  and  approximately  15 
minutes later T1-weighted images were acquired using a CSE sequence with acquisition 
parameters TR=600ms, TE=17ms, matrix 256x256, flip angle 90˚, FOV 240x180mm, 
resulting in 46 contiguous 3mm thick slices.  
 
3.3.2  Relapsing remitting multiple sclerosis and control subjects 
An axial three-dimensional inversion recovery prepared FSPGR sequence was acquired 
with  acquisition  parameters  TR=10.9ms,  TE=4.2ms,  TI=450ms,  matrix  256x160,  flip 
angle 20˚, FOV 300x230mm, resulting in 124 contiguous 1.5mm thick slices. In addition 
a coronal three-dimensional inversion recovery prepared FSPGR sequence was acquired 
with  acquisition  parameters  TR=10.9ms,  TE=4.2ms,  TI=450ms,  matrix  256x192,  flip 
angle 20˚, FOV 240x180mm, resulting in 124 contiguous 1.5mm thick slices. Axial dual 
echo PD and T2-weighted images of the brain were acquired using a FSE sequence with 
acquisition parameters TR=2000ms, TE=17/102ms, matrix 256x256, flip angle 90˚, FOV 
240x180mm, resulting in 28 contiguous 5mm thick slices. T1-weighted images using a  
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CSE sequence were acquired with acquisition parameters TR=550ms, TE=20ms, matrix 
256x256, flip angle 90˚, FOV 240x240mm, resulting in 28 contiguous 5mm thick slices. 
In  patients,  triple  dose  Gd-DTPA  (0.3mmol/kg)  was  injected,  and  approximately  15 
minutes later a further conventional SE sequence was acquired. None of the patients had 
experienced a clinical relapse or received a course of corticosteroids within a month prior 
to imaging. 
 
3.3.3  Control subjects with same-day imaging 
Two  coronal  three-dimensional  inversion  recovery  prepared  FSPGR  sequences  were 
acquired with acquisition parameters TR=15ms, TE=5.4ms, TI=650ms, matrix 256x256, 
flip angle 15˚, FOV 240x240mm, resulting in 124 contiguous 1.5mm thick slices. 
 
3.4  Image analysis algorithms and methods 
3.4.1  MIDAS 
MIDAS  software  (Freeborough  et  al.,  1997)  is  implemented  in  the  C  programming 
language running on a Unix platform. MIDAS allows three dimensional MR images to be 
displayed in simultaneous multiplanar views. Outlining of regions of interest (ROI) can be 
performed using both automated and semi-automated functions. The simultaneous display 
of orthogonal views allows the operator to edit the ROI in one view whilst it is updated in 
real time in the two other views, thereby aiding decisions regarding brain boundaries. 
Rigid-body registrations using Automated Image Registration (AIR) (Woods et al., 1998) 
can be implemented within the MIDAS software, and MIDAS provides an interface for 
quantification of brain atrophy using the BBSI. 
 
3.4.2  FMRIB’s Software Library (FSL) 
The  FMRIB’s  (Functional  Magnetic  Resonance  Imaging  of  the  Brain, 
www.fmrib.ox.ac.uk) software library includes image analysis and statistical tools for the 
analysis of both structural and functional MRI and is run on a Unix platform (Smith et al., 
2004). Version 3.1 was used for all analysis. Structural image analysis tools used in this 
work  include  BET,  an  automated  algorithm  that  segments  brain  from  non-brain  and 
models skull and scalp surfaces (Smith, 2002); input parameters can be altered to optimise 
segmentation. FMRIB’s Automated Segmentation Tool (FAST) can be used for brain 
segmentation into different tissue types and bias field correction (Zhang et al., 2001a). 
FMRIB’s Linear Image Registration Tool (FLIRT) provides linear inter- and intra-modal  
91 
registration (Jenkinson & Smith, 2001). SIENA is an automated algorithm for assessing 
structural brain change and estimating atrophy (Smith et al., 2002). 
 
3.4.3  Statistical parametric mapping 
SPM was developed by the functional imaging laboratory at the Institute of Neurology, 
London  (Frackowiak  et  al.,  1997).  SPM99  was  used  running  on  a  Matlab  platform 
(MathWorks,  Natick,  Mass.,  USA).  SPM  software  was  applied  to  MR  data  to 
automatically delineate GM, WM and CSF. 
 
3.4.4  DispImage 
Dispimage,  a  display  and  image  analysis  package  (D.  Plummer,  University  College 
London Hospitals NHS Trust, UK) (Plummer, 1992) was run on a Unix system. The 
software allows the display of MRI in one plane and outlining of regions of interest using 
automated or semi-automated methods. Lesions on MR images were outlined using either 
an automated thresholding tool within Dispimage, which is based on intensity changes at 
the edge of the lesion, or manually, using a mouse-driven cursor. 
 
3.4.5  Excalp 
Excalp is an automated programme implemented in the C programming language running 
on  a  Unix  platform  (Yoo  Done-Sik,  University  College  London,  UK.  “Imaging  and 
Segmentation of Bone in Neurological Magnetic Resonance”, PhD Thesis, 1998). This 
software was originally designed to perform an accurate segmentation of the skull from 
MR images, but in part achieves this through detection of the brain, and it has therefore 
been used as a brain segmentation tool. It is applied to individual image slices to strip the 
skull from brain images, by combining a histogram-based thresholding method and an 
edge detection method with connected components analysis and morphological operators. 
 
3.5  Statistical analysis 
STATA versions 8 and 9 (Stata Corporation, College Station, Texas, 1999) were used for 
statistical analysis of results.  
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4  Analysis and optimisation of brain atrophy measurement 
by the brain boundary shift integral in multiple sclerosis  
 
4.1  Chapter introduction 
With increasing focus on brain atrophy as a marker of disease progression in MS, and its 
potential  for  use  as  an  outcome  measure  in  clinical  trials,  automated  and  reliable 
measurement methods are currently attractive. Although the BBSI (Freeborough & Fox, 
1997) is a validated technique, its application to patients with MS has been limited. The 
only study performed using this method showed increased brain atrophy rates in patients 
with RRMS, SPMS and PPMS relative to controls, but the number of subjects in each MS 
subgroup  numbered  less  than  10  and  disease  duration  ranged  considerably  between 
subjects (Fox et al., 2000b). In addition this method has not been applied to cohorts of 
subjects in the early stages of the disease who represent likely candidates for inclusion 
into future trials of treatments aimed at slowing the development of disability. Further 
investigation  into  the  application  and  optimisation  of  the  BBSI  to  larger  cohorts  of 
subjects early in the disease course is therefore warranted. 
 
When designing studies investigating brain atrophy, the pulse sequence and parameters, 
and data processing protocol, need to be established and optimised in order to reduce the 
variability and increase the sensitivity of measurements. This may increase the power of 
the  study  to  detect  a  difference  in  atrophy  rates,  for  example  between  patients  on 
treatment and placebo. This chapter investigates ways in which MR images and the BBSI 
method can be optimised for measurement of brain atrophy in patients presenting with a 
CIS and patients with early RRMS. Firstly the effect of image intensity normalisation, 
both within a single image and between serial images, is investigated. Secondly, optimal 
parameters specifying the location and width of the boundary sampling window in these 
cohorts  are  determined,  and  the  influence  of  this  on  atrophy  measures  and  statistical 
power  investigated.  Finally,  this  chapter  explores  whether  averaging  same-day  data 
(images or atrophy rates) can improve measurement precision by the BBSI. 
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4.2  Assessment of non-uniformity correction using a) N3 and b) differential bias 
correction, on the brain boundary shift integral 
4.2.1  Introduction 
Underlying the BBSI is the assumption that any change in volume of the brain will be 
associated with an exactly equivalent shift in the brain boundaries. Following accurate 
registration of two brain images, areas of intensity loss between serial images are likely to 
represent  shifts  in  tissue  near  the  boundaries  as  brain  atrophy  occurs,  and  the  BBSI 
derives an automated measurement of global atrophy by directly comparing the image 
intensity  profiles  of  registered  MR  acquisitions.  It  requires  selection  of  an  intensity 
window which should be contained within all the intensity transitions associated with the 
boundaries of the brain (Figure 1-16), and this window should be standardised for a given 
scan type and cohort. As such, atrophy quantification by the BBSI could be invalid if 
images are affected by either intensity inhomogeneity (bias field, as described in Chapter 
1.5.3) or differential intensity between serial images (differential bias). 
 
A bias field will lead to a shift in the intensity profile of an image so that the intensity 
window may not be encompassed by the relevant boundary intensity transitions at only 
points on the brain boundary surface, i.e. the intensity profile may only partially sit within 
the given intensity window for some region(s), and therefore will contribute less to the 
estimate of atrophy. Figure 4-1a shows that intensity inhomogeneity in both baseline and 
repeat images has shifted the intensity profiles upwards. Consequently brain atrophy is 
underestimated  as  the  boundary  region  is  not  entirely  encompassed  by  the  specified 
intensity window. This intensity profile represents just one point on the brain boundary 
and will therefore vary at different places in the boundary region of a single subject.  In 
the presence of differential bias the intensity profile of one image is moved relative to the 
other, and similarly the intensity window may not encompass the boundary movement. In 
addition  it  is  possible  that  non-boundary  tissue  could  contribute  to  the  measurement 
(Figure 4-1b). In addition to these potential effects of intensity bias, the BBSI requires 
segmentation of the brain both  for image  registration  and  for  estimation of the  brain 
boundary region. Typically this is done using MIDAS which requires specification of 
intensity thresholds to delineate the whole brain (Freeborough et al., 1997), and assumes 
intensity homogeneity within a tissue class. Furthermore, a bias field may make it difficult 
to recognise tissue boundaries for either setting of the thresholds or manual editing of 
regions.   
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Figure 4-1 The effect of intensity inhomogeneity, on single scans and between serial 
images, on the BBSI. Based on a one-dimensional representation of the intensity profile 
through a brain boundary on serial imaging a) intensity inhomogeneity in both images 
has shifted the intensity profiles upwards and consequently the boundary shift ( x) is 
underestimated as the boundary region is not entirely encompassed by the specified 
intensity  window,  b)  differential  bias  has  shifted  the  repeat  image  intensity  profile 
relative to the baseline and consequently the boundary shift ( x) is underestimated. 
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As previously described, a number of methods have been developed to retrospectively 
correct for image intensity inhomogeneity (Chapter 1.5.3). One such method that is freely 
available  on  the  Internet,  is  nonparametric  nonuniform  intensity  normalisation  (N3) 
(http://www.bic.mni.mcgill.ca/software/N3) (Sled et al., 1998). Validated on volumetric 
brain images acquired on a 1.5T scanner, it is a fully automated algorithm that estimates 
the distribution of voxel intensities within an image and then iteratively  sharpens the 
resulting intensity histogram until the CV in the ratio between subsequent estimates of the 
nonuniformity field is below a given value. Although there are a number of other methods 
that could be used for the same purpose, N3 has been shown to be superior (Arnold et al., 
2001).  In  addition,  a  study  investigating  a  variety  of  processing  streams  on  different 
acquisitions found that the choice of algorithm for reducing intensity bias had very little 
effect on tissue segmentation (Clark et al., 2006). Also N3 is a non-parametric method 
which  may  be  important  when  attempting  to  correct  for  intensity  inhomogeneity  in 
patients with MS. WM lesions may cause greater intensity variations, but N3 can deal 
with this feature as this there is no limit to the number of tissue classes in the histogram. 
 
Differential bias correction (DBC) has been described for the standardisation of intensity 
between two images from the same individual to control for differences in the bias field 
that may occur with serial imaging (Lewis & Fox, 2004). Calculation of the differential 
bias field is made on the assumption that in a difference image of registered serial brain 
images, the difference due to atrophy and noise is small-scale. A differential bias field is 
of a much larger scale  and  can be estimated by applying an appropriate filter to the 
difference image, and subsequently can be corrected for. 
 
The aim of this study was to investigate the effect of N3 correction on individual images 
and  DBC  on  serial  images,  and  to  determine  their  influence  on  the  sensitivity  and 
precision of brain atrophy measurements by the BBSI in patients with MS pathology and 
controls.  
 
4.2.2  Methods 
Subjects and imaging 
Eighty-four subjects with serial MR brain imaging ranging in age from 21-56 years were 
identified; 16 control subjects (seven male, mean age 35.1 years (SD 6.3)), 37 subjects 
who presented with a CIS (14 male, 35.0 years (SD 6.2)) and 30 subjects with RRMS  
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(eight male, 37.5 years (SD 7.4)). Subjects with RRMS were within four years of disease 
onset and had a median EDSS of 1.5 at baseline (range 0-3). All subjects had coronal 
FSPGR MRI at baseline and approximately one year later (mean follow-up time 1.14 
years (SD 0.20)) according to the standard acquisition protocols described in Chapter 3.3.  
 
MRI analysis 
MIDAS  was  used  to  segment  the  brain  on  each  image  (Freeborough  et  al.,  1997). 
Delineation of brain/non-brain was achieved by setting intensity thresholds to eliminate 
voxels  that  were  greater  or  less  than  the  given  intensities,  followed  by  erosions  and 
dilations. Manual editing was performed when required. As WM lesions are often visible 
on  T1-weighted  MRI,  appearing  hypointense  in  relation  to  WM,  whole  brain 
segmentation using MIDAS may exclude these regions based on intensity thresholding 
(Figure  4-2).  Subsequently,  these  regions  may  be  classified  erroneously  as  a  brain 
boundary by the BBSI. Therefore these regions were filled in by manual editing of the 
ROI  (Figure  4-2).  All  segmentations  were  performed  blinded  to  subject  identity  and 
image time-point. 
 
Figure 4-2 The effect of hypointense lesions on whole brain segmentation by MIDAS. a) 
T1-weighted image showing lesion (arrow), b) the lesion is excluded from the brain ROI 
by MIDAS, c) following manual correction, the area of the lesion in included in the 
ROI. 
 
 
N3 was applied to each image in order to correct for intensity inhomogeneity within the 
images. Brain regions were then copied and pasted from the original images to the N3-
corrected images and edited if necessary. To calculate the BBSI a registration algorithm  
(AIR) (Woods et al., 1998), determining the rotations, translations and shear required to 
obtain a subvoxel accuracy over the whole brain, positionally matched baseline and repeat  
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brains, and a linear scaling was used to account for variations in voxel size due to scanner 
drift. Spatial scaling factors were estimated from the brain to brain registration. The BBSI 
algorithm  was  applied  to  both  uncorrected  and  N3-corrected  image  pairs.  Each 
registration  and  subsequent  atrophy  calculation  was  performed  with  and  without 
automated DBC, in addition to the normal intensity scaling that the BBSI carries out. 
Thus,  four  atrophy  measures  were  obtained  for  each  subject:  i)  no  correction,  ii)  N3 
correction only, iii) DBC only, iv) N3 correction and DBC.  
 
Evaluation of the effect of N3 correction and DBC 
Visual assessment of each registration was performed to check that it was accurate. In 
addition to analysing the influence on atrophy measures, the effect of N3 correction and 
DBC on the actual images was assessed. Visual assessment of images before and after 
each procedure was performed. The CV of WM intensity was determined in each image 
before and after N3 correction and compared in each subject group using a paired t-test. 
This required delineation of the WM on each baseline, non-corrected image using the 
brain region obtained from MIDAS, and FAST (Zhang et al., 2001a). This WM region 
was eroded once to avoid the inclusion of partial volume voxels at the GM/WM border. 
The baseline scan was registered (affine) to the repeat scan, and using the transformation 
parameters the eroded baseline WM mask was resliced to the repeat image space. The 
same baseline and repeat WM regions were applied respectively to baseline and repeat 
N3-corrected images (non-DBC corrected), and the mean and SD of voxel intensities 
within the WM region were calculated for each image. To assess the influence of DBC 
baseline  brain  voxel  intensities  were  determined,  and  subsequently  correlated  with 
registered  repeat  brain  voxel  intensities  (based  on  the  MIDAS  brain  region).  The 
correlation coefficient was determined before and after DBC and in each subject group a 
paired t-test was used to look for significant differences in these values. 
 
Statistical analysis 
Atrophy  measures  were  corrected  for  scan  interval  and  expressed  as  a  percentage  of 
baseline brain volume. The mean (SD) atrophy rates in each subject group before and 
after N3 correction and DBC were calculated. Mean atrophy rates obtained using the four 
different processing procedures were compared by fitting a model relating atrophy rate to 
procedure utilising a generalised estimating equations approach. The model assumed an 
exchangeable  correlation  structure  and  robust  standard  errors  were  calculated.  This  
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approach allows for correlation between the measures and differences in the variance of 
measures between methods. A joint Wald test was used as an overall test of differences in 
mean  atrophy  rates between  procedures. Where  a significant difference  was observed 
(p<0.05),  paired  t-tests  were  used  to  investigate  pairwise  differences.  Likewise,  a 
generalisation of Pitman’s test to more than two observations was performed within each 
subject group to determine if there was a significant difference in the variance of atrophy 
rates  when  N3  correction  and  DBC  were  applied  (Han,  1969).  Where  a  significant 
difference was observed (p<0.05), Pitman’s test was applied pairwise to observations. 
 
The statistical power of any future trial using brain atrophy as an outcome measure will be 
driven by the mean and variance of measures in patients. For any two methods where a 
significant difference in the mean or variance of atrophy rates was found in the RRMS 
patient group, investigation into the relative statistical power was performed. The CV 
(σ/µ) of the two methods was calculated, as the square of this value is proportional to the 
sample size required for a randomised controlled trial with the power to detect a particular 
proportional  reduction  in  brain  atrophy  rate.  Hence  the  square  of  the  ratio  of  the 
respective CVs indicates the relative number of patients required to detect a treatment 
effect  using  atrophy  rates  obtained  using  the  different  processing  methods  (for  any 
expected percentage treatment effect and any required statistical power). A 95% bootstrap 
CI  (bias  corrected  on  the  logarithmic  scale)  for  the  ratio  was  calculated  using  1000 
replicates.  This  CI  was  used  to  determine  whether  differences  were  statistically 
significant.  
 
4.2.3  Results 
On  visual  inspection  none  of  the  images  had  noticeable  intensity  inhomogeneity  or 
differential bias, and following N3 correction it was not felt necessary to edit any of the 
brain regions. However comparing the CV of the WM in each image before and after N3 
correction,  it  was  found  to  be  marginally  but  significantly  reduced  following  N3 
correction  (mean  difference  -0.01120,  SD  0.00654,  95%  CI  -0.01020  to  -0.01221, 
p<0.001). In addition the correlation of voxel intensities in baseline and registered repeat 
brain regions was marginally but significantly greater following DBC than before (mean 
increase 0.00117, SD 0.00157, 95% CI 0.00151 to 0.00082, p<0.001). Mean (SD) BBSI 
atrophy rates for each subject group, with and without N3 and DBC correction are shown 
in Table 4-1 and Figure 4-3.  
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Table 4-1 BBSI mean brain atrophy rates when images are uncorrected, or intensity 
inhomogeneity corrected using N3 and DBC, in controls and subjects with CIS and 
RRMS. 
  No DBC 
Mean (SD) (% year
-1) 
DBC 
Mean (SD) (% year
-1) 
  Controls  -0.08 (0.51)  -0.07 (0.41) 
No N3 correction  CIS  -0.18 (0.45)  -0.18 (0.38) 
  RRMS  -0.56 (0.62)  -0.59 (0.49) 
  Controls  -0.08 (0.52)  -0.07 (0.42) 
N3 correction  CIS  -0.18 (0.46)  -0.19 (0.37) 
  RRMS  -0.56 (0.62)  -0.59 (0.50) 
 
 
 
Figure  4-3  BBSI  brain  atrophy  rates  when  images  are  uncorrected,  or  intensity 
inhomogeneity corrected using N3 and DBC, in controls and subjects with CIS and 
RRMS. 
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Comparison of mean atrophy rates from all four processing methods demonstrated no 
significant  differences  in  mean  values  when  N3  correction  or  DBC  were  applied  to 
images (controls p=0.86, CIS p=0.42, RRMS p=0.74). Applying the generalisation of 
Pitman’s test to results from all four methods revealed a significant difference in the 
variance  of  atrophy  rates  (p<0.001  in  each  subject  group).  Pairwise  Pitman’s  tests 
revealed that the variance of atrophy rates was significantly reduced in each subject group 
when  DBC  was  applied  to  uncorrected  or  N3  corrected  images  (all  p<0.001).  No 
significant differences were observed when N3 correction was applied (p-values ranged 
from 0.16 to 0.66). Relative sample sizes to detect a particular proportionate difference 
were estimated to be 26% smaller using DBC (95% CI 37% to 18% reduction) compared 
with  no  correction,  indicating  significantly  greater  statistical  power  by  application  of 
DBC. 
 
4.2.4  Discussion 
In this study the effect of a nonparametric nonuniform intensity normalisation (N3) on 
single  images,  and  differential  bias  correction  (DBC)  between  serial  images,  on 
quantification of atrophy by the BBSI has been investigated. In the cohort studied it was 
confirmed  that  N3  correction  significantly  reduces  the  variability  of  voxel  intensities 
within  the  WM,  but  correction  did  not  significantly  affect  BBSI-derived  atrophy 
measures.  However  DBC  significantly  increased  correlation  between  brain  voxel 
intensities on serial images, and led to a significant decrease in the variance of atrophy 
rates quantified by the BBSI, which resulted in greater statistical power.  
 
In a previous study that applied the BBSI to MS subjects, N3 correction and DBC were 
not applied (Fox et al., 2000b). On visual inspection of the images included in the present 
study intensity bias was not evident, yet a significant decrease in the variability of WM 
intensity was detected following application of N3 correction. Although the true amount 
of nonuniformity in any MRI image is unknown and it is not possible to measure the 
accuracy of N3 correction directly, this suggests that inhomogeneity correction should be 
applied  routinely  to  images.  However,  it  was  shown  that  N3  correction  did  not 
significantly affect either the mean or variance of atrophy measures suggesting that the 
BBSI is robust to small amounts of intensity bias. This finding is similar to that observed 
in  a  study  applying  a  boundary  shift  integral  method  in  controls  and  patients  with 
Alzheimer’s disease; N3 bias correction had little effect on brain atrophy quantification  
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and did not influence group separation (Gunter et al., 2003). However bias correction 
might be important if investigating serial changes in WM volumes, and this warrants 
further investigation. 
 
Previously it has been shown that the BBSI can be considerably altered when there is a 
change in contrast between serial images (Preboske et al., 2006), and efforts should be 
made to standardise the acquisition over time. Again, visual assessment of images did not 
highlight any differences in intensity between any of the image pairs, but the correlation 
between the intensity of voxels on serial images increased  following DBC. Although 
correlation does not necessarily mean that the intensity values agreed, only that they were 
more  strongly  associated,  analysis  of  atrophy  rates  showed  that  DBC  significantly 
decreased the variance of measures and consequently increased the statistical power. That 
DBC influenced atrophy measures to a greater extent than N3 correction, is likely to have 
been because the BBSI depends to a greater extent on the difference in voxel intensity 
between serial images than the consistency of intensity of a tissue class. Indeed if both 
images  have  a  similar  bias  field  (Figure  4-1a)  there  is  likely  only  to  be  an  under-
estimation  of  atrophy.  However  with  differential  bias,  noise  will  be  added  to  the 
measurement  that  will  increase  measurement  variability.  Unlike  the  original  paper 
describing  DBC  (Lewis  &  Fox,  2004),  there  was  no  apparent  decrease  in  the  mean 
atrophy rate following the application of DBC, which was suggested to be due to some 
atrophy being smoothed away during the processing. This may not have been so apparent 
in the present study due to the lower atrophy rates observed compared with the original 
study which was performed in patients with established Alzheimer’s disease. 
 
If  both  N3  correction  and  DBC  are  to  be  applied  prior  to  the  BBSI,  one  important 
consideration may be the order in which they are applied and the influence of one on the 
other. One may assume that it is logical to improve intensity homogeneity on individual 
scans prior to intensity standardisation.  Indeed a study which investigated this aspect of 
optimisation  of  images  found  that  this  was  the  best  order  to  perform  procedures 
(Madabhushi & Udupa, 2005). 
 
One of the limitations of this study is that the influence of N3 correction on the initial 
brain segmentation and subsequent atrophy quantification was not investigated, as the 
brain ROI was copied from an uncorrected image to the N3-corrected image. This aspect  
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would have been difficult to examine however, given that there is a degree of intra-rater 
error  associated  with  repeated  brain  segmentations,  making  it  difficult  to  determine 
differences  due  to  measurement  error  and  those  due  to  differences  in  boundary 
recognition. Moreover, a study that investigated the effect of intensity bias correction on 
brain segmentation from four different automated and semi-automated algorithms found 
that  it  did  not  affect  method  performance  (Fennema-Notestine  et  al.,  2006),  and  is 
therefore  unlikely  to  have  influenced  the  whole  brain  segmentations  in  this  study.  It 
should also be noted that although N3 should be insensitive to pathology such as lesions, 
this study did not investigate whether there is a threshold beyond which the normalisation 
process may be significantly influenced by hypointense WM lesions. 
 
This  study  demonstrates  that  a)  N3  correction  significantly  increases  intensity 
homogeneity  on  individual  images  and  b)  DBC  significantly  increases  intensity 
homogeneity  between  serial  images.  Most  importantly,  DBC  appears  to  decrease  the 
variance  of  atrophy  rates obtained using the  BBSI suggesting increased  measurement 
precision. The relative reduction in sample size of one quarter that was a consequence of 
this would greatly facilitate the performance of exploratory trials using brain atrophy as 
the outcome measure. Although N3 correction did not influence atrophy rates it is likely 
that  there  is  a  threshold  of  inhomogeneity  beyond  which  N3  correction  could  be  a 
valuable pre-processing step for the BBSI. As N3 correction and DBC are fully automated 
methods that require minimal operator time, these findings suggest that these processes 
should be performed routinely in studies prior to atrophy quantification by the BBSI. 
 
4.3  Selection of optimal parameters for quantification of the brain boundary shift 
integral 
4.3.1  Introduction 
When calculating the BBSI, the range of intensities (I1, I2) over which the integral is 
calculated must be defined. This intensity range or window has a centre Ic = (I1 + I2)/2, 
and width Iw = I1-I2 (Freeborough & Fox, 1997). These parameters are user defined and 
the intensity window should maximise the number of contributing boundary voxels whilst 
falling  entirely  within  all  of  the  intensity  transitions  associated  with  the  boundaries 
between brain and CSF. These opposing requirements are complicated by the fact that the 
brain  is  made  up  of  tissues  with  differing  intensities.  As  shown  in  Figure  1-16  the 
boundary shift is estimated as the area A between two intensity profiles within the defined  
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window, divided by the intensity window Iw. A window that is too wide is likely to 
underestimate brain atrophy as the intensity window falls outside the brain boundary and 
therefore the normalising factor (I1-I2) is disproportionately large relative to A. By using a 
narrower intensity window there will be a greater chance that it falls entirely within the 
intensity transitions of the brain boundary and atrophy will be more reliably detected. 
However too small a window can lead to the window lying entirely outside the intensity 
transitions too often, resulting in measurement error. 
 
The optimum window settings are primarily dependent on the scan acquisition protocol 
which can differ between centres and study cohorts. The arrangement and intensity of 
adjacent brain tissues will not vary significantly between subjects from one cohort or 
scanner. The optimum window settings can therefore be determined for a given scanner 
and scan type and then applied to multiple subjects. The default parameters of I1=0.75 and 
I2=0.25 were those initially published (where 0.75 refers to 75% of mean normalised 
brain  intensity)  (Freeborough  &  Fox,  1997).  Optimised  parameters  (for  the  particular 
image acquisition) can be estimated by comparing the BBSI to segmented brain volume 
differences (BVD), for a range of window parameters, and maximising their association.  
 
The objective of this study was therefore to determine the optimal window settings for 
maximising the sensitivity, precision and accuracy of the BBSI on i) coronal and ii) axial 
T1-weighted  volumetric  acquisitions,  in  the  cohort  of  patients  and  controls  being 
investigated in this thesis. 
 
4.3.2  Methods 
Subjects and imaging 
Eighty-eight  subjects  were  identified  with  coronal  FSPGR  MRI  at  baseline  and 
approximately  12  month  follow-up  (mean  follow-up  time  1.16  years  (SD  0.24));  16 
control subjects (seven male, mean age 35.1 years (SD 6.3)), 42 subjects presenting with a 
CIS (14 male, 34.4 years (SD 6.3)) and 30 patients with RRMS (eight male, 37.5 years 
(SD 7.4)). In addition, 17 control subjects (seven male, mean age 35.2 years (SD 6.2)) and 
29 subjects with RRMS (eight male, mean age 37.7 years (SD (7.5)) had axial FSPGR 
MRI at baseline and approximately 12 month follow-up (mean 1.06 years (SD 0.11)). 
Imaging  was  performed  according  to  the  standard  acquisition  protocols  described  in 
Chapter 3.3.   
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MRI analysis 
The brain was segmented on each image using MIDAS as described in Chapter 4.2.2, and 
N3 correction was applied. Brain volumes were determined from the segmentations and 
the difference in volume between the baseline and repeat image was calculated. The BBSI 
algorithm, with DBC and default parameters (Ic=0.5 and Iw=0.5, i.e. I1=0.75 and I2=0.25), 
was  applied  to  each  serial  image  pair.  Normalisation  of  signal  intensities  within  the 
images was achieved by dividing the intensity of each voxel by the mean intensity of the 
internal intersection region (the intersection between the baseline and registered repeat 
segmented brain regions, eroded once). This approximately scales the voxel intensities 
within the boundary region between zero and one. Visual assessment of each registration 
was performed to check registration accuracy. 
 
Subsequently,  atrophy  was  estimated  from  all  registered  image  pairs  using  different 
window settings. An automated algorithm was designed for this purpose and required 
only specification of I1 and I2. It was hypothesised that reducing the window width (Iw) 
would increase the sensitivity of the BBSI. Therefore based on a window width of 0.3, 
BBSIs were calculated for window centres (Ic) ranging from 0.4 to 0.8 (at 0.05 intervals). 
Segmented  volume  differences  and  atrophy  measures  derived  from  the  BBSI  were 
corrected for scan interval and expressed as a percentage of baseline brain volume. 
 
Statistical analysis 
Data from coronal and axial images were analysed separately. For each window setting 
atrophy rates calculated using the BBSI were plotted against the difference in segmented 
brain volume obtained from MIDAS, and linear regression lines were fitted to the data 
(the values should approximate each other). In each subject group mean (SD) atrophy 
rates were calculated for each window setting tested. In patients with RRMS effect sizes 
(µ/σ) were calculated in order to determine the statistical power of atrophy measures from 
each window setting. 
 
4.3.3  Results 
The linear regression lines fitted to data from coronal images, comparing the segmented 
volume  difference  and  BBSI  measures  obtained  using  different  window  settings,  are 
shown in Figure 4-4. Using a window width of 0.3 it was found that a window centre of 
0.55 gave the closest approximation to the segmented volume difference. The window  
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width was reduced to 0.2 at this window centre which increased the agreement of the 
BBSI and segmented volume difference further. These results can be demonstrated by 
looking at a real example of an intensity profile, seen in Figure 4-5, which shows the 
boundary transitions that fall within different intensity windows.  
 
 
 
Figure 4-4 Correlation of segmented volume difference and BBSI brain atrophy rates, 
obtained using different window settings on coronal T1-weighted volumetric images. 
Atrophy  rates  from  controls  and  subjects  with  CIS  and  RRMS  were  plotted  and 
regression lines fitted to the data. Both the window centre (c) and the window width (w) 
lie between 0 and 1. 
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Figure  4-5  The  effect  of  different  intensity  window  settings  on  BBSI  atrophy 
measurement.  Different  BBSI  intensity  windows  are  overlaid  on  a  one-dimensional 
intensity  profile  through  a  brain,  showing  how  the  window  relates  to  the  intensity 
transitions of the brain boundary. The intensity profile was generated by drawing a line 
one voxel high between the points A and B (top image), and normalising the intensity 
value of each voxel in this region to the mean whole brain intensity. 
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Table 4-2 shows the mean atrophy rates in each subject group for the different intensity 
window parameters tested. When looking at the different window centre settings for a 
window width of 0.3,  mean atrophy  rate peaked in patient  groups  when the window 
centre was set at 0.55. Mean atrophy rate increased when the window width was reduced 
to 0.2 at this window centre. Mean atrophy rate was closest to zero in control subjects for 
a  window  centre  of  0.6.  As  mean  atrophy  rate  increased,  the  variance  of  measures 
increased  also.  However  the  effect  sizes  for  patients  with  RRMS  reveal  that  these 
increases were not proportional, as the effect size was at its highest value when a window 
centre of 0.5 was utilised (Table 4-2). 
 
Table 4-2 BBSI mean brain atrophy rates quantified using different intensity window 
settings for coronal T1-weighted volumetric images, in controls and subjects with CIS 
and RRMS. Effect sizes (µ/σ) are given for subjects with RRMS. 
Mean (SD) atrophy rate (% year
-1)  Window 
centre 
Window 
width  Controls  CIS  RRMS 
Effect size 
0.5 (default)  0.5 (default)  -0.07 (0.42)  -0.18 (0.38)  -0.59 (0.50)  1.17 
0.8  0.3  0.06 (0.26)  -0.03 (0.27)  -0.28 (0.32)  0.86 
0.75  0.3  0.06 (0.33)  -0.06 (0.34)  -0.37 (0.40)  0.92 
0.7  0.3  0.05 (0.39)  -0.09 (0.40)  -0.48 (0.48)  0.99 
0.65  0.3  0.03 (0.44)  -0.13 (0.48)  -0.58 (0.54)  1.08 
0.6  0.3  0.00 (0.48)  -0.17 (0.47)  -0.65 (0.57)  1.15 
0.55  0.3  -0.03 (0.49)  -0.19 (0.47)  -0.68 (0.58)  1.18 
0.5  0.3  -0.06 (0.48)  -0.19 (0.44)  -0.66 (0.56)  1.19 
0.45  0.3  -0.08 (0.44)  -0.19 (0.39)  -0.61 (0.52)  1.18 
0.4  0.3  -0.09 (0.38)  -0.16 (0.32)  -0.52 (0.45)  1.15 
0.55  0.2  -0.04 (0.52)  -0.21 (0.49)  -0.72 (0.60)  1.21 
 
The  linear  regression  lines  fitted  to  data  obtained  using  axial  images,  comparing  the 
segmented  volume  difference  and  BBSI  measures  obtained  using  different  intensity 
window settings, is shown in Figure 4-6. As with coronal images, using a window width 
of 0.3 it was found that a window centre of 0.55 gave the closest approximation to the 
segmented volume difference for brain atrophy rate. Window width was reduced to 0.2 at  
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this window centre which increased the agreement between the  BBSI  and segmented 
volume difference still further, when atrophy was detected.  
 
 
Figure 4-6 Correlation of segmented volume difference and BBSI brain atrophy rates 
obtained  using  different  window  settings  on  axial  T1-weighted  volumetric  images. 
Atrophy rates from controls and subjects with RRMS were plotted and regression lines 
fitted to the data. Both the window centre (c) and the window width (w) lie between 0 
and 1. 
 
 
 
Table 4-3 shows the mean brain atrophy rates in controls and RRMS subjects for the 
different intensity window settings. When looking at the different window centre settings 
for a window width of 0.3, mean atrophy rate peaked in the RRMS group when the 
window centre was set at 0.55. When the window width was decreased to 0.2 at this 
window centre, mean atrophy rate increased. In controls mean atrophy rate was closest to 
zero for a window centre of 0.75. As with coronal images, as mean atrophy rate increased 
the variance of measures increased, but again this was not proportional as the effect sizes 
for patients with RRMS reveal that it was highest for a window centre of 0.55.  
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Table 4-3 BBSI mean brain atrophy rates quantified using different intensity window 
settings for axial T1-weighted volumetric images, in controls and subjects with RRMS. 
Effect sizes (µ/σ) are given for subjects with RRMS. 
Mean (SD) atrophy rate (% year
-1)  Window 
centre 
Window 
width  Controls  RRMS 
Effect size 
0.5 (default)  0.5 (default)  -0.08 (0.37)  -0.54 (0.42)  1.29 
0.8  0.3  0.02 (0.23)  -0.31 (0.33)  0.94 
0.75  0.3  0.00 (0.29)  -0.41 (0.40)  1.03 
0.7  0.3  -0.02 (0.35)  -0.52 (0.46)  1.15 
0.65  0.3  -0.05 (0.40)  -0.63 (0.49)  1.28 
0.6  0.3  -0.07 (0.44)  -0.69 (0.52)  1.33 
0.55  0.3  -0.09 (0.46)  -0.71 (0.52)  1.37 
0.5  0.3  -0.10 (0.45)  -0.67 (0.49)  1.37 
0.45  0.3  -0.10 (0.41)  -0.58 (0.44)  1.32 
0.4  0.3  -0.09 (0.36)  -0.46 (0.37)  1.24 
0.55  0.2  -0.10 (0.48)  -0.76 (0.54)  1.42 
 
4.3.4  Discussion 
This  study  aimed  to  identify  the  optimal  intensity  window  parameters  with  which  to 
calculate the BBSI on both coronal and axial FSPGR acquisitions acquired in the cohort 
under study. It was found that an intensity window of I1=0.65 and I2=0.45 (i.e. Ic=0.55 
and Iw=0.2) provided the most sensitive measure of brain atrophy. Although the variance 
of measures was increased at this value, this was proportionately smaller than the increase 
in sensitivity, which meant that greater statistical power could be achieved using these 
parameters, as measured by the effect size in patients. 
 
The optimal parameters determined for both the coronal and axial images were the same, 
but this is not unexpected given that the scans were acquired on the same MR scanner 
using a similar protocol. Another study which looked at the optimum window settings for 
a dataset obtained on the same scanner as that used in the current study, similarly found 
that the best parameters were an intensity window between I1=0.7 and I2=0.5 (i.e. Ic=0.6 
and Iw=0.2) (Boyes et al., 2004). The marginal difference in parameters between these 
studies may have been due to the fact that the current study included images from patients  
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with  MS,  and  hypointense  periventricular  lesions  may  have  influenced  the  results. 
However in addition to parameters being dependent on the scan dataset they may also 
vary for data acquired on different scanners. This study has shown how atrophy rates can 
vary considerably depending on the window parameters chosen. Although the optimal 
parameters did not influence effect size to a great extent relative to default parameters, 
changes were nonetheless observed, and could be more significant for other datasets. This 
suggests  that  it  may  be  advantageous  to  optimise  window  parameters  for  any  given 
dataset, particularly for clinical trials in which even small improvements in the sensitivity 
or precision of atrophy  measurements could improve the ability to detect a treatment 
effect. Determining optimal parameters can be largely automated with minimal operator 
interaction required. As this was a retrospective investigation, all subjects with available 
imaging were included in the study to give power to the results and optimise over a wide 
range of atrophy rates. For a prospective study or clinical trial however, optimisation 
could  be  performed  on  a  subset  of  subjects  which  would  minimise  the  amount  of 
computer processing time required to assess a number of different window settings on 
larger cohorts. 
 
It should be noted that although increased power was gained from reducing the window 
width to 0.2, it was felt that the window should not be made any smaller. There is the 
potential that reducing Iw further could lead to spurious results in some instances, when 
the window could possibly fall entirely outside many brain boundary shift areas. With a 
wider window setting there is increased confidence that some of the brain boundary shift 
will lie within the window.  
 
One of the limitations of this study is that not every possible window setting was tested, 
and it was not assessed whether atrophy rates for a window centre (Ic) of 0.1 would be 
realistic. For clinical trials, a wider range of intensity windows could be investigated, 
including narrower windows, and the results looked at carefully in correspondence with 
the difference images to determine whether results appear realistic. A further limitation of 
this investigation is that BBSI atrophy rates were assessed against the BVD. This measure 
may be subject to error itself and it is not possible to judge whether it represents the best 
estimate of overall brain atrophy. Indeed with axial acquisitions, positive atrophy rates or 
brain “growth” did not agree well between segmented volume difference and the BBSI 
using  any  of  the  window  parameters.  However  even  without  approximating  BBSI  
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measures to the volume difference, the parameters which give the most realistic, sensitive 
and precise measure should be identified. As such, an intensity window between I1=0.65 
and I2=0.45 (i.e. Ic=0.55 and Iw=0.2) has been shown to increase the sensitivity and power 
of brain atrophy measurements by the BBSI compared with default parameters in both 
coronal and axial FSPGR images. For the remainder of this thesis these parameters will 
be applied in other investigations using the BBSI in this cohort. 
 
4.4  Measurement of brain atrophy by the brain boundary shift integral on different 
volumetric acquisitions and average images 
4.4.1  Introduction 
With most atrophy measurement techniques, optimisation of MR images for the technique 
may increase the sensitivity and precision of atrophy measures. This is important when 
designing large prospective studies of brain atrophy, as the acquisition parameters and 
sequence for images can be decided upon prior to acquiring data in order to maximise the 
reliability  of  measures.  Whilst  the  BBSI  has  been  applied  to  numerous  T1-weighted 
volumetric MRI, these images can vary in appearance depending on the MRI scanner 
used for acquisition and individual scan parameters (Fox et al., 2000b; Fox et al., 2005; 
Henley  et  al.,  2006;  Schott  et  al.,  2005).  Images  that  maximise  SNR  and  CNR,  and 
minimise chemical shift artefact, are likely to produce more reliable results. However no 
direct  comparison  of  atrophy  rates  quantified  on  different  acquisitions  has  been 
performed, so it is unclear to what extent this may effect measured atrophy rates. For 
multicentre studies, it is important to ensure that the BBSI is robust to small variations in 
images  between  subjects  caused  by  differences  in  MRI  hardware  and  acquisition 
parameters. In this study MR data has been acquired at one site only, so it is not possible 
to compare atrophy measures by the BBSI on acquisitions from different sites. However 
two FSPGR images have been acquired on the same day in controls and patients with 
RRMS.  Although  acquisition  parameters  for  the  two  images  were  similar,  the  voxel 
dimensions and acquisition plane of the images are different. Therefore the first aim of 
this study was to investigate relative atrophy quantification by the BBSI on these two T1-
weighted volumetric acquisitions and determine whether the BBSI was robust to these 
small differences and whether there was any systematic bias. 
 
In addition to optimising data acquisition by altering scan parameters, averaging repeated 
data could increase measurement precision. Noise introduced by either the MRI hardware  
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or the atrophy measurement technique could be reduced through this process as the signal 
is effectively doubled. Same-day imaging allows repeated atrophy measurements to be 
obtained and results can subsequently be averaged. A slightly more complex approach 
involves averaging the images themselves prior to analysis, which should increase the 
SNR by a factor of 1.41. It has previously been shown that the increased signal that can 
result from averaging data at each spatial location may increase SNR (Holmes et al., 
1998).  This  may  allow  more  accurate  and  precise  brain  atrophy  measurements  to  be 
made. Indeed one study investigating the impact of different acquisition protocols and 
processing streams on tissue segmentation used an average image as the gold standard 
(Clark et al., 2006). Averaging of volumetric images has also been utilised in Freesurfer, 
where  a  number  of  T1-weighted  images  can  be  combined  prior  to  determination  of 
cortical boundaries (Salat et al., 2004). The second objective of this study was therefore to 
determine whether averaging a) same-day data (BBSI measures) or b) same-day images, 
increased measurement precision of the BBSI. The former involves two separate BBSI 
measurements from two different scan pairs where two baseline and two repeat images 
were obtained on the same day. The latter involves merging images acquired at the same 
time-point and performing one BBSI measurement between the baseline average image 
and the repeat average image. 
 
4.4.2  Methods 
Subjects and MR imaging 
Twenty-nine subjects with RRMS (nine male, mean age 37.5 years (SD 7.5)) and 16 
control subjects (seven male, mean age 35.1 years (SD 6.3)) were identified who had T1-
weighted volumetric FSPGR images acquired in both the coronal  and axial planes at 
baseline and approximately one year follow-up (mean 1.06 years (SD 0.11)). The imaging 
protocols described in Chapter 3.3.2 were used for MRI acquisition, and coronal and axial 
images were acquired in the same scan session. Voxel dimensions were 0.94 x 0.94 x 
1.5mm
3 in the coronal image and 1.17 x 1.17 x 1.5mm
3 in the axial image.  
 
MRI analysis 
Whole brain segmentation was performed on all images using MIDAS, as described in 
Chapter 4.2.2, and N3 correction was applied. Affine registration was used to transform 
each repeat image to the baseline image (coronal to coronal and axial to axial) and the 
BBSI quantified using DBC and the optimised parameters determined in Chapter 4.3.  
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Figure 4-7 gives an overview of the procedure applied to average the axial and coronal 
image for a given subject and time-point. The axial image and region were first reoriented 
to the coronal plane whilst maintaining all voxel dimensions. The reoriented axial image 
was registered to the coronal image using affine registration, and re-sampled to give voxel 
sizes equivalent to the coronal image. An in-house algorithm was used to average the two 
co-registered images. Image intensity was normalised by dividing each image through by 
its mean intensity over the whole brain region, and then image intensities were rescaled 
between 0 and 1000. The transformation matrix used to register the axial image to the 
coronal image was applied to the axial brain ROI. This transformed axial brain ROI and 
the coronal brain ROI were separately copied to the average image. Each average repeat 
image  was  then  registered  to  the  corresponding  average  baseline  image,  using  affine 
registration, and the BBSI was quantified. To avoid biasing results, registration and BBSI 
quantification was performed twice on the averaged images, once using the axial brain 
ROIs and once using the coronal brain ROIs. Again, DBC and the optimised parameters 
determined  in  Chapter  4.3  were  applied.  Visual  assessment  of  all  registrations  was 
performed to check accuracy.  
 
Figure  4-7  Overview  of  the  procedure  used  for  creating  an  average  image  and 
calculation of the BBSI on average, axial and coronal images. 
            
 
Intensity profiles for the coronal, axial and average images of a randomly chosen subject 
were generated. Using MIDAS a line one voxel high was positioned across each image 
(which  were  registered  to  the  same  space),  and  the  intensity  at  each  voxel  was  
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determined. The brain region, eroded once, was used to quantify mean brain intensity, and 
voxel intensities of the line were normalised to this value.  In addition, the SNR was 
measured for each image. For each subject it was ensured that all images were in the same 
space  as  the  coronal  baseline  image.  Due  to  the  procedures  outlined  and  performed 
previously,  only  registration  of  the  coronally  reformatted  repeat  axial  image  to  the 
reformatted  and  registered  (to  coronal)  axial  baseline  image  was  required.  On  each 
coronal baseline image a region of approximately 1000 voxels was drawn within the WM 
of the anterior frontal lobe. It was ensured that this region did not include any GM or 
lesions. For coronal, axial and average images a difference image was generated from the 
registered baseline and repeat images for each subject. SNR was calculated according to 
Equation 4.1 (Price et al., 1990). 
 
image   difference   of   ROI   in WM   signal mean 
image   of   ROI   in WM   signal mean    2
= SNR   (4.1) 
 
Statistical analysis 
SNR  measurements  from  the  different  images  (coronal,  axial  and  average)  were 
compared pairwise using a paired t-test. All BBSI values were corrected for scan interval 
and expressed as a percentage of baseline brain volume. A Bland-Altman plot of BBSI 
values  obtained  on  coronal  and  axial  acquisitions  was  generated  to  investigate  their 
association. The BBSI quantified on serial coronal and axial images was averaged and 
subsequently mean (SD) atrophy rate in controls and RRMS subjects was determined for 
i) coronal images, ii) axial images, iii) average of coronal and axial atrophy rate, iv) 
average images using coronal brain regions, v) average images using axial brain region. 
As in Chapter 4.2 mean atrophy rates obtained on the three different images and average 
values  were  compared  by  fitting  a  model  relating  atrophy  rate  to  method,  utilising  a 
generalised  estimating  equations  approach.  The  model  assumed  an  exchangeable 
correlation structure and robust standard errors were calculated. A joint Wald test was 
used as an overall test of differences in mean atrophy rates between methods. Where a 
significant  difference  was  observed  (p<0.05),  paired  t-tests  were  used  to  investigate 
pairwise  differences.  Again,  a  generalisation  of  Pitman’s  test  to  more  than  two 
observations  was  performed  within  each  subject  group  to  determine  if  there  was  a 
significant  difference  in  the  variance  of  atrophy  rates  using  the  different  images  and  
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methods (Han, 1969). Where a significant difference was observed (p<0.05), Pitman’s 
test was applied pairwise to observations. 
 
Investigation into the relative statistical power of any two methods, where a significant 
difference in the mean or variance of atrophy rates was found, was performed. The CV 
(σ/µ) of the two methods was calculated, and the square of their ratio determined to 
indicate the relative number of patients required to detect a treatment effect using the two 
different methods. 
 
4.4.3  Results 
Upon  visual  inspection,  all  the  registrations  appeared  acceptable.  An  example  of  an 
original coronal and axial image and the average image generated is given in Figure 4-8. 
The average images appeared to be smoother with greater intensity homogeneity within 
each tissue class. The mean SNR was significantly greater in axial images than in coronal 
images  (mean 38.4 versus 29.0, p<0.001) and significantly  greater in average images 
(mean 46.1) than either coronal or axial images (both p<0.001).  
 
Looking first at whether there was any systematic bias between atrophy rates obtained on 
the coronal and axial T1-weighted volumetric acquisitions, Figure 4-9 shows the Bland-
Altman plot of the average of these values and the difference between them for each 
subject. The mean difference in atrophy rates between the two acquisitions (coronal – 
axial) was 0.03% year
-1 (SD 0.58, 95% CI -0.28 to 0.34, p=0.85) in controls and 0.03% 
year
-1 (SD 0.50, 95% CI -0.16 to 0.22, p=0.73) in patients with RRMS. Therefore no bias 
in average measures was evident, although differences up to approximately 1% year
-1 
were  observed  within  individual  patients.  The  95%  reference  range  shows  the  values 
within which 95% of the differences between measures from coronal and axial images are 
expected to lie, and it is interesting to note that this range is wider in control subjects. 
 
Figure 4-10 shows that the intensity profile of the average image lay between those of the 
coronal and axial images. Figure 4-11 shows the scatterplot of atrophy rates obtained for 
all subjects, whilst Table 4-4 gives the mean atrophy rates in each subject group when 
quantified using i) coronal images, ii) axial images, iii) average coronal and axial atrophy 
rate, iv) average image using coronal brain regions, v) average axial image using axial 
brain regions.  
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Figure 4-8 Visual comparison of a coronal, axial and average image from a single subject. Images are shown when viewed in both the coronal 
and axial plane. From left to right: the original coronal image, the original axial image, the axial image following reorientation and registration 
to the coronal image, the average image.  
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Figure  4-9  Bland-Altman  plot  comparing  BBSI  brain  atrophy  rates  quantified  on 
coronal and axial T1-weighted volumetric images, in controls and subjects with RRMS. 
The  reference  ranges  are  the  values  within  which  95%  of  the  differences  between 
atrophy measurements from coronal and axial images are expected to lie. 
 
 
There was no evidence of a difference in mean atrophy rates using the different methods 
in either controls (p=0.24) or subjects with RRMS (p=0.41). The generalised Pitman’s test 
revealed a significant difference in the variance of atrophy rates in both controls and 
subjects with RRMS (both p<0.001). The SD of atrophy rates when BBSIs from coronal 
and  axial  images  were  averaged  was  the  lowest  of  the  five  measures,  and  pairwise 
Pitman’s tests revealed that it was significantly lower than the SD of measures obtained 
on the average images (using either coronal or axial ROIs) (p≤ 0.001). Consequently, 
sample  sizes  were  estimated  to  be  22%  and  18%  higher  (p<0.05)  when  quantifying 
atrophy on average images (coronal and axial ROI respectively) compared with averaging 
BBSI data from the two acquisitions (95% CI 8% to 38% higher when using the coronal 
ROI, and 4% to 35% higher when using the axial ROI). Based on pairwise Pitman’s tests, 
no significant difference was observed in the variance of measures from either the single 
coronal or axial images and the average image, or between the coronal and axial images, 
although the latter had marginally less variance in rates.  
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Figure 4-10 Intensity profiles of an average, axial and coronal image from one subject. 
A one-dimensional intensity profile through the brain on each image was generated by 
drawing a line one voxel high between the points A and B (top image), and normalising 
the intensity value of each voxel in this region to the mean whole brain intensity. 
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Figure 4-11 BBSI brain atrophy rates quantified on average, axial and coronal T1-
weighted volumetric images, in controls and subjects with RRMS. 
 
 
 
 
Table 4-4 BBSI mean brain atrophy rates quantified on average, axial and coronal T1-
weighted volumetric images, in controls and subjects with RRMS. 
Mean (SD) atrophy rate (% year
-1)   
Control  RRMS  
Coronal  -0.04 (0.52)  -0.73 (0.61) 
Axial  -0.07 (0.48)  -0.76 (0.54) 
Average BBSI  -0.05 (0.40)  -0.74 (0.52) 
Average image (coronal ROI)  -0.05 (0.50)  -0.76 (0.65) 
Average image (axial ROI)  -0.08 (0.50)  -0.80 (0.66) 
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4.4.4  Discussion 
The aim of this study was to perform a direct comparison of the BBSI when applied to 
two different T1-weighted volumetric images and to investigate whether averaging data 
could improve the precision and power of atrophy  measurement using the  BBSI.  No 
significant difference was observed between atrophy rates obtained on the two volumetric 
images,  and  it  was  shown  that  averaging  repeated  BBSI  measures  can  decrease  the 
variance of atrophy measurement by the BBSI. Interestingly, this simple strategy was 
superior  to  averaging  MR  images  prior  to  atrophy  measurement,  and  significantly 
increased statistical power. 
 
Although the two images analysed in this study were acquired with similar protocols on 
the same scanner, small differences in their contrast and in the “sharpness” of edges was 
apparent,  possibly  due  to  the  differences  in  the  orientations  of  voxel  dimensions  and 
partial volume effects (Figure 4-8). However on average the SNR was greater in axial 
images compared with coronal images. Although within individual patients differences 
between atrophy rates obtained on coronal and axial images were apparent, there was no 
systematic bias between average measures from the two, suggesting that the differences 
are likely to have been due to noise from either the MR hardware or the measurement 
method. This is advantageous if the technique is to be used in future multicentre studies 
where differences in acquisition may occur between centres. As mentioned previously 
however,  one  of  the  limitations  of  this  study  is  that  the  two  images  compared  were 
acquired on the same scanner. To fully investigate the robustness of the BBSI, direct 
comparison of measures from images acquired on different makes and models of scanner 
should  be  performed.  It  is  noteworthy  that  the  axial  acquisition  had  marginally  less 
variance in measures. This is likely to have been due to the slightly larger voxel sizes of 
this acquisition which led to an increase in SNR. Small increases in voxels sizes for 
volumetric acquisitions may be a useful method by which measurement precision could 
be increased and should be investigated further. 
 
Averaging the coronal and axial images significantly increased SNR relative to either 
individual acquisition. Despite the increased SNR there was no significant increase in the 
precision  of  atrophy  measurement  by  the  BBSI  when  applied  to  the  average  image 
compared with single images (coronal or axial), and the standard deviation was actually 
increased in RRMS patients. One reason for this finding may be due to the images having  
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been acquired in different planes. Correction for gradient distortions performed at the time 
of scanning is applied in-plane, but is not necessarily effective in removing through-plane 
distortion. Therefore distortion may have been different between the two images which 
may have led to more blurring at the edges of the brain and “cancelled out” any gain in 
signal that may have been attained through averaging. It may also have been due the 
limited  number  of  scans  available  for  averaging.  A  study  that  investigated  the 
effectiveness  of  averaging  up  to  20  T1-weighted  volumetric  images  (spoiled  GRASS 
sequence, 1.0 x 1.0 x 1.0mm voxels) in creating enhanced MR images found evidence 
from intensity profiles that noise was reduced and that the GM/WM intensity crossings 
were much clearer on the average images (Holmes et al., 1998). It was also noted in this 
study that the benefit of averaging was apparent with as few as five images, but became 
noticeably greater as the number of images contributing to the average increased. It may 
be that average images have a greater impact on measures of regional or tissue-specific 
atrophy, where the contrast between GM and WM is vital.  
 
The benefits of averaging repeated MR images and increasing measurement precision 
must be balanced against the time and expense of acquiring multiple MRI. As there was 
no significant difference in the variance of atrophy rates from coronal, axial and average 
images this implies that there is unlikely to be any substantial benefit from acquiring 
multiple images for averaging. Simpler, more cost- and time-efficient approaches may 
improve measurement precision. For example, in the study by Holmes et al. (Holmes et 
al., 1998), voxels were resampled to 0.5mm
3 which may have improved measurements 
due to a reduction in partial volume effects. In addition, the current study found that the 
greatest measurement precision was achieved when two repeated BBSI measures were 
averaged; the variance was significantly lower for this measurement than for atrophy rates 
obtained on average images and this method consequently had greater statistical power. 
This result also suggests that noise introduced by the BBSI measurement technique may 
be greater than noise from the MR hardware. 
 
One of the limitations of this study is that brain regions were not resegmented on the 
average  image  following  its  generation.  Another  study  that  investigated  the  use  of 
principal component analysis applied to multispectral data to generate a composite image 
found that segmentation of images was superior on the composite image compared with 
single image segmentation (Zhang et al., 2001b). However the BBSI should be robust to  
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small differences in the segmentation and no significant differences in atrophy rates were 
observed between average images using the coronal or the axial ROIs. 
 
In summary, this study has shown that the BBSI appears to be robust to small differences 
in  acquisitions,  and  obtaining  more  than  one  scan  at  a  study  assessment  for  image 
averaging is not likely to be advantageous when quantifying the BBSI. Whilst averaging 
atrophy measurements by the BBSI increased measurement precision, generating average 
composite  images  did  not  improve  measurement  precision  relative  to  single  image 
analysis, despite significantly increasing SNR relative to single images.  However this 
study has only investigated the averaging of two particular sequences; BBSI measurement 
on different 2D or 3D acquisitions may benefit from image averaging. Moreover, this 
process may be more advantageous when using other image analysis methods or when 
looking at regional brain areas. This study suggests that data averaging may be a simple 
approach to increasing the statistical power of brain atrophy measurement by the BBSI. 
 
4.5  Chapter conclusions 
This  chapter  describes  automated  brain  atrophy  measurement  using  the  BBSI  and 
implementation  of  procedures  designed  to  optimise  atrophy  measurement  using  this 
technique. Whilst some optimisation strategies might be complex or labour intensive, it 
has been determined that using simple widely  available techniques, the  precision and 
sensitivity of measurements can be significantly increased. Correction of differential bias 
was shown to reduce the variability of atrophy rates and suggests that DBC should be 
performed routinely, even when there appears to be no disparity in intensity between 
images on visual inspection. Altering the window parameters for BBSI quantification was 
shown to increase measurement sensitivity. For large cohorts determining the optimal 
parameters with which to run the BBSI should be performed, as it can be fully automated 
and may increase statistical power. It has also been shown that obtaining multiple images 
at a given assessment to allow image averaging is not likely to improve statistical power 
significantly, and will increase the time required for both acquisition and post-processing. 
Whilst it may not be practical to analyse a dataset more than one time in large studies, for 
small exploratory studies averaging repeated measurements may be useful to increase the 
power  of  the  study.  Further  investigation  into  the  relative  advantages  of  different 
acquisitions, specifically 3D images with larger voxel sizes (given the lower variance of 
measures on the axial image with larger voxels than the coronal), should be performed.  
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5  Analysis  and  optimisation  of  brain  atrophy  in  multiple 
sclerosis using SIENA 
 
5.1  Chapter introduction 
As described previously, SIENA (Smith et al., 2002) is an automated algorithm, part of 
the  FSL  toolkit  (www.fmrib.ox.ac.uk)  (Smith  et  al.,  2004),  that  allows  the  direct 
quantification of brain atrophy from serial MR images. It has been applied in numerous 
studies of MS, investigating brain atrophy in people who have experienced a CIS (Paolillo 
et al., 2004) and patients with RRMS (Richert et al., 2006), SPMS (Rovaris et al., 2003) 
and PPMS (Stevenson et al., 2002). Studies have shown brain atrophy rates ranging from 
-0.3  to  -1.4%  year
-1  (Filippi  et  al.,  2004;  Richert  et  al.,  2006;  Rovaris  et  al.,  2003; 
Stevenson  et  al.,  2002).  As  shown  in  Chapter  4  however,  optimisation  of  automated 
methods for a subject group and scan acquisition protocol may increase the sensitivity and 
precision of measurement.  
 
Few  of  the  studies  investigating  brain  atrophy  in  MS  using  SIENA  have  applied  the 
technique  to  3D  volumetric  MRI,  although  the  technique  is  reported  to  be  robust  to 
different MR acquisitions. One of the most likely reasons for the lack of studies applying 
SIENA to 3D images is that if the initial automated  brain extraction is  not accurate, 
manual editing will be time-consuming for acquisitions with over 100 slices. The first aim 
of this experiment was therefore to determine whether accurate brain segmentation could 
be generated on 3D volumetric images by BET, which constitutes the initial stage of the 
SIENA  algorithm.  BET  automatically  removes  skull  and  non-brain  regions  from  the 
image, and certain algorithm parameters can be altered by the operator which will alter 
the resulting extracted region and can be used to alter the accuracy of segmentation. Like 
the BBSI, the brain ROI acts only as a guide to the brain region. Edge detection methods 
are used to determine the true brain boundary within this ROI, from which atrophy is 
calculated  by  comparing  intensity  gradient  profiles  between  images  (intensity 
inhomogeneity correction is performed as part of the algorithm). In theory this means that 
atrophy  measures  by  SIENA  are  relatively  protected  from  small  errors  in  brain 
delineation, and should be less sensitive to these errors than methods that derive volumes 
from  brain  delineation.  This  chapter  therefore  also  investigates  whether  a  propagated 
template (average) brain region, which will not be entirely accurate for each subject, leads  
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to comparable atrophy rates by SIENA from volumetric MRI to those generated when 
individual brain masks are used.  
 
Finally, as few studies have applied SIENA to volumetric acquisitions in MS, this chapter 
examines whether atrophy measurements by SIENA are comparable with those obtained 
on standard T1-weighted CSE imaging, the acquisition that has most commonly been 
utilised in previous studies. 
 
5.2  Optimisation of brain extraction for a volumetric acquisition and investigation 
into the use of brain templates for atrophy measurements using SIENA  
5.2.1  Introduction 
As described previously, BET forms the initial stage of the automated SIENA algorithm 
(Smith et al., 2002; Smith, 2002). Unlike the brain extraction used for the BBSI, BET 
does not attempt to model the brain surface at the finest level following gyri and sulci. 
Instead  a  tessellated  surface  mesh  of  triangles  is  deformed  iteratively  until  a  smooth 
surface fits the brain. Validation against manual methods have shown BET to be accurate 
for T1-weighted images although it was thought that the brain boundary was slightly 
overestimated by approximately one voxel (Smith, 2002). In addition, the validation study 
demonstrated that BET was robust to differences in image slice thickness (images with 
slices  thicknesses  ranging  from  0.8-6mm  were  tested)  and  variations  arising  from 
differences in scanners (scans from 15 different scanners were tested, including 1.5T and 
3T) (Smith, 2002). 
 
With improvements to MRI scanner software and hardware decreasing scan times and 
improving image quality, and the development of new techniques for the analysis of high 
spatial resolution MRI, it is now common to acquire T1-weighted 3D volumetric images 
with  slice  thicknesses  of  1.5mm  or  less.  Despite  validation  of  BET  for  images  with 
thinner  slices,  few  studies  investigating  brain  atrophy  in  MS  have  applied  SIENA  to 
volumetric images. This may be because other factors influencing the appearance of an 
image  may  subsequently  affect  the  performance  of  BET,  such  as  individual  scan 
parameters, resulting in scan contrast, intensity non-uniformity, and chemical shift and 
susceptibility-related  artefacts.  Although  reducing  the  variability  of  atrophy 
measurements is important, high levels of accuracy are also desirable. Therefore prior to 
further processing by SIENA, manual editing of the images may be required, which can  
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be labour intensive for volumetric sequences. BET allows a number of parameters to be 
altered by  the operator,  and these  can be used to optimise the brain  extraction in  an 
automated manner. Given the limited information available on the application of BET to 
3D volumetric images in MS, the first aim of this study was to determine the accuracy of 
brain extraction using this tool on the set of 3D volumetric images being used in this 
thesis. 
 
As slice-by-slice manual editing of sub-optimal brain regions can be labour intensive, it 
would  be  useful  to  develop  methods  which  allowed  accurate,  robust  and  automated 
segmentation of the brain on any acquisition. Based on the hypothesis that SIENA should 
be relatively insensitive to small errors in brain segmentation, the second aim of this study 
was to address whether a standard template (average) brain region could be registered to 
images,  and  processed  by  SIENA,  to  give  comparable  brain  atrophy  rates  to  those 
obtained using accurate subject-specific brain segmentations.  
 
5.2.2  Methods 
Subjects and MR imaging 
Sixteen control subjects (seven male, mean age 35.1 years (SD 6.3)), 42 subjects with CIS 
(14 male, 34.4 years (SD 6.3)) and 30 subjects with RRMS (eight male, 37.5 years (SD 
7.4)) were included in the study. All subjects had coronal T1-weighted volumetric MRI 
(voxel dimensions 0.94 x 0.94 x 1.5) at baseline and approximately one year follow-up 
(mean follow-up time 1.16 years (SD 0.24)), according to the standard protocol described 
in Chapter 3.3. Images were reoriented to axial orientation, as SIENA is conventionally 
applied to axial images, whilst maintaining all voxel dimensions.  
 
MRI analysis 
BET was applied to all images using default parameters and the resulting brain masks 
inspected for accuracy. If the regions were not considered to be sufficiently accurate BET 
algorithm parameters were subsequently altered in order to optimise the automated brain 
extraction and obtain the most accurate brain region. The three parameters that could be 
altered were: i) the fractional intensity threshold, which leads to the overall segmented 
brain becoming larger or smaller, ii) the threshold gradient, which adds a gradient to the 
fractional intensity threshold leading to a larger overall segmented brain at the bottom of 
the image and smaller at the top, or vice versa, iii) the co-ordinates for the centre of the  
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initial  brain  surface  sphere,  which  should  lie  approximately  central  in  the  brain.  To 
estimate  the  co-ordinates  for  the  centre  of  the  brain,  the  MNI-152  standard  space 
reference  image  (www.bic.mni.mcgill.ca/cgi/icbm_view)  (Mazziotta  et  al.,  2001)  was 
registered  to  each  image,  using  the  FLIRT  registration  package  (see  Chapter  3.4.2) 
(12dof), maximising the normalised mutual information (Studholme et al., 1999). The 
brain segmentation available in FSL for this reference scan was transformed to each of the 
individual scans by applying the corresponding transformation parameters obtained from 
image registration, thereby creating an approximate brain mask on each scan in its native 
space.  Using  this  approximate  template  brain  mask,  the  co-ordinates  of  the  centre  of 
gravity of this mask were calculated and used as the brain centre. All optimised BET 
brain masks were visually inspected for accuracy and manually edited where required. 
 
In order to generate template brain regions on each image, the same method used to apply 
an approximate brain mask to each image for estimation of the co-ordinates for the centre 
of the brain was applied, i.e. the MNI-152 standard space reference scan was registered to 
each image and the brain segmentation on this average scan was transformed to each 
individual scan by applying the corresponding transformation parameters. It should be 
noted that generation of the template mask on each image uses the same method as the 
“betpremask” option available in the FSL software package. It has been suggested that 
betpremask can be applied prior to BET, if BET alone is not producing optimal results. It 
was felt however, that the shape of the brain ROI used by betpremask was not always 
optimal for all images and often excluded inferior regions of the temporal and frontal 
lobes.  Therefore  the  MNI-152  standard  space  brain  template  was  manually  edited  to 
improve its  accuracy  before using an in-house script to perform the same process  as 
betpremask. Each individual image was visually assessed to ensure that the template brain 
mask had been successfully transformed. 
 
SIENA was run on all serial image pairs using i) the optimised BET brain mask, and ii) 
the  template  brain  mask.  PBVC  was  output  for  each  subject  using  each  mask  and 
corrected for scan interval. The accuracy of registration of baseline and repeat images was 
checked as was the colour overlay showing regions of atrophy. 
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Statistical analysis 
Mean (SD) atrophy rates (% year
-1) were determined for control, CIS and RRMS subject 
groups when using subject-specific brain masks and the template brain mask. Within each 
subject group a paired t-test and Pitman’s test was performed to determine if there were 
significant differences in the mean and variance of atrophy rates respectively, between 
measures obtained using subject-specific brain masks and the template brain mask. In 
addition, a Bland-Altman plot was created to assess the differences between atrophy rates 
obtained when using the two different brain masks. As in Chapter 4, relative statistical 
power for atrophy measurements obtained using the different masks was calculated if 
there was found to be significant differences in either the mean or variance of measures. 
 
5.2.3  Results 
Figure 5-1 shows examples of the brain regions obtained using BET in one subject from 
the cohort. Default parameters gave inaccurate brain regions which were not improved by 
altering the intensity threshold and threshold gradient (Figure 5-1a to c). By specifying 
the co-ordinates of the centre of the brain for the initial brain surface sphere, accurate 
brain extraction was achieved for all images (Figure 5-1d to f). There were no failures 
when  creating  the  template  brain  region  but  small  errors  were  apparent  on  all  scans 
(Figure 5-1g to i), mainly exclusion of the edges of the inferior and lateral temporal lobes, 
anterior frontal lobes and inferior cerebellum. In addition there was some inclusion of 
dura in the superior regions of the head in some subjects. 
 
In  controls  mean  atrophy  rates  were  -0.07%  year
-1  (SD  0.34)  using  the  optimised 
individual  BET  brain  mask,  and  -0.03  %  year
-1  (SD  0.34)  using  the  template  mask. 
Similarly,  in  CIS  subjects  mean  atrophy  rates  were  -0.31%  year
-1  (SD  0.48)  with 
individual masks and -0.30% year
-1 (SD 0.49) with the template mask, whilst in RRMS 
subjects  they  were  -0.78%  year
-1  (SD  0.59)  and  -0.77%  year
-1  (0.57)  respectively. 
Looking  at  the  Bland-Altman  plot  (Figure  5-2)  there  was  no  apparent  bias  in 
measurements obtained using the two different masks, and the 95% reference range (the 
values within which 95% of values are expected to lie) was relatively narrow with all 
differences below 0.4% year
-1. This was confirmed by quantifying the mean difference 
(individual BET mask – template mask) between atrophy rates, and paired t-tests gave no 
evidence that there was a significant difference.  
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Figure 5-1 Examples of the BET brain extraction using different parameters, and the 
template brain extraction from a coronal T1-weighted volumetric image. a) original 
image, b) BET default parameters, c) changing the fractional intensity and gradient 
thresholds, d)-f) specifying the co-ordinates for the centre of the initial brain surface 
sphere of BET, g)-i) using a template brain mask. 
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Mean differences were -0.04% year
-1 in controls (SD 0.09, 95% CI -0.09 to 0.01, p=0.08),  
-0.01% year
-1 in CIS subjects (SD 0.10, 95% CI -0.04 to 0.02, p=0.62), and -0.01% year
-1 
in  subjects  with  RRMS  (SD  0.13,  95%  CI  -0.06  to  0.04,  p=0.75).  In  addition,  no 
significant differences were seen in the variance of measures calculated using the two 
different masks (controls p=0.94, CIS p=0.42, RRMS p=0.56). 
 
Figure 5-2 Bland-Altman plot comparing SIENA brain atrophy rates quantified using 
optimised  individual  BET  brain  masks  and  a  template  brain  mask  on  T1-weighted 
volumetric images, in controls and subjects with CIS and RRMS. The reference ranges 
are  the  values  within  which  95%  of  the  differences  between  atrophy  measurements 
using the two different masks are expected to lie. 
 
 
5.2.4  Discussion 
This study investigated the performance of BET on T1-weighted volumetric images, and 
the relative brain atrophy rates obtained using SIENA when applying subject-specific 
accurate brain masks and a template brain mask. It was shown that brain extraction can be 
achieved on these images using BET, without the need for manual editing. In addition, it 
was demonstrated that using an average template brain mask, similar brain atrophy rates  
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are quantified by SIENA suggesting that the technique is robust to small errors in the 
brain extraction. 
 
Although using default parameters BET gave poor results on the images included in this 
study, it was found that by specifying the co-ordinates for the centre of gravity of the head 
from which the deformable model is initiated, accurate results could be achieved on all 
images. The most likely reason for this is that images analysed in this study were acquired 
in the coronal plane, and the brain was not positioned centrally within the FOV (when 
viewing it in the coronal plane, i.e. neck was included in the image and the brain therefore 
was positioned higher). If the deformable model is initiated at the centre of the FOV, this 
consequently results in large regions of non-brain, inferior to the brain, being included in 
the extraction. By specifying the approximate co-ordinates for the centre of the head the 
deformable model can achieve accurate brain segmentation. Indeed a study published in 
2007 which included volumetric images that contained a lot of lower non-brain matter 
devised a simple script  that re-ran  BET  several  times, each time intialising the brain 
centre estimation using the centre of gravity found on the previous iteration (Smith et al., 
2007).  In this way accurate brain extraction was achieved for downstream processing by 
SIENA. Another study that used BET to process T1-weighted volumetric MPRAGE and 
SPGR images (both 1mm
3 voxels) similarly found that accurate brain extraction could be 
achieved by altering BET parameters (Clark et al., 2006). In this case the threshold for 
extraction was optimised for the different pulse sequences. It seems that the optimisation 
of BET will depend to a large extent on the acquisition in question. 
 
Use of a registration template is advantageous, as it is fully automated, reproducible, can 
be  applied  to  any  acquisition,  and  the  cost  function  (normalised  mutual  information) 
should  not  be  influenced  by  image  inhomogeneities,  movement  or  lack  of  boundary 
definition  (Maes  et  al.,  1997),  making  it  highly  reproducible  providing  that  the 
registration technique is robust. It also avoids labour intensive manual editing or scan 
specific optimisation (as was used with BET on 3D acquisitions). Although templates 
may represent a trade-off between accuracy versus speed and reproducibility, when using 
a standard template brain mask in this study, atrophy rates closely approximated those 
obtained when the individual and accurate BET brain masks were applied. As already 
mentioned, these results appear to suggest that SIENA may be robust to small errors in 
brain  segmentation.  A  study  that  investigated  intercentre  agreement  of  brain  atrophy  
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measurement  in  MS  using  SIENA  on  2D  images  found  that  manual  editing  of  brain 
regions obtained by BET did not significantly alter mean atrophy rates (Jasperse et al., 
2007b),  suggesting  that  downstream  processing  is  not  affected  when  some  non-brain 
regions are included in the initial brain mask. This is in agreement with the findings of the 
experiments described in this chapter. However the variance of measurements within a 
centre was greater compared with when manual editing of regions was performed which 
is in contrast to the present study.  
 
Although a standard brain mask was used as a template, this can lead to inaccuracies due 
to the normal variation in human brain between subjects. One approach that has been 
investigated that could lead to more accurate segmentation is the creation of a specific 
template for a given dataset. For example a template specific to patients with RRMS or 
controls could be created and applied, or a family of brain templates could be collated 
which are then searched to find the “best” template for a given image, as proposed in one 
study (Wu et al., 2007a). Non-linear registration of a template brain mask to images may 
also improve the accuracy of resulting individual brain masks. 
 
From this study, it appears that high resolution 3D acquisitions should be considered for 
future brain atrophy studies in MS as (i) automated brain segmentation can be achieved 
using BET, and (ii) SIENA appears to be robust to small segmentation errors in the brain 
mask, which may not be true on images that have lower resolution. The use of template 
brain masks on a larger cohort of subjects with T1-weighted volumetric images from 
different MR scanners should be performed. 
 
5.3  A  comparison  of  SIENA  performance  on  “3D”  volumetric  acquisitions  and 
“2D” spin echo acquisitions 
5.3.1  Introduction 
Typically SIENA has been applied to T1-weighted “2D” CSE images with 3mm or 5mm 
thick contiguous slices (Rovaris et al., 2003; Stevenson et al., 2002), in part because the 
acquisition  is  acquired  for  other  analyses,  but  also  because  the  number  of  slices 
comprising the image is limited, minimising manual editing when required. It was shown 
in the last experiment, that an automated and accurate brain extraction can be achieved on 
volumetric T1-weighted acquisitions using BET. If analysis time is not increased, this 
finding may promote the acquisition of 3D volumetric images for future studies using  
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SIENA. One might expect more reliable atrophy measurements to be obtained on images 
with higher resolution (i.e. 3D volumetric images as opposed to 2D CSE images), where 
partial volume effects will be minimised and sensitivity to detect small tissue volume 
changes may be improved. However little investigation comparing atrophy quantification 
by SIENA on the two sequences has been performed. 
 
In the original validation of SIENA by Smith et al. (Smith et al., 2002), it was found that 
image slice thickness had no effect on longitudinal atrophy measures using SIENA. Yet 
this observation was based on analysis of control subjects who had been scanned over a 
short interval and in whom no atrophy was expected. It is unclear whether in patients in 
whom brain volume loss is occurring, longitudinal atrophy measurement by SIENA is 
influenced by image slice thickness and whether using 3D T1-weighted images provides 
better results than 2D images in relation to measurement precision, sensitivity, processing 
speed and reliability. This aim of this experiment was to evaluate the performance of 
SIENA on 2D and 3D T1-weighted acquisitions in patients with RRMS in whom brain 
atrophy was occurring, and control subjects. 
 
5.3.2  Methods 
Subjects and MR imaging 
Twenty-nine subjects with RRMS (seven male) and 14 normal healthy control subjects 
(five male) with MRI at baseline and one year follow-up (mean 1.1 years (SD 0.1)) were 
identified for the study. At baseline the MS group had a mean age of 37.3 years (SD 7.4) 
whilst controls had a mean age of 35.3 years (SD 7.4). Mean disease duration in patients 
was 3.0 years (SD 0.8) and disability was mild, with a median EDSS of 1.5 (range 0-3). 
 
T1-weighted 2D CSE and coronal 3D FSPGR images were obtained using the acquisition 
parameters described in Chapter 3.3.2. Voxel dimensions were 0.94 x 0.94 x 5mm
3 for the 
CSE image and 0.94 x 0.94 x 1.5mm
3 for the FSPGR image. Both acquisitions were 
acquired on the same day. 
 
MRI analysis 
Three-dimensional  volumetric  images  were  reformatted  to  axial  orientation,  whilst 
maintaining all voxel dimensions. Individual brain masks were generated for each 2D and 
3D image using the optimised version of BET described in Chapter 5.2, which required  
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specification of the co-ordinates of the approximate centre of the brain for the initial brain 
surface sphere. Results were visually assessed and in the case of 2D images a judgement 
was made regarding the need for further optimisation of BET. Alteration of the intensity 
threshold, threshold gradient, or manual editing was performed as necessary on the 2D 
images  in  order  to  obtain  an  accurate  brain  mask  on  each  image.  SIENA  was 
subsequently run on each 2D and 3D serial image pair, which registered the repeat brain 
to the baseline brain prior to atrophy quantification. All resulting PBVCs were annualised. 
 
Statistical analysis  
When  assessing  the  results  several  factors  were  considered.    Firstly  the  level  of 
automation and operator time required to obtain an accurate brain mask on a given image 
was considered. It was also noted if there were any failures in either creating the brain 
masks or with SIENA. Mean (SD) atrophy rates in controls and patients with RRMS were 
calculated on the two acquisitions. Atrophy rates obtained on the 2D and 3D acquisitions 
were  compared  pairwise  by  subject  using  a  Bland-Altman  plot  and  paired  t-tests  to 
determine  if  there  was  bias  between  the  two  acquisitions.  Pitman’s  test  was  used  to 
determine if there was a significant difference in the variance of measures obtained on the 
two acquisitions. The mean (SD) difference between 2D and 3D atrophy rates was also 
determined.  
 
Investigation into the relative statistical power of 2D and 3D acquisitions for monitoring 
brain atrophy was performed. As in Chapter 4.2 the CV (σ/µ) of the two methods was 
calculated, and the square of their ratio was determined to indicate the relative number of 
patients required to detect a treatment effect using the two different acquisitions. 
 
5.3.3  Results 
Brain masks obtained on the 2D images using the same optimised version of BET as for 
3D images were sub-optimal, including non-brain regions mainly in the area of the eyes 
(Figure 5-3a). Due to the nature of the errors it was decided that altering the intensity 
thresholds  would  not  significantly  improve  brain  extraction,  so  manual  editing  was 
performed on all images (taking approximately 20 minutes per subject). Creation of the 
brain masks on the 3D images using the optimised version of BET was fully automated 
and none of the subjects failed. An example of the resulting brain mask is shown in Figure 
5-3b.  
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Figure  5-3  Example  of  the  brain  extraction  (outline)  obtained  using  an  optimised 
version of BET on a) a T1-weighted 2D spin echo image and b) a T1-weighted 3D 
volumetric image.  
 
 
 
Figure 5-4 gives an overview of the brain atrophy rates obtained in controls and patients 
with RRMS on each of the acquisitions whilst Figure 5-5 shows the Bland-Altman plot 
comparing  brain  atrophy  rates  obtained  on  the  two  acquisitions.  For  most  subjects 
agreement between the two measures was reasonable, however three patients, who have 
greater  atrophy,  show  much  larger  atrophy  rates  on  the  3D  compared  with  the  2D 
acquisition, suggesting there may be some bias in measures. As can be seen on the plot, 
differences up to around 1% year
-1 between 2D and 3D acquisitions were observed, and 
the range of differences within which 95% of subjects are estimated to lie is wide (shown 
on the Bland-Altman plot).  
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Figure 5-4 SIENA brain atrophy rates quantified on 2D spin echo and 3D volumetric 
acquisitions, in controls and subjects with RRMS. 
 
 
Figure 5-5 Bland-Altman plot comparing SIENA brain atrophy rates quantified on 2D 
spin  echo  and  3D  volumetric  images,  in  controls  and  subjects  with  RRMS.  The 
reference ranges are the values within which 95% of the differences between atrophy 
measurements from 2D and 3D images are expected to lie. 
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In controls, there was no evidence that the atrophy rates differed between 2D and 3D 
acquisitions  with  mean  (SD)  atrophy  rates  of  -0.07%  year
-1  (0.23)  and  -0.02%  year
-1 
(0.30)  acquired  on  2D  and  3D  images  respectively.  The  mean  difference  (2D-3D)  in 
atrophy rate was only -0.05% year
-1 (SD 0.38, 95% CI -0.26 to 0.17, p=0.63). Although 
the variance of atrophy measures was marginally smaller on the 2D acquisition compared 
with the 3D acquisition, this difference was not significant, p=0.37.  
 
In RRMS patients the atrophy rate quantified on 2D and 3D images agreed less than in 
control subjects. Mean atrophy rates were -0.57% year
-1 (SD 0.36) and -0.80% year
-1 (SD 
0.58) acquired on 2D images and 3D images respectively. The mean difference (2D-3D) 
in atrophy rate was statistically significant at 0.24% year
-1 (SD 0.48, 95% CI 0.06 to 0.42, 
p=0.012). The variance of measures was significantly smaller using 2D acquisitions in 
patients  with  RRMS  (p=0.003).  However  the  increased  mean  and  variance  with  3D 
acquisitions were of a similar magnitude and hence sample size requirements using the 
two  acquisitions  were  not  significantly  different.  Sample  sizes  to  detect  a  particular 
proportionate difference were estimated to be 13% smaller (not significantly different) 
using 2D acquisitions (95% CI 45% reduction to 28% increase). 
 
5.3.4  Discussion 
This  study  has  been  able  to  analyse  directly  the  differences  in  brain  atrophy  rate 
quantified on 2D and 3D MR acquisitions by SIENA, using same-day MRI scans of 
controls and subjects with RRMS. This is the first study to directly compare SIENA on 
different MR acquisitions in patients  with a disease-related increase in brain  atrophy. 
Some limitations of the study should be noted however. Firstly, this study was based on 
images that were acquired on one MR scanner, and therefore one should be cautious in 
generalising these results to scans acquired on other scanners or in multicentre studies. 
Secondly, the FOV for 2D images did not include full head coverage superiorly, with 
some skull and the tips of some gyri excluded (Figure 5-3). This may have biased results 
slightly in terms of the stability of both brain extraction and registration of 2D images. 
Edge detection by BET is to some extent based on an intensity gradient, and the lack of 
gradient  when  the  tips  of  gyri  are  excluded  may  have  influenced  the  segmentation. 
However, as can be seen from Figure 5-3, problems with the segmentation were primarily 
around  the  eyes.  Registration  of  images  by  SIENA  is  optimised  using  the  skull  and 
therefore may also have been affected on 2D images. However as described by Smith et  
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al. (Smith et al., 2001b), a small amount of “missing skull” is not generally a problem, 
and in addition all registrations were acceptable when checked. 
 
In the cohort described in this paper it has been shown that within individuals there may 
be differences observed between atrophy rates quantified on 2D and 3D acquisitions. In 
control subjects, in whom little atrophy is occurring, atrophy rates appear to agree on 
average.  However  a  significant  difference  in  atrophy  rates  acquired  on  2D  and  3D 
imaging was found in RRMS patients, a finding driven by the patients showing greater 
atrophy over the course of a year. Differences in measured atrophy rates such as these, 
which are in the order of up to 1% year
-1, will impact on the ability to compare results 
from studies using different acquisitions, as mean brain atrophy rates in RRMS have been 
shown to be in the order of only -0.9 to -0.5% year
-1 (Fox et al., 2000b; Kalkers et al., 
2002; Richert et al., 2006; Rovaris et al., 2003). However, as it is difficult to know the 
true atrophy rate for a subject, it is not feasible to say whether 3D acquisitions provide 
more accurate measures than 2D acquisitions. 
 
In these patients it appeared that 3D acquisitions were more sensitive in detecting atrophy 
than 2D acquisitions. The mean atrophy rates found on 2D acquisitions in this study were 
marginally lower than those observed in previous studies however. A median atrophy rate 
of -0.7% year
-1 (SD 0.9) was found in one study in RRMS where the acquisition consisted 
of 5mm thick slices (Rovaris et al., 2003). In two other studies of RRMS that applied 
SIENA to CSE acquisitions with 3mm thick slices, mean atrophy rates of -0.87% year
-1 
(SD 0.34) (Richert et al., 2006) and 0.9% over a nine month interval (SD 1.2) (Sormani et 
al., 2004) were found. This discrepancy may be due to differences in the cohorts, and 
disease duration and severity are likely to influence rates considerably. It may also have 
been due to the brain region obtained on the 2D acquisitions excluding the most superior 
tips  of  the  gyri  in  some  patients,  which  may  have  decreased  the  amount  of  atrophy 
detectable on 2D acquisitions. It should be noted that the variance of brain atrophy rates 
was significantly lower for 2D acquisitions than 3D acquisitions in RRMS subjects and 
hence  the  two  acquisitions  demonstrated  similar  statistical  power.  In  other  words  the 
increased sensitivity and greater mean atrophy rate on 3D scans was offset by a greater 
interpatient variability in the rates of atrophy. The result is a neutral effect in sample size 
requirements for demonstrating a therapeutic effect on the rate of atrophy. However if the 
difference  between  2D  and  3D  acquisitions  is  greater  in  patients  with  more  atrophy,  
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identification of patients with higher atrophy rates for inclusion into treatment trials could 
provide smaller sample sizes if using 3D imaging, and this should be investigated further. 
One question that should be addressed in relation to the difference in variance between 
the two acquisitions is whether there is a systematic increase in measurement variability 
because 3D acquisitions take longer to acquire and may be more prone to movement 
artefact. 
  
Other  studies  that  have  compared  atrophy  measurements  on  2D  and  3D  acquisitions 
include an investigation into GMFs and WMFs which showed significant differences in 
the  measurements  from  four  different  acquisitions  (including  2D  and  3D  images) 
(Zivadinov  et  al.,  2004b).  The  study  concluded  that  the  optimal  pulse  sequence  for 
measurement was a 3D spoiled gradient echo acquisition. In addition, a cross-sectional 
study investigating measures of BPF found that 2D and 3D acquisitions were equally 
sensitive in distinguishing controls and MS patients (Sharma et al., 2004).  
 
One advantage of the 3D acquisitions that was observed in this cohort was the ability to 
obtain brain regions using fully automated methods, whilst manual editing was required 
on all 2D acquisitions. This may be due to the lower image resolution with increased 
partial volume effects influencing segmentation on the 2D acquisition. A study comparing 
an automated brain extraction algorithm on 2D and 3D acquisitions from 52 MS patients 
also  found  that  unreliable  segmentations  were  obtained  on  2D  images,  whilst  on  3D 
images the segmentations were acceptable (Sharma et al., 2004). However it should be 
noted that in addition to spatial resolution, other factors may affect the appearance of MR 
images, and subsequently the performance of BET, such as the scan parameters, field 
strength,  resulting  scan  contrast,  intensity  non-uniformity,  and  chemical  shift  and 
susceptibility-related artefacts. 
 
Although not investigated in this study, one might expect the reproducibility of atrophy 
measures  to  be  greater  on  3D  than  on  2D  acquisitions.  However  one  study  that 
investigated scan-rescan reproducibility showed worse reproducibility on 3D acquisitions 
compared  with  2D  acquisitions,  when  BPF  was  measured  cross-sectionally  using  an 
automated algorithm (Horsfield et al., 2003). It would be useful to determine the scan-
rescan reproducibility of longitudinal SIENA measures on 2D and 3D acquisitions to add 
to the current findings.  
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In  conclusion,  differences  between  atrophy  measures  using  SIENA  on  2D  and  3D 
acquisitions exist and may be larger when atrophy is occurring. Comparisons between 
studies using SIENA on different acquisitions should be made with caution. However the 
variability of measures relative to the mean was similar for both acquisitions, suggesting 
that they have similar statistical power. It has been shown that it is possible to obtain brain 
regions using BET in a fully automated manner on 3D volumetric acquisitions, negating 
the need for labour-intensive manual editing. Given the similar statistical power of the 
two acquisitions, this suggests that further investigation into the application of SIENA to 
other 3D volumetric images and in other MS clinical subgroups who may have higher 
atrophy rates (e.g. SPMS and PPMS, rapidly deteriorating RRMS) should be performed.  
 
5.4  Chapter conclusions 
This  chapter  has  investigated  the  performance  of  SIENA  on  T1-weighted  volumetric 
MRI, as few studies have previously applied the technique to 3D images. Volumetric 
MRI is now commonly acquired in patients with MS and improvement to MR scanner 
hardware and software means that they can be easily and quickly obtained. This chapter 
has shown that automated brain extraction can be achieved on these images using an 
optimised version of BET, which will increase the reproducibility of measurements. In 
addition, atrophy measurement by SIENA was robust to small errors in brain extraction 
when a template brain mask was used. The use of such a method may be an important 
consideration for large studies where brain atrophy analysis is to be performed at multiple 
centres.  
 
Differences appear to exist in atrophy quantification by SIENA on these 3D volumetric 
images and 2D CSE images to which SIENA has been applied more often. From this 
small study it seems that atrophy measurements should not be compared or combined 
between studies using different acquisitions. Although there may be advantages to using 
3D volumetric acquisitions in future studies, given that automated brain extraction may be 
more robust, 2D acquisitions gave marginally greater statistical power, although this was 
not statistically significant. This may be more important in future studies designed to 
detect differences in atrophy rates between groups. One should be cautious in generalising 
these results to other 2D and 3D acquisitions however, as this study compared only one 
particular 2D acquisition and one particular 3D acquisition. A large number of different 
3D acquisitions exist (and from different vendors) and it may be that 3D acquisitions with  
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larger voxels that could be acquired in a shorter acquisition time (and therefore be less 
noisy) would improve 3D performance. Further investigation into the relative atrophy 
measures from other 2D and 3D acquisitions should be performed in larger cohorts and 
other clinical subgroups to extend these findings. 
 
SIENA has been shown to provide automated reliable brain atrophy measurements in 
patients  with  MS  and  controls.  Investigation  into  the  relative  performance  of  this 
technique with other automated and semi-automated brain atrophy measurement methods 
should be performed.    
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6  A comparison of brain atrophy measurement techniques 
 
6.1  Chapter introduction 
The development of new disease-modifying treatments that may target the underlying 
causes  of  disability  in  MS,  namely  neuroaxonal  damage,  has  increased  the  need  to 
monitor disease progression as precisely (and accurately) as possible. Measurement of 
brain atrophy  is thought to be a promising marker of this  cerebral damage. A major 
motivation for research in this area is that identification of robust, sensitive and precise 
techniques to measure global or regional atrophy may aid in detecting effective treatments 
that slow disease progression.  
 
In Chapters 4 and 5 it was shown that the BBSI and SIENA can be optimised for T1-
weighted volumetric MRI and used to detect brain atrophy in patients with MS early in 
the course of their disease. Other methods commonly used to quantify atrophy rates are 
based on segmentation of ROIs on serially acquired MRI, and calculating the difference 
in ROI volumes over the scan interval. These ROIs include WBV, central cerebral brain 
volume, ventricular volume, GM and WM volumes (Dalton et al., 2006; Rovaris et al., 
2000;  Tiberio  et  al.,  2005).  A  variety  of  software  and  algorithms  used  for  ROI 
segmentation have already been described in Chapter 1.6. Whilst these methods may have 
been validated for atrophy measurement, they have been applied to diverse study cohorts 
making it difficult to determine their relative performance and ability to measure brain 
atrophy in patients with MS. The few studies that have compared atrophy measurement 
techniques have been limited, for example comparing only two techniques (Sormani et 
al., 2004), or comparing the same measurement (e.g. BPF) using different algorithms 
(Sharma et al., 2004; Zivadinov et al., 2005). 
 
This chapter directly compares several commonly used methodologies for measurement 
of brain atrophy in MS, to investigate which might provide the most sensitive, precise and 
reliable  measure  of  atrophy,  and  therefore  which  could  be  the  most  effective  in 
monitoring disease progression in MS. In the first part of this chapter a direct comparison 
of the two registration-based methods, the BBSI and SIENA, is carried out. The second 
part  of  this  chapter  explores  other  methods  that  have  been  applied  in  brain  atrophy 
studies, and are thought to be good markers of brain tissue loss.   
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6.2  A comparison of registration-based methods of brain atrophy 
6.2.1  Introduction 
The previous two chapters have confirmed that the BBSI and SIENA are sensitive to 
disease-related atrophy, and it has been shown that they can be optimised for a given 
cohort and particular MR acquisition to improve the accuracy, sensitivity and precision of 
measurement.  As  has  already  been  described,  both  the  BBSI  and  SIENA  consist  of 
algorithms that register serial MR images from the same individual and estimate brain 
volume change through detection of changes at the edge of the brain. However some 
differences between the two techniques exist, and a comparison of them is presented in 
Table 6-1. It should be noted that although a degree of operator interaction is required to 
obtain an initial brain segmentation for registration, BBSI brain atrophy quantification 
itself is calculated automatically. 
 
Table 6-1 A comparison of BBSI and SIENA methodology. 
Differences  Similarities 
BBSI  SIENA 
Automated registration-
based technique 
Scaling changes optimised 
using brain 
Scaling changes optimised 
using skull 
Brain segmentation 
required prior to 
registration and atrophy 
quantification 
Semi-automated brain 
segmentation using MIDAS 
image analysis software 
Automated brain segmentation 
using brain extraction tool 
Atrophy quantification 
based on movement of 
brain edge 
Quantification based on 
intensity differences between 
brain edges 
Quantification based on 
distance moved by brain edge 
Small segmentation errors 
should not affect 
quantification 
May be affected by intensity 
changes from baseline to repeat 
image 
Relatively insensitive to 
intensity changes 
 
Although both these registration-based methods have been applied to MS subjects in the 
previous chapters, it is unclear how they compare to one another, and to differences in 
segmented brain volumes, in their ability to detect atrophy in subjects with early MS and 
CIS. A study published in 2006 did investigate the effect of registration on measurement 
of  short-term  (three  months)  brain  volume  change  using  different  segmentation  
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techniques  and  SIENA.  However  no  change  in  brain  volume  was  detected  over  this 
period and no significant differences in volume changes were observed on registered and 
non-registered images when comparing results between techniques (Fritz et al., 2006).  
 
The first objective of this study was to compare directly: i) segmented BVD on non-
registered images ii) the BBSI and iii) SIENA, through quantification of brain atrophy 
rates over one year in subjects with CIS, early RRMS and controls. If brain atrophy is to 
be utilised in clinical trials, one might assume that an effective treatment would reduce 
atrophy  rate  to  the  level  observed  in  control  subjects,  and  therefore  the  ability  of  a 
technique to differentiate between control and patient groups may indicate the statistical 
power of a method. Moreover, it is important to determine how well any potential atrophy 
measure relates to disability. Detection of subtle degrees of atrophy early in the course of 
disease,  particularly  at  the  CIS  stage,  may  aid  diagnosis  and  prognosis  of  individual 
patients. The second objective of the study was therefore to compare the ability of each 
method to differentiate between patient groups and controls, and between patients with 
CIS who had developed MS at a three year follow-up compared with those who had not.  
 
6.2.2  Methods 
Subjects and MR imaging 
This study included 83 subjects: 37 patients (14 males) presenting with CIS, 30 patients 
(eight males) with early RRMS (less than four years duration) and 16 control subjects 
(seven males) as described in Chapter 3.1. Thirty-four patients with CIS presented with 
optic neuritis, two with spinal cord syndromes and one with a brain stem syndrome, and 
patients ranged in age from 21 to 48 years at baseline (mean 35.0, SD 6.2). Patients with 
RRMS ranged in age from 26 to 56 years (mean 37.5, SD 7.4), and mean disease duration 
(from the first clinical episode) was 2.0 years (SD 0.8, range 0.5 to 3.8). Two patients 
were on beta interferon from baseline, whilst a further two patients started beta interferon 
treatment during follow-up. Controls ranged in age from 27 to 53 years (mean 35.1, SD 
6.3). The EDSS (Kurtzke, 1983) was used to assess disability in patients at the time of 
baseline MRI and median (range) EDSS score was 1.0 (1.0 to 2.5) in patients with CIS 
and 1.5 (0 to 3.0) in patients with RRMS. A coronal 3D FSPGR sequence was acquired 
on all subjects at baseline and approximately one year later (mean 1.1, SD 0.2, range 0.9 
to 1.8), according to the protocol described in Chapter 3.3. Baseline MRI was performed 
within 12 weeks of symptom onset in patients with CIS (mean 6.0, SD 3.4).  
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MRI analysis 
(i) Segmented brain volume difference 
Semi-automated segmentation of baseline and repeat brains was performed using MIDAS 
as described in Chapter 4.2.2, with correction of images for intensity inhomogeneity using 
N3  (Sled  et  al.,  1998).  Brain  volume  was  determined  from  the  segmentation  within 
MIDAS and the baseline volume subtracted from the follow-up volume. Cerebral volume 
loss was expressed as a percentage of total baseline brain volume and annualised to give a 
global atrophy rate. 
 
(ii) BBSI 
The BBSI was applied to images as described in Chapter 4.2.2. DBC (Lewis & Fox, 
2004) was applied at registration and the BBSI window parameters were set at the optimal 
values determined in Chapter 4.3 (I1=0.65, I2=0.45). Cerebral volume loss was expressed 
as a percentage of total baseline brain volume and annualised to give a global atrophy 
rate. 
 
(iii) SIENA 
SIENA was applied as described in Chapter 5.3.2. This required axial reorientation of all 
images, and the initial brain segmentation was acquired using the optimised version of 
BET, described in Chapter 5.2. PBVC calculated by SIENA was annualised to give a 
global atrophy rate. 
 
Three year clinical assessment of patients with CIS 
All but two of the patients with CIS (n=35, 12 males) had clinical assessment at three-
year follow-up, when they were evaluated for a diagnosis of MS (progression from CIS) 
according to the McDonald criteria (McDonald et al., 2001).  
 
Statistical analysis 
Mean  (SD)  atrophy  rates  in  each  subject  group  for  each  of  the  three  methods  were 
calculated.  To  investigate  bias,  a  Bland-Altman  plot  of  the  BBSI  and  SIENA  was 
generated, and differences in the mean and SD of each method were assessed within 
subject  groups  using  paired  t-tests  and  Pitman’s  test  respectively.  Where  ANOVA 
suggested a significant difference in atrophy rates between subject groups (p<0.05), a 
two-tailed independent samples t-test was applied and the 95% CI of the difference in rate  
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was calculated. In addition, the ability of each method to distinguish between subject 
groups  was  assessed  using  logistic  regression.  Differences  in  the  mean  atrophy  rate 
between CIS subjects who had developed MS at three year follow-up and those who had 
not was assessed using a two-tailed independent samples t-test and the 95% CI of the 
difference in mean rate was calculated. 
 
6.2.3  Results 
Mean (SD) brain atrophy rates within subject groups quantified by each technique are 
presented in Figure 6-1 and Table 6-2. 
 
 
Figure 6-1 Brain atrophy rates quantified using segmented brain volume difference, the 
BBSI and SIENA, in controls and subjects with CIS and RRMS. Subjects with CIS were 
divided into those who had not developed MS at three year follow-up (CIS (CIS)) and 
those who had (CIS (MS)). The two CIS subjects who did not have three year follow-up 
are included in the CIS (CIS) group (their atrophy rates were -0.58% year
-1 and 0.28% 
year
-1 using segmented brain volume difference, -0.41% year
-1 and 0.00% year
-1 using 
the BBSI and -0.16% year
-1 and -0.22% year
-1 using SIENA). 
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Table  6-2  Mean  brain  atrophy  rates  quantified  using  segmented  brain  volume 
difference, the BBSI and SIENA, in controls and subjects with CIS and RRMS. 
Mean/median (SD) atrophy rate (% year
-1)   
Controls  CIS  RRMS 
BVD     0.51/0.44   (1.32)  -0.25/-0.28 (1.04)  -0.76/-1.02 (1.38) 
BBSI    -0.04/-0.02  (0.52)  -0.22/-0.14 (0.48)  -0.72/-0.59 (0.60) 
SIENA  -0.07/-0.10 (0.34)  -0.32/-0.22 (0.47)  -0.78/-0.78 (0.59) 
 
The  Bland-Altman  plot  of  measures  obtained  by  the  BBSI  and  SIENA  showed  no 
significant bias between the two methods (Figure 6-2). No significant differences between 
mean atrophy rates quantified by BVD, BBSI and SIENA were observed in any of the 
subject groups. However Pitman’s tests showed that the variance of atrophy rates within 
each subject group was significantly reduced when quantified either with the BBSI or 
SIENA compared with BVD (all p<0.001). In CIS and RRMS subject groups the variance 
in atrophy rates was very similar between the BBSI and SIENA, but was less similar in 
the control group (p<0.05). However, SIENA and the BBSI were closely correlated; the 
mean difference between the measures (BBSI minus SIENA) was 0.03% year
-1 (SD 0.34, 
95% CI -0.15 to 0.22, p=0.70) in controls, 0.10% year
-1 (SD 0.31, 95% CI -0.007 to 0.20, 
p=0.07) in subjects with a CIS and 0.05% year
-1 (SD 0.28, 95% CI -0.05 to 0.16, p=0.32) 
in subjects with RRMS. 
 
There was no significant difference in mean age (p=0.28) between subject groups. Brain 
atrophy rates calculated using each technique increased between controls and patients 
with CIS and between patients with CIS and those with RRMS (Table 6-2). ANOVA 
indicated significant between group differences using each technique. The difference in 
mean brain atrophy rate between patients with CIS and control subjects using BVD was 
0.76% year
-1 (95% CI 0.08 to 1.44, p=0.0287). No significant difference was observed 
using the BBSI or SIENA. The difference in atrophy rates between patients with RRMS 
and controls was 1.27% year
-1 (95% CI 0.42 to 2.11, p=0.0044) using BVD, 0.69% year
-1 
(95% CI 0.33 to 1.04, p=0.0003) using BBSI and 0.71% year
-1 (95% CI 0.38 to 1.03, 
p=0.0001) using SIENA. Significant differences in brain atrophy rates between patients 
with RRMS and CIS were shown by the BBSI and SIENA: 0.50% year
-1 (95% CI 0.24 to 
0.76, p=0.0003) and 0.46% year
-1 (95% CI 0.20 to 0.71, p=0.0007) respectively.  
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Figure 6-2 Bland-Altman plot comparing brain atrophy rates quantified by SIENA and 
the BBSI, in controls and subjects with CIS and RRMS. The reference ranges are the 
values within which 95% of the differences between atrophy measurements from the 
BBSI and SIENA are expected to lie. 
 
 
Logistic regression demonstrated that subjects were 12 times (95% CI 2 to 60 times) more 
likely to be a RRMS subject than a control for each 1% year
-1 increase in brain atrophy 
rate for the BBSI (p=0.0002) and 111 times (5 to 2600 times) more likely for SIENA 
(p<0.0001), compared with only twice as likely (1.2 to 4 times) with BVD (p=0.0039). 
SIENA was significantly better than both BVD (p=0.0002) and the BBSI (p=0.0058) at 
distinguishing patients with RRMS from control subjects. 
 
Of the 35 patients with CIS who had three year follow-up, 19 had developed MS (17 
RRMS, two SPMS) whilst 16 remained clinically isolated. Table 6-3 lists mean (SD) 
brain atrophy rates in both groups for each of the techniques. Mean brain atrophy rates 
were significantly different between patients who had developed MS and those who had 
not using each technique: 0.83% year
-1 (95% CI 0.15 to 1.51, p=0.0187) using BVD, 
0.45% year
-1 (95% CI 0.14 to 0.76, p=0.0056) using the BBSI and 0.42% year
-1 (95% CI  
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0.12 to 0.72, p=0.0078) using SIENA. In the 19 subjects who had developed MS, all 
methods showed that atrophy rates were significantly greater than in control subjects: 
1.14% year
-1 (95% CI 0.33 to 1.95, p=0.007) using BVD, 0.39% year
-1 (95% CI 0.04 to 
0.74, p=0.0282) using the BBSI, and 0.45% year
-1 (95% CI 0.15 to 0.75, p=0.0048) using 
SIENA. No significant difference was observed between controls and CIS patients who 
did not develop MS. 
 
Table  6-3  Demographics  and  mean  (SD)  brain  atrophy  rates  in  subjects  with  CIS 
according to three year clinical status.  
 
 
Subjects with MS at 
three years 
Subjects remaining 
CIS at three years 
Male:Female  4:15  8:8 
Age, years (mean, SD)  35.6 (6.6)  33.3 (5.2) 
EDSS at baseline (median, range)  1 (1-2)  1 (1-4) 
BVD (% year
-1)  -0.64 (1.04)   0.19 (0.93) 
BBSI (% year
-1)  -0.43 (0.50)   0.02 (0.38) 
SIENA (% year
-1)  -0.52 (0.50)  -0.10 (0.34) 
 
6.2.4  Discussion 
In  this  study  brain  atrophy  rates  quantified  using  BVD  and  two  registration-based 
methods, the BBSI and SIENA, have been compared in controls and subjects with CIS 
and early RRMS.  It has been shown that atrophy  rates obtained using the BBSI  and 
SIENA are well correlated and provide a higher level of measurement precision than 
volume  subtraction  based  on  manual  segmentation  methods.  This  study  has  also 
confirmed brain atrophy rates to be significantly greater in subjects with early RRMS than 
controls, whilst atrophy rates are already increased in some subjects presenting with CIS, 
particularly  those  who  go  on  to  develop  MS.  These  results  were  not  affected  by  the 
atrophy measurement technique used. 
 
Although  atrophy  quantified  from  segmented  BVD  yielded  similar  mean  rates  to  the 
registration-based techniques in patients with CIS and RRMS, there is a much higher 
variance  associated  with  this  measure.  In  agreement  with  these  findings,  a  study 
investigating a segmentation-based technique and SIENA found that SIENA reduced the  
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standard  deviation  of  longitudinal  atrophy  measurements  by  over  half  those  obtained 
using  the  segmentation  technique  (Sormani  et  al.,  2004).  Another  study  investigating 
brain atrophy in PPMS using serial segmentation and SIENA also demonstrated that the 
variance of measurements was lower using SIENA (Sastre-Garriga et al., 2005a).  As 
already described, measurement precision is particularly important if brain atrophy is to 
be used as a primary outcome measure in trials of putative disease-modifying drugs. For a 
given number of subjects the power to detect a significant difference between groups is 
driven by the standard deviation of the measurement technique. Sormani et al. found that 
the power to detect a difference in atrophy rates between the placebo and treatment arms 
of a trial was 32% using the segmentation-based technique but 73% using SIENA, due to 
the  difference  in  standard  deviation  between  methods  (Sormani  et  al.,  2004).  By 
increasing  measurement  precision  and  statistical  power,  sample  sizes  can  be  reduced 
which in turn reduces the length and cost of clinical trials (Fox et al., 2000a). This study 
suggests that the BBSI and SIENA have almost equal power.  In addition to the BBSI and 
SIENA  providing  direct  quantification  of  atrophy  through  image  subtraction,  the 
registration process also compensates for variations in the MR scanner over time, which 
can lead to changes in apparent voxel sizes. It is a possibility that the greater variance in 
atrophy  measures  that  was  observed  using  the  BVD  in  this  study  is  due  not  only  to 
segmentation  errors,  but  that  the  volumes  were  not  normalised.  Some  segmentation 
methods, such as the BPF do perform a normalisation step (Rudick et al., 1999), but may 
still be subject to errors in segmentation at serial time-points. 
 
Results  from  multiple  logistic  regression  suggest  that  SIENA  may  be  slightly  more 
sensitive than the BBSI in distinguishing subjects with RRMS from controls, although 
both  methods  provided  greater  sensitivity  than  BVD.  This  is  confirmation  of  the 
importance  of  using  a  precise  measurement  technique.  Similarly  to  these  findings,  a 
previous study which compared methods derived from SIENA and the BBSI found that 
the SIENA-derived method gave better group separation between control subjects and 
patients with Alzheimer’s disease compared with the BBSI-derived method (Gunter et al., 
2003). However in the work presented in this chapter, the greater sensitivity of SIENA is 
most likely due to the lower variance seen in the control group using this technique. No 
difference between SIENA and the BBSI was observed in distinguishing subjects with 
CIS from controls, and although segmented BVD showed a significantly greater brain 
atrophy rate in CIS than control subjects, this was probably due to the large variance of  
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measurements  in  all  subject  groups  using  segmentation,  and  the  outliers  seen  in  the 
control group leading to an unexpected positive atrophy rate (brain “growth”). 
 
Recently, a cross-validation study of the BBSI and SIENA has been performed in a cohort 
consisting of 23 control subjects and 45 patients with Alzheimer’s disease (Smith et al., 
2007), with MRI data available at seven time-points enabling the quantification of atrophy 
over  multiple  intervals.  This  study  confirmed  the  agreement  shown  in  the  present 
investigation between the BBSI and SIENA, with a median absolute difference in atrophy 
of 0.25%, which compares to a mean difference of 0.07%  year
-1 found in this study. 
Whilst there was a trend for greater brain atrophy rates to be detected using SIENA than 
the BBSI in the study presented here, Smith et al. found that SIENA gave a 20% larger 
estimate  of  atrophy  than  the  BBSI.  This  difference  in  estimates  of  atrophy  is  to  be 
expected from the original report of the BBSI (Freeborough & Fox, 1997) where it was 
reported that the BBSI in effect scaled atrophy by about 0.8. Estimates of effect size 
(Cohen’s d) by Smith et al. showed the BBSI to be slightly more powerful.  
 
Considering whether the results from the BBSI and SIENA presented in this study are 
typical of those that might be expected in such a cohort, the atrophy rates observed in 
subjects with RRMS appear to be similar to those found in previous investigations. One 
study which applied the BBSI found an annual median brain atrophy rate of -0.8% year
-1 
(Fox et al., 2000b). Likewise, application of SIENA to 34 subjects with RRMS showed a 
median  brain  atrophy  rate  of  -0.7%  year
-1  (SD  0.9)  (Rovaris  et  al.,  2003).  A  larger 
analysis of 105 subjects using SIENA found mean brain atrophy was -0.9% (SD 1.2) over 
only nine months (Sormani et al., 2004). 
 
Although no previously published studies have used the BBSI to quantify brain atrophy in 
subjects with CIS, several studies have applied SIENA to these subjects. In agreement 
with these findings, one study of 20 subjects presenting with a CIS found a median brain 
atrophy rate of -0.3% year
-1 (SD 0.6) (Rovaris et al., 2003). However a larger study of 38 
subjects, who had not developed clinically definite MS by an 18 month follow-up, found 
a median brain atrophy rate of -0.58% year
-1 (IQR -1.02 to -0.24) (Paolillo et al., 2004), 
whilst investigation of beta interferon treatment in subjects with CIS found that brain 
atrophy rate in around 100 placebo subjects was -0.83% year
-1 (SD 1.09) during the first 
year of study and -0.67% year
-1 (SD 1.10) during the second year of study (Filippi et al.,  
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2004). Within any group of subjects presenting with a CIS, some may develop MS whilst 
others  remain  clinically  isolated,  and  the  heterogeneity  of  CIS  subject  groups  within 
different studies may account to some extent for the different atrophy rates observed. 
When the CIS subjects were divided into those that had developed MS at three  year 
follow-up and those who had not, all techniques showed that the atrophy rate in the MS 
group  approached  that  seen  in  subjects  with  established  RRMS,  whereas  in  subjects 
remaining  clinically  isolated  the  atrophy  rate  approached  that  of  controls.  Other 
investigations have shown rates of ventricular enlargement (Brex et al., 2000) and GM 
atrophy (Dalton et al., 2004) to be greater in CIS subjects developing MS than in those 
who do not. In a trial of beta interferon in CIS, brain atrophy was used as a secondary 
outcome measure, and atrophy rates of -0.92% were observed during the first year of 
study in subjects who had developed MS at two years, compared with -0.56% in subjects 
remaining stable (Filippi et al., 2004). Over the second year of the trial atrophy was only  
-0.64% in subjects who had developed MS compared with -0.50% in subjects remaining 
stable. These rates are greater than those observed in this study, particularly for subjects 
remaining  CIS,  but  this  may  be  the  result  of  the  treatment  in  some  subjects  (with  a 
treatment-associated  reduction  in  oedema),  the  shorter  follow-up  period  of  two  years 
within which MS could be diagnosed, or the selection of only CIS patients with MRI 
abnormalities (some of the CIS patients in this study had a normal scan). One of the 
limiting  factors  when  investigating  the  differences  between  subjects  with  CIS  who 
develop MS and those who do not is the length of follow-up. It is possible that subjects 
who remained clinically isolated at follow-up may still develop MS, and this may explain 
the difference in atrophy rates observed between other studies and the present one.  
 
In summary, registration-based techniques applied to three-dimensional MRI acquisitions 
provide  more  precise  measurement  of  brain  atrophy  rates  than  segmentation-based 
techniques, with the BBSI and SIENA providing comparable results. Accurate evaluation 
of  brain  atrophy  is  necessary  if  it  is  to  be  used  for  monitoring  treatment  efficacy  in 
controlled trials. Although not investigated in this study directly, accurate evaluation may 
also  aid  in  the  identification  of  patients  most  likely  to  obtain  long-term  benefit  from 
disease-modifying treatment.  
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6.3  Comparison of the BBSI and SIENA with other cerebral atrophy measurement 
techniques, and reliability of measurements 
6.3.1  Introduction 
The previous chapters have confirmed that brain atrophy can be successfully measured at 
the earliest stages of MS using two registration-based techniques. In addition it has been 
shown that these measures may be more precise markers of progression than atrophy rates 
derived  from  the  subtraction  of  absolute  brain  volumes.  Other  techniques  based  on 
different methodology or regional measurements have been proposed as markers of whole 
brain atrophy however (Chard et al., 2002b; Fox et al., 2000b; Losseff et al., 1996; Schott 
et al., 2005), which may provide a similar sensitivity and precision of measurement to the 
BBSI and SIENA.  
 
One such measure is ventricular enlargement, and previous studies in MS and CIS have 
shown ventricular enlargement at the earliest stages of the disease (Brex et al., 2000; 
Dalton  et  al.,  2002a;  Kalkers  et  al.,  2002).  Furthermore,  in  some  studies  significant 
ventricular enlargement has been observed when no significant change in WBV has been 
detected (Horakova et al., 2007; Turner et al., 2003), suggesting that this measure may be 
more sensitive to small changes, as tissue loss throughout the whole brain may result in 
relatively large increases in CSF spaces. Manual outlining of the lateral ventricles can be 
performed quickly and with a high degree of accuracy given the high contrast brain-CSF 
boundary. In the last few years the automated ventricular boundary shift integral (VBSI) 
technique has been applied, which directly quantifies ventricular enlargement following 
the accurate registration of local ventricular regions, using the same methodology as the 
BBSI  (Schott et al., 2005).  It has been shown to provide highly  similar measures to 
volume subtraction following segmentation. 
 
The CCV is defined as a region that includes a large proportion of the lateral ventricles 
(Losseff et al., 1996), and measures of this ROI may therefore be similarly sensitive to 
global tissue loss as ventricular enlargement. One of the main advantages of this measure 
is that segmentation of the superior and inferior limits of the brain is avoided which, 
firstly, may decrease the time required for analysis relative to whole brain segmentation 
methods  and,  secondly,  could  reduce  segmentation  errors  that  may  occur  due  to  the 
complex folding of gyri and sulci or due to image artefacts away from the centre of the  
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image. Significant decreases in CCV have been shown in patients with MS (Losseff et al., 
1996; Rovaris et al., 2000).  
 
As mentioned in Chapter 6.2.4 it is possible that the greater variance in atrophy measures 
observed following the subtraction of brain volumes was due not only to segmentation 
errors,  but  that  the  volumes  were  not  normalised.  SPM  software  allows  normalised 
measures of brain, GM and WM to be generated. Although MS lesions occur within the 
GM they  are thought to be  associated with less inflammation  (Bø et  al., 2003a)  and 
therefore measures of GM atrophy could be more sensitive markers of neuroaxonal loss 
and  disease  progression.  Studies  have  shown  progressive  GM  atrophy  occurring  in 
patients  presenting  with  CIS  and  RRMS  (Chard  et  al.,  2004;  Dalton  et  al.,  2004). 
Moreover it has been shown to progress at a greater rate than atrophy of the WM (Dalton 
et al., 2004; Tiberio et al., 2005), and be correlated with disability (Sanfilipo et al., 2005). 
Atrophy  of  the  cortex  has  also  been  shown  to  correlate  with  measures  of  cognitive 
impairment in people with MS (Portaccio et al., 2006), and therefore measures may be of 
particular clinical relevance. 
 
As  the  methodologies  behind  these  other  techniques  differ  from  those  presented  in 
Chapter 6.2, it is important to determine the relative power of these measures to detect 
brain atrophy and, by implication, disease progression in MS. The primary aim of this 
study was to compare these techniques directly with the BBSI and SIENA. The relative 
sensitivity,  precision  and  effect  sizes  are  investigated  for  BBSI,  SIENA,  ventricular 
enlargement,  VBSI,  CCV,  SPM  BPF,  SPM  GMF  and  SPM  WMF.  As  no  standard 
software has been adopted for the measurement of CCV, a secondary aim of this study 
was to investigate the relative advantages of two different software packages (Excalp and 
MIDAS)  that  could  be  used  to  obtain  this  volume.  In  addition,  one  of  the  potential 
problems with longitudinal CCV measurement is ensuring that subjects are positioned 
consistently within the scanner, so that serial measurements are obtained on the same 
ROI. Therefore it was also investigated whether registration of images could improve 
atrophy rates estimated from CCV. 
 
One of the important features of any potential outcome measure for a clinical trial is its 
reliability  (the  reproducibility  of  a  measurement  when  repeated  in  the  same  subject) 
(Lachin, 2004). Random measurement error will reduce reliability and decrease the power  
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to detect a treatment effect. Whilst reliability can be calculated by performing repeated 
measurements on the same scan, this does not take into account the degree to which the 
measurement is influenced by scanner-related variability. For example, an inaccurate but 
fully automated measure would produce exactly the same result when applied twice to the 
same scan. If, however, measurements on two scans acquired on the same day on the 
same subject produce very different values, the measure (scan plus analysis method) must 
be  deemed  to  lack  reproducibility.  Therefore  this  study  also  analyses  the  relative 
reliability and consistency of different measurement techniques based on same-day scan-
rescan MRI. 
 
6.3.2  Methods 
Subjects and MR imaging 
Fourteen controls (five male, mean age 35.3 years (SD 6.3)), 41 subjects presenting with a 
CIS (15 male, mean age 34.3 years (SD 6.4)) and 29 subjects with RRMS (eight male, 
mean age 37.3 years (SD 7.4)) were identified with both T1-weighted coronal volumetric 
FSPGR and T1-weighted 2D CSE MR imaging. Details of the acquisitions are described 
in Chapter 3.3 and the FSPGR sequence was the same for the three subject groups. In 
controls  and  patients  with  RRMS  CSE  images  had  5mm  thick  slices.  In  subjects 
presenting with CIS, CSE images had 3mm thick slices and were acquired following the 
administration  of  0.1mmol/kg  Gd-DTPA.  MRI  was  acquired  at  baseline  and 
approximately one year later in all patients, with a mean interval of 1.17 years (SD 0.24). 
 
Twenty-two older healthy  control subjects were identified from a longitudinal project 
undertaken  at  the  Institute  of  Neurology,  aimed  at  determining  the  shortest  interval 
required to detect volumetric change based on MRI, to distinguish AD subjects from 
normal controls (11 male, mean age 69.6 years (SD 7.3)). Subjects had two MRI scans 
acquired on the same day (without being removed from the scanner) and a repeat scan 
approximately one  year later (mean interval 1.0 years (SD 0.0)), which were used to 
perform an assessment of the reliability of measurement techniques. Coronal T1-weighted 
MRI was acquired in these subjects according to the protocol described in Chapter 3.3.3. 
 
MRI analysis 
All  methods  were  applied  to  FSPGR  MRI  except  for  estimation  of  CCV  which  was 
determined on CSE images.  
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(i) BBSI and SIENA 
The BBSI and SIENA were obtained as described in Chapter 6.2.2. 
 
(ii) Segmented ventricle volume difference (VVD)  
Images  were  placed  into  standard  space  based  on  the  MNI-152  brain  image 
(www.bic.mni.mcgill.ca/cgi/icbm_view)  (Mazziotta  et  al.,  2001)  and  using  a  9dof6 
registration  (the  transformation  matrix  is  determined  using  9dof,  but  the  image  is 
transformed using only translations and rotations). Each repeat brain in standard space 
was subsequently registered to the corresponding baseline brain in standard space using 
affine registration. An upper threshold value representing 60% of the mean brain intensity 
was used to delineate ventricles (which included the lateral ventricles and temporal horn) 
on registered images using MIDAS (Freeborough et al., 1997). This threshold excluded 
brain, whilst a lower threshold set at zero was used to include CSF. Baseline ventricle 
volume was subtracted from repeat ventricle volume and corrected for scan interval. 
 
(iii) Ventricular boundary shift integral (VBSI)  
Using the ventricle regions obtained in (ii), a local 6dof registration was performed to 
positionally match ventricular regions between the baseline and registered repeat images 
in standard space. The VBSI was calculated over this local region in the same manner as 
the BBSI. Calculation of the VBSI was also performed using only the baseline ventricle 
ROI. VBSI measurements were corrected for scan interval. 
 
(iv) Central cerebral volume 
The “starting slice” (the most inferior slice of the ROI) was determined on each scan by 
identifying  the  velum  interpositum  cerebri,  guidelines  for  which  were  developed  in 
association with an experienced neuroradiologist (Appendix 3). For repeat images, the 
choice of starting slice on the baseline image was referred to in order to match the starting 
slices as closely as possible. Excalp and MIDAS were used to obtain an ROI containing 
this starting slice and the three (RRMS patients) or five (CIS patients) slices above it. 
Prior to application of Excalp (see Chapter 3.4.5) each image slice to be processed was 
saved as a separate file. Excalp was used to automatically strip the skull from each slice 
and the morphological opening operator used to separate the brain from other components 
in the image was set to a diameter of 10mm. Any remaining areas of non-brain were 
removed by manual editing in DispImage (see Chapter 3.4.4). An in-house script was  
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used to calculate the volume of each slice by summing the number of voxels multiplied 
by the voxel dimensions. CCV was the sum of the slice volumes. Baseline CCV was 
subtracted from the repeat CCV and the difference expressed as a percentage of baseline 
CCV volume, before correcting for scan interval to produce a rate of change. 
 
The method used to obtain CCV using MIDAS was similar to that used to obtain WBV. 
Intensity thresholds were set to exclude voxels brighter e.g. dura/scalp, and darker e.g. 
CSF, than these values over the whole image. In contrast to whole brain segmentation the 
most inferior slice was set to be the “starting slice”, which therefore excluded voxels 
inferior to this slice. Erosion and a conditional dilation of the ROI was then performed. 
Following this the most superior slice of the CCV was selected and the voxels on all 
slices above this were deleted. Manual editing was performed on the resulting region if 
required  and  the  total  CCV  was  calculated  automatically  within  MIDAS.  As  before, 
baseline CCV was subtracted from repeat CCV and expressed as a percentage of baseline 
volume before correcting values for scan interval. 
 
Registration of CSE images was performed by registering the MNI-152 standard space 
reference scan (www.bic.mni.mcgill.ca/cgi/icbm_view) (Mazziotta et al., 2001) to each 
image, using the FLIRT registration package (Chapter 3.4.2) (12dof) and maximising the 
normalised  mutual  information  (Studholme  et  al.,  1999).  The  brain  segmentation 
available  in  FSL  for  this  reference  scan  was  transformed  to  each  individual  scan  by 
applying the corresponding transformation parameters obtained from image registration, 
thereby creating an approximate brain mask on each scan in its native space. Using the 
approximate brain regions, each baseline image was subsequently registered to the MNI-
152 standard space brain template using a rigid 9dof6 registration with renormalised sinc 
interpolation  (Thacker  et  al.,  1999).  Transformation  parameters  were  subsequently 
applied  to  the  approximate  baseline  brain  region.  Repeat  images  were  registered  to 
standard  space  baseline  images  using  12dof  and  renormalised  sinc  interpolation.  All 
resulting registrations were  checked  for accuracy.  Starting slices were  determined for 
each subject and CCV was obtained on each scan using MIDAS as described above. 
 
(v) SPM fractional measures 
Images were reoriented axially, maintaining all voxel dimensions. Using SPM99 software 
(Ashburner & Friston, 1997) with inhomogeneity correction (Chard et al., 2002c), GM,  
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WM and CSF segments were automatically generated. Lesions were contoured on each of 
the  images  using  the  semi-automated  DispImage  software  (Chapter  3.4.4)  to  create  a 
lesion mask which was used to generate the final binary masks of GM, WM, CSF and 
lesions in SPM. Tissue inferior to the base of the cerebellum was excluded from the 
masks and all segmentations were visually assessed. Tissue volumes were subsequently 
determined from each binary mask and BPF, GMF and WMF were calculated as follows: 
 
CSF)      volume sue (brain tis contour    surface  within   volume total
ume lesion vol   matter     white matter  grey 
+
+ +
= BPF  
 
CSF)      volume sue (brain tis contour    surface  within   volume total
ume matter vol grey 
+
= GMF  
 
CSF)      volume sue (brain tis contour    surface  within   volume total
ume lesion vol     ume matter vol   white
+
+
= WMF  
 
Changes  in  tissue  fractions  were  obtained  by  subtracting  the  baseline  from  repeat 
estimates, and expressed as a percentage of baseline values. 
 
Reliability 
No scan-rescan CSE images were available and therefore the reliability of CCV measures 
was not assessed. Cross-sectional volume measurements were made on all images from 
the 22 older control subjects (ventricle volume, BPF, GMF and WMF). Atrophy rate was 
subsequently determined between scan pairs for these methods and for the BBSI, SIENA 
and the VBSI: i) baseline A to baseline B, ii) baseline A to one year repeat, iii) baseline B 
to one year repeat.  
 
Statistical analysis 
Mean (SD) atrophy rates for each of the methods was calculated for each subject group, 
and  the  effect  size  (µ/σ)  was  calculated  for  patients  with  RRMS.  As  ventricular 
enlargement  was  not  expressed  as  a  percentage  of  baseline,  due  to  the  large  normal 
variation  that  can  occur  in  baseline  ventricular  size,  these  results  were  analysed 
separately.  In  each  subject  group  a  joint  Wald  test  was  used  as  an  overall  test  of 
differences  in  mean  percentage  atrophy  rates.  Where  a  significant  difference  was  
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observed in RRMS subjects (p<0.05), paired t-tests were used to investigate pairwise 
differences. Likewise, a generalisation of Pitman’s test to more than two observations was 
performed within each subject group to determine if there was a significant difference in 
the variance of atrophy rates using the different methods (Han, 1969). Where a significant 
difference was observed in RRMS subjects (p<0.05), Pitman’s test was applied pairwise.  
 
Measures of VVD were correlated with whole brain atrophy rates from SIENA using 
Pearson’s  correlation  coefficient.  Bland-Altman  plots  of  VVD  and  the  VBSI  were 
generated to assess visually whether there was any bias in measures, and a joint Wald test 
was applied to the three measures of ventricular enlargement to determine if there was a 
significant (p<0.05) difference in mean rates. Likewise, generalisation of Pitman’s test 
was used as overall investigation of differences in the variance of measures obtained 
using  the  three  techniques.  Where  significant  differences  were  observed  in  RRMS 
subjects (p<0.05), pairwise t-tests and Pitman’s tests were applied to observations.  
 
Assessing  reliability,  the  mean  value  of  the  scan-rescan  volume  change  estimate  was 
calculated. This should be zero if there is no systematic bias in the estimation of atrophy. 
A one-sample two-tailed t-test was used to investigate whether the differences observed 
were significantly different from zero. Assessing the consistency of annual atrophy rates 
that were calculated from each of the two baseline images, Bland-Altman plots were 
generated to assess whether there was any bias in measurements. In addition, a paired t-
test was performed and the mean difference (SD, 95% CI) between the two measurements 
was  calculated  for  each  method.  The  coefficient  of  reliability  (intraclass  correlation 
coefficient (ICC)) between the two longitudinal atrophy measures was calculated for each 
method (Lachin, 2004). This value gives an estimate of the proportion of variation that is 
not due to measurement error. Significant differences between ICCs were investigated by 
calculating the 95% bootstrap CI for the difference between the ICC of two techniques. 
 
6.3.3  Results 
Excalp failed on one control subject and SPM failed on one patient with RRMS, therefore 
these two subjects were excluded from further analysis. Both Excalp and MIDAS CCV 
methods  required  minor  editing  of  regions  following  initial  processing.  All  tissue 
segmentations  from  SPM  were  acceptable  on  visual  inspection.  Mean  (SD)  rates  of  
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atrophy and ventricular enlargement, plus effect sizes for each method, are given in Table 
6-4, whilst Figure 6-3 and Figure 6-4 show the changes measured on individual subjects. 
 
Table 6-4 Mean rates of brain atrophy and ventricular enlargement quantified from 
eleven different measurement techniques, in controls and subjects with CIS and RRMS. 
Effect sizes (µ/σ) are given for subjects with RRMS. 
    Controls  CIS  RRMS  Effect 
size 
Excalp CCV  
 
0.69 (1.02)  -0.48 (1.05)  0.66 (2.93)  0.20 
MIDAS CCV  
 
0.96 (1.40)  -0.21 (1.29)  -0.18 (1.53)  0.15 
MIDAS CCV 
(registered images)  
0.40 (0.34)  -0.09 (0.46)  -0.26 (0.48)  0.53 
BBSI  
 
0.04 (0.51)  -0.20 (0.49)  -0.70 (0.55)  1.26 
SIENA  
 
0.00 (0.31)  -0.30 (0.48)  -0.75 (0.51)  1.38 
BPF (SPM) 
 
-0.41 (1.16)  -0.59 (1.39)  -1.16 (1.26)  0.92 
GMF (SPM) 
 
-0.33 (1.22)  -0.97 (1.87)  -1.35 (1.57)  0.86 
Mean (SD) 
atrophy rate 
(% year
-1) 
WMF (SPM) 
 
-0.55 (1.39)  0.23 (1.30)  -0.76 (1.65)  0.46 
VVD  
 
-0.23 (0.68)  0.41 (1.07)  1.32 (1.15)  0.99 
VBSI  
(both ROIs) 
-0.20 (0.67)  0.34 (0.94)  1.22 (1.03)  1.02 
Mean (SD) 
ventricular 
enlargement 
(ml year
-1)  VBSI  
(baseline ROI)  
-0.17 (0.68)  0.31 (0.86)  1.16 (1.00)  0.99 
CCV, central cerebral volume; BPF, brain parenchymal fraction; SPM, statistical parametric mapping; 
GMF, grey matter fraction; WMF, white matter fraction; VVD, segmented ventricular volume difference; 
VBSI, ventricular boundary shift integral; ROI, region of interest. 
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Figure 6-3 Atrophy rates quantified from eight different measurement techniques in 
controls and subjects with CIS and RRMS.  
 
 
Figure  6-4  Rates  of  ventricular  enlargement  quantified  from  segmented  ventricular 
volume difference and the VBSI, in controls and subjects with CIS and RRMS.  
 
CCV, central cerebral volume; BPF, brain parenchymal fraction; SPM, statistical parametric mapping; 
GMF, grey matter fraction; WMF, white matter fraction; VBSI, ventricular boundary shift integral; ROI, 
region of interest.  
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Ventricular  enlargement  and  atrophy  rates  calculated  using  BPF,  GMF,  and  CCV  on 
registered images, increased between controls and patients with CIS, and between patients 
with CIS and those with RRMS. Change in WMF, and CCV measured on unregistered 
images, were less consistent. Positive atrophy rates (brain “growth”) were seen in control 
subjects  using  CCV  methods,  and  in  RRMS  subjects  when  using  the  Excalp  CCV 
method. Small effect sizes were also observed when atrophy was quantified using CCV, 
although  registration  of  images  did  improve  statistical  power  slightly.  The  BBSI  and 
SIENA gave the largest effect sizes, with all three measures of ventricular enlargement 
giving relatively high statistical power also. BPF and GMF gave slightly smaller effect 
sizes, whilst those obtained using atrophy of the WMF were poor. 
 
There was evidence of a significant difference in mean percentage atrophy rates given by 
the different methods in each subject group (p=0.0028 for controls, p=0.0003 for CIS and 
p<0.0001 for RRMS). Paired t-tests in RRMS subjects showed that mean rates of GMF 
atrophy  were  significantly  greater  (more  negative)  than  rates  quantified  by  the  BBSI 
(p=0.0408),  SIENA  (p=0.0405),  and  CCV  (Excalp  p=0.0016,  MIDAS  p=0.0128, 
registered images p=0.0011). Rate of BPF atrophy was significantly greater than rate of 
atrophy from CCV (Excalp p=0.0058, MIDAS p=0.0175, registered images p=0.0008), 
whilst the BBSI and SIENA gave significantly greater atrophy rates than CCV measured 
using Excalp (BBSI p=0.0213, SIENA p=0.0169) or MIDAS on registered images (BBSI 
p=0.0001, SIENA p<0.0001). 
 
There  was  also  evidence  of  a  significant  difference  in  the  variance  of  atrophy  rates 
between techniques (p=0.0032 for controls, p<0.0001 for CIS and p=0.0012 for RRMS). 
Pairwise  Pitman’s  tests  revealed  that  the  variance  of  atrophy  rates  was  significantly 
reduced  when  quantified  with  the  BBSI  and  SIENA  compared  with  SPM  fractional 
atrophy rates, and CCV atrophy rates measured on unregistered images (all p<0.001). 
Percentage rate of change of CCV measured on registered images was significantly less 
variable  than  SPM  fractional  atrophy  rates  and  measures  of  CCV  from  unregistered 
images. BPF measurements were significantly more variable than measurements of GMF 
(p=0.016). 
 
Ventricular  enlargement  was  shown  to  correlate  well  with  whole  brain  measures  of 
atrophy by SIENA (Figure 6-5). The correlation of SIENA with VVD, VBSI with both  
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ROIs and VBSI with the baseline ROI only was r=-0.80, -0.80 and -0.79 respectively (all 
p<0.001). 
 
Figure 6-5 Correlation between rate of ventricular enlargement (segmented ventricle 
volume difference) and rate of whole brain atrophy (SIENA). 
 
 
Pairwise Bland-Altman plots of the different measures of ventricular enlargement showed 
that as ventricular enlargement increased there was a trend for the VBSI (both methods) 
to underestimate the volume change compared  with the VVD (Figure 6-6). This was 
confirmed by the joint Wald test, where in subjects with RRMS there was evidence of a 
significant difference in rates of ventricular enlargement (p=0.0009). In these subjects the 
mean difference between VVD and the VBSI using both ROIs (VVD-VBSI) was 0.10ml 
year
-1 (SD 0.14, 95% CI 0.04 to 0.15, p=0.0011). Similarly the mean difference between 
VVD and the VBSI using only the baseline ROI was 0.16ml year
-1 (SD 0.24, 95% CI 0.07 
to  0.25,  p=0.0015).  Looking  at  the  two  VBSI  measurements,  mean  difference  (VBSI 
(both ROIs) – VBSI (baseline ROI only)) was 0.06ml year
-1 (SD 0.14, 95% CI 0.006 to 
0.11, p=0.0306). 
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Figure 6-6 Bland-Altman plot comparing ventricular enlargement measures quantified 
from the difference in segmented ventricular volume and the ventricular boundary shift 
integral.  The  reference  ranges  are  the  values  within  which  95%  of  the  differences 
between  measurements  from  the  two  methods  are  expected  to  lie.  VVD,  segmented 
ventricular  volume  difference;  VBSI,  ventricular  boundary  shift  integral  (which  was 
calculated using both baseline and repeat ventricular regions of interest (ROI)). 
 
 
In the CIS and RRMS subject groups there was evidence of a significant difference in the 
variance  of  rates  of  ventricular  enlargement  obtained  using  the  three  techniques 
(p<0.0001). Pairwise analysis revealed that the variance of rates was significantly greater 
when  quantified  by  VVD  compared  with  the  VBSI  (both  p<0.001).  As  the  relative 
changes  in  mean  and  variance  of  measures  was  similar,  the  effect  sizes  were  almost 
identical for the three measures. 
 
Reliability and consistency of brain atrophy measures 
The mean difference in volume between scan-rescan baseline images is given in Table 
6-5 for each method. There was evidence that the difference was significantly different 
from zero when quantified using the BBSI.  
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Table 6-5 Scan-rescan analysis using the different atrophy measurement techniques in 
22 control subjects. Mean volume difference between the two images and the results of 
a one-sample t-test are given. 
  Volume change
a  
(mean (SD)) 
One-sample t-test  
(p-value) 
BBSI   0.099% (0.21)  0.04 
SIENA   0.016% (0.32)  0.81 
BPF (SPM)  0.083% (0.83)  0.65 
GMF (SPM)  0.090% (1.36)  0.76 
WMF (SPM)  0.072% (1.00)  0.79 
VVD   -0.043ml (0.27)  0.47 
VBSI (both ROIs)  -0.091ml (0.35)  0.23 
VBSI (baseline ROI only)   -0.185ml (0.45)  0.07 
aexpressed as a percentage of volume ‘A’ except for ventricular measurements. BPF, brain parenchymal 
fraction; SPM, statistical parametric mapping; GMF, grey matter fraction; WMF, white matter fraction; 
VVD, segmented ventricle volume difference; VBSI, ventricular boundary shift integral; ROI, region of 
interest. 
 
 
Looking at the consistency of atrophy rates quantified from the two baseline images to 
repeat one year image, no bias was evident from inspection of the Bland-Altman plots 
(not  shown).  This  was  confirmed  by  paired  t-tests,  and  mean  differences  calculated 
between the two measures were less than 0.06% for percentage atrophy rates and less than 
0.2ml  for  ventricular  enlargement  (Table  6-6).  The  ICC  between  the  atrophy  rates 
calculated on repeated one  year intervals was highest for VVD and was significantly 
greater than those for all other measures except the BBSI. The ICCs of the BBSI and 
VBSI using both ventricular regions were significantly larger than those of SIENA and 
the  VBSI  using  only  the  baseline  region.  The  reliability  of  SPM-derived  fractional 
volumes was significantly lower than those of other measures.  
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Table  6-6  Consistency  of  different  atrophy  measurement  techniques.  In  22  control 
subjects  using  each  of  the  measurement  techniques,  brain  atrophy  or  ventricular 
enlargement was quantified twice between baseline and one year, for each of the two 
(scan-rescan)  baseline  images.  For  each  technique  the  mean  difference  in  rates 
calculated from the two baseline images, and results of a paired t-test on all results for 
a technique are given. The intraclass correlation coefficient (ICC) of repeated measures 
is also given for each technique.  
  Difference in atrophy rate
a 
(mean (SD) (95% CI)) 
Paired t-test  
(p-value) 
ICC 
BBSI   0.047% year
-1  
(0.226, -0.148 to 0.053) 
0.34  0.91 
SIENA   0.033% year
-1  
(0.312, -0.109 to 0.175) 
0.63  0.86 
BPF (SPM)  0.044% year
-1  
(0.839, -0.337 to 0.426) 
0.81  0.65 
GMF (SPM)  0.031% year
-1  
(1.371, -0.593 to 0.655) 
0.92  0.64 
WMF (SPM)  0.058% year
-1  
(1.016, -0.404 to 0.521) 
0.80  0.76 
VVD   -0.048ml year
-1  
(0.274, -0.173 to 0.077) 
0.43  0.94 
VBSI (both ROIs)  -0.109ml year
-1  
(0.345, -0.266 to 0.048) 
0.16  0.91 
VBSI (baseline ROI 
only)  
-0.199ml year
-1  
(0.455, -0.406 to 0.008) 
0.06  0.86 
aexpressed  as  a  percentage  of  baseline  volume  ‘A’  except  for  ventricular  measurements,  BPF,  brain 
parenchymal  fraction;  SPM,  statistical  parametric  mapping;  GMF,  grey  matter  fraction;  WMF,  white 
matter fraction; VVD, segmented ventricle volume difference; VBSI, ventricular boundary shift integral; 
ROI, region of interest. 
 
6.3.4  Discussion 
In  this  study  a  direct  comparison  of  methods  for  monitoring  brain  atrophy  has  been 
performed.  Significant  differences  in  atrophy  rates  and  the  variance  of  measurements 
were observed, suggesting that some methods may be more sensitive to global tissue loss  
166 
and would be a more effective marker of disease progression and treatment effects. In 
addition,  some  techniques  appear  to  be  more  robust  and  provide  more  reliable  and 
consistent results than others, an important factor if these methods are to be utilised in 
future clinical trials.  
 
In contrast to previous investigations, this study found that measures of CCV were poor 
markers of brain atrophy, which appeared to be independent of the software used for 
analysis. CCV has previously been shown to decrease significantly over time in RRMS 
subjects, with changes ranging from -3.4ml year
-1 (approximately -1.1%) (Losseff et al., 
1996)  to  -2.3cm
3  (approximately  -0.8%),  -1.4%  (SD  2.3)  and  -2.6%  over  18  months 
(Rovaris et al., 2000; Rovaris et al., 2001; Sailer et al., 2001). Atrophy rates in RRMS 
patients were much smaller in this study and there was an unexpected positive atrophy 
rate (brain “growth”) in RRMS subjects when using Excalp. This was most likely due to 
the three outliers seen in this group, which also led to the large variance of measures seen 
with this technique. One limitation of the Excalp procedure that may have led to errors is 
that  re-inclusion  of  brain  tissue  erroneously  excluded  by  automatic  processing  is  not 
possible. It was observed that even when baseline and repeat images were of similar 
quality, Excalp sometimes stripped more of one image than the other. Excalp also failed 
to  derive  a  volume  for  one  control  subject  suggesting  that  this  software  may  not  be 
consistently robust. In addition, it takes longer to derive measurements by Excalp than 
MIDAS as it is applied on a slice-by-slice basis. 
 
Although MIDAS CCV gave a greater spread of values in controls and CIS than Excalp, 
both techniques detected highly positive atrophy rates in controls, again suggesting some 
degree of measurement error. It is likely that the greater variability may to some extent 
have  been  due  to  differences  in  slice  thickness,  slice  selection  and  repositioning  for 
follow-up images, leading to volumes of interest not necessarily being equivalent over 
serial  imaging.  Support  for  this  idea  comes  from  the  measurements  performed  on 
registered images, which showed significantly less variability. However despite increased 
precision  following  image  registration,  the  sensitivity  of  measurements  and  statistical 
power  was  still  poor,  and  in  controls  brain  “growth”  of  0.4%  year
-1  was  detected. 
Although  one  study  has  previously  found  CCV  changes  of  0.2%  over  18  months  in 
control subjects (Rovaris et al., 2000), the finding in the current study is likely to have 
been the result of measurement error. Other studies of controls using different atrophy  
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measurement techniques have shown rates of around -0.2 to -0.3% year
-1 (Fox et al., 
2000b;  Richert  et  al.,  2006;  Rovaris  et  al.,  2005b;  Scahill  et  al.,  2003).  One  of  the 
potential problems with registration of CSE images is the interpolation of voxels that is 
performed,  which  may  not  be  entirely  accurate,  and  this  may  have  led  to  the  errors 
observed in controls and the low atrophy rates detected in patients with CIS and RRMS.  
 
Of all the methods tested, the BBSI and SIENA were shown to have the largest statistical 
power  based  on  effect  sizes  calculated  from  atrophy  rates  in  subjects  with  RRMS. 
However  ventricular  enlargement  was  also  shown  to  have  high  statistical  power  and 
correlated well with whole brain atrophy rates measured by SIENA. In addition, analysis 
showed that the mean difference in ventricular enlargement when measurements were 
repeated on scan-rescan images was less than 0.1ml, and over one year VVD was the 
most  consistent  measure.  There  has  been  considerable  variation  in  reported  rates  of 
ventricular enlargement, which may to some extent be due to analysis of different cohorts. 
In  patients with RRMS  with longer disease duration than the subjects studied in this 
investigation, median ventricular enlargement of 0.5ml year
-1 (range -1.7 to 4.2) (Dalton 
et al., 2006), 2.1ml year
-1 (IQR 0.7 to 3.7) (Fox et al., 2000b) and 2.3ml over six months 
(IQR -0.94 to 2.51) (Redmond et al., 2000) has been observed. Although CIS subjects 
were grouped together in this study, rates of ventricular enlargement were intermediate to 
those observed in a three year study of CIS patients who were divided into those who had 
developed MS at follow-up and those who had not; mean change over the three year study 
period was 2.4ml (95% CI 1.3 to 3.5) in patients who progressed to MS and 0.2ml (95% 
CI -1.0 to 1.4) in patients who did not progress (Dalton et al., 2004). 
 
This is the first study to apply the VBSI to patients with MS and whilst there was no 
difference in the correlation of whole brain atrophy to the VBSI compared with VVD, the 
VBSI  appeared  to  underestimate  ventricular  enlargement  relative  to  VVD.  This  is  a 
similar finding to that with whole brain BSI, and may be caused when the window over 
which  the  boundary  shift  is  quantified  does  not  necessarily  include  all  the  intensity 
changes  that  occur  over  the  ventricular  region  (Fox  &  Freeborough,  1997).  This 
discrepancy between the two measures also appeared to be greater when there was more 
ventricular  enlargement.  Periventricular  lesions  may  have  caused  differences  in  the 
intensity transitions at the borders of the ventricles which can be accounted for when 
outlining regions in MIDAS, but may have caused some bias in VBSI measures. The  
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VBSI increased measurement precision relative to VVD however, and effect sizes were 
similar using the VVD and VBSI. One of the advantages of the VBSI when using only the 
baseline ROI is that analysis time would be reduced. This could be particularly useful in 
large  multicentre  studies  where  multiple  assessments  are  performed.  Following  the 
segmentation of the baseline ventricular region, quantification of ventricular enlargement 
at  each  follow-up  could  be  acquired  automatically  with  minimal  operator  interaction. 
Although one might expect that measures using the VBSI would be more reliable and 
consistent over time, as the technique is automated, measurement reliability was slightly 
reduced relative to VVD and mean scan-rescan volume difference was greater. This may 
be because the method is more sensitive to small changes in scan acquisition. Although 
ventricular  enlargement  measures  were  shown  to  be  sensitive,  precise  and  reliable,  it 
should be noted that the relationship between ventricular enlargement and brain atrophy 
may  not  always  be  consistent.  In  patients  with  Alzheimer’s  disease  evidence  was 
presented that the proportion of brain volume loss attributable to ventricular expansion is 
greater with increasing ventricular volumes. However this may not be true for different 
diseases, with different disease mechanisms and distributions of pathology (Schott et al., 
2005). 
 
SPM measures of WMF appeared to be subject to some degree of error, with inconsistent 
atrophy rates quantified between controls, CIS and RRMS subjects. Mean atrophy rates in 
control subjects were larger than might be expected, whilst a positive mean atrophy rate 
(i.e. increased WMF)  was observed in patients  with CIS. A similar finding  has been 
observed previously; change in WMF was 0.2% over three years in CIS patients who had 
remained  stable,  and  1.3%  in  patients  who  had  developed  MS  over  the  study  period 
(Dalton et al., 2004). WMF atrophy rate in subjects with RRMS was similar to that found 
in a previous study that included 28 RRMS patients; -1.2% over three years was observed 
(Zivadinov et al., 2007). Evidence suggests that atrophy of the WM is inversely correlated 
with the volume of Gd-enhancing lesions (Tiberio et al., 2005), adding support to the 
hypothesis  that  inflammatory  disease  preferentially  affects  WM,  which  is  likely  to 
confound  volume  measures  of  this  tissue  compartment.  This  may  partly  explain  the 
inconsistent results between controls, CIS and RRMS patients, and the relatively large 
variance of measures found in this study. However it may be that the distinction between 
WM and GM is inherently sensitive to noise in scan acquisition. 
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SPM measures of BPF and GMF gave more consistent results and the highest percentage 
changes of all the measures investigated, significantly larger in the case of GMF. The 
results from this study were in concordance with previous reports. Over three years a BPF 
change of -0.6% in CIS subjects, and -1.4% in subjects who had developed MS over the 
study period, was observed (Dalton et al., 2004). In subjects with RRMS a -2.5% change 
over  three  years  has  been  reported  (Zivadinov  et  al.,  2007).  In  these  same  patients 
changes in GMF were -1.1%, -3.3% and -1.4% respectively. However the variance of 
these BPF and GMF measures in the present study was also high, and therefore statistical 
power was lower than that of the BBSI, SIENA and ventricular enlargement. Outliers in 
both  the  CIS  and  RRMS  group,  as  observed  in  Figure  6-3,  will  have  increased  the 
variance but show that SPM may not be as robust as other techniques. SPM measures can 
be affected when the FOV is too small and there is either signal drop-off or the CSF is 
somewhat excluded. This may lead to misclassification of voxels and underestimation of 
CSF volume which may have been the cause of the outliers. It should also be mentioned 
at this point that SPM is an automated segmentation tool and therefore inaccurate tissue 
classification may occur, the degree of which can be difficult to assess. SPM also failed 
completely on one subject providing further evidence that it may not be as robust as other 
techniques. Although SPM may be useful to investigate tissue-specific changes that may 
help  to  elucidate  disease  mechanisms,  lesion  contouring  must  be  performed  which  is 
time-consuming and a further disadvantage of this technique, especially for patients with 
high lesion loads. 
 
Measurement reliability is important if atrophy rates are to be utilised in clinical trials 
where  MRI  acquisition  may  be  performed  at  multiple  centres.  Previous  studies  have 
investigated scan-rescan reliability but these have been restricted to cross-sectional rather 
than longitudinal measurements. In addition the CV has usually been reported, making it 
difficult to compare results from this study with those reported previously (Carone et al., 
2006; Fox et al., 2000b; Losseff et al., 1996; Paolillo et al., 2004; Rovaris et al., 2000; 
Zivadinov  et  al.,  2004a;  Zivadinov  et  al.,  2007).  Although  SPM  is  an  automated 
technique it appears that small differences in acquisitions may affect image segmentation, 
as evidenced by the ICC for repeated measurements of baseline to one year atrophy rates. 
The ICC was significantly lower for SPM measurements than all other measurements. 
Although  the  ICC  was  high  for  the  BBSI,  scan-rescan  assessment  estimated  change 
significantly different from zero, which suggests some measurement error. This finding  
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may be due to the fact that the SD of measurements was the lowest of the techniques. 
Over the scan-rescan interval SIENA estimated the lowest change, suggesting it is robust 
to small differences in acquisition. In a cross-validation study of the BBSI and SIENA in 
which 185 scan-rescan image pairs were analysed, mean differences were 0.0006% for 
SIENA and 0.1118% for the BBSI, which are similar to those found in the current study 
(Smith et al., 2007). The ICC of repeated longitudinal measures was similar to that of the 
BBSI. To rigorously test measurement reliability and consistency of measures, it would 
have been valuable to have had scan-rescan images at the one year time-point also.  
 
One of the limitations of this study is the multiple comparisons that were performed to 
investigate  differences  in  the  mean  and  variance  of  measures.  Although  these  were 
limited  to  patients  with  RRMS,  it  is  possible  that  significant  effects  were  found  by 
chance.  However,  in  conclusion,  there  appear  to  be  clear  benefits  to  certain  atrophy 
measurement techniques, namely the BBSI, SIENA and ventricular enlargement. 
 
6.4  Chapter conclusions 
This chapter has investigated the relative advantages and brain atrophy measurements of a 
number of techniques that have previously been applied to MRI of patients with a disease-
related decrease in brain volume. It has been shown that registration of serial images 
increases measurement precision, which consequently increases statistical power and will 
allow better detection of disease progression and treatment effects. In particular the BBSI 
and SIENA, both registration-based methods, were shown to provide more precise brain 
atrophy  measurements  compared  with  techniques  based  on  the  subtraction  of  serial 
volumes. However ventricular enlargement was shown to correlate well with whole brain 
atrophy  measures,  and  these  measurements  were  highly  reliable  with  relatively  high 
statistical power. 
 
Studies of larger cohorts with longer clinical and MRI follow-up are needed to investigate 
these  measures  further,  and  establish  their  potential  as  sensitive  markers  of  the 
development  of  irreversible  disability  which  may  aid  in  identifying  effective  disease-
modifying  treatments  and  in  prognosis  for  individual  patients.  Also,  further  work  is 
needed to try and improve the stability of scan acquisitions.  
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7  Sample  size  calculations  in  relapsing  remitting  multiple 
sclerosis 
 
7.1  Introduction 
The standard primary outcome measures in trials of potential disease-modifying drugs in 
MS are clinically based and include the development of disability or relapse rate (Jacobs 
et al., 1996; Johnson et al., 1995). However, with evidence that neuroaxonal loss is a key 
pathological feature of MS (Peterson et al., 2001; van Waesberghe et al., 1999) which is 
widely considered to be the main pathological substrate of irreversible disability, it is 
likely that current scales which measure clinical disability may not reflect the extent or 
severity  of  this  underlying  and  irreversible  pathology.  There  may  be  a  threshold  of 
neuroaxonal loss only beyond which disability may become apparent, and pathology may 
occur in clinically silent locations which does not immediately cause a measurable change 
in clinical function. Moreover, it can be difficult to monitor the extent of irreversible 
disability in patients when using subjective clinical assessment scales that may not be 
sensitive  enough  to  detect  small  changes  in  function,  especially  if  the  patient  is 
experiencing relapses.  
 
With the development of new disease-modifying treatments and potential neuroprotective 
agents for MS, there is an increasing need to monitor directly the efficacy of these drugs 
on  the  underlying  global  MS  pathology,  especially  neuroaxonal  loss.  This  thesis  has 
investigated  and  optimised  a  number  of  atrophy  measurement  techniques  that  allow 
visualisation and measurement of the irreversible tissue loss that occurs as a result of this 
pathology and that may provide a means by which neuroaxonal loss can be inferred non-
invasively in-vivo from structural MRI. 
 
Currently, brain atrophy has only been used as a secondary (and retrospective) outcome 
measure in treatment trials (Filippi et al., 2004; Rudick et al., 1999), with the sample size 
having been determined for the primary outcome measure, e.g. relapse rate or disability 
for a phase III trial or MRI lesion activity for a phase II trial. If MRI measures of brain 
atrophy are to be adopted as markers of disease progression in future clinical trials of 
disease-modifying treatments for MS, the number of patients required to detect a given 
treatment effect should be determined. This is vital for any trial; if not enough subjects are  
172 
entered, there may be insufficient power to detect a treatment effect, whilst the inclusion 
of more subjects than necessary may expose additional subjects to harmful side effects. 
Both cases will ultimately result in wasted resources. This thesis has already identified 
several  techniques  that  provide  relatively  precise,  reproducible  and  sensitive 
measurements  of  brain  atrophy,  which  may  aid  in  reducing  the  number  of  patients 
required to detect a treatment effect. 
   
In this study, brain atrophy was measured longitudinally at multiple time-points for up to 
three years using the three methods that were identified in Chapter 6 as being relatively 
more  powerful  markers  of  brain  atrophy.  Power  calculations  were  then  performed  to 
determine  the  sample  sizes  required  for  a  placebo-controlled  trial  with  respect  to  the 
atrophy  measurement  method  and  duration  of  study.  For  sample  size  comparison,  an 
atrophy measurement method that was deemed to be a less optimal marker of progression 
was also included. 
 
7.2  Methods 
7.2.1  Subjects and MR imaging 
Sixteen control subjects and 33 patients with clinically definite RRMS (Poser et al., 1983) 
were identified from the cohorts included in this thesis (Chapter 3.1) (Table 7-1). Patients 
had experienced at least two clinical episodes, but were within four years of symptom 
onset (median 1.7, range 0.5-3.8 years). At study entry all patients had an EDSS ≤ 3 
(median 1.5, range 0-3), and only patients with at least two MRI scans and who were not 
on disease-modifying treatment were included. The patients were representative of those 
who would be considered for inclusion in treatment trials. If patients were started on 
disease-modifying treatment, subsequent data was excluded from analysis.  
 
T1-weighted  coronal  3D  FSPGR  imaging  was  acquired  at  baseline  and  at  up  to  six 
subsequent  time-points  (approximately  six  monthly  up  to  36  months)  (Table  7-1), 
according to the protocols described in Chapter 3.3.  
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Table 7-1 Characteristics of controls and subjects with RRMS who had available MRI data at each time-point for sample size calculations. 
    Time-point (months) 
    Baseline  6  12  18  24  30  36 
N (M:F)  7:9  7:9  7:9  6:5  7:6  5:2  6:2 
Age (years) (mean, SD)  35.1 (6.3)  35.7 (6.4)  34.9 (8.4)  38.7 (6.6)  37.3 (7.1)  38.7 (9.0)  38.0 (5.4) 
Controls 
Follow-up time (years) (mean, SD)  …  0.56 (0.06)  1.07 (0.08)  1.66 (0.24)  2.14 (0.18)  2.54 (0.07)  3.00 (0.09) 
N (M:F)  11:22  7:22  7:17  7:14  6:15  6:12  4:7 
Age (years) (mean, SD)  36.0 (7.4)  36.7 (7.6)  39.2 (7.4)  39.3 (6.5)  38.6 (6.5)  40.0 (6.4)  39.9 (6.8) 
Follow-up time (years) (mean, SD)  …  0.54 (0.06)  1.05 (0.07)  1.53 (0.10)  2.03 (0.12)  2.57 (0.16)  3.09 (0.20) 
EDSS (median, range)   1.5 (0-3)  2 (0-3.5)  1.5 (1-3.5)  1.5 (0-3.5)  2 (0-3.5)  2 (0-6)  2 (0-3) 
RRMS 
Disease duration (years) (mean, SD)  1.7 (0.8)  2.5 (0.8)  3.1 (0.8)  3.5 (0.8)  4.0 (0.7)  4.6 (0.7)  5.2 (0.8)  
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7.2.2  MRI analysis 
 (i) Segmented brain volume difference 
Semi-automated segmentation of baseline and repeat brains was performed using MIDAS 
as described in Chapter 4.2.2, with correction of images for intensity inhomogeneity using 
N3  (Sled  et  al.,  1998).  Brain  volume  was  determined  from  the  segmentation  within 
MIDAS. 
 
(ii) BBSI 
The  BBSI  was  applied  to  quantify  atrophy  from  each  repeat  image  to  baseline  as 
described in Chapter 4.2.2. DBC (Lewis & Fox, 2004) was applied at registration and the 
BBSI  window  parameters  were  set  at  the  optimal  values  determined  in  Chapter  4.3 
(I1=0.65, I2=0.45). 
 
(iii) SIENA 
SIENA was applied to quantify atrophy from each repeat image to baseline as described 
in Chapter 5.3.2.  This required  axial reorientation of  all images,  and the initial brain 
segmentation was acquired using the optimised version of BET, described in Chapter 5.2. 
 
(iv) Ventricular enlargement (VE) 
Ventricle volumes were determined on all images as described in Chapter 6.3.2. 
 
7.2.3  Statistical analysis 
Separate linear mixed models for controls and patients were fitted to the data using Stata 
Xtmixed. The logarithm of the brain volume measurements against time from baseline 
was modelled. For BBSI and SIENA, the logarithm of the ratio of volume at the second 
scan to volume at the baseline scan was modelled, with the repeat volume calculated 
using the baseline volume and the BBSI/SIENA change (Frost et al., 2004). By modelling 
log volumes, these three models assume that brain volumes decrease proportionately with 
time. Conversely, for VE the absolute ventricular volume was modelled, consistent with 
an assumption of a constant volume increase with time. 
 
Evidence of acceleration in atrophy rate was tested through the introduction of a fixed 
quadratic effect in time. In each model the repeated within-subject measurements were 
allowed  for  using  random  slopes,  where  estimation  of  the  corresponding  variance  
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component was possible. Random intercept effects were included in the models for BVD 
and VE. A further random effect was included in the BBSI and SIENA models to allow 
for the additional correlation structure inherent in direct measures of change (Frost et al., 
2004). 
 
Sample size calculations were performed for a trial including baseline and one follow-up 
assessment, using the estimated means and variances from these mixed models, and were 
based on the standard formula (Equation 7.1) with 90% power to detect a treatment effect 
and 5% two-tailed significance level. For BBSI and SIENA, calculations were based on 
performing an analysis of change, whereas for BVD and VE, calculations were based on 
an analysis of covariance. A completely effective treatment was considered to be one 
which  reduced  the  atrophy  rate  to  the  level  seen  in  controls,  and  an  immediate  and 
constant effect was assumed. The effect of different methods and trial duration on sample 
sizes  was  assessed  by  determining  ratios  of  sample  sizes,  with  95%  bootstrap  CI 
calculated  to  indicate  whether  differences  were  statistically  significant,  treating  the 
atrophy rate in controls as known. 
 
2
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u = 1.28 to provide 90% power 
v = 1.96 to test at the 5% significance level 
µ1 and µ2 are the mean log brain volume atrophy rates (BVD, BBSI, SIENA) or mean VE 
rates in the placebo and treatment groups.  
σ
2 is the variance of the ANCOVA log BVD atrophy rates, the variance of the log BBSI 
and SIENA atrophy rates or the variance of the ANCOVA VE rates.  
The mean rate in the treatment group was taken as a percentage of the difference between 
control and RRMS rates. A completely effective treatment was considered to be one which 
reduced  the  atrophy  rate  to  the  level  estimated  in  controls,  i.e.  a  30%  reduction  in 
atrophy rate in the treated group was equal to 30% of the difference in mean rate of the 
control and RRMS groups, which was subtracted from the mean RRMS atrophy rate.  
A 5% drop-out of subjects and 5% of scan pairs being unusable was taken into account by 
dividing resulting sample sizes by 0.95
2.  
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7.3  Results 
Eight RRMS patients started treatment with beta interferon during the study period; three 
patients by 12 months, and a further two by 18 months, one by 30 months and two by 36 
months.  Atrophy  rates  while  on  and  off  treatment  were  estimated,  but  there  was  no 
statistically significant evidence that these rates differed. It was therefore judged that bias 
to less disabled patients was not introduced by excluding on-treatment data. 
 
Estimated atrophy in controls and patients with RRMS is shown in Table 7-2. For both 
controls  and  patients  with  RRMS,  there  was  very  little  evidence  of  between  subject 
variability in atrophy rate quantified by BVD (random slope effect could not be fitted). 
Consequently, the model predicted SDs of atrophy over one, two and three years were 
equal. There was no evidence for acceleration in mean atrophy rate over the three years in 
patients with RRMS using the BBSI (p=0.90), SIENA (p=0.31) or BVD (p=0.08). A 
linear rate of atrophy over this period was therefore assumed.  
 
Estimated sample sizes for a parallel group, placebo-controlled design with atrophy rate 
as the outcome variable are shown in Table 7-3. For a given effect size, sample sizes were 
affected  by  measurement  method,  particularly  at  shorter  trial  durations.  The  smallest 
sample sizes were observed using SIENA, followed by VE, the BBSI and BVD. Over all 
trial durations sample sizes were statistically significantly smaller than BVD using the 
three other methods (Table 7-4). Although the BBSI, SIENA and VE showed similar 
sample sizes, SIENA gave marginally smaller estimates over all trial durations, which 
were statistically significantly smaller than the BBSI when considering trials conducted 
over one year. As expected, the longer the length of follow-up, the smaller the sample 
sizes required. For all atrophy measurement methods, statistically significant reductions in 
the sample sizes required were observed as the length of trial increased (Table 7-5).  
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Table 7-2 Brain atrophy and ventricular enlargement over one, two and three year intervals, estimated from linear mixed models, in controls 
and subjects with RRMS. Results for the BBSI and SIENA take into account that the true atrophy rates differ from the mean atrophy rate. 
Interval  Controls 
mean (SD) (95% CI) 
RRMS 
mean (SD) (95% CI) 
  BVD 
 (% baseline 
volume) 
BBSI 
(% baseline 
volume) 
SIENA 
(% baseline 
volume) 
VE  
(ml) 
BVD 
(% baseline 
volume) 
BBSI 
(% baseline 
volume) 
SIENA 
(% baseline 
volume) 
VE 
(ml) 
1 year  -0.22 (2.27) 
(-0.59, 0.15) 
-0.09 (0.39) 
(-0.21, 0.02) 
-0.11 (0.30) 
(-0.22, -0.01) 
0.11 (0.67) 
(-0.14, 0.35) 
-0.84 (2.16) 
(-1.11, -0.57) 
-0.63 (0.59) 
(-0.78, -0.48) 
-0.79 (0.58) 
(-0.96, -0.61) 
-1.51 (1.75) 
(0.98, 2.04) 
2 years  -0.43 (2.27) 
(-1.17, 0.31) 
-0.19 (0.46) 
(-0.42, 0.04) 
-0.23 (0.42) 
(-0.45, -0.01) 
0.21 (0.95) 
(-0.27, 0.69) 
-1.67 (2.16) 
(-2.20, -1.13) 
-1.26 (0.84)  
(-1.56, -0.95) 
-1.57 (0.93) 
(-1.91, -1.22) 
-3.02 (2.94) 
(1.96, 4.07) 
3 years  -0.65 (2.27) 
(-1.75, 0.47) 
-0.28 (0.57) 
(-0.63, 0.06) 
-0.34 (0.56) 
(-0.67, -0.02,) 
0.32 (1.30) 
(-0.41, 1.04) 
-2.49 (2.16) 
(-3.28, -1.70) 
-1.88 (1.13) 
(-2.33, -1.42) 
-2.34 (1.33) 
(-2.85, -1.83) 
-4.52 (4.24) 
(2.94, 6.11)  
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Table 7-3 Estimates of the sample sizes required for parallel group placebo-controlled 
trials of a treatment reducing brain atrophy rate by varying degrees in patients with 
RRMS. Estimates are the numbers of patients required in each trial arm, with 90% 
power to detect a treatment effect at the 5% significance level, and taking into account a 
5% subject drop-out rate and 5% of scans pairs being unusable.  
Treatment effect size (% reduction in atrophy rate)  Trial 
duration 
Measurement 
method  30%  50%  70%  90% 
1 year  BVD  3051  1098  560  339 
  BBSI  314  113  58  35 
  SIENA  191  69  35  21 
  VE  269  97  49  30 
2 years  BVD  763  275  140  85 
  BBSI  157  56  29  17 
  SIENA  123  44  23  14 
  VE  140  50  26  16 
3 years  BVD  339  122  62  38 
  BBSI  128  46  23  14 
  SIENA  111  40  20  12 
  VE  114  41  21  13 
BVD, segmented brain volume difference; VE, ventricular enlargement.  
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Table 7-4 Relative sample sizes for each brain atrophy measurement technique. Relative sample sizes are not affected by power, significance 
level or effect size. 
  1 year  2 years  3 years 
  Relative sample size (95% CI)  Relative sample size (95% CI)  Relative sample size (95% CI) 
BVD  1 
 
…  …  1  …  …  1  …  … 
BBSI     0.10 * 
(0.06, 0.19) 
1  …     0.21 * 
(0.09, 0.38) 
1  …     0.38 * 
(0.16, 0.78) 
1  … 
SIENA     0.06 * 
(0.03, 0.13) 
     0.61 ** 
(0.37, 0.96) 
1     0.16 * 
(0.07, 0.41) 
0.79  
(0.48, 1.28) 
1     0.33 * 
(0.12, 0.86) 
0.87  
(0.49, 1.41) 
1 
VE     0.09 * 
(0.04, 0.21) 
0.86  
 (0.56, 1.59) 
  1.41 
(0.90, 2.88) 
   0.18 * 
(0.09, 0.43) 
0.89 
(0.55, 1.64) 
1.13 
(0.47, 2.44) 
0.34 * 
(0.16, 0.82) 
0.90 
(0.42, 1.78) 
1.03 
(0.32, 2.47) 
* p<0.05 for sample size ratio relative to BVD differing from 1; ** p<0.05 for sample size ratio relative to BBSI differing from 1; BVD, segmented brain volume difference; VE, 
ventricular enlargement.  
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Table 7-5 Relative sample sizes for different trial durations. Relative sample sizes are not affected by power, significance level or effect size. 
  BVD  BBSI  SIENA  Ventricular enlargement 
  Relative sample size (95% CI)  Relative sample size (95% CI)  Relative sample size (95% CI)  Relative sample size (95% CI) 
1 year  1 
 
…  1  …  1  …  1  … 
2 years     0.25 * 
(0.25, 0.28) 
1     0.50 * 
(0.36, 0.69) 
1     0.65 * 
(0.46, 0.86) 
1     0.52 * 
(0.45, 0.81) 
1 
3 years     0.11 * 
(0.11 0.15) 
    0.44 ** 
(0.44, 0.52) 
   0.41 * 
(0.24, 0.63) 
    0.81 ** 
(0.67, 0.92) 
   0.58 * 
(0.36, 0.83) 
    0.90 ** 
(0.78, 0.97) 
   0.43 * 
(0.34, 0.77) 
    0.82 ** 
(0.76, 0.95) 
* p<0.05 for sample size ratio relative to one year; ** p<0.05 for sample size ratio relative to two years; BVD, segmented brain volume difference.  
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7.4  Discussion 
This study estimated the sample sizes required when using brain atrophy measurements 
from serial volumetric MRI to investigate treatment efficacy in MS. Results suggest that 
measurement  of  brain  atrophy  could  be  a  practical  addition  to  clinical  endpoints  for 
monitoring treatment effects on disease progression in phase III placebo-controlled trials 
of treatments for RRMS. However, it has been shown that it is vital for a sensitive and 
precise measurement technique to be used in order to minimise the number of patients 
required. 
 
Studies have shown that it can take long follow-up periods to detect change using clinical 
outcomes (Paolillo et al., 2002; The IFNB Multiple Sclerosis Study Group, 1995). MRI-
based  measures  of  disease  progression,  notably  lesion  load  quantification,  have  been 
investigated to determine their potential over clinical endpoints as a more objective and 
sensitive approach to assessing treatment efficacy in RRMS. One study looked at annual 
T2 lesion load increase and estimated that over a two year trial with 80% power to detect 
a treatment effect, 214 patients per treatment arm would be required to show a 30% 
reduction in the rate of increase (Molyneux et al., 2000b). This compares to an estimated 
123 patients in each treatment arm in this study when using SIENA to measure brain 
atrophy. Of note is the difference in sample sizes estimated over shorter trial durations, 
with 638 patients required per treatment arm for a 30% reduction in lesion load over one 
year (Molyneux et al., 2000b), compared with 191 patients for a 30% slowing of atrophy 
rate (using SIENA).  
 
Counts of new or enlarging lesions on monthly enhanced MRI may be more sensitive to 
treatment effects than T2 lesion load (Frank et al., 2004). Studies of monthly MRI over 
six months or less typically estimate sample sizes of less than 100 patients per treatment 
arm  (Sormani  et  al.,  2001; Tubridy  et al.,  1998).  It  appears however that to achieve 
statistical power greater than 80% with these numbers, treatment effects need to be in the 
order of 50% or more. Moreover, although this outcome measure may appear to require 
smaller  patient  numbers  to  show  a  treatment  effect  over  shorter  durations  than  brain 
atrophy, they are essentially assessing different aspects of MS. Whilst new enhancing 
lesions may reflect the acute stage of the disease, such lesions in general have shown 
limited correlations with future clinical disability (Fisher et al., 2002; Wolinsky et al., 
2001). Brain atrophy is thought to have better pathological specificity for axonal loss and 
has been shown to correlate with later disease progression (Fisher et al., 2002; Paolillo et  
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al., 2002). It may be that counts of new and enlarging lesions are a suitable outcome 
measure for phase II trials, based on the sensitivity to detect treatment effects over short 
periods.  However for longer phase III trials, and treatments hypothesised to prevent or 
slow neuroaxonal loss, brain atrophy is likely to be a more appropriate outcome measure.  
 
In considering the feasibility of brain atrophy as an outcome measure, note that two year 
placebo-controlled phase III trials which have been performed in RRMS, with relapse rate 
or disability as the primary outcome measures, have involved a minimum of 100-200 
patients per treatment arm (Jacobs et al., 1996; Johnson et al., 1995), and sometimes 
considerably more (Polman et al., 2006). These numbers equate to those estimated in this 
study for a 30% slowing in atrophy rate using SIENA, the BBSI and VE. In agreement 
with  these  findings,  a  study  of  interferon  beta-1a  in  subjects  presenting  with  a  CIS 
suggestive  of  MS,  found  a  statistically  significant  slowing  of  brain  atrophy  rate  of 
approximately  30%  over  two  years  using  SIENA,  when  comparing  123  subjects  on 
treatment with 117 placebo patients (Filippi et al., 2004). 
 
It  was  observed  in  Chapter  6  that  measurement  precision  is  greater  using  “direct” 
measures  of  atrophy,  whereby  serial  brain  images  are  positionally  matched  and  the 
difference between them quantified, as opposed to subtracting absolute volumes. This 
study  has  shown  the  clinical  consequences  of  this  finding  as  the  number  of  patients 
required to detect a treatment effect is influenced significantly by the method used to 
quantify  brain  atrophy.  VE,  BBSI  and  SIENA  gave  statistically  significantly  smaller 
sample sizes over all trial durations than BVD. Measurements of VE gave similar sample 
sizes to whole brain atrophy from SIENA and the BBSI. The benefits of this method have 
already  been  discussed,  and  these  results  provide  further  evidence  that  it  should  be 
considered as a suitable measure of brain atrophy and disease progression. However VE 
may not be specific to brain volume loss and could be influenced by factors such as 
hydration to a greater extent than whole brain atrophy measures. In addition it has been 
suggested that treatments could alter ventricular and brain volumes to different extents 
(Schott et al., 2005). However assessing alterations in the relationship of brain volume 
loss  and  ventricular  expansion  could  provide  information  concerning  treatment 
mechanisms. 
 
All atrophy measurement methods gave statistically significantly smaller sample sizes the 
longer the trial duration, although the largest reductions were observed with segmented  
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volume  difference  as  longer  follow-up  periods  will  usually  compensate  for  lower 
measurement precision. It should be noted that a limitation of this study was the small 
number of subjects available at three year follow-up. This may have meant that estimation 
of the variance in atrophy rates at this time-point was poor, which in turn meant that there 
was less change in sample sizes estimated for a three year follow-up compared with a two 
year follow-up for the BBSI, SIENA and VE. In addition, whilst it may be advantageous 
to minimise the length of clinical trials to reduce costs, drop-outs and impact on patients, 
a phase III trial must be of substantial length to determine the efficacy and safety of the 
treatment.  The  hypothesised  treatment  effect  must  be  considered  fully,  for  example 
whether the treatment is effective immediately from administration and whether it has a 
constant effect over time. 
 
Confounding factors that may influence brain atrophy measures such as demyelination, 
remyelination, gliosis, inflammation, oedema, dehydration and anti-inflammatory agents 
may need to be accounted for when designing trials. Studies have found that brain volume 
decrease  was  greater  during  the  first  year  in  patients  receiving  beta  interferon  than 
subsequent years, and it has been hypothesised that this is due to resolution of oedema 
initially  (Hardmeier  et  al.,  2005;  Rudick  et  al.,  2000).  Although  data  acquired  when 
patients were on treatment was excluded from the analysis, which could mean that the 
analysis is based on a patient group with milder disease symptoms, data was additionally 
analysed including patients on treatment, and no statistically significant differences in 
atrophy rates were found. In addition, the atrophy rates reported on patients who are not 
receiving disease-modifying treatment are comparable with those seen in other natural 
history and placebo RRMS cohorts (Rovaris et al., 2003; Rudick et al., 1999). Although 
the finding of no significant difference between on- and off-treatment groups could be 
taken as evidence that these patients need not be excluded from the analysis, it was felt 
that  due  to  the  small  number  of  data-points  that  would  be  excluded  it  was  better  to 
maintain  a  more  homogeneous  group,  given  that  treatment  could  be  causing  subtle 
unknown differences. 
 
With disease-modifying treatments currently available for RRMS, there is an increasing 
possibility that new treatments must be tested against those currently available. Although 
this  study  has  not  addressed  this  aspect  directly,  larger  sample  sizes  are  likely  to  be 
required than for placebo controlled trials. However careful selection of patients recruited 
to clinical trials, focussing on those that have already shown progression in disability may  
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increase the power to detect treatment effects. In addition, data in this study was obtained 
and  analysed in an identical  fashion for  all patients whilst for multicentre drug trials 
scanners,  protocols  and  analysis  may  vary  between  sites  and  researchers.  This  could 
increase the variability in brain atrophy measurements relative to the current study and 
may increase the sample sizes required for a multicentre clinical trial. Note also that this 
study was based on three-dimensional volumetric MRI, whilst most studies and clinical 
trials in RRMS to date have investigated atrophy on scans with limited resolution in one 
plane. Whilst this study has only investigated the feasibility of using brain atrophy as a 
surrogate marker of disease progression in RRMS, it will be of particular relevance to 
determine  the  sample  sizes  required  for  trials  of  disease-modifying  drugs  in  the 
progressive phase of MS when neuroaxonal loss may be more extensive.  
 
Finally, although the sample sizes calculated in this study show that measurements of 
brain atrophy could be utilised to test treatment efficacy in RRMS patients participating in 
phase III clinical trials, recommendation that brain atrophy is the primary and definitive 
outcome measure is premature. This will only be possible when the relationship between 
atrophy and disability is better understood, and consistent evidence has emerged that the 
development of atrophy reflects and predicts disability.   
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8  Methodological  considerations  for  longitudinal  brain 
atrophy measurements: MRI scanner upgrades 
 
8.1  Chapter introduction 
Many  of  the  techniques  that  have  been  developed  to  delineate  regions  and  quantify 
atrophy rely on intensity differences between CSF, GM and WM. Over the duration of a 
longitudinal study, changes in the intensity profile (e.g. contrast between tissues) of an 
image  could  affect  the  reliability  of  segmentation  and  atrophy  measurements.  It  is 
therefore important that the MR image is consistent in appearance and quality over time. 
Techniques that  correct  or normalise image intensity  within and between serial scans 
(non-uniformity) have been developed that improve segmentation accuracy and precision 
(Lewis & Fox, 2004; Sled et al., 1998; Smith et al., 2002). However upgrades of scanner 
hardware and software can alter the quality and contrast of structural MR images in ways 
that  cannot  be  corrected  for  using  commonly  available  algorithms.  Upgrades  may  be 
performed when changes have been made by the scanner manufacturer to improve image 
quality, decrease acquisition time, include additional features or increase the reliability of 
imaging. There are clearly many advantages to performing upgrades, but differences in 
the  quality  of  images  may  be  problematic  when  they  occur  during  the  course  of 
longitudinal  cohort  studies.  Whilst  they  may  not  necessarily  affect  qualitative  visual 
assessment of MRI, they may influence quantitative atrophy measurements of the brain or 
smaller cerebral structures, especially when atrophy is subtle compared with the likely 
measurement error caused by scanner changes. 
 
Whilst scanners invariably undergo upgrades, relatively few studies have reported the 
effect  of  these  changes  on  brain  atrophy  measures.  With  brain  atrophy  being  used 
increasingly in longitudinal trials of potential disease-modifying drugs and studies aiming 
to understand the progression of disease, it is important to determine the possible effect of 
routine scanner upgrades on these measurements. The aim of the first part of this study 
was therefore to determine the effect of a major scanner upgrade on volumetric measures 
of whole brain and lateral ventricles, derived using a semi-automated intensity threshold-
based segmentation tool. In the second part of the study a potential method for correcting 
ventricular volume measurements for upgrade-related effects is explored. 
  
186 
8.2  Investigation  into  the  effect  of  a  major  scanner  upgrade  on  brain  atrophy 
measurements 
8.2.1  Methods 
Subjects and MR imaging 
Five healthy volunteers with no history of neurological complaints (three male, mean age 
at baseline 34.8 years (SD 7.8, range 24.9 to 43.3 years)) were scanned on a 1.5T GE 
Signa scanner, used for imaging of the other subjects included in this thesis, before and 
after  a  major  scanner  upgrade.  Volunteers  were  members  of  staff  at  the  Institute  of 
Neurology and gave informed consent to be scanned. The upgrade included a change in 
the radio frequency transmitter coil, radio frequency amplifier, computer and software 
(Signa Horizon Echospeed 1.5T (5.8) pre-upgrade, and Signa EXCITE 1.5T (11.0) post-
upgrade). Imaging was performed at regular intervals on nine or ten occasions during an 
average 5.3 month (SD 0.27) period prior to the upgrade, and on nine or ten occasions 
during an average 8.6 month (SD 2.3) period post-upgrade. Three of the five subjects 
were  scanned  using  a  coronal  three-dimensional  inversion-prepared  FSPGR  sequence 
with  acquisition  parameters  TR=10.9ms,  TE=4.2ms,  TI=450ms,  matrix  256x192,  flip 
angle 20˚, FOV 240x180, resulting in 124 1.5mm thick slices. The other two subjects 
were scanned using an axial three-dimensional inversion-prepared FSPGR sequence with 
acquisition parameters TR=10.9ms, TE=4.2ms, TI=450ms, matrix 256x160, flip angle 
20˚, FOV 300x230, resulting in 124 1.5mm thick slices.  
 
MRI analysis 
All scans were corrected for intensity inhomogeneity using N3 (Sled et al., 1998). Using 
MIDAS, measures of whole brain and lateral ventricle volume were obtained on all scans 
as described in Chapters 4.2.2 and 6.3.2. For ventricular segmentation, brains in MNI-152 
standard space were registered to the earliest image acquired prior to segmentation. 
 
Statistical analysis 
Mean (SD) brain and ventricle volumes pre-and post-upgrade were calculated for each 
subject and a paired t-test was used to determine if there was a significant difference in 
volumes before and after the scanner upgrade.  
 
Piecewise mixed effect multiple linear regression models (Equation 8.1) were fitted with 
outcomes whole brain volume and ventricular volume measured at different time-points 
on  each  subject,  and  as  covariates  an  upgrade  indicator  (1=after  upgrade,  0=before  
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upgrade),  months  centred  on  the  upgrade  date  (i.e.  taking  value  0  at  the  time  of  the 
upgrade), and a month*upgrade interaction term. The coefficient for the latter term tests 
for before-after difference in rate of change, and is dropped in models where the upgrade 
does not affect this gradient. Subsequently the coefficient for 'months' estimates the mean 
upgrade-adjusted rate of change; models assuming no true change also drop this term. In 
all  models  the  upgrade  indicator  estimates  change  due  to  the  upgrade.  These  factors 
estimate ‘fixed’ effects, which characterise the average trajectories. The remaining terms 
of the model record the residual deviations from these averages, and are used to estimate 
the variabilities around the average: 
 
volumeij = a0 + a1.afterij + (d0+ vj).u_daysij +  d1.u_days*afterij  + uj + eij  (8.1) 
 
volumeij=ith measurement of subject j 
u_daysij=time of ith measurement in subject j, measured in days centred on upgrade date 
afterij=upgrade indicator taking value 1 if the measurement is after upgrade, 0 if before 
u_days*afterij=interaction term  
a0=estimated mean volume just before upgrade 
a1=estimated mean upgrade step, after – before 
d0=estimated gradient of change in volume before upgrade: i.e. change in volume per day 
d1=difference in gradient, after – before upgrade 
uj=random intercept, assessing between-subject variability in intercept 
vj=random slope, assessing between-subject variability in gradient 
eij=within-subject variability around subject-specific means 
 
8.2.2  Results  
Figure 8-1 shows an example of the images obtained before and after the upgrade. Subtle 
differences in the intensity and contrast can be seen between the images. Table 8-1 gives 
the mean (SD) brain and ventricle volumes in each subject before and after the scanner 
upgrade whilst Figure 8-2 shows a plot of the pre- and post-upgrade brain and ventricular 
volumes in the five control subjects. There appears to be a consistent increase in brain 
volumes and a decrease in ventricular volumes following the upgrade. A paired t-test on 
these  average  pre-  and  post-upgrade  volumes  indicated  that  these  differences  were 
significant (both p=0.0012). 
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Figure 8-1 T1-weighted volumetric images showing the differences in appearance when 
obtained  a)  pre-upgrade  and  b)  post-upgrade.  The  images  appear  to  be  a  slightly 
different  intensity  and  contrast.  The  arrows  indicate  some  areas  where  there  is  a 
noticable difference between the two images,  most commonly darker  more enlarged 
CSF spaces in the pre-upgrade image. The voxel intensities are directly comparable as 
the  window  and  level  settings  within  the  viewing  tool  (MIDAS)  are  automatically 
adjusted between the two scans, by linearly scaling the contrast and width settings. 
 
 
 
 
Table 8-1 Mean (SD) brain and ventricle volumes pre- and post-upgrade in five control 
subjects scanned regularly before and after a scanner upgrade. Images were acquired 
in the coronal (three subjects) or axial (two subjects) plane. 
  Brain volume 
pre-upgrade 
(ml) 
Brain volume 
post-upgrade 
(ml) 
Ventricle 
volume pre-
upgrade (ml) 
Ventricle 
volume post-
upgrade (ml) 
Coronal 1  1148 (5.1)  1187 (5.9)  12.00 (0.32)  10.58 (0.29) 
Coronal 2  1225 (5.3)  1258 (3.3)  12.55 (0.22)  11.00 (0.23) 
Coronal 3  1312 (5.5)  1352 (3.7)  7.11 (0.32)  5.75 (0.36) 
Axial 1  1144 (7.2)  1174 (9.1)  5.86 (0.18)  4.08 (0.19) 
Axial 2  1221 (10.4)  1278 (10.7)  13.28 (0.28)  10.60 (0.29)  
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Figure 8-2 Repeated a) brain and b) ventricle volume measurements in five control 
subjects scanned regularly before and after a scanner upgrade. Images were acquired 
in the coronal (three subjects) or axial (two subjects) plane. 
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The graphs suggest that brain and ventricular volumes are stable over time except for the 
“jump” in values over the upgrade. This is to be expected as the upgrade will not change 
the effect of aging and is also unlikely to alter the scanner stability. However as the 
sample was small, this was tested for using the model. For brain volumes, the model 
estimated the difference in gradient of measures  pre- and post-upgrade to be -0.0021 
(95% CI -0.064 to 0.068, p=0.95). For ventricular volumes, the estimated difference in 
gradient pre- and post-upgrade was also small and non-significant: -0.00012 (95% CI  
-0.00272 to 0.00248, p=0.93). Therefore it was assumed that there was no change in the 
gradient  for  either  brain  or  ventricular  volumes  and  this  term  was  dropped  from  the 
model.  Subsequent  reported  results  assume  a  common  gradient  before  and  after  the 
upgrade, with only a step change due to the upgrade. 
 
Assuming a gradient in measured volumes, the model estimated the upgrade-related brain 
volume change to be 38.66ml (95% CI 29.6 to 47.7, p<0.001). The estimated gradient 
was 0.005ml day
-1 (95% CI -0.042 to 0.053, p=0.83). As there was no evidence to suggest 
a statistically significant gradient of change, it is sensible to re-run the model under the 
assumption that the small gradient is not real, and that there is in truth no change. Under 
this assumption the volume change related to the upgrade is slightly increased; a model 
excluding the  gradient term estimated the upgrade-related brain volume  change to be 
40.15ml (95% CI 36.8 to 43.5, p<0.001). Of note is the fact that this model assuming no 
gradient in measured volumes is essentially equivalent to, though more efficient than, the 
paired  t-test,  and  therefore  confirms  the  finding  of  a  statistically  significant  upgrade-
related  change  in  volume.  Based  on  the  model-estimated  mean  brain  volume  of 
1210.56ml prior to the upgrade (a0), the upgrade-related volume change as a percentage 
of total brain volume was 3.3%. 
 
Similarly for ventricular volume, assuming a gradient in measured volumes, the model 
estimated the upgrade-related ventricular volume change to be -2.01ml (95% CI -2.36 to  
-1.65, p<0.001). Again, the estimated gradient of volumes was small and there was no 
evidence  to  suggest  that  it  was  statistically  significant;  0.00095ml  day
-1  (95%  CI  
-0.00119  to  0.00310,  p=0.39).  Excluding  the  gradient  term  from  the  model  led  to  a 
decrease in the estimated upgrade-related change in ventricular volume; -1.76ml (95% CI 
-1.90 to -1.61, p<0.001). This effect was the opposite to that seen in the brain volume 
model because the overall gradient is in the opposite direction to the upgrade step. Based  
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on the model-estimated mean ventricle volume of 10.15ml prior to the upgrade (a0), the 
upgrade-related volume change as a percentage of total ventricle volume was -17.3%. 
 
Assuming a small gradient in volumes, estimates of the variability within and between 
subjects are shown in Table 8-2. Relatively small within-subject variability was detected 
and  there  was  no  evidence  that  this  variability  differed  pre-  and  post-upgrade  (brain 
volumes p=0.74, ventricular volumes p=0.66). The variance in mean volumes was the 
greatest contributor to between subject variability. 
 
Table 8-2 Linear regression model-derived estimates of the variability in brain and 
ventricular volumes between and within control subjects, scanned regularly before and 
after a scanner upgrade, when assuming a small gradient in volumes over time. 
    Brain volumes   
(variance, 95% CI) 
Ventricle volumes 
(variance, 95% CI) 
Slope  0.0015 
(0.0003,0.0069) 
0.0000038 
(0.0000009, 0.000016) 
Intercept  4943.4 
(1235.5, 19779.4) 
11.16 
(2.79, 44.66) 
Estimated 
between- 
subject 
variation 
Covariance 
[correlation] between 
slope and intercept 
0.71 [0.26] 
(-2.19, 3.61) 
-0.0023 [-0.34] 
(-0.0092, 0.0047) 
Estimated within subject variation  44.4 
(32.9, 60.0) 
0.069 
(0.051, 0.093) 
 
8.2.3  Discussion 
This study has shown that MRI scanner upgrades can have a significant effect on MRI-
derived  volumes  of  the  brain  which  are  dependent  on  intensity  threshold-based 
delineation of this structure from CSF. Such effects are significant enough to influence 
brain atrophy measures over the course of longitudinal studies crossing an upgrade. These 
results  suggest  that  ideally  scanner  upgrades  should  be  avoided  during  the  course  of 
longitudinal MR studies of quantitative brain volume measurements. However this may 
be impractical given that scanners are used for multiple studies with overlapping time 
frames.  The  statistical  model  applied  in  this  study  may  be  useful  to  compensate  for 
changes in acquisition without the need for time-consuming post-processing of images. 
This should reduce the amount of unusable data in future longitudinal studies.  
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In this study an upgrade-related increase in brain volume and a decrease in ventricular 
volume were observed. Comparing images obtained pre- and post-upgrade a noticeable 
change  in  image  contrast  and  an  increase  in  intensity  had  occurred.  This  affected 
measurements of brain and ventricular volume which rely on the contrast between brain 
and CSF. The border regions of the brain in the post-upgrade image included more voxels 
of a higher intensity than the pre-upgrade image, and therefore more voxels were defined 
as “brain” and fewer as “CSF”. This is in spite of “normalising” brain intensity over the 
mean intensity of the whole brain, and thresholds for ventricular segmentation being set 
as a percentage of brain intensity. 
 
Although the change in contrast and intensity between pre- and post-upgrade images was 
subtle  when  scans  were  inspected  visually,  the  associated  change  (increase)  in  brain 
volume was estimated to be approximately 3.3% of WBV. This increase is typically much 
greater  than  the  annual  atrophy  rates  (e.g.  decreases  of  0.5-2%)  seen  in  neurological 
disorders such as MS (Rovaris et al., 2003), Alzheimer’s disease (Schott et al., 2005), and 
Huntington  disease  (Henley  et  al.,  2006).  Similarly,  the  upgrade-related  decrease  in 
ventricular volume was approximately 2.0ml (17.3% of estimated ventricular volume), 
which is within the range of annual increases that have previously been observed in these 
diseases (Dalton et al., 2006; Schott et al., 2005). It is also of note that the upgrade-related 
changes observed in this study are in the opposite direction to biological atrophy changes. 
 
In contrast to the current study, a recent investigation found no noticeable bias in cortical 
thickness measurements from images obtained over a major scanner upgrade (Han et al., 
2006).  In  fact  the  upgrade  improved  the  reliability  of  measurements  post-upgrade, 
probably  reflecting  the  increased  SNR.  Another  study,  investigating  brain  atrophy  in 
patients  with  Alzheimer’s  disease  and  controls,  found  that  a  major  hardware  change 
between scan pairs had a negligible effect on the observed atrophy rates quantified using 
two  registration-based  methods,  and  did  not  decrease  the  group  separation  between 
controls  and  patients  (Gunter  et  al.,  2003).  The  difference  in  findings  between  these 
studies and the current one may be due to several factors. Firstly, the actual procedures 
that were performed at the upgrades are likely to have varied, which could cause different 
changes to acquisitions. Secondly, different acquisition parameters and pulse sequences 
were used in the three studies, which may have been affected differently by the associated 
upgrade. Lastly, these studies all used different atrophy measurement methods that may 
be  relatively  more  or  less  robust  to  changes  in  image  quality.  Methods  that  rely  on  
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intensity and contrast differences between brain and CSF are more likely to be affected. It 
would  be  useful  to  investigate  the  effect  of  the  upgrade  on  other  measures  of  brain 
atrophy  used  in  this  thesis,  such  as  those  which  measure  brain  volume  loss  directly 
following the registration of serial images, e.g. SIENA (Smith et al., 2002) and the brain 
and ventricular BSI (Freeborough & Fox, 1997).   
 
With brain atrophy measurements being used increasingly to monitor disease progression 
in  a  number  of  neurological  conditions,  it  is  important  that  potential  upgrade-related 
effects on these measures are identified and corrected for if found to be significant. This 
may be important for relatively short-term studies taking place over one to three years 
when it is desirable to reduce measurement errors that may confound outcomes; disease-
related  brain  atrophy  changes  over  such  periods  are  small,  and  in  trials  of  potential 
disease-modifying  treatments  real  treatment  effects  could  be  obscured  by  larger 
magnitude spurious changes due to an upgrade. It is also important in longer-term follow-
up studies of subjects, which may wish to investigate the progression of atrophy and its 
relationship  to  clinical  outcomes  and  other  MRI  markers.  For  example  a  study  that 
investigated atrophy over eight years in MS patients, initially recruited for a two year 
treatment trial, analysed BPF (Fisher et al., 2000). Although MRI at eight years were 
acquired with pulse sequence parameters as similar as possible to the original study and 
progressive brain atrophy was detected, there is likely to have been subtle changes in the 
images that may have affected outcome measures. 
 
Several strategies could be utilised to minimise upgrade-related changes over longitudinal 
studies. Firstly, changes in the acquisition parameters and pulse sequences can be made to 
obtain an image as close as possible in appearance to pre-upgrade images. However this 
will reduce the advantages of performing the upgrade in terms of obtaining images with 
greater CNR and SNR, and other benefits. Secondly, post-processing of the images could 
be performed that could more closely match images in appearance pre- and post-upgrade. 
Thirdly, statistical modelling of data obtained from pre- and post-upgrade images can be 
performed and used to correct for artificial volume changes. This method will allow more 
realistic changes in MRI measures to be obtained over upgrades for use in future studies, 
whilst  minimising  time-consuming  post-processing  methods.  Techniques  that  do  not 
require absolute or relative intensity values, such as some registration-based methods, to 
determine volume change may be less affected by alterations in image contrast changes 
and should be investigated in this respect.   
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The statistical model included volume measurements from control subjects at multiple 
time-points, and therefore allowed accurate and reliable estimates of the upgrade step and 
gradients of change pre- and post-upgrade. However this model could be adapted to be 
used  in  datasets  of  subjects  in  whom  brain  atrophy  may  be  occurring  more  rapidly 
(involving the gradient terms of the model to a greater extent), and when only single scans 
are  available  for  subjects  pre-  or  post-upgrade.  Adaptations  to  this  model  for  these 
purposes will need to be investigated further. Although the gradient of measures was 
small and non-significant in this control cohort, it could be misleading not to include this 
term  in  models  of  patient  data,  particularly  over  longer  studies  in  neurodegenerative 
diseases,  where  small  gradients  are  expected  due  to  real  volume  changes  over  time. 
Excluding the gradient factor from the model in the current study altered the upgrade-
related volume change estimate marginally. 
 
In  summary,  it  has  been  shown  that  changes  in  image  acquisition  related  to  scanner 
upgrades can occur, despite all attempts to maintain identical acquisition parameters, and 
the effects of these changes need to be taken into account. Other factors may also impact 
on MRI-derived volume and atrophy measures in longitudinal studies, e.g. changes in 
acquisition parameters, subjects being scanned on different scanners, scanner drift, subject 
positioning  and  subject  hydration.  Regular  scanning  of  control  subjects  prior  to  and 
following planned upgrades will help to identify upgrade-related changes which it may 
then be possible to adjust for when investigating true longitudinal biological changes. 
 
8.3  Can a new protocol for ventricular segmentation correct for upgrade-related 
changes in ventricle volume? 
8.3.1  Introduction 
The analysis of control images over an upgrade in the previous study demonstrated that 
significant changes in volume measurements can occur due to scanner upgrades. These 
must be corrected for if reliable quantitative measurements of brain volume and atrophy 
rates are to be obtained. A statistical model for simultaneous estimation and correction of 
upgrade-related changes was described in the previous section, but it may be that for 
cross-sectional  measurements  of  volume,  simple  alterations  to  segmentation  methods 
could  be  performed  which  might  effectively  correct  measures.  This  would  allow 
correction  of  upgrade-related  effects  on  volume  when  specialist  statistical  help  is 
unavailable or when investigating single subjects, when it is not possible to generate a 
regression model. Given the observed changes on visual inspection and through further  
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examination of the images, it was determined that although mean brain intensity was 
similar  on  pre-and  post-upgrade  images,  CSF  was  darker  on  the  pre-upgrade  scans 
relative to post-upgrade scans. Given the fact that many segmentation methods, including 
the brain and ventricular segmentation methods used in the previous section, are based on 
thresholding and rely on image contrast, it was hypothesised that by altering the protocol 
(the  percentage  of  mean  brain  intensity  used  as  the  upper  threshold)  for  ventricular 
segmentation on post-upgrade images, “upgrade-corrected” volumes could be achieved. 
The aim of this study was therefore to determine the optimum percentage of mean brain 
intensity  for  ventricular  segmentation  on  post-upgrade  images,  and  to  test  whether 
ventricular segmentation based on this threshold method did indeed correct for upgrade-
related changes. 
 
8.3.2  Methods 
Theory behind alteration of the segmentation protocol 
Due to the difference in CSF intensity between the pre- and post-upgrade images, there is 
less intensity change across the brain/CSF border on post-upgrade images compared with 
pre-upgrade images. This is demonstrated in Figure 8-3 which shows the intensity profiles 
of  representative  pre-  and  post-upgrade  images  from  one  subject.  Using  the  standard 
upper threshold value of 60% of mean brain intensity for ventricular segmentation, voxels 
which have an intensity above this value are excluded. As the post-upgrade scan has more 
voxels  of  a  higher  intensity  in  the  brain/CSF  boundary  region,  this  means  a  greater 
number of voxels are excluded from the ventricular segmentation compared with the pre-
upgrade  image,  making  the  ventricular  region  smaller  on  the  post-upgrade  scans 
(assuming there is no real change in volume) (Figure 8-4a). Using a higher threshold 
value (as a percentage of mean brain intensity) could compensate for the generally higher 
intensity of the voxels in the border region, by including voxels with intensity >60% (and 
<x%) of the mean brain intensity (Figure 8-4b).  
 
The value that the new threshold for ventricular segmentation on post-upgrade images 
should take can be calculated as a percentage of the gap between CSF and brain intensity 
and so the aim is to match these between pre- and post-upgrade images (Equation 8.2). 
The new value can be expressed as a percentage of mean brain intensity for application to 
other images (Equation 8.3). 
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Figure 8-3 Intensity profiles of a pre-upgrade and a post-upgrade T1-weighted image 
from one subject. A one-dimensional intensity profile through the brain on each image 
was  generated  by  drawing  a  line  one  voxel  high  between  the  points  A  and  B  (top 
image), and normalising the intensity value of each voxel in this region to the mean 
whole brain intensity. The area where the region of interest crosses the ventricles is 
labelled on the intensity profile. 
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Figure  8-4  Effect  of  differences  in  image  contrast  due  to  a  scanner  upgrade  on 
ventricular  segmentation  and  quantification  of  volume.  The  figures  show  one-
dimensional representations of the intensity profiles through a brain boundary for pre- 
and post-upgrade images, and assume no real change in ventricle volume. a) The 60% 
upper threshold used for ventricular segmentation and the corresponding ventricular 
boundaries on pre- and post-upgrade images (-.-.-.-), b) Using a higher threshold (x%) 
for the post-upgrade image, the same boundary region can be achieved on the post-
upgrade image as when using a 60% threshold for the pre-upgrade image 
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T=threshold, I=mean intensity, pre=pre-upgrade image, post=post-upgrade image. 
 
Subjects and MR imaging 
The five control subjects and registered images included in the previous experiment  were 
utilised in this study (see Chapter 8.2.1). 
 
MRI analysis 
The first post-upgrade image available for one of the subjects was selected and the lateral 
ventricles  were  segmented  using  an  upper  threshold  of  68%  of  mean  brain  intensity. 
Based on this ventricular region, and the brain region obtained for this image in Chapter 
8.2.1, new estimates of mean brain and CSF intensity were determined and the values 
entered into Equation 8.2, in conjunction with intensity values for the pre-upgrade image 
of  the  same  subject  (the  last  image  before  the  upgrade).  Based  on  the  result,  it  was 
determined whether the percentage threshold needed to be increased or decreased and the 
segmentation performed again, changing the threshold by one point. This process was 
repeated iteratively until the optimal threshold that most closely matched pre- and post-
upgrade images according to Equation 8.2 was reached. The percentage of mean brain 
intensity that this value represented was then determined according to Equation 8.3, and 
the ventricles segmented on all other post-upgrade images for the five subjects, based on 
this percentage threshold. 
 
8.3.3  Results 
The optimum percentage threshold for ventricular segmentation on post-upgrade images 
was calculated to be 67%. Figure 8-5 shows a plot of the ventricular volumes in the five 
control subjects using this new threshold for post-upgrade images, whilst Table 8-3 gives 
the mean (SD) ventricle volumes in each subject before and after the scanner upgrade. 
Average volumes appear to be more constant over the upgrade using the new threshold, 
and there was no evidence that mean values pre- and post-upgrade were significantly 
different (p=0.98).  
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Figure 8-5 Repeated ventricle volume measurements in five control subjects scanned 
regularly before and after a scanner upgrade, using 67% of mean brain intensity as the 
upper  threshold  for  ventricular  segmentation  on  post-upgrade  images.  Images  were 
acquired in the coronal (three subjects) or axial (two subjects) plane. 
 
 
Table 8-3 Mean (SD) ventricle volumes pre- and post-upgrade in five control subjects 
scanned  regularly  before  and  after  a  scanner  upgrade,  using  67%  of  mean  brain 
intensity as the upper threshold for ventricular segmentation on post-upgrade images. 
Images were acquired in the coronal (three subjects) or axial (two subjects) plane. 
  Ventricle volume pre-upgrade  
(ml) 
Ventricle volume post-upgrade 
(ml) 
Coronal 1  12.00 (0.32)  12.16 (0.29) 
Coronal 2  12.55 (0.22)  12.69 (0.15) 
Coronal 3  7.11 (0.32)  7.01 (0.39) 
Axial 1  5.86 (0.18)  5.50 (0.23) 
Axial 2  13.28 (0.28)  12.60 (0.23) 
 
As the sample was small, these results were tested using the statistical model described in 
the  previous  investigation  (see  Chapter  8.2.1).  The  model  estimated  the  difference  in 
gradient of measures pre- and post-upgrade to be -0.00046 (95% CI -0.0030 to 0.0021,  
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p=0.72). Therefore it was assumed that there was no change in the gradient and this term 
was  dropped  from  the  model.  Assuming  a  gradient  in  measured  volumes,  the  model 
estimated a change in ventricle volume over the upgrade of -0.40ml (95% CI -0.76 to  
-0.05, p=0.025), despite using the altered threshold for ventricular segmentation on post-
upgrade images. The estimated gradient was 0.0018ml day
-1 (95% CI 0.00048 to 0.0032, 
p=0.008). The volume change related to the upgrade as a percentage of total ventricle 
volume was -3.7% (based on a mean ventricle volume of 10.78ml). 
 
8.3.4  Discussion 
This study investigated  a simple method  for  correction of  upgrade-related changes in 
measured ventricle volumes, which required estimation and application of a new intensity 
threshold with which to segment the ventricles on post-upgrade images. Although there 
was no significant difference in mean ventricle volume before and after the upgrade when 
tested for using a paired t-test, the more stringent multiple linear regression model which 
accounted for a gradient in measured volumes found that ventricle volumes post-upgrade 
were significantly smaller than pre-upgrade values.  
 
There are several possible reasons why this method may have failed to adequately correct 
for the upgrade-related changes. Firstly, this method assumes that the intensity profile 
over the brain/CSF boundary is linear. This may not be true if there are local subvoxel 
fluctuations in intensity due to artefacts for example. Secondly the threshold value can 
only be set as an integer, which may account for some variability between pre- and post-
upgrade volumes. The range of intensities over the boundary was relatively small, but the 
intensities  could  be  scaled  over  the  entire  image  to  allow  a  greater  range  of  values 
however. In addition, it is not clear whether ventricular size could affect the method, for 
example larger ventricles may have more partial volume voxels that are included using 
the new method compared with smaller ventricles, therefore causing artificially greater 
enlargement in subjects with bigger ventricles. 
 
As such these results suggest that the proposed method does not completely correct for 
upgrade-related changes in ventricle volume measured using MIDAS. It is possible that a 
similar approach to that presented in this study could be useful for other segmentation and 
volume  quantification  techniques  based  on  methodology  similar  to  that  used  for 
ventricular segmentation. This would have to be investigated further, but could allow 
correction of volumes from a single subject and time-point.  
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8.4  Chapter conclusions 
In summary, this chapter has shown the significant impact major scanner upgrades can 
have  on  brain  volume  measurements.  Due  to  a  scanner  upgrade,  longitudinal 
measurements of brain and ventricular volume showed changes in the opposite direction 
to those expected when brain loss and normal aging occur. Whilst not investigated in this 
study, it is likely that regional measures (e.g. the cortex, caudate, CC) will be similarly 
affected  by  scanner  upgrades.  Only  volumetric  FSPGR  images  acquired  over  one 
particular scanner upgrade were investigated in this study, however it is likely that most 
major scanner upgrades, will have some  effect  on brain volume measurements. Even 
minor scanner upgrades could have subtle effects, and regular scanning of phantoms and 
control subjects should therefore be routinely performed to monitor these effects. 
 
These upgrade-related changes need to be corrected for if reliable longitudinal analysis is 
to be performed. Although a simple method for correction of post-upgrade ventricular 
volumes  was  investigated,  it  did  not  adequately  compensate  for  the  upgrade-related 
changes.  For large longitudinal studies, statistical methods may  prove to be the most 
reliable approach with which to correct brain volumes and atrophy measurements. In this 
chapter a regression model was presented that can be used to estimate upgrade-related 
changes in volume. Simultaneous estimation and correction of post-upgrade volumes in 
control  and  patient  cohorts  using  this  model  must  now  be  investigated.  In  addition, 
investigation into the ability of this model to correct volumes when only one image is 
available pre- or post-upgrade must be performed.  
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9  Relationship  of  brain  atrophy  to  clinical  progression  in 
patients  with  clinically  isolated  syndromes  and  relapsing 
remitting multiple sclerosis 
 
9.1  Chapter introduction 
It has been identified that certain techniques may provide better measures of brain atrophy 
than others, and that the sensitivity and precision of measurement can be optimised to 
allow brain atrophy, and potentially disease progression, to be tracked more efficiently. 
Although the previous chapters have confirmed that brain atrophy occurs from the very 
earliest stages of the disease, it is still necessary to determine how brain atrophy relates to 
the progression of clinical disability in these patients. In addition, cognitive function is 
often affected in patients with MS and the association of brain atrophy to this aspect of the 
disease must also be investigated. Long term follow-up studies are required to explore the 
relationship  of  progression  of  brain  atrophy  to  clinical  disability  and  cognition.  This 
chapter investigates such relationships through five  year clinical follow-up of patients 
presenting with CIS and with RRMS. 
 
9.2  Investigation  into  the  prognostic  value  of  brain  atrophy  rate  for  clinical 
progression in subjects presenting with a clinically isolated syndrome suggestive 
of multiple sclerosis 
9.2.1  Introduction 
In Chapter 6.2 it was shown that brain atrophy rate measured over the first year following 
initial symptoms was significantly greater in CIS subjects who had progressed to MS by 
three year follow-up, than in controls and subjects who remained CIS. This confirmed 
previous reports that have shown ventricular enlargement, and changes in BPF and GMF, 
to be greater in CIS patients progressing to MS over periods of up to three years (Brex et 
al., 2000; Dalton et al., 2004). 
 
Currently, it is known that the probability of progression to a diagnosis of MS in CIS 
subjects  is  greater  in  those  subjects  who  have  visible  T2-weighted  lesions  on  MRI 
acquired at presentation (Barkhof et al., 1997; Brex et al., 2002; Dalton et al., 2002a). 
However with evidence that brain atrophy is an early feature of MS, it is possible that this 
could provide an additional indicator of prognosis in subjects presenting with CIS. With  
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research  showing  a  beneficial  role  of  early  immunomodulatory  treatment  in  patients 
presenting with CIS (Comi et al., 2001; Filippi et al., 2004; Jacobs et al., 2000; Kappos et 
al., 2007), the identification of patients with a high risk of developing MS, and those who 
may  have a faster evolving disease course and  would be likely to benefit most from 
treatment  is  of  clinical  relevance.  The  aim  of  this  study  therefore  was  to  investigate 
whether early brain atrophy rate is independently related to the risk of development of 
MS. One of the limitations of the investigation of CIS in Chapter 6.2 was that subjects 
had been followed-up for only a three year period, and that they may have been diagnosed 
with MS at a later date. Therefore the follow-up period of CIS patients in this study was 
extended, and only subjects that had a clinical assessment at five year follow-up were 
included. 
 
9.2.2  Methods 
Subjects and MR imaging 
Thirty-seven  subjects  (14  male)  presenting  with  a  CIS  were  identified  from  the  total 
cohort  (Chapter  3.1.1).  Subjects  had  clinical  and  MRI  assessment  at  baseline,  three 
months  and  one  year,  and  clinical  follow-up  at  five  years.  Baseline  assessment  was 
performed within 12 weeks of first presentation (median 5.5 weeks) and mean age was 
34.6 years (SD 6.6). Initial presentation was optic neuritis in 34 subjects, spinal cord 
syndrome in two subjects and brainstem syndrome in one subject. Subjects were assessed 
for  progression  to  MS  according  to  the  McDonald  criteria  (McDonald  et  al.,  2001). 
Coronal three-dimensional inversion recovery prepared FSPGR, and FSE sequences, were 
acquired for all subjects at baseline using the acquisition parameters described in Chapter 
3.3.1. A coronal FSPGR image acquired again at one year was also used for this analysis. 
 
MRI analysis 
T2-weighted images were assessed for the presence of lesions at baseline, and the number 
of lesions were determined by a trained neurologist (K. Fernando). Brain atrophy was 
calculated from the FSPGR images using SIENA, as described in Chapter 5.3.2., and 
results were annualised.  
 
Statistical analysis 
Comparisons of demographic data, mean brain atrophy rates and proportion of subjects 
with T2 lesions at baseline was performed between groups (subjects who had progressed 
to MS by five year follow-up (“converters”) and those that had not (“non-converters”))  
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using two-tailed unpaired t-tests  and  Fisher’s  exact test  where  appropriate. A logistic 
regression model was used to relate five year clinical status jointly to the presence of 
lesions at presentation and early brain atrophy rate. Odds ratios (OR) and 95% CI were 
calculated  to  determine  the  predictive  value  of  T2  lesions  at  presentation  and  early 
(baseline to one year) brain atrophy rate for progression to MS. However, a difference 
between  the  p-values  for  the  Wald  and  likelihood  ratio  (LR)  tests  suggested  that  the 
logistic regression model results should not be completely relied on. Therefore, to assess 
the extent to which initial brain atrophy rate was independently useful in differentiating 
converters and non-converters, a linear regression model was used to relate brain atrophy 
rate  to  five  year  clinical  status  whilst  controlling  for  lesions  at  presentation.  Robust 
standard errors were used in these models to allow for differential heterogeneity between 
subjects in each of the two groups. Survival analysis was used to investigate the predictive 
value of brain atrophy rate and T2 lesions at baseline for the risk of subsequent MS 
diagnosis. A Cox multivariable regression analysis was used to relate the risk of MS 
diagnosis to early brain atrophy rate, presence of T2 lesions on baseline MR, and the 
number of T2 lesions detected on baseline MRI. Age at follow-up and gender were also 
included as covariates. The influence of atrophy rate on time to progression was further 
investigated with Kaplan-Meier survival curves. Subjects were divided into three groups 
of approximately equal size and according to their atrophy rates relative to the control 
brain atrophy rates determined in Chapter 6.2; group A (n= 14) had atrophy rates less than 
or equal to the control rate (i.e. x ≥ -0.07), group B (n=11) had atrophy rates greater than 
the control rate but less than one SD from the control rate (i.e. -0.41 ≤ x < -0.07), and 
group C (n=12) had atrophy rates greater than one SD from the control rate (i.e. x <  
-0.41). These cut-off points were chosen because they divided the subjects into groups of 
similar  size.  A  plot  of  the  Kaplan-Meier  estimates  of  survival  function  for  the  three 
groups was generated and differences between the three groups were analysed by the log-
rank test, taking into account the fact that the groups were ordered. 
 
9.2.3  Results 
At five year follow-up 24 subjects (seven male) had progressed to MS according to the 
McDonald  criteria,  whilst  13  subjects  (seven  male)  remained  CIS.  There  were  no 
significant differences in age (p=0.78), gender (p=0.17), time since presentation (p=0.73) 
or interval between baseline and five year follow-up (p=0.52), between converters and 
non-converters. Mean atrophy rate in non-converters was 0.02% year
-1 (SD 0.29), whilst 
in converters it was -0.44% year
-1 (SD 0.49). There was evidence that atrophy rates in the  
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two groups were significantly different (mean difference 0.46% year
-1 (95% CI 0.16 to 
0.77, p=0.001)). Of the 24 converters, 23 had T2 lesions (any number, i.e. ≥ 1) on MRI at 
presentation whilst of the 13 non-converters, five demonstrated T2 lesions on MRI at 
presentation (Fisher’s exact test p<0.001). 
 
Univariate  logistic  regression  analysis  provided  no  evidence  that  gender,  age  or  the 
number of lesions at baseline were significant predictors of a subsequent diagnosis of MS, 
and  these  variables  were  therefore  excluded  from  the  multiple  regression  analysis. 
Multiple  logistic  regression  showed  that  the  odds  of  progressing  to  MS  were 
approximately 25 times greater if subjects presented with T2 lesions (95% CI 2 to 287 
times, Wald test p=0.009, LR test p=0.002), and approximately 22 times greater per 1% 
year
-1 increase in brain atrophy rate (95% CI 0.7 to 668 times, Wald test p=0.074, LR test 
p=0.027). These effects were similar in magnitude to results from models assessing the 
effect  of  each  variable  separately.  These  results  suggest  that  atrophy  rate  may  be  an 
independent predictor of MS diagnosis, but the difference between the p-values for the 
Wald and LR tests suggest that the logistic regression model should not be completely 
relied  on.  Using  linear  regression  with  robust  standard  errors,  atrophy  rate  differed 
significantly  between  converters  and  non-converters  even  after  adjustment  for  the 
presence of lesions at baseline (p=0.006), providing reliable evidence that atrophy rate is 
independently predictive of five year clinical status. 
 
In the Cox regression model it was found that the presence of lesions at baseline and 
atrophy rate during the first year were risk factors for MS diagnosis. The risk (hazard) of 
diagnosis with MS was multiplied by 3.6 (95% CI 1.3 to 10.0, p=0.016) for each 1%  
year
-1 increase in atrophy rate, and by 11.5 (95% CI 1.4 to 91.7, p=0.021) when lesions 
were present at baseline. The number of T2 lesions at baseline, age and gender were not 
independent risk factors for MS diagnosis. When subjects were divided into three groups 
according to one year atrophy rate, there was evidence that subjects with greater atrophy 
rates during the first year were at a greater risk of subsequently being diagnosed with MS; 
median survival times for groups A, B and C respectively were 57.5 months, 60 months 
and 17.5 months, p=0.015 (Figure 9-1).  
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Figure 9-1 Kaplan-Meier curves for subjects presenting with CIS according to brain 
atrophy rate (% year
-1) during the first year after presentation. 
 
 
9.2.4  Discussion 
This study provides evidence that brain atrophy occurring early in the course of disease is 
clinically relevant. Brain atrophy rate during the first year following presentation was 
found to be a significant predictor of a future diagnosis of MS, which was independent of 
the  predictive  value  of  T2  lesions  at  presentation.  Evidence  was  also  found  for  a 
significant relationship between brain atrophy rates during early follow-up and the risk of 
being diagnosed with MS, with greater atrophy rates associated with a higher risk.  
 
The finding that brain atrophy occurs from the earliest stages of disease and that mean 
brain atrophy rate is greater in subjects who progress to MS than in subjects who remain 
stable has been shown previously (Brex et al., 2000; Dalton et al., 2002a; Dalton et al., 
2004). Although not investigated in this study, it has been suggested that this atrophy is 
related to focal inflammatory lesions (Dalton et al., 2002a; Filippi et al., 2004; Paolillo et 
al., 2004). However lesions do not wholly account for the variance in atrophy rate (Dalton 
et  al.,  2002a;  Paolillo  et  al.,  2004)  and  other,  perhaps  unknown,  mechanisms  for 
neuroaxonal damage may be occurring at this stage of the disease.  
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In contrast to other studies of brain atrophy in CIS, subjects in this study had a longer 
clinical follow-up and the value of brain atrophy for future prognosis was investigated. 
The previously  recognised value of T2 lesions  on MRI  at presentation  for  predicting 
progression to MS (Brex et al., 2002; Ghezzi et al., 1999; Optic Neuritis Study Group, 
1997) was confirmed in this study. Logistic regression estimated that subjects were 25 
times more likely to progress to MS if T2 lesions were present on baseline MRI. Due to 
the dichotomous nature of this predictor variable it was not possible to verify the result 
using linear regression, but it was highly significant when tested by both the Wald and LR 
tests. Unlike other studies, the number of T2 lesions at baseline was not prognostic (Brex 
et al., 2002; Tintoré et al., 2006). Regression analysis also showed that brain atrophy rate 
during the first year after presentation was a significant predictor of progression to MS, 
independent of T2 lesions on baseline MRI. This finding was in contrast to a study of 35 
patients with CIS, who showed evidence of disease dissemination in space (Rovaris et al., 
2005b). Despite 24 patients progressing to MS at the end of the one year study, brain 
atrophy measured by SIENA over the first year from presentation did not significantly 
predict subsequent diagnosis. This may have been due to differences in the cohorts; only 
37% of subjects presented with optic neuritis in contrast to 92% of subjects in this study. 
Indeed one of the limiting factors of this study is that the majority of subjects presented 
with  optic  neuritis.  Any  association  between  presenting  symptoms  and  subsequent 
progression could not be investigated. Although optic neuritis has been associated with a 
lower risk for conversion to MS, this appears to be related to normal MRI being more 
commonly observed in these patients (Tintoré et al., 2005). Risk of MS conversion was 
similar in patients  with  different presenting symptoms when only those  subjects with 
abnormal MRI were studied. Another study observed that in patients with an abnormal 
baseline  scan,  progression  to  MS  is  highest  in  those  presenting  with  optic  neuritis, 
followed by those with a brainstem syndrome, and the lowest rates were seen in patients 
with spinal cord syndrome (Morrissey et al., 1993). This may account for the discrepancy 
of findings between this study and that by Rovaris et al. (Rovaris et al., 2005b). 
 
Evidence from this study that progressive brain atrophy is greater in patients who progress 
to  MS  earlier,  supports  the  hypothesis  that  even  in  CIS  patients  the  more  active  the 
disease the greater the accumulation of permanent damage. The number of lesions (T2 
and Gd-enhancing) on baseline MRI has been associated with an early MS diagnosis 
(Pestalozza et al., 2005), and patients with worse clinical outcomes have been shown to 
have larger numbers and volumes of lesions on MRI at baseline (Brex et al., 2002). In  
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addition, greater increases in T2 lesion volumes have been seen in subjects who develop 
MS compared  with those that  remain CIS (Dalton et al., 2004),  and in patients  with 
abnormal MRI at baseline a trend has been shown for those with more lesions to develop 
MS more frequently (Morrissey et al., 1993). However the finding that higher atrophy 
rates were associated with a higher risk of MS diagnosis was most likely driven by the 
patients with particularly high atrophy rates. In fact, the Kaplan-Meier plot shows that 
survival  without  progression  to  MS  was  very  similar  for  patients  with  intermediate 
atrophy rates and for patients with atrophy rates at the level of controls or less during the 
first year. This may have been due to the cut-offs used to group patients which, although 
based  on  mean  control  atrophy  rates  and  dividing  the  cohort  equally,  are  relatively 
arbitrary. In fact the 95% CI for the atrophy rate in control subjects was -0.25 to 0.11, 
which spans atrophy rates included in the intermediate atrophy group (B), suggesting that 
a significant proportion of CIS patients have cerebral losses over one year that are within 
the  control  range.  Those  subjects  with  rates  outside  this  range  (group  C)  have  much 
higher rates of conversion to MS at five years. It is also likely that pathology occurring 
after the one year observation period in subjects from groups A and B will influence 
whether patients develop MS. This illustrates that although brain atrophy rate may be a 
significant  independent  risk  factor  for  progression  to  MS,  it  would  be  difficult  to 
incorporate  this  indicator  for  diagnostic  purposes  or  development  of  management 
strategies. There is difficulty determining what is normal and abnormal, and a continuum 
of atrophy rates exists in CIS subjects that may also vary depending on the measurement 
technique, person measuring the atrophy and the scanner and acquisition. In addition, 
pathology occurring beyond one year follow-up may contribute to progression to MS. 
 
Further investigation of the prognostic value of brain atrophy rate in larger cohorts of CIS 
subjects with longer clinical and MRI follow-up need to be performed. In addition to the 
small number of subjects included in this study, the investigation presented has several 
limitations, some of which have already been mentioned. Partly as a result of the small 
sample size, it was not possible to include a large number of explanatory variables in 
relation to subsequent MS diagnosis. Larger, prospective studies would have the power to 
investigate additional MRI, clinical, demographic and genetic factors that may aid in the 
prognosis for patients presenting with a CIS. Also, the log-rank test showing a significant 
relationship between atrophy rate and the survival time does not provide a comparison of 
the total survival experience of the three groups, but rather gives a comparison at an 
arbitrary time-point (in this study the median survival time). In addition, the survival  
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analysis  included  subjects  who  had  been  diagnosed  with  MS  during  the  first  year  of 
follow-up,  when  measurement  of  brain  atrophy  had  been  performed.  However  it  is 
impossible to measure brain  atrophy  rate prior to clinical presentation,  and excluding 
those patients who converted during the first year is likely to bias the results. Therefore as 
this experiment was exploratory it was felt that all patients should be included.  
 
Although clinical follow-up was extended to five years in this study, the time during 
which there is the highest probability of developing MS, of the 13 subjects remaining 
clinically isolated at follow-up, some could still progress to MS. In a 14 year follow-up 
study of 71 CIS patients, amongst those with a normal baseline MRI scan who converted 
to clinically definite MS, the median time to development of MS was 7.5 years (range 5 to 
11  years)  (Brex  et  al.,  2002).  However  that  study  found  that  approximately  68%  of 
patients overall had developed MS at follow-up, which is a similar proportion to that 
found at follow-up in this study (65%). In contrast, a 10 year follow-up study of 102 
subjects presenting with optic neuritis found that the risk of progressing to MS was only 
42% after 10 years (Ghezzi et al., 1999). Obviously it cannot be concluded with any 
certainty that of the patients remaining stable at five year follow-up in this study few will 
progress to MS at a later date, as the cohorts are different and MS is a heterogeneous 
disease, but these studies might be considered suggestive that the majority of patients in 
this study who are going to progress to MS have already done so.  
 
In conclusion, the findings in this investigation indicate that initial brain atrophy rate 
following presentation with a CIS could be an additional prognostic factor in patients 
presenting with a CIS. These results need to be confirmed in bigger cohorts with longer 
clinical and MRI follow-up. 
 
9.3  Investigation  into  the  predictive  value  of  brain  atrophy  rate  for  clinical 
disability in patients with relapsing remitting multiple sclerosis 
9.3.1  Introduction 
Many  studies  previously  investigating  the  association  between  brain  atrophy  and 
subsequent  disability  may  have  been  limited  by  the  cross-sectional  study  design 
(Calabrese  et  al.,  2007a;  Chard  et  al.,  2002b;  Filippi  et  al.,  1998;  Ge  et  al.,  2001; 
Quarantelli et al., 2003), or short clinical follow-up which could have been insufficient to 
detect a significant change in disability using EDSS scores (Gasperini et al., 2002; Luks 
et al., 2000). This may explain the weak or absent associations observed between atrophy  
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and disability in RRMS (De Stefano et al., 2003; Lin et al., 2003; Losseff et al., 1996; 
Luks et al., 2000; Lycklama á Nijeholt et al., 1998; Rovaris et al., 2003). Associations 
between changes in global or regional brain volumes and concurrent changes in EDSS 
score have also been mixed (Audoin et al., 2006; Audoin et al., 2007c; Kalkers et al., 
2002;  Rudick  et  al.,  2000).  Several  reasons  have  been  suggested  for  these  findings, 
including that brain atrophy may not immediately lead to changes in disability, that there 
may  be  a  threshold  of  neuroaxonal  damage  before  which  disability  is  not  clinically 
apparent,  that  cortical  reorganisation  may  limit  clinical  manifestations,  and  that 
neuroaxonal damage may occur in clinically silent areas. It has also been suggested that 
the EDSS may be too heavily weighted towards motor disability, it is insensitive to small 
amounts of change and is subject to high inter-rater variability (Noseworthy, 1994).  
 
Longer clinical follow-up studies have greater potential to determine relevant associations 
between  brain  atrophy  and  subsequent  development  of  disability.  Inclusion  of 
longitudinal measures of brain atrophy, as opposed to cross-sectional volumes, may allow 
additional  associations  to  be  seen.  Furthermore,  new  MS  rating  scales  have  been 
developed, including the MSFC (Cutter et al., 1999), which is thought to provide a more 
sensitive  measure  of  clinical  disease  progression  than  the  EDSS  (Cutter  et  al.,  1999; 
Hobart et al., 2004). A study in 2001showed MRI measures of brain T1 and T2 lesion 
loads to correlate significantly with MSFC scores but not EDSS scores in a large group of 
relapse-onset patient (Kalkers et al., 2001b). The MSFC is comprised of three objective 
and quantitative tests: leg function/ambulation, arm/hand function, and cognitive function, 
and standardised z-scores are used to relate an individual’s performance to the average 
performance in the population.  
 
The aim of this study was to investigate the relationship of annual atrophy rate early in the 
course of RRMS to the development of disability by five year follow-up, as measured by 
the  MSFC,  and  investigate  whether  brain  atrophy  might  explain  subsequent  clinical 
disability better than established MRI measures of focal inflammation. 
 
9.3.2  Methods 
Subjects and MR imaging 
Twenty-five subjects (six males) with RRMS were identified from the total cohort of 41 
subjects enrolled in a longitudinal clinical and MRI study (Chapter 3.1.2). All subjects 
had been recruited within four years of symptom onset (median 1.7, range 0.5-3.8), and  
211 
had been assessed at baseline, one year and five years. Median EDSS at baseline was 1.5 
(range 0-2). Mean follow-up time was 5.0 years (SD 0.92) when mean age was 42.1 years 
(SD 7.5) and mean disease duration was 6.9 years (SD 1.3). Seventeen patients were on 
disease-modifying  treatments  at  follow-up.  At  baseline  a  coronal  T1-weighted  three-
dimensional  inversion  recovery  prepared  FSPGR,  a  T1-weighted  CSE  and  a  FSE 
sequence were acquired using the sequences outlined in Chapter 3.3.2. The T1-weighted 
three-dimensional inversion recovery prepared FSPGR was repeated at approximately one 
year follow-up.  
 
MRI analysis 
T1-  and  T2-weighted  lesion  areas  were  identified  on  the  T1-weighted  CSE  and  PD-
weighted images respectively, and contoured using DispImage (Plummer, 1992) (Chapter 
3.4.4) by a trained neurologist (W. Rashid). Annual percentage brain atrophy rate was 
determined from the baseline and one year T1-weighted FSPGR images using SIENA, 
according to the optimised method described in Chapter 5.3.2. 
 
Multiple Sclerosis Functional Composite score 
The MSFC was administered at baseline and five year follow-up as outlined in Appendix 
2 (Cutter et al., 1999; Fischer et al., 1999). Z-scores at follow-up were calculated using 
the baseline scores from the whole RRMS cohort (n=41) as the reference population. 
 
Statistical analysis 
Univariate  linear  regression  was  performed  to  investigate  linearity  between  each 
independent variable (MRI and demographic factors) and the dependent variable (MSFC 
z-score).  Multiple  linear  regression  analysis  was  performed  to  determine  significant 
relationships between MSFC z-score and MRI or demographic variables, using a forward 
stepwise procedure. A p-value of 0.05 was required for a variable to be included in the 
model and p-value of 0.1 was required to retain the variable in the final model. Predictor 
variables  investigated  were  baseline  T1  lesion  volume,  baseline  T2  lesion  volume, 
baseline to one year atrophy rate, disease duration, age at follow-up, interval (baseline to 
five year follow-up), gender and treatment status at five year follow-up. 
 
9.3.3  Results 
Mean atrophy rate in the 25 subjects was -0.81% year
-1 (SD 0.50). Mean baseline T1-
weighted  lesion  load  was  1.30cm
3  (SD  1.28,  range  0-3.75)  and  mean  baseline  T2- 
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weighted lesion load was 6.84cm
3 (SD 4.64, range 0.86-19.61). Median EDSS at five year 
follow-up was 2.5 (range 0-6) whilst mean MSFC z-score was -0.10 (SD 1.10, range  
-3.13 to 1.16). Using forward stepwise linear regression, brain atrophy rate during the first 
year  of  study,  treatment  status  at  follow-up  and  baseline  T1  lesion  volume  were  all 
retained in the final model as significant independent predictors of MSFC z-score at five 
years  (Table  9-1).  T2  lesion  volume,  disease  duration,  age  at  follow-up,  interval  and 
gender were found not to be significant independent predictors of MSFC z-score at five 
year follow-up (Table 9-1). For each 1% year
-1 increase in atrophy rate, MSFC z-score 
decreased by 1.03 (95% CI 0.38 to 1.69, p=0.003). Similarly, when on treatment MSFC z-
score decreased by 1.01 (95% CI 0.31 to 1.70, p=0.007). For each 1cm
3 increment in 
baseline T1-weighted lesion volume, MSFC z-score decreased by 0.29 (95% CI 0.031 to 
0.54, p=0.030). The final model accounted for 58% of the variance in MSFC z-score. 
 
Table 9-1 Crude and adjusted regression coefficients for independent variables entered 
into a linear regression analysis looking at association with MSFC z-score.  
Predictor variable  Effect on MSFC z-score 
  Univariate regression 
coefficient (β), (95% CI) 
Adjusted regression 
coefficient (β), (95% CI) 
Baseline T1 lesion volume 
(cm
3) 
-0.32 (-0.66, 0.023) 
p=0.066 
-0.29 (-0.54, -0.031) 
p=0.030 
Baseline T2 lesion volume 
(cm
3) 
-0.033 (-0.13, 0.068) 
p=0.502 
0.084 (-0.095, 0.26) 
p=0.339 
Brain atrophy rate  
(% year
-1) 
1.07 (0.24, 1.90),  
p=0.014 
1.03 (0.38, 1.69) 
p=0.003 
Disease duration  
(years) 
0.24 (-0.13, 0.60) 
p=0.189 
0.12 (-0.16, 0.41) 
p=0.377 
Age at follow-up  
(years) 
-0.0031 (-0.067, 0.061) 
p=0.921 
0.017 (-0.031, 0.034) 
p=0.474 
Interval baseline to 5 years 
(years) 
0.37 (-0.12, 0.86) 
p=0.133 
0.28 (-0.093, 0.65) 
p=0.134 
Gender  
(male vs female) 
0.29 (-0.79, 1.38) 
p=0.579 
-0.41 (-1.21, 0.39) 
p=0.300 
Treatment status  
(no DMT vs DMT) 
-1.19 (-2.05, -0.34) 
p=0.008 
-1.01 (-1.70, -0.31) 
p=0.007  
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9.3.4  Discussion 
This investigation has provided evidence that brain atrophy rate early in the course of MS 
(within  four  years  of  symptom  onset)  is  significantly  related  to  subsequent  disability 
measured  by  the  MSFC.  In  addition,  the  volume  of  T1-weighted  lesions,  which  are 
thought to be the result of severe focal tissue damage, was also a significant independent 
predictor of disability five years later. These findings are important in the search for valid 
markers of disease progression in MS and understanding disease mechanisms. 
 
One of the strengths of this study was that patients had a relatively long clinical follow-
up, and had been recruited into the study within four years of symptom onset. Partly 
because of the mixed correlations between atrophy and disability over shorter follow-up 
periods, it is thought that effects on disability may lag relative to changes in rates of brain 
atrophy. Studies such as this one, which include longer patient follow-up may aid in 
establishing the relationship between brain atrophy and permanent disability. One such 
long-term follow-up study of 138 RRMS patients who had taken part in a treatment trial 
of  beta  interferon,  found  that  brain  atrophy  during  the  original  two  year  trial  was 
significantly correlated to MSFC at eight year follow-up (r=0.35). Moreover, in a logistic 
regression  analysis,  brain  atrophy  during  the  original  two  year  trial  was  a  significant 
predictor of patients having an EDSS greater than or equal to six (Fisher et al., 2002). 
However the patients had longer disease duration and larger lesion volumes at baseline 
than the cohort investigated in the current study, which suggests that even an increased 
atrophy rate early in the course of the disease may be relevant to future disability. A 
recent study published in 2007, investigating patients with a disease duration of less than 
two years, found that atrophy rate over approximately two years was significantly related 
to MSFC score at follow-up (Jasperse et al., 2007c).  
 
The findings in a six year follow-up study of 55 RRMS patients who had been enrolled in 
a two year trial of interferon beta-1a were similar to this study, in that T1 lesion volume at 
baseline was a significant predictor of the change in disability over the six years (Paolillo 
et al., 2002). However in contrast to the current study, T2 lesion volume at baseline was 
also a significant predictor of the change in disability whilst atrophy was not. That study 
utilised the EDSS as a measure of disability, which as already mentioned may be subject 
to  interater  variability,  and  therefore  may  to  some  extent  explain  the  difference  in 
findings. The difference may also be because brain atrophy was measured using the CCV 
which,  as  has  been  shown  in  Chapter  6.3,  may  not  be  as  sensitive  or  precise  in  
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measurements as SIENA. Inconsistencies in the association of atrophy with disability due 
to differences in the atrophy measurement technique have been seen in other studies. A 
four year investigation of 20 patients with RRMS and 18 patients with SPMS showed no 
significant difference in the change in EDSS over this period between subjects classified 
with  brain  atrophy  and  those  without  brain  atrophy  (Turner  et  al.,  2003).  However 
significantly  greater  disability  was  observed  in  the  same  patients  classified  as  having 
ventricular enlargement compared with those who did not – this discrepancy suggests a 
difference in the sensitivity of methods. 
 
In contrast to the current study, several investigations have shown that T2 lesion volume 
correlates with or is predictive of EDSS. In 142 RRMS patients taking part in a trial of 
glatiramer acetate, a correlation was observed between T2 lesion volume at baseline and 
EDSS approximately six years later (Rovaris et al., 2007). A smaller study that included 
patients with both RRMS and SPMS found baseline T2 lesion volume was predictive of 
EDSS deterioration at a follow-up of approximately 4.5 years (logistic regression analysis 
of stable versus sustained increase in EDSS) (Rovaris et al., 2003). Baseline T1 lesion 
volume and atrophy rate measured over the first year of the study using SIENA were not 
significantly associated. An eight year follow-up of the same patient cohort confirmed 
baseline T2 lesion volume was a predictor of EDSS worsening, and by this stage T1 
lesion volume was also a significant independent predictor (Agosta et al., 2006). That 
baseline T1 lesion volume became predictive of EDSS worsening at a later stage may be 
further evidence of a delay between permanent tissue damage and disability. Although 
brain atrophy remained a non-significant predictor of EDSS worsening in the eight year 
follow-up  study,  analysis  included  changes  in  BPF,  GMF  and  WMF.  Again,  the 
discrepancy  in  results  with  the  current  study  could  be  because  different  atrophy 
measurement techniques were used and the fact that EDSS was utilised as the measure of 
clinical disability. 
 
Interestingly, it was observed in this analysis that patients who were on disease-modifying 
treatments had significantly worse disability measured by the MSFC at five year follow-
up. This is likely to be because patients who had a more aggressive disease course were 
placed on treatment, rather than that treatment was causing increased disability. 
 
Limitations of this study should be noted. Firstly, although the MSFC is thought to be a 
more sensitive marker of clinical disability than other clinical scales, including the EDSS,  
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it  may  still  be  subject  to  error  and  it  is  difficult  to  determine  the  actual  amount  of 
permanent  disability  that  a  patient  has  accumulated.  One  of  the  primary  reasons  for 
investigating  markers  of  disease  progression  is  that  pathology  may  be  occurring  in 
clinically silent locations, and therefore rating scales and MRI markers measure different 
manifestations of MS and are unlikely to correlate completely. A further limitation of the 
study is that the MSFC had been administered in these patients at approximately six-
monthly intervals for three years prior to the five year follow-up assessment. Practice 
effects, particularly with regard to the PASAT may therefore have influenced the MSFC 
score to some extent. Also, it was not possible to investigate other clinical and MRI 
variables that may be related to subsequent disability, such as relapse rate and quantitative 
measures from DW-MRI. This was in part due to the small sample size which did not 
allow the inclusion of many more variables in the regression model. This study did not 
investigate concurrent changes in atrophy and disability either, which has been presented 
in some studies previously (Fisher et al., 2000; Rudick et al., 2001), and may help to 
further elucidate the relationship between brain atrophy and disability. Investigation of 
associations between regional brain atrophy rates and scores of localised function may 
also aid in this endeavour (Calabrese et al., 2007a). 
 
In conclusion, these results provide further evidence that neuroaxonal damage is a cause 
of permanent disability in MS which may precede clinical manifestations, and that brain 
atrophy may be a good marker of that damage and thereby of disease progression. MRI 
measures of disease activity in the early years of the disease appear to be important in the 
long-term prognosis for disability in MS patients. Larger studies and investigation of the 
associations of atrophy and disability in progressive MS need to be performed. 
 
9.4  Investigation  into  the  predictive  value  of  brain  atrophy  rate  for  cognitive 
impairment in patients with relapsing remitting multiple sclerosis 
9.4.1  Introduction 
As described in Chapter 2.6.2, cognitive impairment is known to occur in patients with 
MS. It is thought that between approximately 40-60% of MS patients exhibit cognitive 
impairment (Achiron & Barak, 2003; Rao et al., 1991), and subtle cognitive changes have 
been detected in subjects presenting with a CIS (Feuillet et al., 2007) and subjects with 
early RRMS (Amato et al., 2001; Deloire et al., 2005). Deficits in attention, speed of 
information  processing,  working  memory  and  verbal  and  visuospatial  memory  are 
commonly observed (Amato et al., 2001; Benedict et al., 2005; Benedict et al., 2006;  
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Deloire et al., 2005; Lazeron et al., 2006). These deficits may significantly impact on 
daily living in relation to both occupational and social functioning. Cognitive impairment 
is  progressive  over  the  course  of  the  disease  and  deficits  may  extend  to  additional 
domains and functions over time (Amato et al., 2001). 
 
Associations between global and regional brain volumes and cognitive dysfunction have 
been shown in cross-sectional studies (Amato et al., 2004; Christodoulou et al., 2003; 
Sanfilipo et al., 2006). Moreover brain atrophy has been shown to account for greater 
variance in cognitive functioning than lesion burden in cross-sectional studies (Benedict 
et al., 2004; Lazeron et al., 2006). However some cross-sectional studies have not shown 
significant  associations  between  cognitive  impairment  and  MRI  measures  of  disease 
burden (Achiron & Barak, 2003; Deloire et al., 2005). The true relationship of brain 
atrophy and cognitive changes need to be explored further through longitudinal studies. 
Little is known about the ability of MRI parameters, including early brain atrophy, to 
predict the development of specific cognitive deficits. Identification of patients who might 
go on to develop such deficits may aid in the screening of patients and provide a rationale 
for administration of disease-modifying therapy, whilst in addition allowing management 
strategies to be developed, and support for individual patients. This study explores the 
value  of  MRI  parameters  obtained  at  baseline  in  predicting  cognitive  impairment  in 
specific domains five years later.   
 
9.4.2  Methods 
Subjects and MR imaging 
Of  the  initial  41  patients  with  RRMS  (Chapter  3.1.2),  34  subjects  had  returned  for 
cognitive assessment at five year follow-up. Mann-Whitney tests showed no significant 
differences between subjects that returned for cognitive assessment and those that did not 
in age at onset, disease duration, EDSS at five year follow-up, baseline lesion volume, or 
brain atrophy rate during the first year of follow-up. Of the subjects that returned for 
cognitive  assessment,  26  (six  male)  had  baseline  and  one  year  follow-up  MRI  scans 
available for atrophy measurement. Subjects had been recruited within four years of first 
presentation. At baseline, mean age was 37.2 years (SD 7.5), mean disease duration was 
2.0  years (SD 0.8) and median EDSS was 1.5 (range 0-3). At baseline and one  year 
follow-up  assessment  a  coronal  T1-weighted  three-dimensional  inversion  recovery 
prepared  FSPGR,  a  T1-weighted  CSE  and  a  FSE  sequence  were  acquired  using  the 
parameters outlined in Chapter 3.3.2.  
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MRI analysis 
Annual percentage brain atrophy rate over the first year from baseline assessment was 
determined  using  SIENA  on  T1-weighted  coronal  FSPGR  images,  according  to  the 
optimised method described in Chapter 5.3.2. T1- and T2-weighted lesion areas were 
identified on the baseline T1-weighted CSE and PD-weighted images respectively and 
contoured using Dispimage (Plummer, 1992) (Chapter 3.4.4) by a trained neurologist (W. 
Rashid). 
 
Clinical and neuropsychological assessment 
At five-year follow-up, self-reported symptoms of anxiety and depression were rated with 
the Hospital Anxiety and Depression Scale (HADS) (Snaith & Zigmond, 1986). A score 
of 11 or above was used as a cut-off point for both subscales. 
 
A neuropsychological test battery was administered at five year follow-up by a trained 
psychologist (M. Summers) and the following cognitive domains were assessed: 
 
(i) General intellectual functioning was assessed with a shortened version of the Wechsler 
Adult Intelligence Scale – Revised (WAIS-R) (Wechsler, 1981) and measures of verbal 
(vocabulary,  digit  span,  arithmetic  and  similarities  subtests),  performance  (picture 
completion,  picture  arrangement  and  block  design  subtests)  and  full-scale  IQ  were 
obtained. Optimal premorbid intellectual functioning was estimated using the National 
Adult Reading Test (NART) (Nelson, 1982). The difference between the NART IQ and 
the WAIS IQ was considered an index of IQ change. Patients with measures of current IQ 
15 or more points below premorbid estimates were considered to have IQ decline. 
 
(ii)  Verbal  and  visual  recall  memory  were  assessed  using  the  story  and  figure  recall 
subtests of the Adult Memory and Information Processing Battery (AMIPB) (Coughlan & 
Hollows, 1985). In the story recall subtest, participants are asked to freely recall a short 
story immediately after presentation and again after a 30-minute delay. The score is the 
number of correctly recalled story segments, out of a maximum 56. In the figure recall 
subtest,  participants  must  copy  a  complex  figure,  then  re-draw  it  from  memory 
immediately, and after a 30-minute delay. The score is the number of correctly drawn 
design elements, out of a maximum 80. 
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(iii) Attention/speed of information processing were assessed with the PASAT (Sampson, 
1956)  and  the  Symbol  Digit  Modalities  Test  (SDMT)  (Smith,  1982).  In  the  PASAT, 
subjects have to add successive pairs of digits which are presented aurally at three second 
intervals. The score is the number of correct additions, out of a maximum 60. In the 
SDMT, subjects have to transcribe single digits from symbols according to a visually 
presented key. The score is the number of digits correctly transcribed in 90 seconds. 
 
(iv)  Executive  functioning  was  assessed  using  the  Spatial  Working  Memory  (SWM) 
subtest  of  the  Cambridge  Neuropsychological  Test  Automated  Battery  (CANTAB) 
(Sahakian & Owen, 1992), the Hayling Sentence Completion Test (Burgess & Shallice, 
1997) and the Brixton Spatial Anticipation Test (Burgess & Shallice, 1997).  In the SWM 
subtest, participants search for tokens in  an  array  of boxes  (four-, six- and eight-box 
arrays) presented on a computer monitor, remembering and avoiding locations where they 
have already found a token. The number of times participants return to a location where a 
token has been found during an earlier search is the error score. A strategy score is also 
given,  which  is  a  measure  of  search  pattern  consistency,  with  a  lower  strategy  score 
indicating a more efficient search strategy. The Hayling sentence completion task consists 
of  two  parts.  Part  one  measures  verbal  response  generation,  where  participants  must 
complete  a  sentence  with  an  appropriate  word,  and  part  two  measures  response 
suppression, where participants must  complete a sentence  with an unconnected word, 
suppressing connected response words. The score is derived from a composite of response 
times for each item in  parts one  and two and the number  of  errors  (connected  word 
responses) made in part two. Longer response times and more errors yield a lower score. 
In  the  Brixton  test,  participants  are  presented  with  a  10-position  array,  in  which  one 
position is marked by a filled circle. On subsequent presentations, the marked position 
changes according to a pattern and participants are required to guess which position will 
be  marked  on  the  subsequent  presentation,  based  on  the  current  spatial  pattern  of 
movement. The score is the total number of incorrect guesses made. 
 
Analysis of neuropsychological data 
To determine whether patients were impaired in each cognitive domain, patients’ raw 
scores  were  compared  with  those  from  age-related  healthy  controls  in  the  published 
literature, and converted into percentiles. As the normative controls came from a variety 
of educational backgrounds, cognitive impairment was not adjusted for educational level. 
Following standard practice, scores falling at or below the 5
th percentile of published  
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norms were considered impaired. The total number of tests failed (i.e. performance at or 
below the 5
th percentile of published norms) was also determined for each patient. 
 
Composite and domain-specific z-scores were obtained in order to analyse associations 
between MRI parameters and neuropsychological performance. For each test score, mean 
and standard deviation was calculated for the 26 patients, allowing each patient’s score to 
be expressed as a z-score, referenced against other patients’ performance.  Z-scores from 
measures of IQ deficit were averaged to produce an IQ deficit z-score (such that a smaller 
IQ deficit constituted a higher z-score). Likewise, z-scores from all memory, attention and 
executive  function  tests  were  averaged  to  produce  memory,  attention  and  executive 
function z-scores respectively. These z-scores were averaged for each patient to produce a 
composite z-score in which each cognitive domain was equally weighted. 
 
Statistical analysis 
Multiple linear regression analysis was performed to determine significant relationships 
between cognitive performance and MRI variables. Due to the small sample size in this 
study  and  the  large  number  of  demographic  and  clinical  variables,  univariate  linear 
regression analyses were performed for each variable and only those that were significant 
were  retained  for  the  multivariable  model.  The  variables  considered  were  disease 
duration, age at follow-up, interval (baseline to five year follow-up), gender, medication, 
years of education, EDSS at follow-up, premorbid IQ and anxiety and depression ratings. 
Significant variables were retained and entered into the multivariable linear regression 
using a forward stepwise procedure with the MRI predictor variables which included 
baseline to one year brain atrophy rate, and baseline T1 and T2 lesion volumes. A p-value 
of 0.05 was required for a variable to be included in the model and p-value of 0.1 was 
required to retain the variable in the final model. 
 
9.4.3  Results 
At five year follow-up mean age was 42.2 years (SD 7.5), mean disease duration was 7.0 
years (SD 1.2) and median EDSS (based on only 24 subjects) was 2.5 (range 0-6). Fifteen 
patients were on disease-modifying treatment and the mean interval between baseline and 
follow-up assessments was 5.0  years (SD 0.9).  Two patients  were not  rated  with the 
HADS, whilst three patients did not complete the NART and consequently IQ deficit 
could not be established for these subjects. At follow-up, the HADS scores were above 
the threshold for depression in one patient and above the threshold for anxiety in six.   
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In  the  23  subjects  in  whom  premorbid  IQ  was  established,  seven  (30%)  showed  IQ 
decline  from  premorbid  estimates  in  at  least  one  IQ  measure  (five  verbal  IQ,  five 
performance IQ, four full-scale IQ). Scores for individual neuropsychological tests and 
the number of subjects impaired at five year follow-up are shown in Table 9-2. 
 
Table  9-2  Standardised  neuropsychological  test  scores  and  numbers  of  patients 
impaired at five year follow-up. 
Test  Mean (SD)   Range  Impaired  Composite 
z-score 
(mean) 
Premorbid full-scale IQ  108.6 (10.1)  86-124  0/23  General 
intelligence  Full-scale IQ deficit  8.8 (6.8)  -5-22  4/23 
2.11x10
-9 
Story recall: immediate 
(max 56) 
36.6 (8.2)  19-53  0/26 
Story recall: delayed  
(max 56) 
34.1 (9.5)  18-53  0/26 
Figure copy  
(max 80) 
78.1 (2.5)  70-80  0/26 
Figure recall: immediate 
(max 80) 
61.2 (14.3)  28-80  1/26 
Memory 
Figure recall: delayed  
(max 80) 
60.0 (13.2)  38-80  0/26 
-4.01x10
-9 
SWM: within-trials error  3.5 (4.8)  0-16  2/26 
SWM: strategy  33.2 (7.2)  8-42  0/25 
Hayling test: overall 
score (max 23) 
17.4 (3.1)  6-21  0/25 
Executive 
function 
Brixton test: errors  
(max 54) 
14.4 (6.1)  3-29  2/25 
2.31x10
-3 
PASAT 3  
(max 60) 
46.5 (15.0)  0-60  3/26  Attention 
SDMT  46.4 (10.8)  23-65  6/26 
1.50x10
-9 
Overall cognition        -0.021 
PASAT, Paced Auditory Serial Addition Test; SDMT, Symbol Digit Modalities Test; SWM, Spatial Working 
Memory. 
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Mean atrophy rate in the 26 subjects was -0.81% year
-1 (SD 0.50). Mean baseline T1-
weighted  lesion  load  was  1.51cm
3  (SD  1.63,  range  0-6.62)  and  mean  baseline  T2-
weighted lesion load was 7.34cm
3 (SD 5.40, range 1.42-21.3). 
 
Of  the  demographic  and  clinical  variables,  gender  was  associated  with  IQ  deficit, 
premorbid IQ was associated with tests of attention and executive function, and anxiety 
rating was associated with executive function. Using multiple regression, brain atrophy 
rate in the first year from baseline was retained in the final models as the only significant 
independent predictor for memory z-score and overall cognitive z-score. For each 1% 
year
-1 increase in atrophy rate, memory z-score decreased by 0.65 (95% CI 0.09 to 1.20, 
p=0.024) and overall cognitive z-score decreased by 0.56 (95% CI 0.15 to 0.96, p=0.009). 
Brain atrophy rate accounted for 16% and 22% of the variance in memory and cognitive 
z-scores  respectively.  Baseline  T1  lesion  volume  was  the  only  significant  predictor 
retained in the model for attention z-score. For each 1cm
3 increase in T1-weighted lesion 
volume, attention z-score decreased by 0.21 (95% CI 0.03 to 0.38, p=0.021). IQ deficit 
and executive function were not significantly predicted by atrophy rate or lesion volumes. 
 
9.4.4  Discussion 
This study has demonstrated that a higher brain atrophy rate early in the course of the 
disease is  associated with lower scores on tests  of cognition in patients  with RRMS. 
Specifically, a higher brain atrophy rate was found to be an independent predictor of 
overall cognitive functioning and memory impairment. In addition, T1 lesions were found 
to be an independent predictor of performance in tasks of attention. These results were 
found even when clinical and demographic variables had been taken into account and are 
unlikely to have been influenced by the education level of subjects, as years of education 
and premorbid IQ were included as variables.  
 
At five year follow-up the patients included in this investigation demonstrated only subtle 
cognitive deficits and very few patients were considered impaired on individual tests. 
There are several possible reasons for this. Firstly, the patients included in this study were 
at  an  early  stage  of  their  disease  when  cognitive  reserve,  functional  and  structural 
plasticity, and brain reorganisation may limit cognitive symptoms (Audoin et al., 2007b). 
Other studies have shown cognitive function to be well preserved in groups of RRMS 
patients  with  longer  disease  durations  than  those  subjects  investigated  in  this  study 
(Olivares et al., 2005; Schwid et al., 2007). It has also been suggested that MS patients  
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may  perform  similarly  to  control  subjects  in  tests  which  assess  the  accuracy  of 
performance  rather  than  the  time  taken  to  complete  the  task  (Achiron  et  al.,  2007; 
Lazeron et al., 2006). Most of the test scores in this study (with the exception of the 
PASAT, SDMT and Hayling tests) were not time-limited and therefore may not have 
identified subtle changes. In addition, there may have been a bias in the patients who 
returned  for  cognitive  testing  at  five  years.  It  is  likely  that  subjects  who  were  more 
impaired would be less likely to return or agree to cognitive testing. Four patients in 
whom baseline lesion volumes and first year brain atrophy rate could be quantified did 
not have cognitive assessment at five year follow-up and were therefore not included in 
the study. Of these patients, three were unable to come in for testing due to disability and 
it is likely that these patients had worse cognition. Although no significant difference in 
disability was found between those subjects that returned for cognitive testing and those 
that did not, this analysis may have been limited by the small numbers of patients who did 
not return for assessment giving the analysis limited power. 
 
Despite the minimal impairment in most subjects (which reduced the power to determine 
an  association),  this  study  found  that  brain  atrophy  rate  was  the  only  independent 
predictor of overall cognitive test score at five year follow-up, when taking into account 
clinical and demographic variables and, importantly, T1 and T2 lesion load. This finding 
supports  the  idea  that  whole  brain  atrophy  is  an  integral  measure  of  diffuse  damage 
including cortical neuronal loss. It also supports the hypothesis that brain atrophy is a 
relevant marker of the disease that may aid in monitoring the progression of disease and 
predicting future disability. Moreover, and perhaps surprisingly, T2 lesion volume was 
not  predictive  of  any  of  the  composite  cognitive  scores.  This  implies  that  diffuse 
neuroaxonal damage plays a more important role in future disability in MS than T2 lesion 
volumes. Arguably lesion volumes are measures of focal transient damage which do not 
take into account longer term global pathology.  
 
Interestingly, T1 lesion volume, not brain atrophy rate, was found to be predictive of 
deficits  in  attention  and  information  processing  speed.  Patients  were  most  commonly 
impaired on tests in this domain, in agreement with previous studies showing deficits in 
this area early in the disease (Achiron & Barak, 2003; Feuillet et al., 2007; Olivares et al., 
2005). Long axonal fibres connecting cerebral regions are contained within the WM and it 
is thought that demyelination leads to slowing in the speed of neuronal conduction. This 
could explain the predictive value of T1 lesions which are considered to represent chronic  
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demyelination  and  tissue  damage.  It  may  be  that  WM  atrophy  rather  than  T1  lesion 
volume or whole brain atrophy could be a better predictor in this domain, as diffuse 
pathological  changes  are  taken  into  account  in  an  area  more  relevant  to  deficits  in 
processing speed. A cross-sectional study has previously found that WM volume was the 
best predictor of mental processing speed and working memory (over GM and lesion 
volumes) in a group of 40 MS patients (Sanfilipo et al., 2006). Area of the CC has also 
been associated with deficits in information processing speed (Lin et al., 2007; Pelletier et 
al.,  2001;  Rao  et  al.,  1989).  Furthermore,  studies  have  found  ventricular  size  and 
enlargement to be associated with performance in the PASAT and SDMT (Benedict et al., 
2002; Benedict et al., 2006; Christodoulou et al., 2003; Jasperse et al., 2007c), and it has 
been hypothesised that this ventricular enlargement is due to damage of periventricular 
WM  tracts.  In  one  study,  the  BPF  was  only  significantly  associated  with  cognitive 
performance when third ventricular width was excluded from the analysis (Benedict et al., 
2004). 
 
Only one patient was considered impaired on tests of memory but it has been suggested 
that memory may be one of the earliest cognitive domains to be affected in MS (Amato et 
al., 2007; Christodoulou et al., 2003; Deloire et al., 2005; Feuillet et al., 2007; Piras et al., 
2003). Performance on the memory tests was significantly predicted by brain atrophy rate 
in the first year from baseline. Functions mediated by widely dispersed cortical regions, 
such as memory,  are likely to be related to global cortical damage and disruption of 
connections between cortical associative areas and cortical/subcortical structures. Brain 
atrophy is a global measure and so subjects with widespread atrophy are more likely to 
have cortical dysfunction in multiple areas. MRI studies have shown GM and cortical 
volumes to be correlated significantly with verbal memory (Amato et al., 2004; Benedict 
et al., 2006; Portaccio et al., 2006; Sanfilipo et al., 2006). At a more focal level, lesions 
have recently been shown to occur frequently within the hippocampus, a structure thought 
to play an important role in memory function (Geurts et al., 2007; Roosendaal et al., 
2008). 
 
Over a quarter of patients showed significant IQ decline in at least one IQ measure, but 
this was not predicted by any MR measure. However premorbid IQ was shown to be 
related to scores in tests of attention and information processing speed, and executive 
function which may be evidence of cognitive reserve as has been observed in previous 
studies (Corral et al., 2006). Similarly to IQ decline, performance on tests of executive  
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function was not predicted by  any MR measure. However, high anxiety  ratings were 
associated with poorer executive function. Increased anxiety may use available cognitive 
capacity in this domain, thus lessening capacity on more demanding tasks. It may also be 
that impairments in these areas generally take longer to manifest and that impairment is 
related to many years of pathological damage. 
 
Despite the significant predictive value of brain atrophy rate and T1 lesion volume in 
certain cognitive domains, they explained only a small proportion of the variance in test 
scores  at  five  year  follow-up.  This  may  be  due  to  several  factors.  Firstly,  as  already 
mentioned, cognitive reserve and structural and functional reorganisation may alter the 
relationship between brain damage and cognitive performance. Secondly, it is likely that 
the location of pathology will affect the cognitive changes observed. Therefore, regional 
measures of atrophy may  be more sensitive in predicting cognitive deficits in certain 
domains. Cross-sectional studies found that measures of temporal lobe atrophy accounted 
for more variance in tests assessing verbal and spatial memory dysfunction than whole 
brain atrophy (Benedict et al., 2005), and that superior frontal lobe atrophy predicted 
impairment  in  verbal  learning,  spatial  learning,  attention  and  conceptual  reasoning 
(Benedict et al., 2002; Locatelli et al., 2004). These results were corroborated recently in 
the  first  study  to  investigate  associations  between  regional  GM  volume  and 
neuropsychological  function  (Tekok-Kilic  et  al.,  2007).  It  found  that  left  frontal  GM 
atrophy was associated with tests of verbal memory whilst right frontal GM atrophy was 
associated with impairment in visual and working memory. 
 
A limitation of the current study is the small sample size and the results of this study need 
to be confirmed in larger cohorts of patients. This will also allow the inclusion of other 
clinical and MRI criteria which may be important predictors of future cognitive status, 
such as relapse rate or measures from other MR modalities. In addition, these patients did 
not  have  baseline  cognitive  assessments,  which  would  have  allowed  a  more  precise 
assessment of cognitive deterioration and association of the development of cognitive 
impairment with early MRI markers of disease. 
 
In summary, these results suggest that early brain atrophy rate may be predictive of future 
cognitive deficits in patients with RRMS. It appears to be a more relevant indicator of 
prognosis  than  MRI  measures  of  T2  lesions,  as  cognitive  performance  requires  the 
integrity of functional networks between different brain areas. However, the individual  
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predictive value of GM, WM and regional atrophy rates for future cognitive impairment 
need to be determined. This could allow identification of patients early in the disease 
course  who  are  most  likely  to  develop  cognitive  problems  that  may  impact  on  daily 
living, and as such allow preventative and support strategies to be established prior to 
significant impairment. 
 
9.5  Chapter conclusions 
This  chapter  has  investigated  the  relationship  of  brain  atrophy  early  in  the  course  of 
disease to the future development of clinical disability and cognitive impairment in CIS 
and RRMS. Mean brain atrophy rate is significantly increased from clinical presentation 
in subjects who are later diagnosed with MS, whilst in those who remain with a clinically 
isolated syndrome it is close to zero. This finding suggests that brain atrophy may be 
occurring prior to clinical presentation and that brain atrophy could be used as a marker of 
disease progression from the very earliest stages of disease. Whilst this study confirmed 
that  the  presence  of  T2  lesions  at  initial  clinical  presentation  is  highly  predictive  of 
whether a subject will be diagnosed subsequently with MS, brain atrophy rate during the 
first year after presentation was found to be independently predictive of the risk of a 
diagnosis of MS at five year follow-up. This highlights the relevance of brain atrophy to 
clinical progression and prognosis, but it is premature to suggest that brain atrophy could 
be used for diagnostic purposes in individual patients. 
 
This  chapter  has  also  shown  that  brain  atrophy  rate  early  in  the  course  of  relapsing 
remitting disease is predictive of disability rated by the MSFC, and cognitive impairment. 
This is further evidence that neuroaxonal loss early in the disease course is of clinical 
relevance. As such, these results confirm the importance of brain atrophy measurements 
as a marker of disease progression. However longer follow-up studies are required that 
include more patients, to explore in more detail the relationship of brain atrophy and other 
MR markers of disease to clinical disability and cognition. These studies may help to 
elucidate the mechanisms relating pathology, MR markers and clinical disability in MS.  
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10  Thesis conclusions 
This thesis investigated the application of a wide range of image analysis techniques for 
measurement of brain atrophy, and their relative potential to monitor disease progression 
and assess therapeutic efficacy in MS. Despite increasing application of brain atrophy as 
an outcome measure in trials of putative disease-modifying treatments for MS, the most 
appropriate technique for this purpose has not been established. It may be that different 
techniques  have  value  in  different  cohorts  or  with  different  acquisitions  and  clinical 
questions. However given that there are a number of potential measures it would be worth 
optimising and comparing techniques for possible use in common clinical trial scenarios. 
Furthermore, robust sample size calculations for using brain atrophy rate as an outcome 
measure have not been performed. The techniques investigated in this thesis range in their 
methodology and automation, and include those that have previously been applied widely 
to MS subjects and those that are novel in MS studies.  
 
The focus of this thesis was therefore to assess the most powerful measures of brain 
atrophy in CIS and RRMS patients who were early in the course of their disease and 
typical of the subjects who would be included in future treatment trials. Robust sample 
size calculations were performed to determine the number of RRMS subjects that would 
be  required  for  a  placebo-controlled  trial  of  a  potential  disease-modifying  treatment. 
Lastly, this thesis evaluated the prognostic value of brain atrophy rate early in the disease 
for future clinical disease progression.   
 
10.1 Assessment of brain atrophy measurement techniques 
In  order  to  assess  the  relative  advantages  and  disadvantages  of  atrophy  measurement 
techniques  a  range  of  factors  were  considered  including  the  sensitivity,  precision, 
robustness, reproducibility and degree of operator input required. Measurement error must 
be minimised as it can reduce sensitivity to change, particularly when atrophy rates are 
low, as they may be in the early stages of disease, or treatment effects small. With this in 
mind, automated techniques that directly quantify brain atrophy following registration are 
attractive. These techniques avoid quantification of brain volumes at serial time-points 
when  errors  associated  with  obtaining  each  volume  may  be  additive.  However  such 
automated techniques often consist of a series of processes and the output of each need to 
be examined carefully to ensure the general accuracy and precision of the method. In 
addition, these techniques may not allow for differences in the appearance of images (e.g.  
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contrast), and selection of the optimal acquisition and processing parameters for a specific 
dataset may increase the validity of measurements. The initial part of this thesis focussed 
on the assessment and improvement of brain atrophy measures using two such automated 
registration-based techniques, the BBSI and SIENA, in MS subjects. 
 
Small, but significant amounts of intensity inhomogeneity between serial images acquired 
using an identical acquisition protocol on the same scanner may occur during longitudinal 
studies. Differential bias correction between serial images appeared to increase intensity 
homogeneity between them, and can significantly increase measurement precision by the 
BBSI.  Application  of  intensity  inhomogeneity  correction  on  single  images  was  also 
described. Although the BBSI appeared to be robust to small amounts of inhomogeneity 
within individual images, correction of this artefact may become more relevant as an 
increasing number of MRI studies are performed on 3T scanners and inhomogeneity may 
be more prominent. Improvement of acquisitions prior to BBSI atrophy quantification, 
using fully automated processes that require minimal operator time, such as DBC, can 
provide significant increases in statistical power, suggesting that these processing steps 
should be performed routinely. 
 
Application of the BBSI to two FSPGR sequences was described. A small reduction in 
the  variance  of  measures  was  observed  using  the  acquisition  with  marginally  larger 
voxels. However this was non-significant and it was concluded that the BBSI was robust 
to small differences in acquisition protocol. Interestingly, averaging BBSI measurements 
obtained  from  the  two  FSPGR  sequences  increased  (albeit  non-significantly) 
measurement precision. Averaging two volumetric images has been used in this thesis in 
an attempt to increase the SNR and provide an image that may allow more sensitive and 
precise atrophy measurement by the BBSI. This work showed that despite increasing 
SNR significantly, brain atrophy measurements were not improved and it was concluded 
that to  benefit atrophy  measurements significantly, images obtained using exactly  the 
same acquisition parameters, are required. In addition it may be that greater than two 
images are necessary, and this would be impractical in the context of large clinical trials. 
Therefore, there was no strong evidence to suggest a benefit from combining two scans at 
each MRI session for atrophy measurement in a given patient. 
 
Brain  atrophy  rates  quantified  by  the  BBSI  can  vary  considerably  depending  on  the 
processing parameters used for analysis. Altering the intensity window over which the  
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BBSI is calculated,  can  increase brain  atrophy  measurements. Although measurement 
precision is reduced in association with this increase, the changes are not proportional and 
marginal gains in statistical power can be obtained. However the best method by which to 
assess the optimal intensity window needs to be determined.  
 
SIENA is often applied to “two-dimensional” images with limited resolution in one plane. 
This  thesis  showed  that  high  resolution  three-dimensional  images  could  be  used  for 
reliable brain atrophy quantification and should be considered for future brain atrophy 
studies in MS. Accurate automated brain extraction can be achieved on these images 
when processing parameters are carefully selected, whilst manual editing was required on 
images with lower resolution. The use of affine registration of a template brain mask to 
high-resolution images, prior to atrophy quantification by SIENA, was shown to produce 
results  consistent  with  those  obtained  following  generation  of  subject-specific  brain 
masks. SIENA appears to be robust to small errors in the initial brain extraction. This 
technique has potential for future analysis of brain atrophy in clinical trials, as generation 
of brain masks does not rely on image contrast or subject positioning within the FOV. 
Validation  of  the  technique  is  required  based  on  different  volumetric  acquisitions  to 
determine the potential application of this method. Further work to assess ways in which 
the  accuracy  of  a  template  brain  mask  could  be  improved  should  be  performed,  for 
example non-linear registration of the template to target images, or use of a template 
library.  
 
High resolution volumetric images may not only provide an easier and more automated 
means  of  initial  brain  extraction  than  “2D”  images,  but  a  systematic  bias  in  atrophy 
quantification may occur on these two acquisitions. Brain atrophy may be underestimated 
by SIENA on 2D acquisitions. However higher measurement variability using volumetric 
acquisitions  resulted  in  the  two  sequences  having  similar  statistical  power.  Further 
investigation of these findings in patients with greater atrophy rates, and application to 2D 
and 3D images acquired using different parameters or from different scanners needs to be 
performed. 
 
Direct comparison of brain atrophy rates quantified using different techniques in the same 
control and MS subjects highlighted some substantial differences in measurements. In 
addition  to  being  automated,  it  was  determined  that  the  “direct”  (registration-based) 
measures  of  whole  brain  atrophy,  SIENA  and  the  BBSI,  gave  significantly  better  
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precision  of  atrophy  measurements  than  methods  based  on  the  segmentation  and 
subtraction of volumes at serial time-points. Atrophy measurements from the BBSI and 
SIENA correlated well, although SIENA had marginally more statistical power than the 
BBSI. Another automated technique, SPM segmentation of brain tissue fractions, showed 
BPF and GMF to have the highest percentage volume changes of all methods. Unlike the 
other methods investigated, this method provides an indication of pathology in both GM 
and  WM,  and  as  such  is  useful  in  increasing  understanding  of  disease  mechanisms. 
However the technique was affected by high measurement variability and was not as 
robust or reliable as the other techniques, and had much lower statistical power to track 
atrophy.  Automated  segmentation  techniques  such  as  SPM  may  be  limited  by  the 
accuracy of tissue segmentation and the appearance of images is more likely to affect the 
performance  of  the  algorithm  than  semi-automated  segmentation  methods  that  allow 
manual  adjustment  of  regions.  Optimisation  of  acquisitions  for  this  technique  could 
improve the results and further work is required to assess the value of other regional 
atrophy measures that may be applicable for monitoring disease progression in MS.  
 
Measures  of  ventricular  enlargement  were  an  exception  to  the  generally  inferior 
performance  of  segmentation  and  subtraction  methods.  Compared  with  whole  brain 
measures, the simple (no complex folding of gyri) high contrast boundary between brain 
and ventricular CSF, and use of a standard intensity threshold for segmentation, mean that 
there are fewer subjective decisions about the boundaries, and therefore segmentation is 
highly reproducible and precise. Application of a previously untried method in MS, the 
VBSI,  was  described  to  register  local  ventricular  regions  and  automatically  quantify 
ventricular enlargement. It was found that there was no significant improvement in the 
precision of measurement as assessed by comparison with semi-automated segmentation 
of regions, and underestimation of ventricular enlargement at higher values was apparent. 
Scan-rescan analysis showed it to be less reliable than semi-automated segmentation and 
subtraction of volumes, and with similar effect sizes obtained by segmentation and the 
VBSI,  there  was  no  evidence  to  suggest  that  the  VBSI  should  be  used  instead  of 
calculation of segmented ventricle volume difference. 
 
Measures of CCV,  which attempt to  capture the change occurring in  and around the 
lateral  ventricles,  appear  limited  due  to  application  of  this  technique  to  “2D”  CSE 
acquisitions. Differences in slice selection and positioning, and possible problems with  
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interpolation of low resolution images following registration, lead to poor measurement 
precision and robustness.   
 
To aid reliable quantification of brain atrophy rates, images should ideally be consistent 
over time. Changes to scanner hardware and software can lead to changes in images that 
are incorrectly interpreted as brain volume change by some segmentation techniques that 
are driven by tissue contrast. Altering methodology to correct for these changes in images 
is one possible solution, but may not adequately compensate for scanner-related changes, 
and it is impossible to know the true value that should be obtained. Regular scanning of 
control subjects allows changes over time, and those related to specific changes in MRI 
hardware and software, to be determined. Regression analysis provides a means by which 
to estimate and correct for upgrade-related changes in volume. Future work could assess 
registration  based  methods  and  histogram  correction  of  scans  combined  with  atrophy 
measurement techniques that are driven less by absolute tissue contrast and may be more 
robust to such changes in acquisitions. 
 
10.2 Sample size calculations 
Sample size calculations for RRMS patients were performed for the techniques that had 
been  identified  as  the  more  effective  techniques  for  measurement  of  brain  atrophy, 
namely SIENA, the  BBSI  and ventricular enlargement. Using a sensitive and precise 
measurement  technique,  brain  atrophy  rate  could  be  a  practical  addition  to  outcome 
measures  in  clinical  trials  for  MS.  The  number  of  RRMS  subjects  required  in  each 
treatment arm for a placebo-controlled trial of a potential disease-modifying treatment 
was estimated to be comparable to or less than that required for studies using clinical 
outcome measures, currently the gold standard for phase III trials. SIENA was the most 
powerful measure, with estimates that only 123 subjects were required per treatment arm 
to show a 30% slowing in atrophy rate over two years. Over a two year trial no significant 
difference in the number of subjects required was observed between SIENA, the BBSI 
and ventricular enlargement, but comparison with a less precise measure of brain atrophy 
(segmented brain volume difference) highlighted the importance of using a less variable 
measurement technique. Reduced variability minimises the number of subjects that would 
need to be exposed to treatments that may be ineffective and have side effects, and reduce 
the cost of clinical trials. The cost of a trial could potentially also be reduced by shorter 
follow-up intervals. However it was shown that sample sizes were significantly increased 
with short trial duration. Furthermore, the mechanism of treatment needs to be considered  
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to make sure that a delayed effect on disease progression is not overlooked due to a short 
trial duration.  
 
10.3 Clinical findings 
Throughout this thesis application of atrophy measurement techniques to control subjects, 
subjects  presenting  with  a  CIS  and  patients  with  RRMS  have  been  described.  Brain 
atrophy  is  not  specific  for  pathology  and  represents  a  net  (integral)  effect.  Transient 
inflammation, remyelination and gliosis, amongst other factors, may have a confounding 
effect  on  brain  atrophy  measurements  and  future  studies  need  to  investigate  the 
relationship between brain atrophy and these other pathological features of MS. Despite 
this limitation, a comparison of atrophy rates in early RRMS subjects showed significant 
differences  in  rates  of  whole  brain  and  GM  atrophy,  and  expansion  of  the  lateral 
ventricles. When global brain atrophy was studied over three years it was concluded that 
there was no consistent acceleration or deceleration in rate, which might be expected in an 
inflammatory disease particularly if there is a confound of different treatment being taken 
during the study, but longer MRI follow-up is required in order to confirm this finding. 
 
This  study  showed  clearly  that  brain  atrophy  rates  are  increased  from  first  clinical 
presentation. Evidence of significantly increased rates of atrophy in CIS subjects who go 
on to develop MS relative to control subjects and those who remain stable was presented. 
Subjects  with  higher  brain  atrophy  rates  from  first  presentation  are  at  a  significantly 
increased risk of development of MS, and this measure may therefore aid in the prognosis 
of patients presenting with a CIS. The prognostic value of brain atrophy in CIS patients is 
independent  of  that  gained  from  the  detection  of  T2  lesions  on  MRI  at  presentation. 
Further  investigation  of  the  value  of  brain  atrophy  rates  in  CIS  patients  needs  to  be 
investigated in larger cohorts.  
 
Evidence from the studies presented in Chapter 9 suggested that rates of atrophy in early 
RRMS  were  predictive  of  future  disability  and,  importantly,  of  deficits  in  cognition, 
independent of the predictive value of MRI lesion measures. Brain atrophy rate was a 
significant independent predictor of disability five years later, as measured by the MSFC, 
a measure of ambulation, arm/hand function and cognition. Subtle cognitive impairment 
was observed in RRMS patients when cognitive testing was performed in subjects at five 
year  follow-up.  Brain  atrophy  rate  was  found  to  be  the  most  significant  independent 
predictor of overall cognitive score and memory function at follow-up. Future studies  
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investigating  regional  brain  atrophy  and  cognitive  deficits  may  reveal  specific 
associations that could more reliably predict future cognitive impairment. 
 
10.4 Summary 
Brain atrophy is a clinically relevant marker of disease progression in MS. This thesis 
investigates  a  range  of  brain  atrophy  measurement  techniques  in  MS.  It  shows  that 
techniques vary considerably in their sensitivity, precision, robustness and reproducibility. 
Choosing appropriate atrophy measurement techniques, it is possible to reliably detect 
treatment  effects  using  brain  atrophy  as  an  outcome  measure.  The  possibility  of 
improving the reliability of these measures and thereby contributing to improved drug 
discovery in MS is an important and feasible aim. Despite a number of important caveats 
and cautions it appears likely that treatments that slow atrophy progression, especially 
over  longer  studies,  may  truly  be  reducing  the  long  term  burden  of  disability  in  this 
devastating disease.  
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Appendices 
Appendix 1: Kurtzke Expanded Disability Scale 
The Kurtzke Expanded Disability Status Scale (EDSS) (Kurtzke, 1983) is a method of 
quantifying disability in MS. The EDSS quantifies disability in eight functional systems 
(FS) and allows neurologists to assign a functional system score in each of these. 
 
The function systems are: 
·  Pyramidal 
·  Cerebellar 
·  Brainstem 
·  Sensory 
·  Bowel and bladder 
·  Visual 
·  Cerebral 
·  Other 
 
EDSS steps 1.0 to 4.5 refer to people with MS who are fully ambulatory, and the precise 
step is defined by the functional system scores. EDSS steps 5.0 to 9.5 are defined by the 
impairment to ambulation.  
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Score  Description 
0  Normal neurological examination (all grade 0 in FS). 
1.0  No disability, minimal signs in one FS. 
1.5  No disability, minimal signs in more than one FS. 
2.0  Minimal disability in one FS. 
2.5  Mild disability in one FS or minimal disability in two FS. 
3.0  Moderate disability in one FS, or mild disability in three or four FS. Fully ambulatory. 
3.5  Fully  ambulatory  but  with  moderate  disability  in  one  FS  and  more  than  minimal 
disability in several others. 
4.0  Fully ambulatory without aid, self-sufficient, up and about some 12 hours a day despite 
relatively severe disability; able to walk without aid or rest some 500 metres. 
4.5  Fully ambulatory without aid, up and about much of the day, able to work a full day, 
may  otherwise  have  some  limitation  of  full  activity  or  require  minimal  assistance; 
characterised by relatively severe disability; able to walk without aid or rest some 300m. 
5.0  Ambulatory without aid or rest for about 200 metres; disability severe enough to impair 
full daily activities (work a full day without special provisions). 
5.5  Ambulatory  without  aid  or  rest  for  about  100  metres;  disability  severe  enough  to 
preclude full daily activities. 
6.0  Intermittent or unilateral constant assistance (cane, crutch, brace) required to walk about 
100 metres with or without resting. 
6.5  Constant bilateral assistance (canes, crutches, braces) required to walk about 20 metres 
without resting. 
7.0  Unable to walk beyond approximately five metres even with aid, essentially restricted to 
wheelchair; wheels self in standard wheelchair and transfers alone; up and about in 
wheelchair some 12 hours a day. 
7.5  Unable to take more than a few steps; restricted to wheelchair; may need aid in transfer; 
wheels self but cannot carry on in standard wheelchair a full day; may require motorised 
wheelchair. 
8.0  Essentially restricted to bed or chair or perambulated in wheelchair, but may be out of 
bed itself much of the day; retains many self-care functions; generally has effective use 
of arms. 
8.5  Essentially restricted to bed much of day; has some effective use of arms; retains some 
self care functions. 
9.0  Confined to bed; can still communicate and eat. 
9.5  Totally helpless bed patient; unable to communicate effectively or eat/swallow. 
10.0  Death due to MS.  
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Appendix 2: The Multiple Sclerosis Functional Composite 
The Multiple Sclerosis Functional Composite (MSFC) (Fischer et al., 1999) is a multi-
dimensional measure which reflects the varied clinical expression, including cognitive 
function, of MS across patients and over time, and allows for the dimensions to change 
relatively independently over time. The MSFC is comprised of: 
 
1. Timed 25-foot walk (TW) 
2. Nine-hole peg test (9HPT) 
3. Paced auditory serial addition test (PASAT-3 version).  
 
The results from each of these three tests are transformed into z-scores and averaged to 
yield a composite score for each patient at each time-point. 
 
Timed 25-foot walk 
The TW is a quantitative measure of lower extremity function. The patient is directed to 
one end of a clearly marked 25-foot course and is instructed to walk 25 feet as quickly as 
possible, but safely. The task is immediately administered again by having the patient 
walk back the same distance. Patients may use assistive devices when doing this task. The 
time taken for each trial is recorded.  
 
Nine-hole peg test 
The 9HPT is a quantitative measure of upper extremity (arm and hand) function. Both the 
dominant and non-dominant hands are tested twice. The patient must pick up pegs one at 
a time, using one hand only, and put them into holes as quickly as possible until all the 
holes are filled. Then without pausing, the patient must remove the pegs one at a time and 
return  them  to  the  container  as  quickly  as  possible.  The  time  taken  for  each  trial  is 
recorded. 
 
Paced auditory serial addition test 
The  PASAT  is  a  measure  of  cognitive  function  that  specifically  assesses  auditory 
information processing speed and flexibility, as well as calculation ability. It requires the 
patient to listen to a series of single digit numbers on a CD which are presented at a rate 
of one every three seconds. The patient is required to listen to the first two numbers, add 
them up and tell the tester the answer. When the next number is presented the patient must  
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add it to the number preceding it. The patient continues to add each number presented to 
the one preceding it. The number of correct responses is recorded. 
 
MSFC score 
TW: the times from the two trials are averaged. 
Nine-HPT: the two trials for each hand are averaged, converted to reciprocals of the mean 
times for each hand, and then the two reciprocals are averaged. 
PASAT: the number correct from the PASAT-3. 
 
Z-scores are created for each of the component scores, using test results from the baseline 
visit  from  all  patients  in  a  study  cohort.  Thus  the  z-score  is  a  standardised  number 
representing how close a test result is to the mean of a standard reference population to 
which the result is compared. Overall MSFC z-score is calculated as follows: 
 
MSFC z-score =  
[{(average(1/9HPT) – baseline mean (1/9HPT))/baseline SD(1/9HPT)} 
+ {-(average TW – baseline mean TW)/baseline SD TW} 
+ {(PASAT-3 – baseline mean PASAT-3)/baseline SD PASAT-3}] /3 
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Appendix 3: Starting slice for Losseff technique 
 
Proceeding  superiorly,  the  slice  where  the  third  ventricle  had  disappeared  and  the 
splenium of the corpus callosum had appeared, was determined. In addition, the presence 
of  the  internal  cerebral  veins  were  be  used  as  a  guide  to  the  best  slice  to  start 
measurements  especially  on  images  acquired  with  gadolinium  where  they  were 
particularly visible.   
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List of abbreviations 
9HPT  Nine-hole peg test 
AIR  Automated image registration 
ApoE  Apolipoprotein E 
BBSI  Brain boundary shift integral 
BET  Brain extraction tool 
BICCR  Brain to intracranial capacity ratio 
BPF  Brain parenchymal fraction 
BVD  Brain volume difference 
CC  Corpus callosum 
CCV  Central cerebral volume 
CI  Confidence interval 
CIS  Clinically isolated syndrome 
CNR  Contrast-to-noise ratio 
CNS  Central nervous system 
Cr  Creatine 
CSE  Conventional spin echo 
CSF  Cerebrospinal fluid 
CV  Coefficient of variation 
DBC  Differential bias correction 
DTI  Diffusion tensor imaging 
DW-MRI  Diffusion weighted magnetic resonance imaging 
EDSS  Expanded disability status scale 
FAST  FMRIB’s automated segmentation tool 
FCP  Fuzzy connected principles 
FLAIR  Fluid attenuated inversion recovery 
FLIRT  FMRIB’s linear image registration tool 
FMRIB  Functional magnetic resonance imaging of the brain 
FOV  Field of view 
FSE  Fast spin echo 
FSL  FMRIB’s software library 
FSPGR  Fast spoiled gradient recall 
FS  Functional system 
Gd-DTPA  Gadolinium diethyltriaminepentaacetic acid  
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GM  Grey matter 
GMF  Grey matter fraction 
GRASS  Gradient recalled at steady state 
1H-MRS  Proton magnetic resonance spectroscopy 
HADS  Hospital anxiety and depression scale 
ICC  Intraclass correlation coefficient 
IQR  Interquartile range 
LR  Likelihood ratio 
MIDAS  Medical image display and analysis system 
MNI  Montreal Neurological Institute 
MPRAGE  Magnetisation-prepared rapid acquisition gradient echo 
MRI  Magnetic resonance imaging 
MS  Multiple sclerosis 
MSFC  Multiple sclerosis functional composite 
MT-MRI  Magnetisation transfer-magnetic resonance imaging 
MTR  Magnetisation transfer ratio 
N3  Nonparametric nonuniform intensity normalisation 
NAA  N-acetylaspartate 
NAGM  Normal appearing grey matter 
NART  National adult reading test 
NAWM  Normal appearing white matter 
NBV  Normalised brain volume 
OR  Odds ratio 
PASAT  Paced Auditory Serial Addition Test 
PBVC  Percentage brain volume change 
PD  Proton density 
PPMS  Primary progressive multiple sclerosis 
ROI  Region of interest 
RRMS  Relapsing remitting multiple sclerosis 
SDMT  Symbol digits modalities test 
SIENA  Structural image evaluation, using normalisation, of atrophy 
SIENAX  Structural image evaluation, using normalisation, of atrophy–cross-sectional 
SNR  Signal-to-noise ratio 
SPGR  Spoiled gradient recall 
SPM  Statistical parametric mapping  
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SPMS  Secondary progressive multiple sclerosis 
SWM  Spatial working memory 
TE  Time to echo  
TI  Time to inversion  
TR  Time to repeat  
TW  Twenty-five foot timed walk 
VBM  Voxel based morphometry 
VBSI  Ventricular boundary shift integral 
VE  Ventricular enlargement 
VVD  Ventricular volume difference 
WAIS  Weschler adult intelligence scale 
WBV  Whole brain volume 
WM  White matter 
WMF  White matter fraction  
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